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Ag: antigen
AMP: ampicillin
APTS: 3-aminopropyl-tri ethoxy silane
CHI: first constant domain of the heavy chain of antibody molecules
CDR: complementarity determining region
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i.v.: intravenously
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MW: molecular weight
NP-40: Nonidet P40
pill: bacteriophage protein III, product of the gene III
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PC'R: polymerase chain reaction
Pl'Xi: polyethylene glycol
PMSF: phenylmethylsulfonyl fluoride (oc-toluenesulfonyl fluoride)
psp: phage shock promoter
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scFv: single-chain Fv
SCLC: small cell lung cancer
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SPR: surface plasmon resonance
V; variable
V,,: variable domain of the heavy chain of Ig molecules
V,: variable domain of the light chain of Ig molecules
TET: tetracyclin
TIL: tumor infiltrating lymphocyte
TU: transforming units
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Chapter 1
Introduction
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Chapter 1
1. Colorectal carcinoma
Colorcctal carcinoma (CRC) is the third most common cancer in the Western World, only
preceded by lung cancer, breast cancer among women and prostate cancer among men. The
mortality due to this type of cancer has not declined over the last years [ 1 ]. Surgery is the only
curative treatment option for patients with low stage CRC. Other treatment modalities, such as
chemotherapy and radiotherapy, are mostly given in an adjuvant setting to reduce the risk of
recurrences after surgical removal of the primary rumour. Staging of CRC is based on the depth
of invasion of the primary tumour (T), the extent of lymph node involvement (N) and the
presence of distant metastascs (M), called the "TNM-classification" [2,3]. Also frequently used
is the Dukes' classification: Table 1. Adjuvant treatment is mandatory for patients with stage III
colon cancer. At present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be
considered standard therapy. Recently, the dose of folinic acid given and the possible
combination of this treatment with levamisole were investigated and shown not to have any
beneficial effect [4J. Despite dcbulking surgery and adjuvant treatment, the prognosis for
advanced stages of the disease remains relatively poor (Table I).
Table 1'
Dukes' staging system for colorectal cancer
Stage
A
B
Cl
C2
D
Description
Confined to bowel wall, i.e. mucosa and
submucosa, or early muscular invasion
Invasion through the muscle wall but no lymph
node involvement
l.ymph node involvement, but not up to
highest point of vascular ligation
Nodes involved up to highest nodes at the
point of ligation
Distant metastases to other organs
5-year survival:
>90%
70-85%
25-65%
<5%
* adapted from [5]
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The relatively low percentage of patients having Dukes" C CRC that survives 5 years indicates
that despite surgery and adjuvant chemo- and radiotherapy, residual tumour cells frequently
survive that eventually grow out to local recurrences or give rise to distant mctastnses after a
variable period of dormancy. The selective killing of tumour cells by conventional therapeutic
strategies usually depends on differential vulnerability of tumour cells »rrm« normal cells for
cytotoxic drugs. This limited specificity leads to systemic toxicity in patients, thereby limiting
the dose that can safely be given to patients and restricting the available "therapeutic window".
Therefore, alternative therapies are needed to further reduce the mortality of the disease.
2. The first generation of cancer targeting antibodies
Paul Ehrlich already envisioned at the beginning of last century that antibodies may be
used as highly specific targeting molecules to deliver anti-tumour agents to the tumour site,
thereby postulating the idea of the "magic bullet". However, efforts to use polyclonul antibody
preparations, for example from horses immunised with cancer cells [6] (reviewed in [7]) were
largely unsuccessful.
The historic report of the immortalisation of B-cclls of a single specificity using the
hybridoma technology [8] opened a route to obtain monoclonal antibodies. This technology
initiated a search for antibodies reactive with cancer, involving the immunisation of mice with
cancer cells, cell lines or cell-extracts and the subsequent screening of hybridomus for antibodies
that bind the target cell [9-11 ]. A whole range of anti-tumour antibodies has been generated by
this technique [12,13], the specificity of which was not always known. In many cases, the
antigens these antibodies recognised have later been identified as tumour associated antigens (i.e.
structures that distinguish normal from malignant cells: sec section 5) and cloned [ 14,15). Fvcr
since, antibodies have extensively been used as vehicles to specifically target and eradicate
tumours (for review, see [16,17]).
2. / 77ie M.ve o/murme a»r»7>o<fler
The most obvious way to employ antibodies in the treatment of cancer is passive
immunotherapy using antibodies directed to tumour antigens. The idea behind this treatment
regime is that the specific homing of the therapeutic antibody to the tumour will recruit the
natural effector mechanisms of antibodies to the rumour site, resulting in destruction of tumour
cells. Dependent on their isotype, antibodies possess several natural effector functions that may
be effective in tumour eradication. These include complement mediated lysis (CML),
opsonisation, the formation of immune complexes (if the antigen is shed into the circulation) and
antibody-dependant cell-mediated cytotoxicity (ADCC). The latter is thought to be one of the
-II-
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major effector mechanisms by which 'naked' antibodies directed to tumour-associated antigens
exert their therapeutic effect. An important enhancement of this effect may be achieved by
increasing the affinity of the antibody used [18], or by using combinations of non-competing
antibodies directed to the same antigen [19].
Since it is known that murine antibodies of several i so types can interact with human Fc
receptors, these monoclonal antibodies could mediate an anti-tumour effect. Indeed, this strategy
of using intact murine IgG for cancer treatment has met with a few successes, notably in the
cancer field. In an adjuvant setting, treating patients with resected Dukes' C CRC, the "Panorex"
antibody, targeting the T,p-C'AM antigen (see section 5.3) increased the overall 5-year survival
rate with approximately 30% [20,21 ]. However, overall response rates in patients were generally
low. This can be attributed to several reasons, some of which involve the immunogenicity of
murine antibodies in humans, the pharmacokinetic behaviour of antibodies in man and
characteristics of solid tumours. In addition, a major problem has been the lack of tumour-
specific targets. Only in the case of lymphoma, the B-cell receptor (BCR) or antibody specificity
provides a tumour antigen that is truly tumour-specific and that constitutes an excellent target for
antibody treatment [22]. In addition, the target antigen on the malignant cell is freely accessible
from the blood. In solid tumours, however, the high molecular weight of antibodies (between 150
and 1K0 kl)a for lg(i, much larger for IgA or IgM) causes their poor penetration into the tumour.
In addition, the physiology of solid tumours disfavours accretion of antibody at the tumour site
[231; e.g. solid tumours frequently lack draining lymphatic vessels, which causes high interstitial
fluid pressure in the tumour micro-environment, thereby further decreasing the depth of
penetration of antibodies. Even more important reasons for failure of antibody treatment may be
the fact that most tumour antigens are heterogeneously expressed in tumours [24] and that
antigen-loss variants occur |25| that are resistant to antibody treatment [26]. The use of murine
antibodies in man is further hampered by the induction of an immune response to the foreign
protein, resulting in a HAM A (human anti mouse antibody) response [27], which causes toxicity
in patients and frequently prevents repeated administration of antibody. In theory, however, this
HAM A response could also have beneficial effects for the patient, since it may result in an anti-
idiotype antibody cascade.
The induction of such an anti-idiotype antibody response upon immunisation with an
antibody is relatively poorly understood and its contribution to any therapeutic effect of antibody
treatment is still under debate. Immunisation may induce a humoral immune response directed
to the antigen-binding site of that antibody, resulting in anti-idiotype antibodies (Ab2). This in
tum may cause a response to the antigen-combining site of the anti-idiotype antibody, giving rise
to an anti-anti-idiotypc response (Ab3 or Abl') that may partially be directed to the same epitope
as the original antibody used for immunisation. The induction of this anti-idiotypic antibody
•12-
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network is generally believed to have a beneficial effect for the patient. Recently, however, it was
shown that the presence of such anti-idiotyne antibodies did not correlate with the clinical
response of patients treated with the 17-1A anti-l-p-C'AM antibody |28| On the other hand,
therapeutic strategics using anti-idiotypc antibodies, designed to induce an unn-idiotypc network
have been shown to yield clinical responses in cancer patients [29-31 ]. thereby proving that the
anti-idiotype network may contribute to tumour eradication.
2.2
In an attempt to endow antibodies with a different, potentially more potent effector
function, several new types of antibodies have been generated. Bispecific antibodies arc hivalcnl
molecules in which the two antigen-binding sites of the antibody are directed to two different
antigens. Antibodies of this format were initially synthesised by fusion of two hybridomas. called
tetradomas or quadromas [32), by chemical cross-linking [33.34] and later by rccombinunt DNA
technology (see section 3). Bispccitic antibodies have been used in immunotherapy of cuncer to
retarget important immune effector cells to tumours, e.g. by cross-linking T-cclls to tumour cells
[35.36], by cross-linking monocytes/macrophages to tumour cells [37] or by recruiting natural
killer cells for rumour eradication [38,39]. A few of these molecules have now entered clinical
trials with some promising results [38,40]. Another approach to augment the cytotoxic effect of
whole antibodies is radio-immuno targeting. In radio-immuno targeting, antibodies arc used as
targeting vehicles to deliver radio isotopes to the tumour site. By using y-emitting radionuclidcs,
this strategy can be used to visualise tumours (radio-immuno-imaging) [41,42] or as radio-
immuno guided surgery [43] and through the use of ^-emitting radionuclidcs, the approach can
be used as therapy (radio-immuno-therapy: RIT) [44,45]. However, although many reports have
emerged that describe the successful use of antibodies for radio-immuno-imaging (diagnosis) of
cancer, successful RIT has been mostly limited to haematological malignancies. Again, this lack
of success is partly due to unfavourable pharmacokinetic properties of antibodies and partly to
tumour type. For review, see [46]. However, by means of antibody engineering and recombinant
DNA technology, the format of antibodies may be optimised for this particular application (see
section 3). To improve on existing protocols for RIT, bispecific antibodies have been used in
two-phase radio immunotherapy (RIT). This alters and improves the uptake of radiolabcl in the
tumour [47]. Although promising results have been obtained in munnc models for solid tumours,
e.g. using bivalent chelates carrying the radio-isotope [48], clinical trials based on this targeting
approach have been scarce [49,50].
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3. Improving anti-cancer antibodies by molecular engineering •
Antibody molecules are proteins consisting of four polypeptide chains: two heavy chains
and two light chains. Every chain is composed of a number of discrete domains having a similar
overall structure consisting of several p sheets forming a barrel-like structure [SI]. Since the
advent of the hybridoma technology [8], monoclonal antibodies of a single specificity could be
generated against a broad range of target antigens. However, this technology still requires
immunisation of rodents with the antigen of interest, which limits the scala of antigens that can
be used to those that are immunogenic and non-toxic ;n v/v». As discussed, the antibodies
obtained arc of murinc origin, which limits their usefulness as tumour targeting vehicles in man
through the induction of a HAMA (human anti mouse antibody) response [27]. These limitations
were partially overcome by the synthesis of chimcric molecules consisting of human Fc regions
fused to murinc variable regions [52-56], which substantially reduces the amount of foreign
sequence in an antibody. Antibodies were even further "humanised" by grafting the antigen-
binding loops (complementarity-determining regions: CDR's) of a murine antibody with known
specificity onto a fully human framework [57]. Fully human antibodies have been obtained
through I'BV-immortalisation |5K| of human B-cclls, although this technique mostly yields
hybridomas of poor stability (reviewed in [59|). Recently, recombinant DNA technology has
permitted the cloning of genes encoding antibodies [60] and the subsequent expression of
functional antibody molecules in E.ro/i [61-63]. Together with the development of the display
of proteins on filamentous bactcriophage, this has led to the development of the phage antibody
display technology [64]. The latter has permitted the isolation of a broad scala of fully human
antibodies to a wide range of antigens. Finally, an even more recent development is the use of
transgenic mice to generate "human" hybridomas. By endowing mice deficient in
immunoglobulin production with large portions of the human immunoglobulin loci,
"conventional" hybridoma technology can be used to produce fully human antibodies [65].
The cloning of the genes encoding (human) antibodies also permits the manipulation of
their format to better fit the envisaged application. As smallest antigen-binding molecules, Fv
and scFv have been described [61-63]. In a scFv, the variable domains of heavy- and light chain
(VH and VI.) are joined by a flexible peptide sequence keeping them together. By shortening this
linker between VH and VL. multimcric molecules are synthesised, i.e. diabodies [66], triabodies
[67] and tetrabodies [68] containing two. three and four binding sites respectively. In addition,
by fusing the VH of antibody A to the VL. of antibody B and Wra versa, bispecific molecules can
be created |66]. Minibodies are composed of two scFv moieties that are fused via a CH3
domain, thereby creating a bivalent antibody format [69]. This format has been shown to be well
suited for cancer imaging purposes using short-lived radio-isotopes, since it combines bivalency
-14-
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with a lower molecular weight compared with whole IgG [70.71 ]. Multivalcnt molecules have
also been designed on the basis of an amphipathic helix, which causes tetramcrisation of scFv
moieties [72] or by linking diabodics together with a flexible linker [73]. For review, see [74|.
The availability of the genes encoding anti-tumour antibodies permits their fusion with a range
of molecules, limited only by the imagination-including en/ymes, toxins, viruses, liposomes,
cationic tails and many more (see section 4).
4. Recombinant antibodies in cancer targeting
The availability of the genes encoding antibodies opens up a range of possibilities to
manipulate their format, size and valency to meet the specific requirements of the application (for
review, see [75]). The development of monoclonal- and recombinant antibodies for cancer
therapy has recently culminated in the FDA approval of the first recombinant antibodies
"Rituxan" (Rituximab), targeting CD20 for the treatment of non-llodgkin's lymphomn 176.77],
"Hcrccptin" (Trastuzumab) for therapy of mctastasised breast cancer [78] and Mylolarg
(Gcntuzumab zogamicin) for the treatment of acute mycloid leukaemia (AMI.). These antibodies
are either chimeric (Rituximab) or humanised (Hcrceptin and Mylotarg) versions of murinc
monoclonal antibodies. Indeed, most of the antibodies which are currently being tested in clinical
trials are humanised antibodies, the technology for which was developed towards the end of the
eighties. However, Mylotarg is the first antibody-targeted chemotherapy for cancer treatment.
This illustrates the time needed to develop a promising research candidate antibody into a clinical
grade product and explains why the novel engineering methods described have not yet been
translated into clinically better products. As discussed, antibody engineering has made it possible
to adapt and optimise the format (i.e. valency, size, charge, flexibility ) of antibodies to meet
the requirements of the application, being cither visualisation or treatment of the tumour. An
illustrative example of the use of a recombinant antibody in the diagnosis of cancer is given by
the development and application of the anti-CEA scFv MFE-23. First, immunisation of mice and
antibody phage display was used to obtain a high affinity scFv fragment against C'KA [79], This
antibody fragment was subsequently engineered to incorporate a C-terminal peptide tag to
directly label the protein with the commonly used """I c radionuclidc [80] for tumour imaging.
Finally, this recombinant MFE-23 scFv was shown to be a valuable tool for radio-immuno
imaging of cancer patients [81 ] and for radio-immuno guided surgery [82]. In addition, fusion
molecules are being made between the scFv and carboxypeptidasc G2 [83,84] to further improve
on antibody-dependent enzyme prodrug therapy (ADEPT). For excellent reviews on the use of
recombinant antibodies in cancer targeting and therapy, see [85,86].
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5. Tumour antigens for antibody-mediated cancer targeting
Although these novel engineering strategies may lead to large improvements in the design
and generation of antibodies for cancer targeting and therapy, the success of the use of these
recombinant antibodies heavily depends on the availability of suitable tumour antigens. Tumour
specific cpitopcs (i.e. proteins, part of proteins, post translational modifications of proteins, lipid
or carbohydrate structures) that distinguish malignant cancer cells from their normal counterparts,
may arise through a number of mechanisms: </e novo expression of an antigen on otherwise
antigen-negative tissue [87], through mutation of the gene coding for the protein [88], through
the expression of different splice variants of a protein [89], through demethylation of the
promotor region of the gene [90] or through aberrant post-translational modification [91]. In
addition, overcxprcssion of normal proteins can give rise to tumour-associated antigens [92,93].
The latter are not tumour specific in the strict sense, but distinguish tumour from normal tissue
by the amount of antigen expressed in the tissue.
Ideally and theoretically, the perfect rumour antigen for antibody-based targeting should
have a number of characteristics. Some of the most important ones are: it should be
homogeneously and strongly expressed on the cell surface in malignant, but not in non-malignant
tissues. In addition, it should not be shed from the cell surface, since this would cause the
forming of unwanted antibody-antigen complexes in the circulation. For antibody-based targeting
of toxins, the antigen should be internalised upon antibody binding. Finally, the protein should
possess a biological role that is indispensable for the survival of the tumour cell, e.g. a growth
factor receptor. Such a phenomenon would cause antigen-loss variants of the rumour not to
survive, thereby augmenting the therapeutic effect of antibody targeting.
5.
The hybridoma technology described earlier (see section 2) has also been extensively used
in the search for new target antigens expressed in cancer. Again, this has involved the
immunization of mice and the subsequent screening of hybridomas for antibodies with the
desired specificity [9-111. In addition, tumour antigens have been identified by the cloning of
T-cells that recognise MHC-I restricted peptides derived from the antigen [94-%]. Phage display
of antibody fragments [64] (sec chapter I of this thesis) has also been used as a tool for the
identification of antigens expressed in tumours. This has involved the selection of phage antibody
repertoires on tumour material and the subsequent screening for antibodies with reactivity
towards the tumour [97,98]. More recently, genetic approaches are increasingly being used to
define genes that are associated with malignant transformation [99-103] or to define distinct
genetic subtypes of a malignancy [104] at the transcriptional level. Although this approach will
-16-
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certainly identify a number of new genes that are useful tumour targets, it does not directly
provide information on the in Win immunogenicity of the expressed protein.
5.2 Tumour a/i/ige/u in ft>/ort»c/a/ctirtino/na
A number of antigens has been described as tumour-antigen in CRC. Among these are
a number of intraccllular proteins functioning as transcription factors (P53, c-myc) or as signal
transduction molecules (Ras), but also cell-surface expressed molecules which could be used as
target for immunotargeting: CHA, Fp-CAM, blood group related antigens (e.g. 1 e(\). l.c(y)....
[105]), several mucin-likc molecules and carbohydrate epitopes (e.g. Tn, sTn) and an antigen
related to the annexin family of proteins (28A32-32K). In addition, several growth factor
receptors have been described to be over expressed in CRC, notably the c-F.RB-2 gene product.
The GA733-2 antigen or F.p-CAM (epithelial cell adhesion molecule) is discussed in more detail,
since part of the work described in this thesis focuses on this protein.
5.5
The Epithelial Cell Adhesion Molecule (Ep-CAM; also known as Epithelial
Glycoprotein-2 (EGP-2), 17-1A antigen or GA733-2 antigen) is a member of the class of tumour-
associated antigens. The antigen is a glycosylated type I transmembrane protein, originally
described as a cluster of reactivity of murine antibodies directed to lung cancer cell lines
[15,106]. The cDNA encoding the antigen was independantly cloned by four different groups
[107-110]. It has homology to nidogen, a basement membrane protein [110] and comprises a
cysteine-rich N-terminal part containing two Epidermal-Growth-Factor (F.GF)-like repeats, a 23
amino acid transmembrane domain and a 26 amino acid C-tcrminal cytoplasmic tail (Fig. I).
The function of the antigen is still only partially known. Ep-CAM has been shown to act as a
homophilic cell adhesion molecule [113,114] and to influence the cadherin-based intercellular
junctions [115,116]. The C-terminal cytoplasmic tail has been shown to regulate the intercellular
adhesion functions and to contain two actinin binding sites [117] via which it is linked to the
actin-based cytoskeleton. However, its role in colorectal carcinogenisis and in particular
metastatic spread of the disease, is somewhat contradictory. The antigen is uprcgulated on
carcinomas of different origin [92,118], but when transfected into antigen negative-cells, it
increases cellular adhesion and decreases their metastatic potential [ 119,120]. On the other hand,
Ep-CAM has been shown to modulate cadherin-based intercellular junctions, causing a
redistribution of E-cadherin and catenins and a downrcgulation of o-catcnin in transfected L-cells
and epithelial cells [115]. This suggests that increased expression of Ep-CAM may lead to a
decrease of the number of cadherin-based junctions, thereby possibly destabilising intercellular
contacts and promoting metastasis. The murine homologue of Ep-CAM has been shown to be
-17-
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expressed by developing thymocytes and thymic dendritic cells, suggesting a role in lympho-
stromal interactions during thymocyte development [121]. For an excellent review of the biology
of the antigen, see Balzar t7 a/. [111].
N-lerm C-term
B
Loop-like configuration
(•Her Schon <•( u/ . 1993)
c • • • •C/5C/1 Cfl C/3
Cell Membrane
1-CiK-likc globes conformation
(alter Iliil/ar <f u/, submitted)
Figure I
•S'/rurfu/r
A: schemutic rcprcscnlalion of the I p-C AM polypcptidc backbone showing the N-terminal signal peptide (sp), the
I (il -like repeats in the extracellular domain (F.GFI and ECJF1I) and transmembrane domain (TM). Oval circlo
containing an "N" indicate sites for N-glycosylation.
B: Conformation of the Hp-t AM molecule. The disulphide bridges formed between cysteine residues in the N
terminal half of the extracellular domain may result in two conformational models for the molecule: a loop-lile
conformation, us postulated by 1112| anda model based on correct folding of the F.GF-like repeaLs. The black arrow
indicates the potential proteolytic cleavage site at the position of Arg80.
Although Ep-CAM has extensively and successfully been used as tumour target (see
section 2), the problems encountered in clinical trials using high affinity antibodies [122] to this
antigen emphasise its limitations as tumour target. Therefore, an urgent need exists for the
identification and validation of new and ideally more specific tumour targets.
-18-
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6. Display technology based antibodies and tumour antigens for cancer
targeting
6. / PAajfe Jisp/ay
The display of foreign molecules on the surface of filamentous bacteriophage was first
described in 1985 by George Smith, who showed that short peptides could be expressed on the
surface of phage by fusion to one of the minor coat proteins 1123). The genes encoding peptides
were genetically fused to the gene of one of the coat proteins of the bacteriophage, which, after
infection into £.<•«//, caused these peptides to be displayed on the tip of the phage. Since one
particular phage only expresses one peptide. genotype and phenotype are linked. This linkage
permits the selection of rare phage carrying a peptide of interest by means of the characteristics
of the peptide and the simultaneous co-selection of the encoding gene. In 1990 it was shown that
the antigen-binding moiety of an antibody (as scFv) could also be expressed in this system |641
while retaining the epitopc specificity of that antibody. The synthesis of phage antibody libraries
was reported in 1991 with the successful selection of antibody specificities from large collections
of randomly paired heavy- and light chain genes f 124]. This then led to the development of large,
non-immunised 'single pot' human phage antibody repertoires [125], from which antibodies with
specificities to a wide range of cpitopes could be obtained, including non-immunogenic and
"self'-antigens [126]. In addition, it provides the genes encoding the selected antibodies for the
subsequent engineering of the format for any envisaged application.
To date, only a limited number of antigens expressed by tumours that arc useful for
tumour targeting have been described. Novel tumour antigens may possibly be identified by
differential selection using large 'single pot' phage antibody repertoires. And since phage display
works outside the immune system [125], these repertoires will also contain antibodies to non-
immunogenic and self-antigens [ 126], thereby avoiding possible restrictions induced by /n v/v«
tolerance mechanisms. Thus, by using a powerful selection procedure for phage library selection
on cell surfaces, it may be possible to identify novel tumour antigens by virtue of the antibodies
that recognise them. Therefore, this technology may be an ideal tool to use in the identification
of possibly novel antigens expressed in CRC.
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7. Aim and outline of this thesis •.., y
The work presented in this thesis focuses on two goals in the tumour immunology /
immunothcrapy of colorectal carcinoma: 1) the selection and development/engineering of fully
human antibodies to known colon tumour antigens and 2) the identification of possibly novel
antigens expressed in CRC.
Chapter one gives a detailed description of the phage antibody display technology and of
its possible applications. It highlights the many possibilities, but also the limitations of the
technique and extensively describes the possible applications.
The tumour antigen lip-CAM has been shown to be a promising target antigen, especially
for the visualisation of solid tumours [41,127], but also for treatment of minimal residual disease
[20,21]. Since it is known that the affinity of an antibody (and especially the off-rate) is an
important parameter for efficient tumour targeting, we first conducted a systematic analysis of
the kinetics of binding of several well-characterised murine anti-Ep-CAM antibodies. In chapter
two we then aimed at the isolation of the V-gcnes of the highest affinity antibody to obtain
building blocks for the rational design and engineering of antibodies.
Using antibody engineering, the format of antibodies may be adapted and optimised for
almost any given application. It has been shown that the apparent affinity of an antibody may be
increased through avidity, i.e. multiple binding sites being present in the same molecule. To
further increase the affinity of the anti-lip-CAM antibody through avidity, multivalent forms of
this antibody were designed and synthesised. Chapter three describes the design and applications
of these multivalent molecules for cancer targeting.
The use of murine antibodies in humans is limited by the induction of an immune
response to the foreign molecule, called HAMA response [27]. Therefore, to improve the
applicability of the murine anti-Ep-CAM antibody described in chapter two for tumour targeting,
we aimed at the humanisation of this antibody. Chapter four reports this humanisation through
a phage display procedure termed "guided selection".
The influence of the exact epitope specificity of anti-Ep-CAM antibodies on their tumour
targeting properties is not known. Thus, a human antibody recognising an epitope on the antigen
different from that of the well-characterised murine hybridomas may offer advantages in tumour
targeting. In chapter six, therefore, in parallel to the studies described in chapters two and four,
we aimed at the isolation of such antibodies by performing selections on recombinant, purified
Ep-CAM using a large, human, non-immunised phage antibody repertoire. To obtain an antibody
format that is well-suited for the imaging of solid tumours, we additionally engineered and re-
formatted the genes of the selected antibody into the minibody format [69].
When the phage antibody display technology is used to search for antigenic (and possibly
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novel) antigens on CRC, the target antigen is unknown and phage antibody selections have to be
performed on complex mixtures of antigens (e.g. cell surfaces or tissue sections of patient
material). To determine whether phage antibody selections on these complex antigen sources arc
feasible and to compare their relative efficiency in the selection of binding phage. we have set
up model systems to study these selections. These models and the conclusions that can be drawn
from them arc described in chapter six.
Large, "non-immunised" phage antibody repertoires [125,128*130] WO BOtbiMtd by « y
tolerance mechanisms of the m Wvo immune system and arc therefore suitable for the selection
of anti-tumour antibodies, since the latter may consist of (mutated) "self-antigens. In chapter
seven, we aimed at the identification of novel cell surface-expressed antigens in CRC. To this
aim, a large, non-immunised human phage antibody repertoire was used to select antibodies that
recognise CRC-associated antigens.
C)n the other hand, the /'« Ww> immunogenicity of a number of tumour antigens has clearly
been demonstrated by serum IgG tilers to that antigen 1131-13-4J. Thus, lymphoid tissue of cancer
patients may also be a valuable source of V-gencs encoding anti tumour antibodies. In addition,
the identification of these antigens causing an immune response in patients will lead to a better
understanding of this response and could eventually provide handles for vaccine development.
Therefore, we synthesiscd phage antibody repertoires made from different. CRC patient-derived
lymhoid tissues and compared these repertoires with a large, non-immunised repertoire lor the
selection of antibodies reactive with patient tumours.
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Abstract
In recent years, the use of </up/oy vectors and HI Wfro selection technologies has
transformed the way in which we generate ligands, such as antibodies and peptides, for a given
target. Using this technology, we are now able to design repertoires of ligands from scratch and
use the power of phagc selection to select those ligands having the desired (biological) properties.
With phagc display, tailor-made antibodies may be synthesized and selected to retain the desired
affinity of binding and specificity for /« w/ro and in v/vo diagnosis, or for immunotherapy of
human disease. This review addresses recent progress in the construction of, and selection from
phagc antibody libraries, together with novel approaches for screening phage antibodies. As the
quality of large naive and synthetic antibody repertoires improves and libraries becomes more
generally available, new and exciting applications arc pioneered such as the identification of
novel antigens using differential selection and the generation of receptor a(nta)gonists.
Combining the design and generation of millions to billions of different ligands, together with
phagc display for the isolation of binding ligands and with functional assays for identifying (and
possibly selecting) bio-active ligands, will open even more challenging applications of this
inspiring technology, and provide a powerful tool for drug and target discovery well into the next
decade.
1. Introduction
The generation of new drugs has long involved the search amongst hundreds of thousands
of components using well defined iw vi/ra screening tests, the output of which was chosen to
mimic as closely as possible the desired in vivo activity of the new drug. Now new library
methodologies offer many alternative and at least as powerful routes, by combining the creation
of billions of components with a fast screening or selection procedure to identify the most
interesting lead candidates. One of the most widely used library methodologies is based on the
use of filamentous phage [ 1 ], a bacteriophage that lives on fw/ienc/iia c«/i. Phage-display has
proven to be a very powerful technique to display libraries containing millions or even billions
of different peptides or proteins. One of the most successful applications of phage display has
been the isolation of monoclonal antibodies using large phage antibody libraries [2]. Indeed, in
the last few years, very efficient techniques have been developed to design and build large
libraries of antibody fragments, and ingenious selection procedures have been established to
derive antibodies with the desired characteristics. Here, we review the progress made in this
rapidly developing field, and discuss a broad range of applications, including the use of large
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phage antibody libraries to discover novel targets on cells and methods tor selection of
biologically active ligands. Finally, we address the potential of combining phugc display with
complementary technologies, to increase the scope and range of applications of this technology.
2. Antibody Phage display
The power of the phage display system is illustrated in Fig. I. DNA encoding millions
o f variants o f a certain ligands (e.g. peptides. proteins or fragments thereof) is bnlch-cloned into
the phagc genome as a fusion to the gene encoding one of the phage coat proteins (pill. pVI or
pVW). Upon expression of the ligands. the coat protein fusion will be incorporated into new
phagc particles that are assembled in the bacterium. Expression of the fusion product and its
subsequent incorporation into the mature phagc coat results in the ligand being presented on the
phagc surface, while its genetic material resides within the phagc particle. This linkage between
ligand genotype and phenotype allows the enrichment o f antigen-specific phugc. e g using
selection on immobilised antigen. Phage that display a relevant ligund will be retained on 11
surface coated with antigen, while non-adherent phages will be washed away. Hound phuges can
be recovered from the surface, reinfected into bacteria and re-grown for further enrichment, and
eventually for analysis of binding.
The success of ligand phage display
hinges on the combination of this
display and enrichment method, with
| Display variants on the creation of large combinatorial
repertoires on phagc.
iilii
DNA manipulation
to create library of variants
(e.g. peptkJes. proteins)
Analyse
Amplify
Figuri' I
Waste
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DNA encoding lor million* of variants of
certain ligands (e.g. pcplidcs. proteins or
fragments thereof) is hatch-cloned into the
phagc genome as part of one of the phagc
coat proteins (pill. pVI or pVIII). Large
libraries containing millions of different
ligands can be obtained by force cloning
in £\c»/i. From these repertoires phage
carrying specific binding ligands can be
isolated by a scries of recursive cycles of
selection on antigen, each of which involve*
binding, washing, elution and amplification.
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2.2
By far the most popular phage that has been used for display is the filamentous
bactcriophage. The non-lytic filamentous phage fd or M13 infect strains off. co// containing the
F conjugative plasmid. Phage particles attach to the tip of the F pilus that is encoded by genes
on this plasmid, and the phage genome, a circular single-stranded DNA molecule, is translocated
into the cytoplasm. The genome is replicated involving both phage and host derived proteins, and
packaged by the infected cell into a rod-shaped particle, which is released into the media. All
virion proteins will undergo transport to the cell periplasm prior to assembly and extrusion.
Several filamentous phage coat proteins have been used for display of ligands (for review, see
an excellent issue of Methods in Enzymology [3] and a book on phage biology and display
applications [4]). By far the most extensively used is the pill phage protein, which is involved
in bacterial infection and is present in three to five copies per phage particle.
2.J
Antibodies were the first proteins to be displayed successfully on the surface of phage [5].
This was achieved by fusing the coding sequence of the antibody variable (V) regions encoding
a single-chain Fv (scKv) fragment to the amino terminus of the phage minor coat protein pill. The
antibody was displayed using a phage vector, based on phage fd-tet [6] and its gene III as fusion
partner. In this vector, the genes encoding an antibody scFv fragment were cloned in frame with
gene III and downstream of the gene III signal sequence, which normally directs the adsorption
protein to the periplasm. Here, the VH and VL domains will fold correctly, both stabilised by
a intramolecular disulphide-bridge, and pair to form a functional scFv [7, 8]. Initially, phage
vectors that carry all the genetic information required for the phage life cycle were used [5, 9].
Now, phagemids, have become a more popular type of vector for display. Phagemids are small
plasmid vectors that carry gene III with appropriate cloning sites and a phage packaging signal
[10-12]. In phagemids, the scFv may be fused at the N-terminus of the mature gene III protein
[5. 11 ] or at the N-terminus of a truncated pill lacking the first two N-terminal domains [10, 13].
Phagemids have high transformation efficiencies and are therefore ideally suited for generating
very large repertoires, as well as providing a format for direct secretion of the unfused antibody
fragment, without subcloning [ I I ] .
Many phagemids utilize the /a<Z promoter to drive expression of the antibody-pill fusion [11,
13-15). For display of the antibody-pill product, either the catabolic reprcssor (glucose) of the
/«t'Z promoter is removed or depleted, leading to expression of sufficient fusion product to derive
'monovalcnt' phage particles. Whenever expression-mediated toxicity is an issue (which is the
case for some, mostly hybridoma-derived, antibody fragments [16]), it may be required to
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regulate the expression more tightly. The use of a /ucZ promoter with an additional
transcnptional terminator [ 17] or of the phage shock promoter (psp) (18] may allow display of
relatively toxic products and reduce expression-mediated library bias.
The phagemid DNA encoding the antibody-pill fusion will be preferentially packaged into phage
particles using a helper phage such as MI3KO7 or VCS-M13. which supplies all structural
proteins. Since helper phage also encode wild-type pill, typically over 90% of rescued phage
display no antibody at all and the vast majority of the rescued phage particles that do display the
fusion product will only contain a single copy. Ideally, more efficient, even multivalent display
would therefore be preferable when selecting very large antibody libraries to guarantee selection
with a limited number of phage particles per clone. Monovalent display, on the other hand, may
be essential when selecting antibodies of higher affinity. Therefore the use of induciblc
promoters (19] or the use of a helper phage with gene III deleted [20. 21], which may be
produced efficiently in cells containing gill under control of psp | IK], may in the future allow the
modulation of the valency of displayed antibodies.
2.¥ Formats /or anfi/Wi' d7.vp/av
Effective display formats for antibodies arc scFv [5, 9, 22], Fab fragments [10, II. 13,
23], Fv's with an engineered intermolecular disulphide bond to stabilize the V ,,-V, pair ('dsFv's:
[24]), and diabody fragments [25, 26]. The smaller si/c of the scFv format makes these libraries
genetically more stable than Fab libraries. However, many scFVs can form higher molecular
weight species including dimers and trimers, which can complicate selection and characterisation
(see [25]). Fab fragments, on the other hand, lack this tendency to dimcrisc. which facilitates for
example assays to screen the kinetics of binding (see 5.2). To display Fab fragments on phage,
either the light or heavy (Fd) chain is fused v/o its C-terminus to pill and the partner chain is
expressed unfused and secreted into the periplasmic space, where it can associate to form an
intact Fab fragment, as illustrated in Fig. 2. A similar method is used to express bispecifie
diabodies [26]. Such bispecifie dimers of scFv's were displayed on phage by expression from a
bicistronic cassette containing two VH-VL fusion products, one of which is also fused to gill.
The advantage of the diabody format is that either bivalent antibodies may be isolated, a feature
that could be used for 'functional' screening (see 5.4) or that large panels of bispecific molecules
may be generated, avoiding extensive recloning after selection [26J.
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P/jagem/d vector pCESf
P l a c Z •-• I | i / ' . . / »'" ... f ^ i Fab fragments may
be displayed on
phagc using
phagemids (pCF.SI
is shown as an
example) that
express the heavy
chain (Fd) fragment
containing the
variable domain and
the first constant
domain fused to a
coat protein gene,
gene III, of
filamentous phage
fd. in combination
with separate expression of the partner (light) chain. Bacteria harbouring this phagemid vector arc superinfectcd
with helper phugc to drive production of phagc particles carrying the Fab fragment, asa fusion product with the
phagc coat protein pill, on the surface, and the DNA encoding the immunoglobulins inside the particle
Abbreviations : rbs, ribosome binding site; AMPr. ampicillingresistance, H^and tag. Histidinc stretch and peptide
tag respectively, for purification and detection purposes; amber codon (TAG) that allows expression of solubt
antibody fragment in non-suppressor strains; gill, gene III for phagc fd; S, signal sequence directing the cxpressd
protein to the bacterial pcriplasm.
3. Antibody libraries
One of the most successful applications of phagc display has been the isolation of monoclonal
antibodies from large phage antibody libraries (Fig. 3). We will discuss the three types of such
phage libraries, immune, naive and synthetic antibody libraries.
3. / <4/if»/w«/v ///varies yro/n imffiun/:«/ an/ma/.v or /mmu/te </onors
Repertoires may be created from the IgG genes of spleen B-cclls of mice immunised with
antigen |9 | or from immune donors. An immune phage antibody repertoire will be enriched in
antigen-specific antibodies, some of which will also have been affinity matured by the immune
system [9, 27], This method gives access to more and sometimes antibodies with higher affinity
than obtained from hybridomas, as was reported for an anti-CEA antibody [28]. Other advantages
of this procedure are that, compared to the hybridoma technology, many more antibodies may
be accessed from the material of a single immunised donor, and selected antibodies can be
rapidly derived or further manipulated.
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of Immune donors
VH (or VHCH1) VL (of VLCL)
uene Ass«fflorV ano*
cloning of Stepwfs* ctonJng
fnfroduc* /nto E.colt
ImmuM, NarVa
or Synthetic
Antibody Library
of Human Fab
fragmcnta
Figure 3
C'cMivrnft-rion <>/' u Auimin /
/i/>rary </i/>/</m/ on />/ii/y<'
cDNA fragments encoding for the
heavy and the light variable regions
of antibodies (VJJ . Vj ) are amplified
from human B-eells b> IH'R and
assembled. The assembled genes arc
inserted in a phagcmid vector in
frame \s ith the gene encoding the coat
protein pill. I lie vector is introduced
into /-.". c-<»/i. After rescue with helper
phage, the random combinatorial
library of antibodies is displayed on
phage, and selection performed.
The construction of immune libraries
from a variety of species has been
reported, including mouse |9, 2K. 29|,
human [30, 31 ], chicken [32, 33], rabbit [34], and camel [35]. Active immunization is. however,
not always possible due to ethical constraints, neither always effective due to tolerance
mechanisms towards or toxieity of the antigen involved. Tolerance mechanisms may be put to
use in some cases, for example to deplete antibodies to certain antigens ;>i v/w before
immunization and selection of the new phage library on antigen iw vi/r« [31). Provided suitable
sources of antibody producing B-cells or plasma cells arc accessible, immune phage libraries arc
useful in analyzing natural humoral responses, for example in patients with autoimmune disease
[36-38], viral infection (for review see [39]) or neoplastic diseases [31,40,41] (R.C.R. f/a/., in
preparation), or to study /« v/7ro immunisation procedures [42]. In addition, when studying
specific (e.g. mucosal) humoral responses, mRNA coding for specific Ig isotypes (e.g. IgA) may
be selectively used for library synthesis [43].
From immune libraries, antibodies can be obtained only against the set of antigens to
which an immune response was induced, which necessitates repeated immunization and library
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construction. Ideally, universal, antigen-unbiased libraries would be available, from which very
high affinity antibodies to any chosen antigen may directly be selected, independent of the
immune history. At present, several of such 'single-pot' libraries have been described (reviewed
in [2, 44]), which are particularly useful for the selection of human antibodies since these are
very difficult to establish with more traditional techniques. We discriminate 'naive' and
'synthetic' antibody libraries, depending on the source of immunoglobulin genes. For most
applications, the availability of large pre-made collections of non-immune repertoires has thus
superseded the use of immune repertoires.
The primary (unsclected) antibody repertoire contains a large array of IgM antibodies thai
recognize a variety of antigens. This array can be cloned as a 'naive' repertoire of rearranged
genes, by harvesting the V-genes from the IgM mRNA of B-cells of unimmunized human
donors, isolated from peripheral blood lymphocytes [22], spleen (de Haard, H.R.H., rf a/,
unpublished), bone marrow or tonsil B-cclls [45], or from similar animal sources [46]. In theory,
the use of possibly heavily mutated and antigen-biased IgG V-genes should be avoided.
However, even when using random priming to include mRNA of all Ig isotypes, a repertoire with
px<a>ll»«nt,nerformaru-j« haf hften svnJhe<jiz«\f4^1 libraries nniilrl al«r> Jv* madi" ftnm fhp,rw««ihjv
more "naive" pool of IgD mRNA.
The V-gencs arc amplified from the cDNA using family-based oligonucleotides [47], and heavy
and light chains arc randomly combined and cloned to encode a combinatotial library of scFv or
Fab antibody fragments. This procedure generates access to antibodies that have not yet
encountered antigen, although the frequency of those genuine 'germline antibodies' will depend
heavily on the source of B-cells [48], A single 'naive' library, if sufficiently large and diverse,
can indeed be used to generate antibodies for a large panel of antigens, including self, non-
immunogenic and relatively toxic antigens [20,22,45].
The affinity of antibodies selected from a naive library is proportional to the size of the library,
ranging from 10*"'' M ' for a small library, with 3 x 10^  clones [20. 22], to l(f' '° Ivt' for a very
largo repertoire with 10 clones made by brute force cloning [45], a finding which is in line with
theoretical considerations [49]. Other large naive human scFv libraries (6.7 x 10 clones) (J.D.
Marks, unpublished) and a very large Fab library (4.1 x 10 clones) (de Haard, H.R.H., e/ a/.,
unpublished), made via an efficient 2-step restriction fragment cloning procedure, also seem to
perform very well.
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J.?.2 SvnfAfftr aitft/xx/v ///varies rs
In the second type o f ' s ing le pot' repertoires, the antibodies are built artificially, by»'» Wrn>
assembly o f V'-gene s e g m e n t s and D J segments . V - g e n e s m a y b e assembled by introducing a
predetermined level o f randomization o f CT)R regions (and poss ibly a l so o f bordering
framework-regions) into germ I m e V - g c n e s e g m e n t s ( 5 0 ) . or rearranged V - g e n c s [511. The
regions and degree o f diversity may be chosen to correspond to areas o f highest natural diversity
o f the antibody repertoire. Most natural structural and sequence diversity is found in the loop
most central to the antigen c o m b i n i n g site, the CT)R3 o f the heavy chain, whi le the l ive other
C'DRs have limited variation [52 ] . This has therefore been the target for introduction o f diversity
in the first synthetic libraries.
In tho first synthetic antibody library constructed according to these principles [ 5 0 ] , a set o f 4 9
human V H - s e g m e n t s w a s as sembled via PCR with a short l l ) R 3 region (encoding either 5 or
8 amino acids) and a J-region, and c loned for display us a scFv with a luimiin lumbdii light chain.
From this repertoire many antibodies to haptens and one against a protein antigen, were isolated
[ 5 0 ] . Subsequent ly , the C D R 3 - r c g i o n s were enlarged (ranging from 4 to 12 residues) to supply
more length diversity in this loop [53]. Other original designs have used only one (cloned)
rearranged V-gcne pair with a single-size randomized CDR3 region in the heavy chain [51 ], or
have used complete randomization of all 3 CDR-loops in one antibody V-domain |54, 55|. Some
of these libraries have yielded antibodies against many different antigens, including haptens (50,
51]. proteins [53], and cell-surface markers [56], but their affinities are typically in the
micromolar range.
Antibodies with nanomolar affinity were eventually isolated from a synthetic antibody library
which combined a novel synthesis method to construct combinatorial libraries, m vivo
recombination, with an effort to maximally mimic natural antibody diversity (i.e. to optimally
use 'sequence space'). In the largest synthetic library made to date [57], the 49 human heavy
chain segments that were used earlier [50] were combined with a collection of 47 human kappa
and lambda light chain segments with partially randomised CDR3 regions. The heavy and light
chain V-gene repertoires were combined on a phage vector in bacteria using the /or-Crc site-
specific recombination system to create a large 6.5 x 10 clone repertoire of Fab fragments
displayed on phage. The library yielded antibodies with in some cases nanomolar affinity against
numerous different antigens [36, 57]. This phage library proved to be difficult to re-propagate
without significant loss of diversity. However, a more stable, large 1.2 x 10 clone scFv
phagemid library made by standard cloning methods and using the same synthetic V-gcncs was
recently shown to be equally effective (Heather Griffin, personal communication).
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It would seem desirable to synthesize even larger collections of antibodies. However, there are
physical limitations to the enrichment that may be achieved in the selection procedure, which
limits the size of accessible genetic diversity. With enrichment factors for a single selection
round never reported to be higher than 10 per round and a typical phage titre of 10 clones
eluted in the first, critical, round of selection, the total genetic diversity accessed by the selection
procedure would be at the most 10 clones. If selection conditions are so stringent that very few
phage particles arc recovered in the first round (typical for, for example, panning on cells
followed by sorting via flow cytometry [56]), chances arc that different subsets of antibodies will
be selected every time the selection is repeated. It therefore appears that it becomes more crucial
to optimise the quality of the displayed antibodies (with regard to display and expression level),
and the selection procedure itself. This is where synthetic antibody libraries will have a major
advantage over naive libraries using naturally rearranged V-genes. For example: the choice of
V-gcnc segments for the construction of synthetic antibody repertoires may be guided by factors
that will increase the overall performance of the library, such as good expression and folding and
low toxicity in E.co//; this will increase the functional library size. Large differences in V-gene
usage both /w v/w and in phage repertoires [57] also suggest that some scaffolds may be better
suited to form antigen-binders than others. Such a promising second generation synthetic
anlibody library is being built by MorphSys, using V-gene segments based on 'master'
frameworks representing each of the Kabat subclasses, incorporating in principle only well
expressed scaffolds. To overcome the problem of introducing stop-codons within the area of
diversity, which would also decrease the functional library size, they assembled V-genes with
oligonuceotides made from trinucleotides instead of from single bases [58] (MorhoSys,
unpublished).
It is likely that further thoughtful design will continue to improve the performance of these
libraries. For example, pre-selection of amplified and displayed synthetic V-domains on Ig-
domain binding proteins (protein A for V,,, protein L for V^etc. [59]) would remove clones with
stop codons and frameshifts, as well as select for functional expression (Tomlinson,
unpublished). Finally, an exciting idea is to combine the complementary diversity of the primary
(germline) and secundary (somatic hypermutation) antibody libraries in one single phage
antibody library. This may be feasible, since only a few residues are known to be hotspots for the
hypennutation machinery. These developments may well eventually establish a 'super' library,
which may contain antibodies of a superior affinity than what nature-made B-cells have on offer
[44, M)].
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Although the antibodies selected from many of the immune and even the largo single pot
repertoires may be extremely useful for the researcher for ELISA. Western blot,
immunofluorescencc etc.. their affinity is often not sufficiently high for therapeutic applications
as immunotherapy. viral neutralization, or for use in sensitive diagnosis. Sufficient gain in
apparent affinity' may be achieved by simply constructing multivalcnt molecules, as reviewed in
[61. 62]; however there will be situations in which m u/ro affinity maturation of the selected
antibodies is required.
The process essentially involves three steps. (I) introduction of diversity in the V-gcnes of the
anibody (or antibodies) chosen to mature, creating a 'secondary' library. (2) selection of the
higher affinity from the low affinity variants, and (3) screening to allow discrimination of
antibody variants with differences in affinity or kinetics of binding. Diversity in the antibody
genes may be introduced using a variety of methods, either more or less random using imitator
strains [63. 64]. error-prone Pl'R [65]. chain shuffling |<), 66). and ONA shuffling |67|, or
directed to defined residues or regions of the V-gencs using codon based inutagcnesis.
oligonucleotidc-directed mutagencsis and PC'R techniques |5K, 68-71]. The non-direcled
approaches have been used to mature some antibodies with relatively low starting affinity |63,
66, 70, 72]. Once antibodies with nanomolar affinities arc used as starling leads, it appears that
CDR-directed approaches are more successful. For example, residues that modulate affinity may
be randomised, ideally 4-6 residues at a time to allow efficient sampling of the sequence space.
Such residues that contact the antigen or influence other residues contacting the antigen may be
defined experimentally by chain shuffling [16], by alaninc-scanning of the CDR-rcgions [73],
by parsimonious mutagenesis [74,75], or by modeling [73]. Targeting C'DRs in parallel has been
carried out [71 ], but additive effects of mutants are frequently unpredictable. The most successful
approaches report improvements of affinity to below 100 pM, by saturation mutagencsis and
affinity selection of CDR3 of heavy and light chain which form the centre of the antibody
combining site [70, 71]. A detailed study of the sequence diversity of human antibodies created
in the primary and secondary immune responses also suggests other key residues for targeting
in affinity maturation studies [60, 76]. Several chapters in [77] give detailed protocols for
creating secondary phage libraries; the selection and screening for clones with affinity differences
is discussed below.
3.4. fievom/p/iage (/up/oy
Before we discuss selection and screening procedures in detail, we report on a very recent
development that may well allow even larger repertoires of biomolecules to be made, as well as
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facilitate antibody affinity maturation. A display method has been described in which proteins
are entirely 1/1 vi/r« translated by, displayed- and selected on ribosomes [78, 79]. The polysome
complex containing the encoding mRNA and translated amino acid sequence are utilized for
selection with a ligand. The mRNA from selected polysomes is converted into cDNA and used
for the next transcription, translation and selection round. Antibody fragments, and in particular
scFv's, may form functional molecules in several cell-free translation systems ([80] and ref. in
[79]). This approach has therefore recently been used for the display [79, 81 ] and evolution of
a scFv antibody /n W/ro [79]. This system has the major advantage that the diversity of any
repertoire of proteins will not be limited by the host cell/phage life cycle. The size of repertoire
that can be sampled is potentially unlimited, and its generation would be very fast and greatly
simplified. It remains to be seen whether these m vi'/w methods will compete with the rather
robust /« WVH display technologies, but the fact that they are more amenable to automation will
definitely favour a swift development.
4. Phage antibody selection procedures and applications
4. /. D/'verv/Yv in .ve/ecfio/»
Phage antibody selections involve the sequential enrichment of specific binding phage
from a large excess of non-binding clones. This is achieved by multiple rounds of phage binding
to the target, washing to remove non-specific phage and elution to retrieve specific binding phage
(a schematic outline is depicted in Fig. I). Any method that separates clones that bind from those
that do not, can be used as a selection method, and as such, many different selection methods
have been used. In Fig. 4, top panel, the most popular procedures are listed. These include
biopanning on immobilised antigen coated onto plastic plates, columns or BIAcore sensorchips
[9, 22, 57, 82], selection using biotinylated antigen [65], panning on fixed prokayotic cells [83]
and on mammalian cells [31. 56], subrractive selection using sorting procedures [56], enrichment
on tissue sections or pieces of tissue [84], and, in principle selections using living animals, as was
reported for peptide phage libraires [85]. The selection methods described in Fig. 4, panel A-F,
have been extensively described and were reviewed elsewhere [2,44, 77].
Phage antibodies bound to antigen can be eluted in different ways: with (one step or gradients
of) acidic solutions such as HC1 or glycine buffers [86, 87], with basic solutions like
tricthyluminc [22], with DTT when biotin was linked to antigen by a disulphidc bridge [20], by
enzymatic cleavage of a protease site engineered between the antibody and gene HI [88], or by
competition with excess antigen [9] or antibodies to the antigen [89].
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Phagc background binding to the matrix or antigen itself inevitably necessitates the
repetition of the selection procedure. Background problems may diminish when repeated
selections of phagc libraries are carried out without amplification step, by reusing the cluted and
neutralized polyclonal phage ligands directly for selection, as reported for protca.se inhibitors
[90]. Some recent evidence indicates that anti-haptcn antibodies may also by isolated by 3
rounds of panning without re-amplification, using a very large naive Fab library (de Haard,
H.R.H., cf a/., unpublished). If in i7v« re-amplification steps could be by-passed, it might be
possible to fully automate the isolation of antibody fragments from very large libraries. During
affinity maturation studies direct selection without re-amplification may speed up the procedure
and reduce selection of aberrant clones with a growth but no affinity advantage [16,65].
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4.2 //i/ec/io/i-Aavec/«e/ec/ion
Alternative selection methods have been described that aim at the co-selection of
antibodies and their cognate antigens. In the 'selectively infective phage' (SIP) method, an
antibody library is made using non-infective phage particles, by deleting part of the gene III
protein. Infection will be restored by binding a fusion protein consisting of the cognate antigen
and the two first amino terminal domains of gene HI which are responsible for pilus binding (Fig.
5) [91-93], reviewed in [94]. The fusion product may be supplied ;w v//ro; infection of the
antibody-displaying phage will be mediated in a small concentration window. In the alternative,
i/i vivo, system, both antibody and antigen are encoded on the same phage genome. Both affinity
and folding properties have been shown to influence the selection of antibodies with the SIP
methodology [95]. Finally, in a recently reported procedure, bacteria expressing epitopes within
the context of the F pilus were proven to be infected by phage only when they displayed an
antibody recognising the epitopc |96]. It still remains to be seen whether these selection systems
will be more efficient than standard procedures in isolating antibodies from very large naive or
synthetic antibody libraries. A better understanding of the infection process itself [97] may
eventually lead to more generic application of these procedures in isolating interacting protein-
ligund pairs.
4.J Se/«7/on./or a/
In a similar fashion to what happens ;>i \7w during B-cell selection, phage antibodies with
higher affinity may be enriched during successive rounds of selection by decreasing the
concentration of antigen used for selection. The selection may be chosen to favour affinity or
kinetic parameters such as off-rate; this hinges on the use of limited and decreasing amounts of
antigen and on performing the selections in solution rather than by avidity-prone panning on
coated antigen [65]. When selecting from a secondary phage library (see section 3.3), the antigen
concentration is typically reduced below the Kj of the parent clone to allow preferential selection
of higher affinity mutants [65]. In one of the most thorough studies on antibody affinity
maturation carried out to date [73], it was necessary to empirically determine the antigen
concentration to be used for selection, as well as the elution condition for phage retrieval, using
BIAcorc [98]. The SIP procedure may also be used to enrich antibodies for certain kinetic
parameters [95, 99].
4.4 SWfr/i'on on <wn/>/t'.v
Most successes with selections have been reported using purified antigen. Selections on
impure antigens are significantly more difficult, due to the problem of limited amount of target
antigen present in the mixture, and of enrichment of phage antibodies specific for non-relevant
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antigens. Examples of complex, "difficult" antigens arc those that cannot easily be purified from
contaminants with similar properties, or cell surface receptors that are only functionally retained
in lipid bilayers. Depletion and or subtraction methods, competitive elution with an antibody or
the antigen itself (89). or selection by alternating between different sources of antigen | IOO| may
be used. Theoretical, as well as experimental studies may help to understand the extent to which
different parameters govern the outcome of subtractivc selection processes [101-103], The
enrichment of phage antibodies specific for the target antigen is also influenced by the
background binding of non-specific phage particles, which necessitates reiteration of the
selection procedure. Background problems may diminish when repeated selections of phage
libraries are carried out without amplification step, by reusing the cluted and neutralized
polyclonal phage ligands directly for selection, as reported for protease inhibitors |*X)|. During
affinity maturation studies, direct selection without re-amplification may speed up the procedure
and reduce selection of abberant clones with growth advantages |65|. Some recent evidence
indicates that anti-haptcn antibodies may also by isolated by 3 rounds of panning without re-
amplification, using a very large naive Fab library (dc Haard, H.R.II, «7 <//, unpublished). If m
W»» re-amplification steps could be by-passed, it might be possible to fully automate the isolation
of antibody fragments from very large libraries. Background binding of phage has also been a
major obstacle to carry out selection on antigens blotted onto nitrocellulose or other membranes.
Such a procedure could be applied to batch-select phage antibodies to very large collections of
(denatured) antigens, and possibly to isolate antibodies to small quantities of partially purified
proteins. Using combinations of detergents, we have recently succeeded in obtaining a 10-50-fold
enrichment on Western blots using a low affinity phage antibody (10' M ') to the UIA protein
(Fig. 4H: R.M.H. f/ u/., in preparation).
4.5. Se/ecf/o/i on ce//s
A special case form the antigens present on cell surfaces. Direct panning on cell surfaces
carrying the antigen may be carried out on adherent cells grown in monolaycrs, or on intact cells
in suspension (Fig. 4E) [31, 104, 105]. This may fortuitously select for antigen-specific phage
antibodies, in particular when using immune libraries in which the frequency of irrelevant phage
antibodies will be lower [31, 104]. Depiction and/or subtraction methods, cell sorting (Fig. 4F)
using flow cytometry [56] or magnetic bead systems [106], competitive elution with an antigen-
specific ligand or antibody, or selection by alternating between different cell types all carrying
the antigen, are possible, at least in theory. However, it should be noted that in many cases,
antigens will be present at very low densities on the cell surface, and antigen concentrations
during selections will reach values much lower than the K^ j of any antibody in the library. Even
when antigen concentration is sufficient for antibody binding and retrieval, antigen inaccessibility
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through steric hindrance caused by the presence of other proteins or glycosylation may prevent
the selection of antibodies specific for the target antigen. This may be illustrated by an example
of a naive library selection [45] that we carried out on cell transfectants, which expressed
relatively high levels (200.000 copies per cell) of one of two very different membrane antigens.
Strikingly different results were obtained, depending on the structure and nature of the
transmembrane protein. Selections on CHO cells one of the G-protein coupled seven-helix
transmembrane receptors for somatostatin were unsuccessful, despite extensive pre-absorption
of phagc with receptor-negative cells. On the other hand, direct panning (without depiction) on
cells carrying the transmembrane glycoproteins CD36 at similar surface density, generated a large
collection of antigen-specific antibodies to a selection-dominant cpitope on the antigen
(Lutgcrink, H.R.H., e/ a/., in preparation). It is therefore difficult to assess the value of
subtractivc methods, i.e. cell sorting by flow cytometry [56] or magnetic activated cell separation
[ l()6|, without a direct comparison with cell panning. Nevertheless, for most applications, it is
likely that more refined subtraction methods will be required to home in on antigen-specific
phage antibodies.
The feasibility of selecting antibodies to "difficult" complex antigens and in particular to cell
surface molecules would expand the utility of phage antibody libraries tremendously. However,
for such antigens the selection conditions including prc-treatment of the samples, incubation
conditions, washing procedure and phage retrieval, need to be established empirically. We have
developed a model that can compare and determine the relative efficacies of the various
enrichment procedures on complex sources of antigen. Phage carrying a scFv specific for the
tumor-associated antigen epithelial glycoprotein-2 (EGP-2) were mixed with an excess of
irrelevant phage and the enrichment factor and recovery of specific phage were determined after
a single round of selection. As antigen source we used a tumour cell line, a tissue cryosection of
primary colon carcinoma and (subcutaneous) m Wvo grown solid tumours in mice (Fig. 4E, G
and I). Our results, summarised in Table 1, show that there are major differences with regards
to selection efficacy; however, antibody-displaying phage were enriched in all but one selection
method.
The efficacy of the procedure depends on the antigen amount and concentration (Table 1;
estimated to decline from top to bottom) and on antigen accessibility. The most efficient
procedure, recovery of phage using panning on cells in suspension (2-5% recovery of the input
phage), reaches an enrichment factor similar to what has been reported for purified antigens
[102]. For the»'« mw selection, antibody-displaying phage are enriched over non-binding phage
only when phage arc directly injected into the tumour interstitium. but not when injected
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intravenously. Efficient I'/I im» selection may thus be suited only tor antigens that arc in direct
contact with the blood stream i.e. endothclial cell antigens {IO7|. Such model selections help in
defining the optimal experimental parameters tor selections on complex antigens.
Table 1
Enrichment factors and phagc recovery after a single round of selection on different complex
antigens '
Antigen source
Colon cancer
cell line
Tissue
cryoscction
/n Wvo grown
rumour
//» Wvo grown
tumour
Mode of selection
Panning on cells in sus-
pension
Panning on glass slide-
mounted cryoscctions
Injection of phagc into
tumour mtcrstilium
Injection of phagc into the
tail vein
Enrichment
10,000
80
10
none
Recovery of specific
phn|>f ("a of input)
2-5
0.02
0.005
0.001
' Phage mixtures of an excess of control phage over specific (anti F.GP-2) phage were selected on a number <1
different antigen sources. Since antigen-specific and control phagc confer a different antibiotic resistance to tit
bacterial host upon infection (ampicillin (AMP) and tetracyclin (TI:T) respectively), airichment und recovery of
binding phagc can easily be determined by titration and parallel selection on both antibiotics. Recovery of snecift
phagc was calculated as the amount (percentage) of AMP-rcsistant colonies (cfu). recovered uftcr one round it
selection. Enrichment factors were calculated as the product of atios of AMP and Tl T-rcsistant colonies before
and after selection, according to the formula (in = input liter; out output tiler): enrichment factor (fclu^/
4.6 F/m/;>ig new a/i/ige/w w/7/i
Selection from phage antibody libraries provides a new tool for the isolation of novel self
antigens, such as disease- (e.g. tumour-) associated antigens. Both the </t' wow combined V-
domain pairs in naive and synthetic antibody libraries (but particularly the latter) arc not shaped
by the constraints of the immune system, and avoid library bias caused by m Wvw tolerance
mechanisms. Therefore, antibodies to unique self-epitopes can be isolated, provided powerful
cell depletion or subtraction methods arc available. To date, this application has been used for
probing lymphocyte [56] and tumor [31 ] cell surfaces, yielding antibodies to known antigens and
a number of promising but as yet uncloned new cell-type specific antigens. We have recently
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generated panels of anti-epithelial cell antibodies by panning a large naive antibody library on
tumour cell lines, but also with libraries derived from the B-cells of a tumour draining lymph
node of a patient with colorectal cancer (R.C.R. e/ a/., in preparation). These studies will help
to study the natural humoral immune response of cancer patients to the autologous tumour and
will possibly identify alternative targets for active or passive immunotherapy. ;
A recently described method, called 'Pathfinder' selection, might be suitable to overcome several
difficulties associated with phage antibody selections, i.e. the use of complex antigens like cell
surfaces for selection and the preferential selection of antibodies to dominant cpitopes on a given
antigen [ I OK]; the procedure is schematically depicted in Fig. 4K. The method uses a peroxidase-
conjugated ligand ("lead") to deposit biotin-tyramine free radicals in a local area around the
binding site of the lead. If phage arc bound within this radius (of approximately 25nm). they will
be biotinylatcd and therefore retrievable on streplavidin-coated beads. The target antigen in this
procedure can be anything from a purified protein to a receptor on a cell surface, or an antigen
fixed on tissue sections. The procedure was cxamplified by selecting antibodies to TGF-p 1, CEA
and a cell surface receptor, CC-CKR5. The method may overcome problems of 'selection-
dominant' epitopes. as well as provide a means to select phage antibodies to rare cell surface
receptors of orphan ligands.
5. Pha|>e antibody screening procedures and applications
5. / fiu.vi'c .«r«vM/i£ a.wav.v
The outcome of any selection procedure is a mixture of binding ligands with differing
properties. It may be necessary to screen large numbers of antibodies to identify those variants
with the most optimal characteristics. The best screening assays are fast, robust, amenable to
automation (96-well format), and use unpurified phage antibodies, or the soluble antibody
fragments from the bacterial supernatant. The screening assay should also be linked as closely
as possible to the ultimate (functional) requirements of the ligand. Binding of poly- or
monoclonal phage antibodies to the antigen has been tested with diverse assays, ranging from a
simple EL1SA with coated antigen [22], to bioassays that screen for direct neutralization upon
binding [10*)], and whole cell ELISA or flow cytometry. Typically, for a first screen EL1SA-
bascd assays are used, in combination with restriction-fingerprinting of the antibody-DNA to
identify different clones [22], Further, specificity of antibodies may be tested using
immunoprecipitation [36] or immunocyto- or histochemistry [84, 110].
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To speed up screening procedures, phagemid vectors that incorporate a dual purpose have been
developed. These allow both monovalent display of antibody fragments and the production of
soluble antibody fragments for screening without the necessity to subclonc the antibody V-genes.
In such systems, an amber codon is positioned between the antibody and pill genes; in £. roft
suppressor strains, expression of the fusion product for incorporation into the phage coat is
possible; in non-suppressor strains, this amber serves as a stop codon yielding soluble antibody
fragments [11) (due to incomplete suppression, this will also happen to some extend in
suppressor strains). A variety of tags have been described that are appended to the antibody
fragment for detection, including the myc-derived tag recognised by the antibody 9EI0 [221. and
the Flag sequence (111. 112]. This set-up will allow the use of unpurificd phage antibodies or
antibody fragments, present in crude supernatant or pcriplasmic extracts, for screening assays.
Finally, it is possible to fuse, for example in between the antibody and gill, u Histidine-encoding
tag, for purification of soluble antibodies using Immobilised Metal Affinity Chromalogiuphy
[113, 114] and detection with antibodies.
y or
After selection of the higher affinity from the low affinity variants, the screening assuy
will need to differentiate between antibody variants with differences in affinity or kinetics of
binding. ELISA-based methods have been described as well as screening using BIAcorc [71, 73];
for extensive discussion see [115] and various chapters in [77]). Affinity and dissociation rate
screening on the BIAcore is particularly straight forward when using antibody Fab fragments.
These lack the problem of the multimerisation behaviour inherent to many scFv formats |ftl |,
which complicates measurement of the kinetics of antigen binding of unpurificd scFv fragments.
We have developed on- and off-rate screening assays for panels of unpurificd Fab fragments
using periplasmic extracts (A. Reurs, H.R.H., in preparation; an example of an off-rate screen
is shown in Fig. 5A). In combination with BIAcorc-based methods to determine the amount of
Fab in these crude preparations (necessary for accurate determination of the association rate
constants [116]), the affinity of large panels of antibodies may be determined. A routine, reliable
determination of affinity constants is very important in deciding which molecules to use in
further analysis and affinity maturation steps. It should be kept in mind that it will be necessary
to test biological potency, cross-reactivity and expression level to further assess the potential of
the affinity matured candidates, as these parameters may change with changing affinity [117,
118J.
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A. Screening for binding Screening for affinity / kinetics using SPR
CelbinrJng assay
(whole cell BJSA. flow -
Figure 5
EUSA on coated
antigen or indrectfy
immobMsed antigen
B. Functional screening
Selection on
extracellular domain
of receptor
C. Functional aatecMon
Screening lor
function on cells
expressing receptor
hooked up to
reporter system
D. Combining procedures
Selection of phage
for tending
Transfection into eukaryodc
cells lollowed by selection for
survival
Mni-library ol
binders
Display on cell
surfaces for sorting
5/rategies
screem'/ig
(a) Primary screens of
selected phage ligands
frequently involve tests
to measure binding,
including ELISA, cell
binding methods and
BIAcore screening, (b)
Alternatively, selected
phage ligands may be
tested for bioaclivity,
for example by
selecting on a receplor-
immunoadhesin. and
screening for receptor
triggering on cells, (c)
Direct selection of
phage ligands for a
particular function may
be envisaged using a
variety of methods;
depicted here are cell-
related methods only,
(d) Example of a
combined procedure,
involving selection of
antigen-binding phage
ligands. and a
secundary selection in
an alternative system,
i.e. using a prokayotic
or eukaryotic cell
system. either for
affinity sorting, or for
selection based on cell
survival (see text for
details).
5.3 /tec/owmg «7«7«/ pAagf an/iY»oc/iev./<>r etpreKiow in ofAer /loste
One drawback for analysis after the /irsv screen is that antibody expression levels in E.co/i
are dependent on the primary sequence of the individual antibody, and can be extremely variable
(from 10 /vg to UK) mg'L). Unless expression is at sufficiently high levels, consideration should
be given to re-cloning the antibody into another expression system (for review see [61 ]). To re-
format selected antibodies, however, fast recloning methods are needed in those cases where
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large numbers of clones need to be screened. Recently a eukaryotic expression vector was
described that may be used for one-step re-cloning of V-genes derived from any phagc repertoire,
and cloned for expression as Fab fragments or whole antibody, or for targeting to different
intraccllular compartments [119, 120). This permits facile and rapid, one-step cloning of
antibody genes for either transient or stable expression in mammalian cells. By carefully
choosing restriction sites that arc rare in human V genes, the immunoglohulin genes of seleetetl
populations may be batch-cloned into these expression vectors. All the important elements in the
vectors -promoter, leader sequence, constant domains and selectable markers- arc flunked by
unique restriction sites, allowing simple substitution of elements, and further engineering. By
design of the correct promoter cassette, ribosome binding site, 'consensus' signal sequences and
by using "intron space' appropriately, it should be possible to create vectors that mediate both
phagc display of antibody fragments in prokaryotic hosts, as well as expression of iiMiibtHly
fragments or whole antibodies from eukaryotic hosts (A. Bradbury and H.R.H., unpublished).
Such shuttle vectors would be suitable for linking selection of panels of binding antibodies, with
a screening assay based on a particular format of the antibody, to be expressed in eukaryotic cells.
In addition, it would allow the combination of different methods of display or combinatorial
library screening. For example, a pre-sclcction for binding from a very large baetenophagc
display library, followed by a fine-tuned affinity selection by means of tlow cytomctry of the
medium-sized library using yeast or bacterial surface display (Fig. 5D) can be envisaged. In a
milestone study which is further discussed in section 5.S, Ciargano and Cattanco |I2I]
demonstrate the power of such combined methods for retrieving biologically active anti-viral
agents.
5.¥ flioacf/v/Yv assays w/7/ip/iage a/i///>oa7es a/!<//><y>//dev
Fast read-out is particularly required for screening methods where the influence of affinity
or kinetic behaviour is unclear or less important than the functional result ol binding, e.g. virus
or cytokine neutralization and receptor blocking or triggering. In such assays many different
factors besides cpitope recognition or antibody affinity will determine antibody. Methods have
been reported to quickly test phage derived Fab or scFv fragments for their blocking or enhancing
effect on the activity of a growth factor [109], or for their direct receptor triggering effects based
on receptor dimerisation [122]. In the latter case, high affinity anti-MuSK antibodies were
selected from a large naive antibody library by selection on an MuSK-Fc immuno-adhesin, and
scFv-agonists were identified by screening on cells expressing a chimcric MuSK-MpI receptor
(Fig. 5B). An elegant study with Epidermal Growth Factor displayed on phage demonstrates that
phage particles themselves may also induce receptor triggering [123]. The applicability of this
screening method for phage antibodies has to be proven still, and will depend on the mechanism
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of receptor triggering and receptor accessibility. ;;
In the example of MuSK, receptor dimerization is required for signal transduction. thus the
ligand needs to be dimcric, cither by multivalent display on phage or via natural dimerisation,
like has been noted for scFv fragments [122]. The use of repertoires of bivalent ligands, such as
'diabody' libraries [26], would be preferable for these applications. Phage-mediated receptor
triggering is, however, also feasible for receptors that do not require dimerisation for activation,
in particular for phagc that recognise G-protein coupled receptors with multiple membrane
spanning regions, which arc normally triggered directly via ligand interaction. Such receptors
have a wide range of activities and have therefore been used as target for ligand screening using
chemical peptide and other libraries. We have recently obtained evidence that peptide ligand-
displaying phagc themselves may act as receptor agonists (Rousch, H.R.H. era/., submitted), a
feature which will dramatically simplify screening for phage-bascd ligands in search of
a(ntu)gonistic lead compounds. Phagc carrying somatostatin, a 14-mer cyclic peptide. were
shown to be enriched via panning on cells expressing one of its receptors, and also scored
positive in How cytometry, whole cell ELISA and ELISA using anti-ligand sera. Upon cell
binding, this phagc lowered intracellular cAMP concentration and reduced adenylyl cyclase
activity, providing evidence for specific triggering of this G-protein coupled 7-TM receptor. To
date only one other study has addressed phage-mediated triggering of 7-TM receptors [124]: in
this study the melanocortin receptor was triggered using one of the receptor's natural ligands
displayed on phage. It should thus be feasible to isolate receptor-specific ligands from phage
libraries, using panning on cells that overexpress the target receptor, and screen the selected
phage directly for activity. After selection for binding, individual phage clones may be screened
for receptor triggering effects, to differentiate agonists from antagonists from irrelevant binders.
6. New avenues for phage libraries
rt. / Sc'/«7iow./Jj
With large libraries at hand, we may go beyond the ;'w V/V/D binding interaction itself, and
select for a particular function. For example, provided reporter systems with sufficient sensitivity
are used, it may eventually be possible to sort cells which have been triggered by a phage particle
displaying an a(nta)gonistic ligand. Such sorting procedures could allow the direct selection of
phage particles with agonist or antagonist activity for a given receptor directly from the phage
library. With new reporter genes and sensitive fluorescent read-out methods under development
(for review, see Ref. [ 125]), we envisage that such 'functional selection' schemes will be useful
tools for drag discovery. Such methods may be used to identify peptide ligands for orphan
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receptors (such as the many related opioid receptors), for which a function but not a natural
ligand is known. Examples of already demonstrated functional .v»7«vr/on methods arc found in
retrieving catalytic antibodies (126); as yet underexplored routes arc selection for cell
intemalization [127], cell survival or killing (induction of apoptosis) upon ligund binding, cell
transfection. specific inhibition of certain cell surface molecules such as drug pumps, (inhibition
of) viral entry, and. finally, receptor cross-linking or triggering. The list of these novel
applications, some of which are depicted in Fig. 5C". will keep growing as access to the
technology widens.
Functional selection may also be carried out. after pnttfect ion of antigen-specific phtfi
antibodies, using selection schemes in other cellular systems. In Fig. X two of such possible
procedures are described. The first hypothetical application is to display the selected library on
the surface of particles which arc large enough to allow affinity sorting (bacteria, yeast or
mammalian cells [128], reviewed in (129]). This could possibly provide a rapid method for
antibody affinity maturation. The other application involves a selection step for bioactivity.
which allows to select for a subset of phagc library-derived ligands from a mini-library of Uganda
that interact with the target antigen. An elegant example of this, using intracellular selection, was
described by Gargano and Cattaneo [121]. They developed a model system showing that
intracellularly (cytosolic) expressed antibody fragments that block the activity of reverse
transcriptase (RT), can inhibit integration of a retrovirus containing the Herpes Simplex
Thymidine Kinase gene, resulting in the selective survival of transfected cells through protection
against the cytotoxic action of Gancyclovir. Using pools of antibody fragments, cloned in
expression vectors that mediate cytosolic expression of the antibodies, it was possible to select
the antibody with neutralizing activity for reverse transcriptase from a polyclonal population of
antibodies that just bound (but not blocked) RT. This suggests that it may be possible to combine
the power of the large phage libraries, to select pools of antigen-specific phage antibodies
together with their genetic material, with a subsequent selection of the population using a
mammalian host cell [121], or other cell systems [130]. This combination of technologies may
indeed optimally utilize the advantages of each system and also by-pass some of the
disadvantages of individual methods.
7. Beyond antibodies
The ideas on functional selections and screening procedures may be expanded to the use
of alternative proteins or protein domains for constructing binding molecules (reviewed in [ 131 ]).
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Scaffolds different from antibodies have been reported to form suitable binding ligands for many
types of antigens. There are ample examples of'host scaffolds' that contain sufficient permissive
regions to accomodatc a reasonable numbers of substitutions, which may be used to generate a
library of localised variability. Alternative scaffolds reported to date include P-sheet proteins
[132, 133], a-hclical bundle proteins [134-138], combinations of these two [139, 140], a separate
group of highly constrained protease inhibitors (141-143), and, most recently. Green Fluorescent
Protein (CiFP) (144). Since secreted as well as cytoplasmic and nuclear proteins have been
displayed on phagc (for review sec [3]), display on phagc is often the first strategy to define
permissive sites for randomization and to generate ligand-binding variants [ 145]. Alternatively,
the use of lambda [ 146], bacterial [ 129] or eukaryotic cell display methods has been reported.
In regards of 'functional selection' methods, choosing other types of molecule besides antibodies
is validated by the fact that antibody expression and folding may be impaired in the subcellular
location where the desired functional activity is required. It would be advantageous to engineer
the antibody for intrucellular expression, for example by building stable disulphide free
antibodies 1147], or to use libraries of scaffolds that arc naturally produced in the targeted cell
organcllc, provided that effective structural diversity may be obtained.
8. Perspectives
This review highlights the advantages and possible applications of phage display for the
development of antibodies. With this technology, antibody engineering for the first time may be
used to design antibodies from scratch, with an option to choose its building blocks, its affinity
(up to the picomolar range), its format (size and valency) and its effector function (natural (igG)
or novel (en/ymes etc.) [ 148]. Tailor-made reagents may thus be generated, for in ivV/o or /« Ww
diagnosis and for therapy. We expect that the number and quality of naive and synthetic phage-
antibody libraries will increase over the next few years. The extent of the use of phage antibody
libraries in academic research will benefit from a virtual unrestricted availability of such very
large and stable phagc libraries. The libraries may be used for the search for new drug targets,
cell receptors and their ligands, which will interface with the human genome project and
functional genomics. Combining the design and generation of millions to billions of different
ligands. with a function-based selection procedure rather than mere selection for binding, will
open even more challenging applications of this inspiring technology, and provide a powerful
tool for drug and target discovery well into the next decade.
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Abstract
The tumour-associated antigen epithelial glycoprotein-2 (EGP-2) is a promising targe:
for detection and treatment of a variety of human carcinomas. Antibodies to this antigen have
been successfully used in patients for imaging of small cell lung cancer and for adjuvan:
treatment of minimal residual disease of colon cancer. We describe here the isolation anc
complete characterisation of high affinity single-chain variable fragments (scFv) to the EGP-2
antigen. First, the binding kinetics of four murine whole antibodies directed to EGP-2 (17-1 A.
323/A3, M(X'-31 and M(X'-I61) were determined using surface plasmon resonance (SPR). The
M0C-3I antibody has the lowest apparent off-rate, followed by MOC-161 and 323/A3. The V-
gencs of the two MOC-hybridomas were cloned as scFv in a phage display vector and antigen-
binding phage were selected by panning on recombinant antigen. The scFvs compete with the
original hybridoma antibodies for binding to antigen and specifically bind to human carcinoma*
in immunohistochemistry. M(X'-31 scFv has an off-rate which is better than those of the bivalent
17-1A and 323/A3 whole antibodies, providing it with an essential characteristic for tumour
retention /« v/Vu. The availability of these high affinity anti-EGP-2 antibody fragments and of
their encoding V-gcncs creates a variety of possibilities for their futur use as tumour targeting
vehicles.
Introduction
During colorectal carcinogenisis, a number of (membrane) antigens is uprcgulated,
mutated or differently processed, providing targets for (adjuvant) immunotherapy of the disease.
Several tumour antigens have been described and used for targeting or as indicators of
progression of disease (e.g. carcinoembryonic antigen (CEA), TAG72, c-erB2,
(underglycosylatcd) MUC-I, p53). The epithelial glycoprotein-2 (EGP-2, also named CO17-1A
antigen, KSA, EGP40 or Ep-CAM) is a tumour-associated antigen present on human simple
epithelia and their derived tumours. The abundant expression of EGP-2 on a number of human
carcinomas, its limited expression on the luminal side of normal non-squamous epithelia only
and the fact that it is not shed into the circulation make this antigen a favourable target for
imaging and immunotherapy of cancer. Murine antibodies to EGP-2 have been used in radio
immune detection trials [1.2], as well as in phase 1 and II clinical trials [3]. The most successful
study has been the treatment of minimal residual disease (MRD) in patients with Dukes' C colon
carcinoma using the 17-1A antibody [4]. In this study [5], an overall 30% reduction in 5-year
mortality was observed, proving that passive immunotherapy in an adjuvant setting may be as
effective as chemotherapy.
Other therapeutic strategies based on the use of antibodies to EGP-2 have also been
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described. These include the recruitment and activation of T-cclls by using a fusion of an EGP-2
reactive antibody fragment with the bacterial superantigen staphylococcal cntcrotoxin A |f>| or
by using bispecific antibodies, directed both to EGP-2 and the T-cell CD3 antigen |7|. In a
different approach, the conjugation of anti EGP-2 antibodies to different bacterial toxins has been
shown to yield potent immunotoxins |S, 9]. These (preK'linical studies all underline the
possibilities of using antibodies (in different format) to EGP-2 for (adjuvant) imnuinotluT.ipy.
Careful expenmental analysis of scFv vanants of an anti c-crB2 antibody with a range
of afTinities indicated that there is a clear correlation between affinity increase and enhanced
tumour retention [10]. The availability of high affinity recombinant anti EGP-2 antibody
fragments would therefore be highly desirable. Indeed, the potential use of such scFv antibody
fragments for imaging of human carcinoma has already been demonstrated with a scFv directed
to carcinoembryonic antigen (CM A; (111).
In this study, we first compared the binding kinetics of four murinc whole antibodies (17-
1 A. 323/A3 [12], MOC-31 and MOC-I6I [13] to the antigen EGP-2 using SPK in a BIAeorc.
Our results show that the MOC-31 antibody has by far the lowest off-rate of all antibodies tested
and that VIOC-161 is comparable to the 323/A3 antibody. The V-gcnes of the two antibodies
with lowest off-rate (MOC-31 and M(X'-IGl) were cloned in scFv format and the off-rate and
specificity of the scFv antibody fragments determined. These high affinity anti EGP-2 scFvs may
have important applications in imaging and possibly immunothcrapy of different human
carcinomas and may provide useful building blocks for further rational therapeutic antibody
design.
Materials and Methods
The antibodies 17-1 A, chimeric 17-1A and 323/A3 were a kind gift from Dr. S.O.
Wamaar (Centocor, Leiden, the Netherlands). The two hybridomas cloned in this study (MOC-31
(IgGl/K) and MOC-161 (IgG2a/K)) were generated by hybridoma technology [13]. Bis-1
bispecific antibody [7] is produced by a quadroma clone made from the hybridomas MOC-31
(anti EGP-2) and RIV-9 (anti CD3) and was kindly donated by Dr. B-J Kroesen (University
Hospital Groningen).
Recombinant EGP-2 was expressed in the baculovirus system as described [14, 15], a
kind gift of Prof. D. Herlyn (the Wistar Institute)). The antigen was covalently coupled to a CM-5
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scnsorchip (Pharmacia, Uppsala, Sweden) via free amide chemistry, resulting in a surface of 350
resonance units (RU). All kinetic measurements were performed on this antigen surface. To
determine the binding kinetics of different whole antibodies (17-1 A, chimeric 17-1 A, 323/A3.
MOC-I61.MOC-31 and Bis-1) and antibody fragments (MOC-31 scFv and MOC-161 scFv).
this 'low density' EGP-2 surface was saturated with antibody (at [200nM]) or antibody fragment
using a flow rate of 5ul/min (Fig. 1). Dissociation rates (k,,J were then calculated using the
BIAcvalualion software (Pharmacia, Uppsala, Sweden) from the sensorgrams depicted in Fig.
1. The off-rates were determined by curve fitting on the time interval t=315 to 320 s, with one
exception: because of its very low value, it was impossible to determine the off-rate of the MOC-
31 whole antibody in this time period. In this case, an average value of three independent fittings
on different parts of the curve is given. Since the kinetics of binding of the MOC-161 whole
antibody were determined with concentrated hybridoma supernatant, the antibody concentration
was unknown and the sensorgram is not shown. However, the same experimental setup was used,
in which the antigen surface was saturated with antibody. All measurements were carried out at
room temperature. «
Association rates (k^) were determined from a plot of k, (= (k^ x C + K.^ )) versus
antibody concentration (C). Briefly, antibodies were run over the low density antigen surface at
different concentrations and k,, values were determined using the BIAevaluation software. From
a plot of the obtained k, values as function of C, k^ values were obtained by linear fitting as the
slope of the curve. The half life of antibody-antigen complex was calculated as 11/2=
(Table 2).
pCANTAB6 is a derivative of pHEN I [16], carrying an additional stretch of six histidine
residues (to allow immobilised metal ion affinity chromatography (IMAC) purification) upstream
of the c-mvf-derived sequence (which allows detection with the 9E10 antibody). ScFv cassettes
are cloned as 5//I - M>rl fragments in frame with the upstream pelB leader sequence and LacZ
promoter and with the downstream bacteriophage gene III. The vector also contains an amber
stop codon between the f-#»iyc sequence and gene III, allowing production of soluble scFv in a
non-suppressor strain of £.ro/i. Plasmid pUCl 19-polyHlS6myc (a kind gift from Dr. A.D.
Griffiths) is a derivative of pUCl 19 and carries 5' 5//I / Ncol and 3' NofI cloning sites. ScFv
cassettes are cloned in frame with an upstream AacZ promoter and pe/fl signal sequence and a
downstream cassette of six histidine residues and a c'-ww derived sequence. As in the related
pUCl 19-His6mycXba [ 17], the bacteriophage gene III is absent.
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TGI: K.12, D(/ac-/>ro>,«v>£, rti, **/D5/F/niD36,/w»,4B\ /at/*, /a<Zl)MI5
Primers used for the amplification of variable parts of the heavy chain (VH) and of MM
light chain (VL) of murinc immunoglobulin genes, for the synthesis of the linker fragment and
for re-amplification of the assembled scFv cassettes are listed in Table I. All pnmers were
purchased from Eurogentec (Liege, Belgium).
Table 1
Oligonucleotides used for cloning of munnc V-gencs
.1 /Vim«"n luerf /or rtr /jnmar>- om/i/i/ira/ion of KW
MVHIBACK 5 -AGG T(C GMA/C) A(A/G)C TGC AG<C/G) AGTC(A/T)G G-3'
MVHIFOR-2: 5-TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC-3'
fl /Vimers i««//or rtcpnman' <»ity»/iyiai/i<M «/ >'/.
MVKBAC'Kmix; an equimolar mix of:
-MVKABACK 5 -GAT (iTT TTG ATG ACC CAA ACT CCA-3'
-MVKC BAC K: 5-GAC ATT (iTG CT( A/G) ACC CA(A/G)TCTCCA-3"
-MVKDBACK: 5-GAC ATC CAG ATG AC(T/C/G/A) CAG TCT CCA-3'
-MVKKBACK: 5-CAA ATT GTT CTC ACC CAG TCT CCA-3'
-MVKFBACK: 5-GAA AAT GTG CTC ACC CAG TCT CCA-3'
MVKFOR4; an equimolar mix of:
-MJKIFONX: 5-CCG TTT GAT TTC CAG CTT GGT GCC-3'
-MJK2FONX: 5-CCG TTT TAT TTC CAG CTT GGT CCC-3'
-MJK4FONX: 5-CCG TTT TAT TTC CAA CTT TGT CCC-3'
-MJK5FONX: 5-CCG TTT CAG CTC CAG CTT GGT CCC-3'
C. /V/miT.v /or (Ac .WMfAcw.v o/ //i<- /mi<-r ^
MLINKBACK: 5-GGG ACC ACG GTC AC C GTC TCC TCA-3'
MLINKFORmix; an equimolar mix of:
MLINK-A-FOR: 5 -TGG AGT TTG GGT CAT CAA AAC ATC CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-C-FOR: 5-TGG AGA CTG GGT (T/C)AG CAC AAT GTC CGA TCC GCC ACC GCC AGA -3'
-MLINK-D-FOR: 5-TGG AGA CTG NGT CAT CTG GAT GTC CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-E-FOR: 5-TGG AGA CTG GGT GAG AAC AAT TTG CGA TCC GCC ACC GCC AGA GCC-3'
-MLINK-F-FOR: 5-TGG AGA CTG GGT GAG CAC ATT TTC CGA TCC GCC ACC GCC AGA GCC-3'
D. /?e"-am/>/i/irarto/iprimers fto irt/rw/i«-e rei/ric/ion ntev in f/reat.tcmWef/couture .te^uencei «uvx//>ig r«/ric/ton
/ / /
MVH 1BACKSFI; (introduces aS/?l site at the 5' end of the assembled scFv cassette):
5-CAT GCC ATG ACT CGC GGC CCA GCC GGC CAT GGC C(C/G)A GGT (C7GKA/C)A (AyG)CT OCA
G(C/G)A GTC (AT)GG-3"
MVK4FORNOT (introduces a .Vofl site at the 3' end of the assembled scFv cassette); an equimolar mix of:
-MJK IFORNOT: 5-GAG TCA TTC TCG ACT TGC GCX: CGC CCG TTT GAT TTC CAG CTT GGT GCC-T
-MJK2FORNOT: 5-GAG TCA TTC TCG ACT TGC GGC CGC CCG TTT TAT TTC CAG CTT GGT CCC-T
-MJK4FORNOT. 5-GAG TCA TTC TCG ACT TGC GGC CGC CCG TTT TAT TTC CAA CTT TGT CCC-J
-MJK5FORNOT: 5-GAG TCA TTC TCG ACT TGC GGC CGC CCG TTT CAG CTC CAG CTT CX»T CCC-3'
For se^ue/icing.
pUC-FOR: 5-CGA CGT TGT AAA ACG ACG GCC AGT-3'
pUC-REVERSE: 5-CAG GAA ACA GCT ATG AC-3'
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C/o/if'/ig 0/7m/nu/io#/uAu/;;i gene.v
Total cellular RNA was extracted from 10' cells of each of the hybridoma cell lines
MOC-31 and MOC-I6I by means of the RNazol™ method (Biotecx Laboratories, Houston,
USA). After precipitation, the RNA was dissolved in 20|il water and used as template to
synthesise cDNA using random hexamer primers (Promega, Madison, USA) in a 50 (il reverse
transcripta.se (RT-) reaction according to standard procedures. Variable domains of both heavy
(VH) and light chain (VL) genes were then amplified from cDNA using heavy or light chain
specific primer mixes (sec Table I) and assembled with a linker sequence encoding a 15-residue
Gly/Ser sequence by means of Splice Overlap Extension PCR, as described by [18]. The
assembled cassette was gel-purified, cut with the restriction enzymes 5//1 and Afo/I and gel-
pun (led again. ScFv cassettes were cloned into 3#I/M)fI digested pCANTAB6 DNA and the
ligation mix was clectroporatcd into £>«// TGI using standard procedures. Bacteria were plated
on 2xTY (1.6% (w/v) trypton; 1% (w/v) yeast extract; 0.5% (w/v) NaCI) plates, supplemented
with 2% (w/v) glucose and 100 ug/ml ampicillin, and harvested after overnight growth to form
u library of transformants.
-2 Ay
A small repertoire of transformed bacteria (approximately 10* in size) containing the
MOC-31 scFv ligated into pCANTAB6 was rescued with helper phage M13K07 and phage were
panned for binding to the antigen EGP-2 (coated at lO^g/ml concentration using immunorubes
(Maxisorb; Nunc/Life Technologies, Gaithersburg, U.S.A.)) as described [19]. Two rounds of
selection were performed; after each round, single clones were screened for binding to antigen
in ELISA as described (see below).
To identify binding scFvs from the individual clones selected for further analysis, an
ELISA using soluble scFv was performed on purified, recombinant EGP-2. Individual bacterial
clones were picked and production of soluble scFv was induced by activation of the upstream
LacZ promoter with isopropyl-P-D-thiogalactopyranoside (1PTG) as described [19]. ELISA
plates (Costar, Cambridge. USA) were coated overnight with 1 ug/ml of EGP-2 in phosphate
buffered saline (PBS), washed three times with PBS-T (PBS, 0.5% (v/v) Tween-20), three times
with PBS and blocked during I hr at room temperature (rt) with 2%MPBS (2% (w/v) Marvel -
skimmed milk powder- in PBS). After blocking, induced bacterial supematants were added (50%
(v/v) in 2% MPBS) and incubated for I'" hrs at rt. Bound antibody fragments were detected with
the 9E10 antibody (50% (v/v) hybridoma supernatant in 2% MPBS), peroxidase-conjugated
rabbit anti mouse immunoglobulines (Dako. Glostrup, Denmark; 0.1% (v/v) in 2% MPBS) and
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suining with trimethylbenzidine (TMB) and H,().. Optical density was measured at 450nm.
For competition ELISA. scFv antibody fragments expressed as pill fusions on the tip of
bacteriophage were detected in the presence of excess whole antibody (due to cross-reactivity of
anti-mouse Ig antibodies -used to delect the 9E10 antibody bound to scl-'vs- with the original
whole munnc antibodies, this test was not performed with soluble scKvs). Briefly. M(K'-3I and
MOC-I6I phage were rescued with helper phage MI3KO7 as described 1I9|. Approximately
10'" colony forming units (cfii) of phage were then mixed with KM) ul hybridoma supenmtant and
simultaneously added to different wells of an antigen-coated 111.ISA plate. Hound phage were
detected with a sheep polyclonal antiserum (sheep anti-Id; Pharmacia. Uppsala. Sweden; 0.02%
(v v) in 2°o MPBS). pcroxidase conjugated rabbit anti goat immunoglobulincs (l)ako. (iloslnip,
Sweden; 0.05% (v/v) in 2% MPBS) and staining with TMB/H.O,.
The nucleotide sequences of both the MO0-3I and M(X'-I6I scFvs were determined
using the dideoxy sequencing method of Sanger. Products of the sequencing reaction were
analysed on a semi-automated sequencer (Alt' Express; Pharmacia, Uppsala, Sweden).
Oligonuclcotides used were pUC-FOR and pUC-REV (Table I).
To produce large quantities of both antibody fragments. scFv cassettes were subcloned
as 5/? I/iVor I fragments into pUC-119polyHIS6myc. lacking the bacteriophage gene ill. This
expression plasmid ensures less toxicity to bacteria due to expression of gene III during induction
and thus a higher yield of antibody. Both the supernatant and the pcriplasmic fraction of bacteria,
grown at three different temperatures and harvested after two different time intervals (growth at
20°. 30° and 37°C; induction during 4hrs or overnight) were first tested for the amount of
functional scFv in ELISA.
Five hundred ml of 2xTY/A/G (2xTY, supplemented with 100 ug/ml ampicillin and 2%
(w/v) glucose) were inoculated with £.co// TGI harbouring MOC-31 or MOC-161 scFv in
pUCI 19-polyHIS6myc and bacteria were grown at 37°C to an O D ^ o f 1.0. Bacteria were spun
down, resuspended in 2xTY containing lOOug/ml ampicillin and IPTCi to a final concentration
of 1 mM, and grown for 4 hrs at 30°C while shaking. After 4 hrs of induction, bacteria were
pelleted and pcriplasmic fractions were prepared by rcsuspending the pellet in 8 ml ice-cold TES
(200mM Tris-HCl; 0.5mM EDTA; 500mM sucrose: pH8.0). adding 12 ml of ice-cold diluted
TES (1:3 in water) and incubation on ice for 30 min. Bacteria were spun down (4500rpm, 15min,
4°C) and the supernatant was collected. The cell pellet was resuspended again in 10 ml TES, 150
Hi 1M MgSO4 was added and the mix was incubated on ice for 30 min. Cells were spun down
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again and the supernatant was added to the first periplasmic preparation. EDTA was largely
removed by means of dialysis against 20 mM Tris-HCI, 100 mM NaCl (pH8.O). The Histidine-
tagged scFv fragments were further purified by means of 1MAC on TALON™ resin (Clontech,
Palo Alto, USA) using elution with 100 mM imidazole, according to the manufacturers protocol.
Monomcric and dimcric forms of the scFvs were separated by gelfiltration chromatography (on
a Superdex* column; Pharmacia, Uppsala, Sweden) using a Biologic Apparatus (BioRad.
Hercules, U.S.A.). Different fractions were finally analysed by means of SDS-polyacrylamide
gel elcctroforcsc (SDS-PAGt).
o/.vcFv c/ones
Six urn frozen sections (of normal colon epithelium, melanoma and colon carcinoma)
were cul, mounted on 3-aminopropyI tri-cthoxy silan (APTS) coated glass slides, force-dried on
air and fixed in acetone on ice for 15 min. Slides were force-dried on air again, bacterial
periplasmic preparations were added (50% (v/v) in PBS/1% bovine serum albumin (BSA)) and
incubated for 30 minutes at 4°C. Slides were washed with PBS and bound scFv antibodies were
detected with the 9F.I0 antibody (50% (v/v) hybridoma supernatant in PBS/1%BSA), peroxidase-
conjugated rabbit anli mouse immunoglobulincs (0.1% (v/v) in PBS/1%BSA) and staining with
diuminoben/idin (l)AB)/Hj(X. The slides were counter stained with haematoxylin.
Results
One of the most important characteristics of antibodies is the rate with which they detach
from bound antigen, given by the off-rate of the molecule (k ,^,,). To select the antibody with most
promising properties for tumour targeting, we set out to screen the binding characteristics (and
in particular the off-rate) of four monoclonal antibodies directed to the pan-carcinoma antigen
EGP-2: 17-1A (and a chimeric version thereof). 323/A3, MOC-31 and MOC-161. The on- and
off-rates of these (whole) antibodies were determined using a BIAcore2000 (Fig. 1 and Table 2).
The off-rate we measured for MOC-31 whole antibody is the lowest of all antibodies
tested; it would yield a half-life of the antibody-antigen complex in solution of approximately
4 hrs. The antibody that has been most often used for clinical applications, 17-1 A, has an
apparent off-rate which translates into an antibody-antigen complex half-life of less than a minute
(Table 2).
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Figure I
Sensorgrams showing association and dissociation of different anti F.(iP-2 antibodies and antibody
A) whole antibodies (I: 17-1 A; 2: chimene 17-1 A; V 3 2 3 A 3 . 4 M(X -II; 5 His-1)
B) antibody fragments (I: MOC-31 scFv; 2: M(X'-IM scFv) to the antigen coated to the surfaccof • aenaor chip.
Association starts at t 130 s; dissociation starts al t 310 s
Table 2
Kinetic data and affinities of anti EGP-2 antibodies and antibody fragments
Antibody
17-1A
chim. 17-1A
323/A3
His-I
MOC -31
MOC-I6I
MOC-31 scFv
MOC-161 scFv
(10'MV)
+/- SE
5 . 9 5 + - 0 . 2 X
10.9 • - 0.2
2.51 +/-0.29
0.48 +/- 0.03
1.06 +/-0.16
N.D.
N.D.
N.D
I I O ' s ' l « -SF
(monovalcnl)
-
-
0.25 +/- 0.03
-
0.34 +/- 0.05
2.05 +/- 0.08
( I O ' s ' » t / - S F
(bivalent)
38.2+/- l.2»
58.3 -I/-2.2*
1.06 */-0.02
0.05 t / - 0 . 0 l
1.55 +/-0.0I
Ku
(IO"M')
N.D.
N.I)
N.D.
1 92
4.24
N.I).
N.I).
N.I)
I'/i
18"
12"
IO'54"
46'13"
3h5l'O3"
777"
33'59"
5'38"
* Because of the very high off-rates of these antibodies, the low density F.GP-2 surface could not be saturated wib
antibody (Fig. 1). These off-rates arc therefore underestimations of the true values, which may account for lit
unexpectedly observed difference.
Antibody MOC-161 has an apparent off-rate which is comparable to that of 323/A3
antibody. These off-rates are apparent values; they arc most likely underestimations of the real
off-rates because of the bivalent nature of the antibodies causing rebinding events during
dissociation of antibody from the antigen surface [20] and they arc influenced by the
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experimental conditions used to measure them. However, because all antibodies tested recognise
the same cpitope on ECiP-2 and the same expenmcntal setup was used for all, the relative ranking
will be correct.
To obtain absolute values for the binding kinetics of the best antibody, MOC-31, it was
necessary to determine those of the monovalent antibody Bis-1, a bispecific antibody with one
MOC-31 binding site and one anti-CD3 site. The same antigen surface bound approximately
twice the amount (in RUs) of Bis-1 when compared to MOC-31 (Fig. 1). This indicates that,
despite the use of a low density EGP-2 surface, simultaneous binding of both Fab arms was a
very frequent event for all bivalent molecules, which may be partially explained by the flexibility
of the antigen surface. As expected, the off-rate of Bis-1 was shown to be higher (approximately
5-fold: Table 2) than that of MOC-31 antibody. It can be concluded that, because MOC-31 has
the lowest off-rate of the antibodies tested, followed by MOC-I6I and 323/A3 (Table 2). the
M(X antibodies were the most promising starting points for the cloning of rccombinant antibody
fragments.
The genes encoding the variable parts of heavy (VH) and light chain (VL) of the
hybridomas MOC-31 and MCX-I6I were amplified by means of RT-PCR and assembled to form
a scFv construct with a 15 residue (Gly.,Ser>, linker. The set of oligonucleotides used in this study
was similar to the one used by [18], with one important improvement: a re-designed set of
MVKBACK primers was used, which was expanded to 5 oligonucleotides on the basis of the
collection of murinc VK genes present in the Kabat (1991) database [21]; Table I). Extensive
tests indicate that this new primer set successfully amplifies over 95% of all rearranged murine
VK genes (Pope t'/ «/., personal communication). For MOC-31, a 250nt by-product was
preferentially found during amplification of the VK domain when using a mix of MVKBACK
primers. However, when all BACK primers were used separately in different reactions, the band
of expected size (approximately 340nt) was predominantly found (>90% of the PCR product)
with primers MVKCBACK and MVKDBACK.
ScFv cassettes were cloned into phagemid vector pCANTAB6 which allows expression
as cither fusion protein to the bacteriophage gene III product or as soluble scFv in a non-
suppressor strain of £.co/i. For MOC-161, binding scFvs were detected by means of ELISA
directly after cloning, in a frequency of 11/90. This is a typical frequency when rescuing V-genes
from hybridomas [18]. For the MOC-31 hybridoma, however, the initial screen did not reveal
any active scFvs. Therefore, a small scFv antibody repertoire (approximately 10*recombinant
clones in size) derived from the MOC-31 hybridoma was used for two successive rounds of
phage selection on antigen. After two rounds, antigen binding scFvs were found at a frequency
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of 15 positives in 90 clones analysed. For each of the two hybridomas. several binding scFv
clones were further analysed. Eventually, two representative clones were selected on the basis
of DNA fingerprint patterns (MOC-31 scFv and MOC-161 scFv respectively; data not shown),
for which the data are presented here. ;-:> a-;f
The V-gene nucleic acid sequences of Kith antibody fragments were determined using
a semi-automated sequencer and sequences were submitted to (ienBank (accession numbers:
U80187-U80I90). The primers used to amplify light chain genes were for M(X'-3I:
MVKCBACK (consistent with the results of the primary amplification of the light chain gene)
and MJKIFONX; for MOC-161 these were: MVKDBACK and MJK5FONX. A comparison of
the amino acid sequences of MOC-31 and-161 with those of the 323/A3 and 17-1A antibodies
is shown in Table 3 (for both MOC-antibodies. primer encoded regions arc depicted in lowcrease
letters). Both hybridomas use very different VH and VK genes. The M(X'-3I VII and Vtc gene
segments are members of the Kabat II and VII family respectively; for M(X'-lftl, the designated
families are VII and XIV. Both antibody VH-gcncs use the same gcrmlinc J-segment. being
either JH2 or JH4 (both encoding a 'DY' sequence in the C-terminal end of the CT)R3 loop:
Table 3). Besides these two residues, the antibodies share an additional two residues ('K(i') in
the C-tcrminal half of the VH-CDR3. which arc most likely not encoded by any D-scgmcnl.
Table 3
Comparison of deduced aminoacid sequences of anti EGP-2 antibodies
A: Heavy chain V-genes
FRl CDR1 FR2 CDR2
MOC-31 qvqlqqsgpeLKKPGETVKISCKASGYTFT NYGMN WVKQAPGKGLKWMG WINTYTGESTY
323/A3 .I..V R..S.E P..
MOC-161 t..IR..TS A.. D.WLG . . . HR. . H. .E. I . D.YPGSDNTY.
17-1A A..VR..TS..V A.. ..LIE R..Q..E.I. V..PGS.GTN.
FR3 CDR3 FR4
MOC-31 ADDFKG RFAFSLETSASAAYLQINNLKNEDTATYFCAR FAIKGDY wgqgttvtvss
323/A3 GE T GNYV L
MOC-161 HEK... KATLTTDK.S.T. .M.LSS.TS. .S.V -GL
17-1A NEK... KATLTADK.S.T. .M.LSS.TSD.S.V DGPWFA L....A
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B: Light chain V-genes
FRl CDRl FR2 CDR2
MOC-31 divltqspFSNPVTLGTSASISC RSTKSLLHSNGITYLY WYLQKPGQSPQLLIY QMSNLAS
3 2 3 / A 3 . . . M . . A A
MOC-161 ..qm....S.LSAFS.GKVT.T.
17-1A N. .M. . . . K. MSMSV. ERVTLT.
S.N
KASQD-IK-KS.A
KAS E-.W..VS
H
. . Q H . . . K G . R . . . H YT.T .QP
. . Q . . . E . . .K . . . . GA. .RYT
FR3 CDR3 FR4
GVPDRFSSSGSGTDFTLRISRVEAEDVGVYYC AQNLEIPRT FGGgtkleikrMOC-31
323/A3
MOC-161 .I.S. . .G. . . .EEYSFS. .NL.P. .IAT. . . -.QYDNL 1
17-1A TG...A T. .S.Q. . .LAD.H. G.GYSY.Y
1 2 1 « S t 7
Praccwnt
I
JOKDi
to
B
Figure 2
(A: Top) SDS-PAGE analysis of
(I) MOC-31 induced bacterial
pcnplasm; (2) IMAC-purified
MOC-31 scFv; (3-8) FPLC
fractions of IMAC-purified MOC-
31 scFv (fraction 19-24); (9)
Molecular Weight standards: (10)
MOC-31 induced bacterial
periplasm after IMAC purification.
(B: Middle) OD.«, profile of the
llowthrough after gclfiltration of
the different scFv preparations;
MOC-31 and MOC-161. (C:
Bottom) Protein standards 1-5(1:
dextran (V,,); 2: albumin
(7l.7kDa); 3: ovalbumm
(45.7kDa); 4: chymotrypsinogen
(20.2kDa) and 5: ribonuclca.se A
(15.7kDa))
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ScFv antibody production was induced in bacteria harbouring the MCX-31 and -161 scFv
cassettes in pUCI l9polyHIS6myc. The highest amount of antibody (as judged by titmting the
fractions in ELISA) was observed in the periplasm of bacteria after 4 hrs of induction at 30°C
(data not shown). These conditions were therefore used to produce soluble scFv for purification.
ScFv fragments were then purified from a periplasmic extract of a large scale induced culture of
bacteria by means of 1MAC". This purification procedure permitted both antibody fragments to
be recovered in highly pure form (purity >95%; Fig. 2). Sinec scFv fragments huve been noted
to be capable of forming dimcrs. the scFv proteins were further purified by gelfiltration
chromatography to separate monomers and dimers. The typical yield of purified monomcric scFv
antibody after IMAC and gelfiltration was 100-200 ug/L bacterial culture.
Figure 3
A/*ri/i< i/v /•.7./.V.*
Binding o l M < K » l (solid ban.) and of M(K -Ihi
(hatched ban) scKv phagc antibody lo rctomhinunt
F.GP-2 in the presence of'(A) mi compel inn antibody
(B) an excess of an irrelevant antibody (KITS, m
anti CD25 hybridoma), ((') the M(X"-.1I whole
antibody and (D) the MOC-I6I whole antibody. OD
values (Y-axis) arc corrected tor background (whidi
was approximately 0.0K)
The isolated scFv antibody fragments specifically bind EGP-2 in ELISA (data not
shown). Using competition ELISA, we could demonstrate that the binding of both scFv
antibodies, expressed as pi 11 fusions on the tip of filamentoas phage, was competitively inhibited
by both of the original bivalent whole antibodies (Fig. 3), whereas an irrelevant antibody (RFT5;
an anti-CD25 antibody) failed to inhibit binding of the recombinant antibody fragments to li(iP-
2. This is an indication that the original epitopc recognition is retained by these recombinant
scFvs.
By means of immunohistochemistry using soluble scFvs, we further showed that both
scFv antibody fragments specifically bound EGP-2 positive tissues (Fig. 4). As expected, both
antibody fragments reacted with normal and malignant non-squamous epithelia and did not stain
malignant tissue reported to be negative for the antigen (melanoma; [4]).
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Figure 4
5/r>' H7//I
2 scFvs
Six )im frozen sections
of normal colonic
epithelium. colon
carcinoma and
melanoma were stained
with MOC-31 scFv
ih.d.D or without
primary antibody
{negative controls:
a.c.e) respectively;
sect ions were
counlerstained with
hucmatoxylin. Similar
results were obtained
with MOC-I6I scFv
(data not shown).
The kinetics of binding of purified monomeric scFv antibody fragments were determined
using SPR in a BIAcore (Fig. IB and Table 2). The off-rate of monovalent MOC-31 scFv (3.4
x 10"* s') only differs by a factor of less than 1.5 from that of the original monovalent interaction
(Bis-l antibody: 2.5 x 10"* s ' ; Table 2). The monovalent MOC-31 scFv has a three times lower
off-rate than the bivalent 323/A3 antibody and is the best antibody of the present series. The off-
rate of MOC-161 scFv is significantly higher (2.05 x 10 V ) , but still compares well to those of
the whole (bivalent) antibodies 323/A3 (1.06 x 10 ' s ') and 17-1A (38.2 x 10' s').
Discussion
We compared the kinetics of binding of four well-characterised antibodies directed to the
pan-carcinoma antigen E-GP-2. using SPR in a BIAcore (Fig. 1A and Table 2). The MOC-31
whole antibody has by far the lowest apparent off-rate. To account for the avidity of the bivalent
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MOC-31 antibody, we also determined the kinetics of binding of the bispecitic antibody Bis-1.
As can be seen in Table 2. the absence of a second KGP-2 binding site in Bis-1 is reflected in a
5-fold increase in off-rate (k,,,, = 2.5x10"* s ') when compared to MOC-31 whole bivalent
antibody. Since only apparent kinetic constants were obtained, it is difficult to compare our data
to affinity values that have been reported for the antibodies (17-1 A: 7x 10 M ' 1221 and 323/A3:
2 x 10" M' (23]). However, dividing the on-rate of the M(X'-3I whole antibody by the oIT-mtc
of the monovalent interaction (Bis-1) gives an affinity value of 4.2x10" M ' for this antibody
(Table 2). Since the off-rate of the MOC-31 antibody is by far the lowest and the on-rales of
MOC-31 and 323/A3 only differ by a factor of two, the affinity of M(X'-31 is expected to be
higher than that of 323/A3. Unexpectedly, however, the value we find for MOC-31 is
approximately five-fold lower than the one reported for 323/A3 (23). which may be due to the
different experimental setup used (cell binding versus SPR analysis in a BIAcorc). We cannot
exclude an effect of the different glycosylation of the recombinant antigen us compared to the
antigen present on human tumours on the kinetic parameters we measured. However, there lire
strong indications that the differences in off-rate we measured are genuine, since affinity
differences were also found by means of binding analysis on a human cell line (24).
The short half-life of the 17-1 A-antigen complex (IK seconds for the bivalent antibody)
explains the inefficient /n v/vo tumour targeting of this antibody [23], but also suggests that the
clinical responses obtained with this antibody may be largely caused by other factors than tumour
accretion (e.g. the immunogenicity of this antibody). Indeed, treatment of colorectal carcinoma
patients with an anti-idiotypc antibody to the 17-1A antibody has been shown to result in a
humoral, as well as a cellular immune response to the EGP-2 antigen [25].
The use of the phage display system turned out to be necessary to retrieve binding MOC-
31 scFv clones; we had to perform two rounds of phage selection of a mini-repertoire in order
to find MOC-31 binding scFvs. When cloning V-genes from hybridomas, a certain percentage
(typically 5O%-95%) of non-binding or non-functional scFvs may be generated because of errors
introduced during PCR amplification of the genes, Ig mRNA contribution of the myeloma fusion
partner, alterations in the genes introduced by the primer set used, cloning artefacts (e.g.
deletions, recombinations, insertions or frameshifts (for review, see [26]) or a combination of
these factors. Furthermore, the antigen binding surface might be slightly distorted or deformed
by the introduction of a linker sequence between the VH and VL domains. The use of cloning
vectors that allow expression of both secreted soluble scFv molecules and of phage displayed
antibodies (16) is therefore recommended for hybridoma V-genc cloning. Using an wi w7ro
model system (Roovers «•/ a/., in preparation) we could estimate the enrichment factor of specific
MOC-31 phage over non-binding phage to be 150 per selection round, which means that the
estimated starting frequency of functional MOC-31 scFv in the small library was at least I in
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135000. This very low frequency of functional MOC-31 scFv necessitated the use of the phage
display system to retrieve binding clones, an observation that has also been reported by others
[27J.
The sequences of MOC-31 and MOC-161 antibody V-genes are different from the
previously cloned anti F.GP-2 antibodies (17-1 A: [28]; 323/A3: [24]. MOC-31 is very similar
to 323/A3 in both heavy and light chain sequence: there are 11 amino acid differences for VH
and 3 for VK, with an additional 6 and 2 silent mutations respectively in the non-primer encoded
sequences. The CDR3 of the heavy chain is different, but equal in length; the CDR3 of the light
chains arc identical. The MCX'-I6I VH on the contrary, shows a higher homology to 17-1A (with
22 amino acid differences in the non primer-encoded V gene segment) than to MOC-31 or
323/A3; its VK is very different from all other reported sequences (Table 3). It is intriguing that
all anti EGP-2 antibodies studied here use VH-scgments with a CDR3 length of 6-7 residues.
These homologies may be a reflection of the fact that all four antibodies bind to the same
immunotlominant epitope on I-XiP-2.
We have tested and confirmed the fine specificity of the cloned antibody fragments using
immunohistochcmical staining of human carcinoma, in addition to an ELISA-bascd assay (data
not .shown). This is an important issue when cloned antibody fragments are to be used in
targeting studies, since the cloning procedure itself may slightly alter the epitope recognition of
the antibody.
To use the isolated scFvs in tumour targeting studies, antibody fragments with very low
off-rates are required, since the loss of avidity of these monovalent fragments combined with
their rapid clearance from blood leads to reduced retention in the tumour [10]. It can be
calculated that for efficient tumour retention, off-rates in the region of 10' s ' or better are
required |29], yielding a half-life of bound complexes of 19 hours or longer. Since the MOC-31
antibody V-genes were cloned in a phagemid vector allowing expression on phage, it is possible
to affinity mature the antibody fragments (and in particular the off-rate), for example by chain
shuffling or by random mutagenesis of the genes (for review, see [30].
Alternatively, rather than affinity maturation, more avid molecules such as bivalent or
multivalent versions of MOC-31 scFv may be made (for review, see [31]. A second antigen
binding site in the same molecule creates a large avidity effect, which makes the apparent affinity
of such bivalent antibody species much higher. ScFv dimers. including non-covalently associated
diabodies, have indeed been reported to show superior imaging characteristics of solid tumours
than their monovalent counterparts [10,32, 33], mainly due to the slower off-rate of these avid
molecules. Our cloned scFv antibody fragments already show a variable degree of dimerisation,
as shown by gel filtration chroinatography of the IMAC-purified scFv preparations (Fig. 2). Non-
covalent scFv-dimers or trimers of MOC-31 and MOC-161 may easily be made by shortening
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the linker sequence separating the VH and Vtc domains to less than 10 residues to yield diabodies
(31]. or by deleting the linker completely to generate trimeric molecules [34].
In conclusion, the V-genes encoding these antibodies arc useful building blocks tor the
rational design and generation ot" immunotherapcutics lor the treatment of solid tumours. The
antibodies may for example be converted to fully human ones by guided selection [35], which
will reduce the chance of inducing a human anti mouse antibody (HAMA) immune response
during repeated administration to patients. Alternatively, bispecific antibodies (based on an anti
EGP-2 binding site and an anti CT)3 binding site) may. together with costimululory signals, be
used to provide T-cells with tumour specificity and cytotoxic potential [7|. We have recently
synthesised such a bispecific molecule: a diabody consisting of the MOC-31 V-gcncs in
combination with the V-gencs of an anti CD3 antibody. This diabody is capable of in vi'fro
retargeting T-cells to lung cancer cells [36]. Additional antibody engineering is expected to lead
to the development of completely human immunothcrapcutics based on the HGP-2 antigen with
improved affinity, dissociation rate, format and -thus- pharmacokinctics to achieve maximal
clinical efficacy.
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Multivalent recombinant antibody fragments provide high binding avidity and unique
specificity to a wide range of target antigens and haptens. This review describes the design and
expression of diabodies, triabodies and tetrabodics using examples of scFv molecules that target
viruses (influenza ncuraminida.se) and cancer (Ep-CAM; epithelial cell adhesion molecule). We
discuss the preferred choice of linker length between V-domains to direct the formation of either
diabodies (60kDa), triabodies (90kDa) or tctrabodies (120kDa), each with size, flexibility and
valency suited to different applications for /« Wvo imaging and therapy. The increased binding
valency of these scFv multimers results in high avidity (low off-rates). A particular advantage
for tumour targeting is that molecules of 60-100kDa have increased rumour penetration and fast
clearance rates compared to the parent Ig (150kDa). We highlight a number of cancer-targeting
scFv multimers that have recently successfully undergone pre-clinical trials for /n v/vo stability
and efficacy. We also review the design of multi-specific Fv modules suited to cross-link two or
more different target antigens. These bi- and tri-specific multimers can be formed by association
of different scFv molecules and. in the first examples, have been designed as cross-linking
reagents for T-ccll recruitment into tumours (immunothcrapy), viral retargeting (gene therapy)
and as red blood cell agglutination reagents (immunodiagnostics).
1. Introduction
Whole antibodies provide excellent target-binding specificity but are limited in clinical
imaging applications /« Ww due to their long circulating lives and associated effector functions.
Similarly, for iw W/w diagnostics, antibody fragments alone (without Fc) can provide the full
range of immunoassays, which represents 30% of the US$20 billion per annum diagnostic
industry. Recombinant antibodies and their fragments have become the paradigm for the design
of these high-affinity, protein-based targeting reagents (Hudson, 1998; Hudson, 1999; Hudson,
2000; Dall'Acqua and Carter, 1998) which now represent over 30% of all biological proteins
undergoing clinical trials. This has recently culminated in FDA approval for the first engineered
cancer therapeutic antibodies (Rituxan™ and Bexxar™ for non-Hodgkin lymphoma, HerceptirP*
for breast cancer). These immunotherapcutic antibodies are designed to include the Fc domain
for prolonged scrum half-life and complement-mediated effects.
Recent successes in the design and applications of engineered antibodies are based on their
reduction in size, dissection into minimal binding fragments, and rebuilding into multivalent
high-avidity reagents (Fig. 1). Antibody fragments have also been fused with a range of
molecules limited only by the imagination, including radioisotopes for cancer imaging, enzymes
for prodrug therapy, toxins for targeted cell killing, viruses for gene therapy, lipids for improved
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systemic delivery and biosensors for real-time detection of target molecules. Revomhinant
antibodies now capture a significant share of the US$6 billion per annum immuinHiiugnostic
market, from in W/ro immunoassays to m v/vo tumour and clot imaging reagents.
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Single chain Fv antibody fragments (scFvs) arc predominantly monomcric when the V,,
and V, domains arc joined by polypcptidc linkers of at least 12 residues (Hudson ami Kortt,
1999). This review describes how selection of the V-domain orientation as well as linker length
between V-domains creates new forms of Fv modules with different size, flexibility and valency
suited for in v/vo imaging and therapy. An scFv molecule with a linker of 3 to 12 residues cannot
fold into a functional Fv domain and instead associates with a second scFv molecule to form a
bivalent dimer (diabody, ~60kDa). Reducing the linker length below 3 residues can force scFv
association into trimers (tnabodies, ~90kDa) or tctramers (~ 120Kda) depending on linker length,
composition and V-domain orientation. We discuss two of our own model scFv systems in detail;
a) the NCI0 antibody that targets influenza neuraminidasc (Kortt ct al., 1997; Atwcll ct al., 1999)
and b) the anti-cancer MOC-31 antibody (Souhami ct al., 19X8; Roovcrsct al., 1998) that targets
epithelial cell adhesion molecule (Ep-C'AM, also known as IiGP-2). Further, we review the
design and expression of multi-specific Fv modules suited to cross-linking target antigens for
cell-recruitment, viral delivery and immunodiagnostics (Segal ct al., 1999).
2. Multivalent antibody fragments
To expand the versatility of antigen-binding proteins, antibodies have been redesigned
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to tailor binding properties, valency and pharmacokinetic behaviour using genetic engineering
and rational protein modeling. Intact antibodies are naturally occurring, multivalent molecules
(Fig. I), which provide a significant increase in functional affinity (avidity), particularly for
pentameric IgM molecules which can potentially interact with 10 antigen sites at a time. A
similar increase in functional affinity is achievable when Fab or scFv fragments are complexed
into dimers, trimers or larger aggregates (Pluckthun and Pack, 1997). Whole Igs allow flexibility
between antigen binding sites and this remains important for engineered antibody fragments; in
intact Igs the 'elbow' angle within Fab arms and 'hinge' angles between Fab arms allow significant
flexibility, and numerous cross-linking geometries (Roux et al., 1997; Roux et al., 1998). Despite
this flexibility, intact Igs are often not able to cross-link adjacent receptors on the same viral or
cell surface (Thouvenin et al., 1997; Ghetie ct al., 1997). Recently, cross-linked whole Igs
(presumably tctravalent) were shown to cross-link adjacent receptors on the same cell surface,
and thereby activate intraccllular signalling and apoptosis (Ghetie et al., 1997). However, the
large (3(H)kDa) size of cross-linked whole Igs is probably ineffective for tumour penetration. For
these very reasons, there have been many attempts to conjugate Fab or scFv molecules into
dimers or higher multimers (Fig. I) to produce high-avidity reagents of optimal size (60-
I2()kl)a). capable of rapid tumour penetration without fast renal clearance. Such designs have
included chemical cross-linking strategies and a variety of recombinant fusions using adhesive
protein domains or peptides (Hudson, 1998; Hudson, 1999; Hudson, 2000; Pluckthun and Pack,
1997). This review describes a far simpler strategy to create multimers, by manipulating the
linker length between V domains (Fig. 2; Hudson and Kortt, 1999). These scFv molecules
associate into multimers and can be designed with either high avidity to a single target antigen
or with multiple specificities to different target antigens.
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3. Linker design and \-domain orientation in the formation of scFv
multimers
The single chain variable fragment (scFv) in which the antigen binding domains of an
antibody (V,, and V,) are joined by a flexible potypcpiidc linker provides the minimal antigen
binding format of an antibody which can be expressed in /-." to// (Huston et al.. 1988; Bird et ul.,
1988). The most common linker designs contain a combination of glycine and serine residues
to provide flexibility and protease resistance, although the linker sequence can also be optimised
by phage display (Turner et al., 1997). Linkers greater than 12 amino acids in length provide
enough flexibility for the V,,and V, domains to assemble in the natural I'v orientation to form
a monovalcnt antigen combining site comparable to the hah fragment ol the parent antibody (Fig.
1; Kortt et al., 1994; Whitlow et al., 1994; Zdanov et al.. 1994). Shortening of the linker to 12
residues or less prevents the V,, domain from interacting with its attached V, domain in the
natural Fv orientation. Instead, two separate scFv molecules are required for complementary V „
/V, pairs to associate to form a bivalent dimcr. termed a diabody (Figs. 2. 3a; llolliger et ul.,
1993. 1996; Pensic et al.. 1994; Atwell et al.. 1996). Complete removal ol a linker from scFv
molecules in V^ -V, orientation drives three scFv molecules to associate into a trimer, termed a
triabody (Fig. 3; Kortt et al., 1997; Iliades et al.. 1997; Pei et al., 1997). Atwell et al. (1999)
refined this definition of linker dependent oligomeric transition further and established with the
murinc NCIO (anti ncuraminidase) scFvs that triabodies were formed exclusively when linkers
of 0-2 residues were used whereas diabodics were formed with linkers of 3-5 residues (Figs. 3a,
4a). The transition from dimcr (diabody) to trimer (triabody) was distinct as the linker length was
reduced from three to two glycine residues; modeling studies were consistent with three residues
as the minimum linker length compatible with diabody formation for NCIO (Fig. 3a).
A precise definition of the N- and C-tcrminal residues of the V-domains is required when
designing the linker length. In this review, antibody residues arc numbered according to Kabat
et al., (1991). The murinc NCIO scFvs (V^-V, orientation) were described precisely in Atwell
et al. (1999) and had linker residues shown in Fig. 2. The linker sequences were carefully chosen
after examination of the 2.4A resolution structure from X-ray diffraction analysis of the NCIO
Fab-NA complexes (Malby et al., 1994; Malby et al., 1998). Scr""- wa.s selected as the V,, C-
terminus because it was not in any direct hydrogen bonded contact with other V,, domain
residues, whereas Thr""° and Val"'" contacted framework residues Vaf" and Scr""'
respectively. The V, N-terminal residues were Asp-Ile-Glu in which side chain atoms in Asp''
and lie'" contacted framework residues Glu" and Thr''" and could not act as defacto linker
residues. Therefore, V,, Scr""' was joined to V, Asp"' either directly or by additional (flexible)
Gly/Ser resides to give linkers of various defined lengths; 0-2 residues formed triabodies, 3-10
residues formed diabodies (Figs 3a, 4a; Atwell et al., 1999).
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Fig, In shows the effect of linker Icnglh in directing formation of NCI 0 scFv diabody or triabody in V,, linker-
V, orientation: molecular models (Co traces) are shown of diabodies with linkers of 3 or 4 residues and triabodies
with linkers ol 0 or 2 residues. Diabody orientation corresponds to the crystal structure described by Pcrisic et al
(IW4) mid truibody orientation is shown with the three-fold symmetry axis perpendicular to the page similar to tn?
model described by Kortt et al. (IW7). The Co backbone for the different scFv molecules are shown in pink, whit
and purple; C I)R loops in the VII and VL. domains are highlighted in blue andycllow and the linkers are coloured
green, Fig. 3b shows molecular models (Co traces) of NCI 0 scFv triabody (a) and tetrabody (b) with V, linked
directly to V,,. The I'v modules were aligned by rigid 3-fold and 4-fold symmetry for triabody and tetrabody
respectively. The V, domains are shaded light grey and V,, domains are dark grey. To highlight the interactions
across the I'v interface and the stcric clash in triabody configuration, loops LI5-L17 and L55-L6I are shown h
green and magenta, respectively.
Modeling studies based on the X-ray crystal structure of a different diabody (L5MKI6;
5-residue linker scFv) also showed that reducing the linker to 'just one or two residues' seriously
strained the diabody association (Perisic et al., 1994). Further, a one-residue linker that joined
mismatched V-domains (V,, from Bl-8 antibody and V^  from NQ11 antibody) indeed formed
a triabody. but V-domain orientation was distorted and a CDR loop structure was misplaced (Pei
et al., 1997). A report of an scFv 'diabody' library in which V,, and V[ domains were joined
without a linker confused the field since the molecular mass of these 'diabodies' was not
determined and many were likely to be triabodies (McGuiness et al., 1996).
Reversal of V-domains to \VV,, orientation was observed to play a significant role in multimer
configuration for the murine NC10 scFv-0 (Fig 4b). Arg"""" was selected as the C-terminal
residue of V, and linked to Gin'" of V,, either directly or with one to five Gly/Ser residues (Figs.
2,3a,4a; Dokval et al., 2000). Diabodies were the predominant conformation for 3, 4 and 5
residue linkers whilst tetrabodies were the preferred conformation for V^-V^ domains joined
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dirccily (scFv-0; Fig 4b). The transition between dia'tria'tetrabodies was not as distinct as with
VH-V, orientation: for example, reducing the scFv linker length in NC'IO V, -V,, from 3 to 2
residues did not precisely dictate a transition between diabodies and triabodics. Instead. 2-residue
linked V, -V^ domains formed a mixture of diabodies. tnabodics and tctrabodics. Molecular
models of V, -VH tetrabodies (Fig. 3b; Dolezal et al.. 2000) showed that the stcric restriction that
caused the preference for 4 instead of 3 scFv molecules to combine into tctramers might he due
to loop L55-L62 (particularly residues L55-L58) clashing with residues L15 and Lib and resulted
in unstable V, -V,, triabodies (Fig. 3b). The structurally similar loop (H58-H67) in the V,,-V,
tnabodies does not have this steric clash (Fig 3a; Arwcll ct al.. 1444). In addition, other subtle
differences in Fv contact interfaces for NC10 between V ,,-V, and V ,-V „ orientations could be
responsible for the different transitions in multimcric state.
We have shown that NCI0 tetrabodies (scFv-0, Fig. 3b) have 4 fully active antigen binding sites
(Dolezal et al.. 2000). To date, active tetrabodies have been described for only one other scFv
(HD37, targeting CD 19; Le Gall et al., 1999). This HD37 antibody had unusual associations
since tetrabodies were the preferred form in V,,-V, orientation with a single-residue linker.
However, the diabody-triabody-tctrabody transition was not precisely defined since only scFv-18,
-10. -1. -0 were characterised. HD37 scFv IX formed a mixture of monomer, dimer and small
amount of tetramer, the scFv-10 formed mainly dimcr with some tetramer, the scl-'v 1 formed
exclusively tetramers whilst the scFv-0 formed exclusively trimers. The formation of a tetramer
with scFv-1 and a trimer with scFv-0 for HD37 was unexpected and contradicts our previous
data with NC10 scFvs (Atwell et al., 1999; Dolezal ct al., 2000). However, binding assays with
the scFv 0 triabody suggested a monovalent interaction with the antigen (Le Ciall et al., 1999),
indicating that this triabody may be incorrectly folded and is therefore an aberrant molecular form
since it did not possess three active antigen binding sites.
It has been documented that V,, and V, domains are not related by a rotation of IK0T about the
pseudo two-fold axis (parallel to the interface), but only by about 1701' (Huston ct al., 1991;
Padlan, 1994). Therefore, the C-tcrminus of V, is further away from the N-terminus of V,, ( 3 9 -
43) than the C terminus of V^ is from the N-tcrminus of V, (-32-34 7). Consequently, when the
two isomers are linked with identical linkers the greater constraints in the V, to V,, construct
would be expected to favour a larger proportion of higher-order oligomers (Pliickthun and Pack,
1997). This expectation is contradicted in our studies on NC'IO which showed that the scFv 2
and scFv-1 V,-V,, protein preparations contain functional dimcrs (Dolezal et al.. 2000) whereas
their V^-V, isomers arc trimcric (Atwell et al., 1999). It is tempting to speculate that in the
V^-VH proteins the C-tcrminal residues of V, domain and/or N-tcrminal residues of \{, domain
provide additional flexibility in the linker region, which dictates the transition between dimcrs,
trimers and tetramers. There is some structural consistency between different antibodies that
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could lead to a generic definition of linker effect even though the association of Fv modules is
unlikely to depend on the linker length and linker flexibility alone. The Fv interface in crystal
structures of diabodies and triabodies is observed to be almost exclusively between V ^domains
when scFvs are in the V,,-V, orientation (Fig. 3a; Malby et al., 1998; Pei et al., 1997; Perisic et
al., 1996). The detailed molecular interactions between V-domain interfaces, Fv interfaces and
the terminal residues held in contact within the V-domain framework are obviously unique for
each antibody and therefore will affect both flexibility and stoichiometry of diabodies, triabodies
and tetrabodies.
We can only hypothesize that these studies on murine NC10 and HD37 linker lengths will be
representative for other antibody scFvs. Therefore, for other scFvs, we suggest that residues
equivalent to NC10 Ser""* of V,, and Asp''' of V^ be used to define the zero-residue, minimal
contact for V-domains joined in V^-V, orientation and Arg""' of V, and Gin"' of >/„ in X - V,
orientation. With this numbering, we predict that linkers of 3-12 residues will predominantly, if
not exclusively, form diabodies.
4. Expression and stability of scFv multimers
ScFv molecules can be expressed into the periplasm of £.co/; with efficient signal peptide
excision, correct V-domain folding and disulphidc bond formation (Power and Hudson. 2000;
Verma et al., 1998). These antibody fragments fold efficiently in the oxidising extracellular
environment and are targeted to the periplasm using secretion signals (most commonly pe/B and
o/n/>A). Bacterial synthesis of scFv molecules was originally done in 'primitive' periplasmic
expression vectors using leaky promoters (/ac, fr/> and /at\), all of which are not effectively
repressed. For example. /</<• promoters are controlled inefficiently by the /ac repressor and are
induced by the addition of isopropyl-P-galactosidase (1TPG). Although these expression systems
can be improved (Coia et al., 1996; Kipriyanov et al., 1997) the levels of protein recovered are
usually low (below Img/litre from shake flasks). A far more effective strategy is to use strong
promoters (fe/, pAoA, araBAD and lambda), initially with tight repression to ensure efficient
cell/vector growth, followed by short burst of induction (Power and Hudson, 2000). We have
shown that it is possible to extract correctly folded scFv multimers either from the periplasm by
osmotic shock, or by recovery in denaturants followed by refolding (Iliades et al., 1997; Kortt
et al., 1997). Final purification is most easily achieved by affinity chromatography using an
epitope tag such as the octapeptide (FLAG) or His,, fused to the C-terminus of an antibody (Kortt
et al.. 1994; Casey et al.. 1995). The use of eukaryotic expression systems for recombinant
antibody fragments was reviewed by Verma et al.. (1998) and indeed, was recently shown to be
successful for bispecific diabodies (5mer linker) (Kontermann and Muller, 1999). Although the
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yeast Pk'Wa pas/oris is particularly attractive (Fitzgerald et al., 1997). bacterial systems have
provided the most cost-effective route to date for production of small multimeric scFvs in our
expenence. Prokayotic expression systems routinely produce greater yields of scFv monomers
and multimers, particularly if a strong promoter is used to drive product synthesis (Power and
Hudson. 2000).
How do scFv multimers assemble in the pcriplasm? If linker length prevents natural Fv
formation, then the V-domains of one scFv molecule will associate with those of an adjacent
scFv molecule (Fig. 3). Thus, two scFv molecules will preferably combine into a diuhody
providing the linker is of sufficient length. For triabodies. two scFv molecules initially combine
by association of a single V,, to a single V ,^ but linker length prevents the second Fv module
from forming correctly, thus allowing combination with a third scFv molecule through the
uncomplexed V,, or V, domains. There is a strong preference for the minimum sized, correctly
folded structure; thus scFv monomers dominate when the linker is greater than 12 residues
(Amdt et al., 1998), and diabodies dominate when the linker is between .1 anil 12 residues (Kortt
et al., 1997; Atwell et al., 1999). As the linker length is reduced, a higher percentage of tritihodics
is produced (i.e. there are more triabodies in scFv-3 than scFv 5), since the shorter linker
restricts V-domain flexibility and increases the time required for complete diubody association,
thus allowing a third scFv to associate into a triabody. Diabodies cannot form with linkers of two
residues or less with NC10 scFv in V,|-V, orientation and only higher multimers arc produced
(with correctly formed Fv modules).
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•) ScFv in V,,-V| orientation with profiles superimposed on the same scale for triabodies (scFv-O, scFv-1. scFv-2)
and diabodics (scFv 3, scFv 4). The major peak ofscFv I (green) and scFv 2 (blue) peakeluted at a similar time
to the scFv- 0 iriabody (red; -23 min, -70kDa) while scFv 3 (black) and scFv 4(aqua) eluted at a time (-24.5 mia
-54kDa) similar to the scFv-S diabody of Kortt ct al., 1997. b) scFv-0 tetrabody (V,-VH orientation; Fig. 2)
compared to scFv-0 iriabody (V,,-V, orientation: Fig. 2).
Concentration of protein samples, typically to Img/ml, increases multimer formation;
thus the monomer/dimcr equilibrium in scFvs (linkers greater than 12 residues) becomes biased
towards dimcrs (diabodies). Similarly, concentration can increase the proportion of triabodies
and higher aggregates in scFv diabodics (linkers between 3 and 12 residues). This phenomenon
suggests that the V,, /V, interface in the Fv module can dissociate, enabling V-domains to shuffle
and realign The rate of Fv dissociation will be unique to each particular antibody. Several
methods can be used to increase the stability of Fv modules, including storage as antibody-
antigen complex (Lawrence ct al., 1998), the addition of buffer components, adjusting pH and
ionic strength (Arndt ct al.. 1998), design of'knobs-into-holes' mutations (Zhu et al., 1997;
Dall'Aqua and Carter, 1998), or by design of inter-domain disulphides (Brinkmann et al., 1997).
All these methods arc effective for scFv momomcrs and multimcrs.
5. Size of scFv multimers and effect on m vivo pharmacokinetics
ScFv multimers such as diabodies (~60kda) and triabodies (~90kDa) are significantly
larger than scFv monomers (~30kDa) and thereby have an advantage for />; v/v« applications by
minimising the rapid, first-pass clearance from the circulation (Colcher et al.,1999). This
advantage of increased size in clearance rate is offset by decreased tumour penetration, since
dissemination rate through the vascular network into tumours is correlated to the size of the in
vivo therapeutic molecule. Indeed, the most recent /n v/'vo data using radiolabelled diabodies in
three different xenograft tumour models shows that diabodies have a significant advantage over
monomcric scFv (Wu et al., 1996; Wu et al., 1999; Adams et al., 1998; Adams et al., 1999; Viti
et al., 1999). Similarly, the small size of dia/triabodies has advantages for tumour penetration
over the larger multimeric Fab chemical conjugates and intact whole Ig (Fig. 1; Antoniw et al.,
1996; Casey et al., 1996). In our own unpublished in vivo studies using murine xenografts, the
60kDa diabodies gave optimal tumourblood (T:B) ratios through to 10 hours post injection at
which time the larger 120kDa F(ab'), began to outperform diabodies. In these studies, the T: B
ratio at 24 hours for an anti-Le- diabody was 30:1 and the F(ab')_, was 55: 1. Previous
investigations with anti-CEA diabodies (Wu et al., 1999) and anti-HER2/neu diabodies (Adams
et al., 1998) reported T: B ratios of 48.7:1 and 30:1 respectively at this time point, while a T: B
ratio of 3.7:1 was observed in a study with an anti-CEA F(ab'),(Pedley et al., 1993; Casey et al.,
1999). The pharmacokinctic results also concur with the biodistribution observations illustrating
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a rapid tenninal clearance from the blood. The anti-CE A diabody gave maximal tumour uptake
at 2 hours of 13.68% ID/g. with /, ,a =0.25 ± 0.02 hr and /, ,(J= 2.89 ± 0.74 hr (Wu ct al.. I999).
In comparison, the anti-HER2neu '"M-labelled C6.5 diabody gave a tumour peak level of 10.1%
ILVg with r, ^a= 0.67 hr and f, ;(J= 6.42 hr (Adams et al.. 1998). Two separate investigations with
'"l-anti-CEA F(ab"),constructs, observed maximal tumour uptakes of 12.8°o II) g at 6 hrs p.i.
and 32% ID/g at 8 hours p.i. resectively (Pedlcy et al.. 1993). These phannacokinetic profiles arc
typical of antibody based molecules with sizes beneath the renal threshold for first-pass
clearance.
The clearance of smaller molecules by the kidney may impair the ability to concentrate the
molecule in the tumour (Dillman. 1989). Improvements in the pharmacokinetics of these small,
recombinant antibody fragments can be achieved by increasing their surface negative charge, or
modifying the radionuclidc chemistry, both strategies reducing the frequently observed renal
uptake (Pavlinkova ct al.. 1999a; Arano et al.. 1999). These strategies include prc-treatment or
co-administration of cationic amino acids such as D-lysine (Behr, 1997; Arano et al., 1999;
Carrasquillo, 1998).
The actual benefit for tumour targeting can be estimated by an 'Imaging Figure of Merit' score
according to the formula described by Wu et al., (1999). For short-lived radioisotopes ( "1 . "I"),
60kDa diabodies are ideal for /w v/io imaging due to the faster clearance rates and greater IFOM
score over 90kDa triabodies and minibodies (scFv-CH3 dimers). For longer half-life radiolabels
(**Y, '"In), the slower clearance of triabodies/minibodics compared to diabodies generates a
higher IFOM score. An intriguing result by Adams et al., (1998) showed that diabodies had
improved tumour targeting compared to scFvs that had been dimerised by disulphide bonds and
might reflect higher iw Wv« stability in the diabodies (Adams et al., 1993; McCartney et al.,
1995). Indeed, the linkers in diabodies and triabodies arc relatively inaccessible to proteases
compared to the long linkers required for monomeric scFv (Fig. 3a).
Although several groups continue to develop covalent scFv dimers (Pavlinkova et al., 1999b;
Beresford et al., 1999), we predict that diabodies (60kDa) will be more stable than these scFv
dimers and, since diabodies also provide more rapid tumour penetration and clearance than Fab'2
(lOOKda), they are therefore the preferred reagent for radioimaging with short half-life
radionuclides such as Technctium (gamma) or Fluorine (positron). Conversely, for longer half-
life radiolabels designed for immunotherapy (**Y, '"In), the slower clearance of Fab'2 compared
to diabodies generates a higher T:B ratio and higher total tumour uptake and radiothcrapeutic
index. In a study comparing Fab'2 dimers versus Fab'3 trimers (TFM. Fig. 1, Casey et al., 1999),
optimal cumulative dose indexes were obtained with Fab'3 when *'Y-labclled and an optimal
T;B ratio with Fab'2 when '"l-labelled. Following the trend, we would expect that radiolabclled
triabodies (90 kDa) and tetrabodies (120 kDa) would outperform diabodies in total tumour
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uptake due to higher avidity and reduced blood clearance (Atwell et al., 1999; Hudson and Kortt.
1999; LcCiall el al., 1999), which makes them an attractive target for further development and
evaluation. Therefore, the optimal construct size is an intelligent prediction that balances the
rapidity of blood clearance, the absolute rumour uptake, and the tumour to blood ratios.
6. Flexibility and avidity in scFv multimers
The most important advantage of multivalent scFvs over monovalent scFv and Fab
fragments is the gain in functional binding affinity (avidity) to target antigens. High avidity
requires that scFv multimers arc capable of binding simultaneously to separate target antigens.
This avidity gain also occurs from multivalent binding to cancer cell surfaces as demonstrated
in the improved /« V/VM tumour imaging of diabodics over scFv monomers (Wu et al., 1999; Wu
ct al., 1996; Viti ct al.. 1999; Adams et al., 1998; Adams et al., 1999). The gain in functional
affinity for scFv dia/triabodics compared to scFv monomers is significant and is seen primarily
in reduced off-rates, which result from multiple binding to two or more target antigens (on a
surface) and to rcbinding when one Fv dissociates (Kortt ct al., 1997; Pluckthun and Pack, 1997).
For these reasons, it is difficult to quantitate accurate kinetic rate constants from binding data
measured for multivalent binding interactions on immobilised target antigens, using ELISA or
biosensors (Muller et al., 1998a). Multiple binding to surface-bound antigens is dependent on
correct alignment and orientation in the Fv modules of diabodies and triabodies. For full avidity,
multivalent scFvs must bind to two or more adjacent molecules on the same cell surface and the
antigen binding sites must therefore point towards the same direction. If multiple binding is not
sterically possible, particularly for surface-bound antigens, then apparent gains in functional
affinity are likely to be small and due only to the effect of increased rebinding, which is
dependent on diffusion rates and surface antigen concentration. Antigen orientation also affects
the ability of diabodics and triabodies to simultaneously bind to multiple antigens on a cell
surface, and this factor is particularly important in the design of any therapeutic reagent required
to cross-link surface receptors on either the same or adjacent cells (Pluckthun and Pack, 1997;
Packetal., 1995).
Flexibility in both scFv diabodies and triabodies is evident in our single-molecule imaging
studies using electron microscopy (Lawrence et al., 1998; Atwell et al., 1999). NC10 diabodies
were 'tagged' with Fab anus (using an anti-idiotype Fab fragment as the target antigen) and EM
images revealed considerable flexibility with angles between antigen binding sites ranging from
60 to ISO degrees (mean 116°, Lawrence et al., 1998). This flexibility was also noticed in
modelling studies of a different (L5MK16) diabody (Holliger et al.. 1996) in which the predicted
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angle between the Fv domains was larger than 122° and ranged from 138° to 166°. Triabodies
are also flexible molecules since only 10"o of the 'tagged' tripod-like projections have three
equal inter-arm angles of 120° (±5°), consistent with the rigid model of 3-fold symmetry (Atwcll
et al., 1999). The observed distribution of angles between Fab arms in the Nt'K) triabody
complexes ranged around three angles of mean 88°, 121" and 149" (Atwcll et it 1. 1999;
Lawrence et al.. 1998). The molecular models of NC10 tnabodics show that the contacts Ivnuvn
Fv modules arc minimal and would allow considerable flexibility (Fig. 3). The IM NIUI:<.N ,IIM>
showed that all antigen binding sites in diabodies and triabodies were active and capable of
binding target antigens. Furthermore, analysis of binding kinetics revealed that the antigen
binding sites had equivalent binding affinity, and each site was comparable to the monomcric
scFv (Kortt ct al.. 1997).
7. //i w/ro application of multimeric murine MOC-31 scFv (anti Ep-CAM)
Using MOC-31, a cell-targeting antibody with specificity to Fp-CAM (Souhami ct at.. 1988;
Roovers et al., 1998), we intended to show the first definitive data thut both diabodies and
triabodies can bind and cross-link adjacent surface receptors in v»'vo. This will obviously depend
on flexibility between the Fv modules and the orientation of the antigen binding sites, as well as
the structure of the receptor. The tumour antigen epithelial cell adhesion molecule (Ep-CAM,
also known as EGP-2 receptor and 17-1A antigen) is a type-1 transmembrane protein
overexpressed on a variety of human carcinomas (Gottlinger et al., 1986; Hal/ar ct al., 1999). The
molecule may function as a homophilic cellular adhesion molecule (Litvinov ct al., 1994) and
interacts with the cadherin-based junctions (Litvinov et al., 1997; Balzar et al., 1999). Despite
the fact that relatively little is known about the exact function of Ep-CAM, a number of clinical
studies using murine monoclonal antibodies in cancer patients have validated the approach of
targeting this antigen for the treatment and imaging of solid tumours (Frodin et al., 1988;
Riethmuller et al.. 1994; Riethmiiller et al., 1998; Kosterink et al., 1995). Monomcric and
multimeric forms of MOC-31 were constructed in scFv format (V^V, orientation) containing
15-, 5- and 0-residue linkers, tagged at the C-terminus with FLAG and His,,. The linkers
consisted of (GlyjSer), for the monomer (scFv-15) and Gly,Ser for the diabody (scFv-5); the \(,
C-terminal was directly fused to the V, N-terminus for the triabody (scFv-0). In the design of
MOC-31 monomer scFvs (15 residue) and diabodies (5-residue), linkers joining V,, and V,
domains are attached immediately following Ser-113 at the C-terminal VTVSS sequence of V „
This is consistent with the numbering system of Peresic et al. (1994) and Iliadeset al. (1997).
However, Ser-113 can be considered to be part of the flexible polypeptidc linker and, according
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to the scFv numbering of Atwell et al. (1999) and Dolezal et al. (2000), MOC-31 15mer and
5mer would be described as having sixteen and six residues in the linker, respectively. Similarly,
Ser-113 in the MOC-31 Omer would be a single-residue linker according to Atwell et al. (1999)
and Dolezal et al. (2000). We show that these scFvs, dependant on the linker length, indeed form
monomer scFv, diabody and triabody which are all able to recognise the native antigen present
on the cell surface as determined by FACS analysis and present in primary, patient-derived
tumour sections as shown by immunohistochemistry. MOC-31 scFv-15, -5 and -0 were isolated
from the pcriplasm and purified by IMAC following expression in £.co//. The molecular mass
and multimcric state of each scFv was estimated by size exclusion chromatography on a Superose
12 column (Fig. 5).
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Figure 5
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.vc-Fv-5. . u F v - 0
p/i<//ng f« monomer,
(/WKY ««</ frimfr rev/wrf/ve/y.
The column was equilibrated with
PBS, pH 7.4 and run at a flow rate of
0.5ml/min.
The retention times observed for the major component of each scFv were consistent with
a trimer (24.31 min), dimer (25.95 min) and monomer (27.75 min) as previously reported for
NC10 V,,-V, scFvs (Kortt et al., 1997, Atwell et al., 1999 and Dolezal et al., 2000). The MOC-31
scFv multimers were peak purified on Superose 12 to remove aggregates prior to binding analysis
by BIAcorc, FACS and immunohistochemistry. In our experience with NC10 and MOC-31
scFvs, the yields of soluble diabodies (5mer) and triabodies (Omer) are marginally lower than
monomeric scFv (usually a 15mer). However, it would not be correct to state that yields are
routinely lower as valency increases and indeed, yields vary widely between different scFv
constructs and vector/ host cell expression systems.
Rinding of the MOC-31 scFv. diabody and triabody to recombinant Ep-CAM was measured
using Surface Plusmon Resonance (BlAcore 2000) (Figure 6). Purified, recombinant Ep-CAM
was covalently coupled to a CM5 sensor chip via amine coupling to produce a relatively low
density antigen surface of 750 resonance units (RU) to reduce overcrowding of binding sites and
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to allow maximal contact between antibody and antigen. Furthermore, a high flow rate was used
to minimize rebinding events during the dissociation phase. Analysis of the kinetics of binding
of the MOC-31 scFv. diabody and triabody revealed that the appamet dissociation rates
decreased with increasing valency of the molecules: the bi trivalent forms of MOC-31 scFv have
decreased dissociation rates compared with the monomeric form (Tig. 6). Although u direct
measurement of the cell surface retention was not performed, a decrease in dissolution rate,
measured by SPR. has been described to correlate to an extended residence time on the cell-
surface (Adams et al., 1998). Thus, the gain in apparent affinity caused by avidity and the
increase in size of these multimeric anti-Ep-CAM scFv reagents is expected to improve their /it
viVo localisation into solid tumours, thereby improving their usefulness as tumour targeting
vehicles.
Figure 6
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A BIAcorc 2(XX) was used to
analyse the binding of MCK'-JI
multimer sclvs to Ilp-CAM
coated onto (he surface of a CM5
sensor chip al a density of 7.MIRU
and a flow rate of 20ul/min.
Dissociation rate constants (kj
were evaluated using
BIAevalualion 3.0.2.
Fluorescence activated cell sorting (FACS) was used to assess the ability of each of the
MOC-31 scFvs to interact with antigen as presented on the cell surface using the colorcctal
cancer cell line CaCo2 (ATCC-HTB37) (Fig 7). An irrelevant scFv was used as a negative
control to show that binding of the MOC-31 scFvs was specific. These data demonstrate that the
monovalent, bivalent and trivalent MOC-31 scFv conformations are capable of binding to cell
surface-expressed Ep-CAM in its natural configuration. To investigate the versatility of this
reagent further, we performed immunohistochemistry with cryosections of different tissue
samples (Fig. 8). These data show specific labeling with one of the multivalent MOC-31 scFvs
to tumour cells in situ.
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Figure 7
i / scFvs Z>iWi/ig to /Ae £/>-G4A/
CaCo2 co/orec/a/ cancer ce// /wie.
Cancer cells were incubated with an excess of scFv and
binding to the CaCo2 cells was detected with the M2 anl
FLAG antibody and HTC-conjugated rabbit ami mouse
antibody. Cells were analyzed by flow cytometry using a
FAC'S-Calibur (Becton & Dickinson. Heidelberg. Germany)
and data were analyzed using thcCcllqucst software program
(Becton & Dickinson. Heidelberg. Germany) a) Only viable,
intact cells were selected as indicated in the region labeled
•Rl', b) An overlay of images illustrating the shift n
fluorescence intensity of the cell population upon staining
with the F.P-CAM specific MOC-31 mullimeric scFvs: control
scFv directed to tetanus toxoid showing background-bindhg
to the CaCo2 cells (black), monomeric MOC-31 scFv -15
(blue), dimeric MOC-31 scFv0-5 (grey) and trimenc MOC-31
scFv-0 (red).
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Bound scFv was detected with an
antibody directed to the hcxahistidine tag
(Dianova) and peroxydase-conjugated
rabbit anti-mouse immunoglobulins
(Dako). Staining was performed with
diaminoben/idin (DABVH.O,; nuclei
worecounterstained with hematoxilin. As
expected. MOC-31 scFv-5 diabody
specifically reacts with epithelial cells of
both normal colon and colorectal
. ncinoma and docs not recognise
cndothclial cells, fibroblast or other
stromal cells and lymphoid cells.
8. Multispecific scFv multimers
The discussion above lias t'ocussed on the association of identical scFv molecules to form
diatxHlics, triabodies and tetrabodies that comprise a number of identical Fv modules. These
reagents are therefore multivalent, but monospecific. The association of two different scFv
Design ami application of Duhodics. Tnabodics and Tctrahodics for
molecules, each comprising a V,, and V, domain derived from ditTerent parent Ig can form a fully
functional bispecific diabody (Holliger ct al., 1993; Atwcll c! al.. 1996). Diubodics still provide
the neatest solution for creation of bispecific scFvs and arc simpler to design and produce than
the fusion of scFvs to adhesive domains as described by Mullcr et al., (1998b) and Plucktlum and
Pack (1997). A unique application of bispecific scFvs is to bind two sites simultaneously on the
same target molecule via two (adjacent) surface epitopes (Neri et al., 1995; Robert ct al., 1999).
These 'biparatopic' reagents or 'CRAbs' gain a significant avidity advantage over a single scFv
or Fab fragments with obvious advantages for therapy and diagnosis.
Bispecific diabodies have been synthesized using a bicistronic expression vector that enables the
two scFvs to associate iw .w/u, in the /•."<•<>// periplasm. Fully active, soluble bispecific diabody
can then be isolated by osmotic shock. The construction of tricistronic expression vectors that
express three different scFv that fold into trispecific triabodies has not yet been achieved.
Multispecific scFvs that are capable of cross-linking different target antigens, arc a major goal
in clinical therapy particularly for recruitment of cytoloxic T cells for cancer treatment or ancrgy
of T-cclls for transplant therapy (Segal et al., 1999). Bispecific diabodies have three advantuges
over quadromas (bispecific whole Ig); the first is that by lacking Fc domains, bispecific duihodics
will only activate T-cclls when cross-linked to target (cancer) cells. The second advantage IN that
the anti-bispecific response in the host is minimised due to the small diabody size (lacking Fc
domains) and thirdly, the small size assists in tumour penetration.
In one example (Holliger et al., 1997), bispecific diabodies were designed to cross-link colon
cancer cells to scrum immunoglobulin (Ig) thereby inducing the complement cascade including
mononuclcar phagocyte respiratory burst and phagocytosis, and directing synergistic T-ccll
cytotoxicity. Further, by virtue of binding to serum Ig their half-life (beta-phase) was increased
fivefold compared to a control diabody of the same molecular weight. In a second example
(Kontermann et al., 1997a). bispecific diabodies with specificity to Clq recruited the complement
cascade directly. Most recent examples have focusscd on T-cell recruitment; using one Fv
module targeted to CD3 on T-cclls and with a second Fv module targeted to a cancer marker such
as EP-CAM, CEA or CD19, in one case via NIP-tagged ligands (Helfrich et al., 1998; Krcbs ct
al., 1998; Kipriyanov ct al., 1998; Manzkc ct al., 1999, Holliger ct al., 1999; Arndt ct al., 1999).
There are also numerous diagnostic applications (immunoassays) that require bispecific cross-
linking reagents (Atwell et al.. 1996; Kontermann ct al.. 1997b).
One of the more notable recent achievements has been the design of tandem bispecific
antibodies, which effectively behave as tctrabodics and thereby comprise two bivalent
components that provide both high target avidity and receptor activation (Kipriyanov ct al.,
1999).
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9. Conclusions
During the past 12 months, there has been a rapid increase in both scientific and
commercial interest in multivalent scFvs leading to the large number of publications covered in
this review. Clinical interest is due to encouraging results from phase 3 trials which has lead to
several recent FDA approvals for humanised therapeutic antibodies (Farah et al., 1998; Hudson,
1999; Hudson, 2000). Scientific interest has stemmed from the elucidation of the key elements
required for multivalent antibody design and efficient expression (Hudson and Kortt, 1999; Segal
ct al., 1999). in the next 12 months, it is likely that we will have generic solutions for improved
Fv stability, leading to improved expression yields, and generic strategies for the design of
multimers, immunotoxins and other innovative fusion proteins. It is likely that these designed
reagents will be capable of intraccllular targeting, or of redirecting T-cells for cancer therapy and
retargeting viruses for gene therapy (Worn et al., 1998; Eshhar, 1997; Wickham et al., 1997;
Watkins ct al., 1997). By providing a highly stable, protease-resistant scaffold, rccombinant scFv
multimers will continue to be the paradigm for selection of high-affinity protein-based
therapeutic and diagnostic reagents.
Acknowledgements
We thank all our colleagues in the antibody engineering program at CSIRO Health Science and
Nutrition for their helpful advice on the design and expression of scFv multimers and for their
agreement to cite unpublished results in this review. We also thank Airlie McCoy, currently at
the Heamatology Dcpt, Addenbrookes Hospital, University of Cambridge, UK, for the modelling
studies on scFv multimers and Mrs. E. van der Linden (Maastricht University, Maastricht, The
Netherlands) for excellent technical assistance in immunohistochemical analysis.
References
Adams, G.P.. Schier, R., 1999. Generating improved single-chain Fv molecules for rumour
targeting. 7 /mmimo/ A/I'/ACM/V 231, 249-260.
Adams, G.P., McCartney, J.E., Tai, M-S., Opperman, H., Huston, J.S., Stafford. W.F.,
Bookman, M.A., Fand, I., Houston, L.L., Weiner, L.M., 1993. Highly specific /n v/vo
tumour targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain
Fv. C«m-fr flt'.v. 53. 4026-4034.
Adams, G.P.. Schier. R.. McCall. A.M., Crawford, R.S.. Wolf, E.J.. Weiner. L.M.. Marks,
J.D., 1998. Prolonged in Wvo tumour retention of a human diabody targeting the
extracellular domain of human HER2/neu. flrjV. 7. Cancer 77, 1405-1412.
Antoniw. P.. Famsworth. A.P.. Turner, A., Haines, A.M., Mountain. A.. Mackintosh. J.,
Shochat. D.. llumm, J.. Welt, S.. Old. L.J.. Yarranton, G.T., King. D.J.. 1996.
-98-
Design and application ol Dtahodies. Tnarxnltcs and 1 ctrarHxiics lor c
Radioimmunothcrapy of colorectal carcinoma xenografts in nude mice with yttrium-90
A33 IgG and Tri-Fab (TFM). fin/. / Camrr 74. 513-524.
Arano. Y., Fujioka. Y., Akizawa. H.. Ono, M.. Uehara. T.. Wakisaka. K.. Nakayama. M.,
Sakahara. H.. Konishi. J., Saji, H.. I999. Chemical design of radiolubcled antibody
fragments for low renal radioactivity levels. Cantfr /?r.v 59. 128-134.
Amdt, K.M., Mullcr. K.M., Pluckthun. A.. 1998. Factors influencing (he dimcr to monomer
transition of an antibody single-chain Fv fragmenl. fi/<x7i<7ni.v/rv 37. 129IX-12926.
Amdt. M.A.. Kauss. J.. Kipriyanov. S.M.. Pfreundschuh. M.. Little. M., 1999. A bispecitic
diabody that mediates natural killer cell cytotoxicity against xenotransplantated human
Hodgkin's tumours. fi/W 94. 2562-2568.
Arwell, J.. Breheney. K.A.. Lawrence. L.J., McCoy. A.J.. Kortt. A.A. Hudson. P.J.. 1999.
scFv Multimcrs: Length of the linker between V,, and V, domains dictates precisely the
transition between diabodics and triabodics. r*ro/ci>i £n#. 12. 597-604.
Arwell. J.L.. Pearcc. L A , Lah. M., Gruen, L.C.. Kortt, A.A.. Hudson. P.J.. I W . Design and
expression of a stable bispecific scFv dimcr with affinity for both glycophonn and N9
neuraminidasc A/«/t'c. /mwiM/w/. 33, 1301-1312.
Balzar. M.. Winter. M.J.. De Boer. C.J.. Litvinov, S.V. 1999. The biology of the 17-1A
antigen (Ep-C'AM). 7. A/o/. A/e</. 77. 699.
Behr. T.M.. Sharkey. R.M.. Sgouros. G.. Blumcnthal. R.D.. Dunn. R.M.. Kolbcrt. K..
Griffiths. G.L.. Siegel. J.A.. Becker. W.S., Goldenberg. DM. . 1997. Overcoming ihc
ncphrotoxicity of radiometal-labcled immuniKonjugates: improved cancer therapy
administered to a nude mouse model in relation to the internal radiation dosimetry.
Cancer. 80, 2591-610.
Beresford. G.W., Pavlinkova, G.. Booth. B.J., Batra, S.K., Colcher, D., 1999. Binding
characteristics and tumour targeting of a covalently linked divalent CC49 single-chain
antibody. //»/ 7 Camrr 81,911-917.
Bird, R.E., Hardman, K.D., Jacobson, J.W, Johnson, S., Kaufman, B.M., Lee, S-L., Lee, T.,
Pope, S.H., Riodan, G.S., Whitlow, M., 1988. Single-chain antigen-binding proteins.
Sfii'/ic-e 242, 423-426.
Brinkmann, U., Dicarlo, A., Vasmatzis, G., Kurochkina, N., Beers, R., Lee, B.. Pastan, I.,
1997. Stabilisation of a recombinant Fv fragment by base-loop interconnection and
VH - VL permutation. 7. A/o/. fl/W. 268. 107-117.
Carrasquillo, J.A., Lang, L., Whatley, M., Herscovitch, P., Wang, Q.C., Pastan, I., Eckelman,
W.C., 1998. Aminosyn II effectively blocks renal uptake of I8F-Iabelcd anti-tac
disulfide-stabilized Fv. Cancfr/fe.v. 58, 2612-2617.
Casey, J.L.. Keep, PA., Chester, K.A.. Robson. L.. Hawkins, RE.. Begent. R.H., 1995.
Purification of bacterially expressed single chain Fv antibodies for clinical
applications using metal chelate chromatography. 7 //n/nwW A/e//»w/.v 179, 105-116.
Casey, J.L., King, D.J., Chaplin, L.C., Haines, A.M., Pedley, R.B., Mountain, A., Yarranton,
G.T., Begent. R.H., 1996. Preparation, characterisation and tumour targeting of cross-
linked divalent and trivalent anti-tumour Fab' fragments, fir/7. 7. Cancer 74, 1397-1405.
Casey. J.L.. Pedley, R.B., King, D.J., Green, A.J., Yarranton, G.T., Begent, R.H.J., 1999.
Dosimetric evaluation and radioimmunothcrapy of anti-tumour multivalent Fab
fragments, fir// J Cancer 81, 972-980.
Coia, G., Hudson, P.J., Lilley, G.G., 19%. Construction of recombinant extended single-
-99-
Chapter 4
chain antibody peptidc conjugates for use in the diagnosis of HIV 1 and HIV2. 7.
//«««««/. A/<?/W.V 192, 13-23.
Colcher, D., Goel, A., Pavlinkova, G., Beresford, G., Booth, B., Batra, S.K., 1999. Effects of
genetic engineering on the pharmacokinetics of antibodies. £). 7. M/c7. A/ea". 43, 132-139.
Dall'Acqua, W., Carter, P., 1998. Antibody engineering. G/rr Oipi/i S/rwc/ B/o/ 8, 443-450.
Dillman, R.O. 1989. Monoclonal antibodies for treating cancer. .4/7/7 /ntern A/e</. I l l , 592-
603.
Dole/al, ()., Pearce, LA.. Lawrence, L.J.. McCoy. A.J., Hudson, P.J., Kortt, A.A., 2000.
ScFv Multimers of the anti-ncuraminidase antibody NC10: shortening of the linker in
single-chain Fv fragment assembled in V, to V,, orientation drives the formation of
dimers, trimers, tetramcrs and higher molecular mass multimers. Pra/e/n £ng. 13. 565-
574.
Eshhar, Z., 1997. Tumour-specific T-bodies: towards clinical application. Cancer /mmu/ia/
/mmMNu/nrr 45, 131-136.
Farah. R.A.. Clinchy, B., Hcrrcra, L., Vitctta, E.S., 1998. The development of monoclonal
antibodies for the therapy of cancer. Cr/7 /ft'v £n/tarwr G<w Ev/)r. 8, 321-356.
Fit/gcrald, K., llolhgcr. P., Winter, (i.. 1997. Improved tumour targeting by disulphide .;
stabilized diuhodics expressed in Pichia pastoris. Pr«/e;/i E/i#. 10, 1221-1225.
Frodin. J.K., Harmenberg, U., Biberfcld, P.. Christensson, B., Lefvcrt, A.K., Riegcr, A.,
Shetyc, J., Wahren. B. and Mellstcdt, H., 1988. Clinical effects of monoclonal antibodies
(MAb 17-1 A) in patients with metastatic colorectal carcinomas. //»7>r/aV;ma 7, 309-321.
Ghetie, M.A.. Podar, EM., llgen, Gordon, BE., Uhr, J.W., Vitetta, E.S., 1997.
Homodimerization of tumour-reactive monoclonal antibodies markedly increases their
ability to induce growth arrest or apoptosis of tumour cells. Prac Afar/. -4cW. 5ci. [/S/4
94,7509-7514.
Gottlinger. H.G., Funke, I.. Johnson, J.P., Gokel, J.M.. Riethmuller, G.. 1986. The epithelial
cell surface antigen 17-1 A. a target for antibody-mediated tumour therapy: its
biochemical nature, tissue distribution and recognition by different monoclonal
antibodies. /«/ J Cuncf r 38, 47-53.
Helfrich. W., Krocscn, B.J., Roovers, R.C., Westers, L.. Molema. G., Hoogenboom. H.R.. De
Leij, 1... 1998. Construction and characterisation of a bispecific diabody for retargeting
T-cells to human carcinomas. //!/. 7. Ca/jrer 76. 232-239.
Holliger. P.. Brissinick, J.. Williams. R.L.. Thielcmans, K., Winter, G., 1996. Specific killing
of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Pro/f/w £/» .^ 9,
299-305.
Holliger, P.. Manzkc, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua. L.. Wolf. J..
Diehl, V., Cochet, O., Winter. G., Bohlen. H.C.. 1999. Carcinoembryonic antigen
(CEA)-spccific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA
bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer /?es. 59,
2909-2916.
Holliger. P.. Prospero, T., Winter, G., 1993. "Diabodies": small bivalent and bispecific
antibody fragments. Prcu\ /VW/. /lc«</. Sc/. t/5.4, 90, 6444-6448.
Holliger, P.. Wing. M., Pound. J.D., Bohlen. H.. Winter, G., 1997. Retargeting serum
immunoglobulin with bispecific diaKniies. .Va/M«» S/o/ec/i. 15, 632-636.
Hudson, P.J., 1998. Recombinant Antibody Fragments. C W 0/wn fl/t>ffcn. 9, 395-402.
-100-
Design ami application of Diabodics. Tnabodics and Tclrabodics for c
Hudson. P.J., 1999. Rccombinanl Antibody Constructs in Cancer Therapy. C'wrr O/M'N
/mmM/to/og\ 11. 548-557. ^ I
Hudson. P.J.. 2000. Recombinant antibodies: a novel approach to cancer diagnosis and
therapy. £i/>. C^M/I. /mtw/. Dru#.\ 9, 1231-1242.
Hudson. P.J.. Kortt A.A., 1999. High Avidity scFv Multimcrs: Diabodics and Triubodics.
J.Immunol. Methods 231. 177-190.
Huston. J.S.. Levinson. I).. Mudgett-Huntcr. M.. Tai. M.S.. Novotny. J.. Margolics. M.N.,
Ridge. R.J.. Bruccoleri. RE., Haber, E., Crea, R.. Opperman. H.. 1988. Protein
engineering of antibody binding sites: recovery of specific activity in un unti-digoxin
single-chain F\ analogue produced in £.vt7i«'r/c/iitf i •»/«'. /Vot'. A/a//. .4<<i</. .SV/. (/&4,
85. 5879-5883.
Iliadcs. P., Kortt. A. A.. Hudson. P.J., 1997. Triabodics: Single Chain Fv Fragments without u
linker form trivalent trimers. f£flSL*»H. 409, 437-441.
Kabat. E.A.. Wu. T.T., Perry. H.M.. Gottensman. K.S.. Foclcr. C . I99|. .SV</n«mr.v«»/
Pr«/fi'n.v 0/7mmum>/(>#/c'<i/ //»fm".v/. US Department of Health and Human Service. US
Public Health sen-ice. NIH. Bcthesda. MI).
Kipriyanov. S.M.. Moldcnhauer. G.. Strauss, G . Little. M.. I99K. Bispecific Cl)3 x CDI9
diabody for T cell-mediated lysis of malignant human B cells. /«/../. (Vmcrr 77. 763-772.
Kipriyanov. S.M., Moldenhauer. Ci. Little. M., 1997. High level production of soluble single
chain antibodies in small-scale £.vc7ifr/c/iw t-o/i cultures. 7. /mmunn/. A/cr/tcxA 200, 69-
77.
Kipriyanov, S.M., Moldenhauer, G.. Schuhmacher, J., Colchlovius. B., Von der Licth, C.W.,
Matys. E.R.. Little. M., 1999. Bispecific tandem diabody for tumour therapy with
improved antigen binding and pharmacokinctics. 7 A/o/ fl/W. 293, 41 -56.
Kontermann, R.E., Martineau, P., Cummings, C.E., Karpas, A., Allen, D., Derbyshire, E.,
Winter, G., 1997b. Enzyme immunoassays using bispecific diabodies. /mmumjfc't'/r/ia/rjgy
3, 137-144.
Kontermann, R.E. and Muller, R., (1999). Intracellular and cell surface displayed single-chain
diabodies. ytawumi/. A/e/A. 226, 179-188.
Kontermann. RE.. Wing, M.G., Winter, G. (1997a) Complement recruitment using bispecific
diabodics. /Va/«/-f A/'o/ec/i/io/. 15, 629-631.
Kortt, A.A., Lah. M., Oddie, G.W.. Gruen, L.C.. Burns. J.E., Pearcc, LA., Atwcll, J.L.,
McCoy, A.J., Howlett, G.J., Mctzger. D.W.. Webster. R.G., Hudson, P.J.. 1997. Single
Chain Fv Fragments of anti-neuraminidasc antibody NC10 containing five and ten residue
linkers form dimers and with zero residue linker a trimcr. /V«fe//j /:'«#. 10, 423-428.
Kortt, A.A., Malby, R.L., Caldwell, J.B.. Grucn. L.C., Ivancic. N.M, Lawrence, M.C.,
Howlett, G.J., Webster, R.G.. Hudson, P.J.. Colman, P.M., 1994. Recombinant
antineuraminida.se single chain Fv antibody: characterization, formation of dimer and
higher molecular mass multimers and the solution of the crystal structure of the scFv-
neuraminidase complex. Ewr. J. fl/VxTitw.. 221. 151-157.
Kosterink. J.G., De-Jonge, M.W., Smit, E.F., Piers, D.A., Kcngcn, R.A., Postmus, P.E.,
Shochat, D., Groen, H.J., The, H.T., De-Leij, L. 1995. Pharmacokinctics and scintigraphy
of indium-11 l-DTPA-MOC-31 in small-cell lung carcinoma. / AW7. A/ft/. 36, 2356.
Krebs, B., Ackermann, B., Rose-John. S.. 1998. Specific targeting of cytokinc-sccrcting cells:
a bispecific diabody recognizing human intcrlcukin-6 and CD3 induces T cell-mediated
-101-
Chapter 4
killing. 7 //i/erfmm Cy/oftne /?«. 18, 783-791.
Lawrence, L.J.. Kortt, A.A., Iliades, P., Tulloch, P.A., Hudson, P.J., 1998. Orientation of
antigen binding sites in dimcric and trimeric single chain Fv antibody fragments.
/>//. 425, 479-484.
Le Gall, F., Kipriyanov, S.M., Moldenhauer, G., Little, M., 1999. Di-, tri- and tetrameric
single chain Fv antibody fragments against human CD 19: effect of valency on cell
binding. /•Afl.V /,rM. 453, 164-168. • :M
Litvinov, S.V., Balzar, M., Winter, M.J., Bakker, HA , Briaire-de Bruijn, I.H., Prins, F.,
Flcuren, G.J.. Warnaar, SO.. 1997. Epithelial cell adhesion molecule (Ep-CAM)
modulates cell-cell interactions mediated by classic cadhcrins. 7 CV// fl/o/139, 1337-
1348.
Litvinov, S.V.. Vcldcrs, M.P., Bakker. H.A.. Flcuren. G.J., Wamaar. SO., 1994. Ep-CAM: a
human epithelial antigen is a homophilic cell-cell adhesion molecule. J C*7/ fl/o/125.
437-446.
Malby. R.I... McCoy, A.J., Kortt. A.A.. Hudson. P.J., Colman. P.M.. 1998. Single-chain
fv/ncuraminidase complexes: DitTcrent stoichiomctry in solution and crystals. 7. A/o/.
#/W 279.901-910.
Malby, R.L.. Tulip. W.R., Harlcy. V.R.. McKimm-Brcschkin. J.L., Laver. W.G., Webster.
R.G., Colman. P.M., 1994. The structure of a complex between the NCIO antibody and
influenza virus neuraminidasc and comparison with the overlapping binding site of the
NC4I antibody. .SV/W/M/T 2. 733-746.
Manzkc, ()., Fitzgerald, K.J., Holligcr, P., Klock, J., Span, M., Fleischmann, B., Hescheler,
J.. Qinghua. 1... Johnson. K.S., Diehl. V.. Hoogenboom, H.R.. Bohlen. H.. 1999. CD3x
anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting
T cells to tumours. /«r 7 Cu/tcer 82, 700-708.
McCartney , J.E.. Tai. M-S.. Hudziak, R.M., Dams, G.P., Weiner, L.M.. Jin. D.. Stafford.
W.F.. Liu, S.. Bookman, M.A., Laminet, A.A., Fand, I., Houston, L.L., Oppermann, H.
and Huston, J.S., 1995. Engineering disulfide-linked single-chain Fv dimers [(sFv')2]
with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-
erbB-2 741FX (sFv')2 made by protein folding and bonded through C-terminal cysteinyl
peptides. /V»ft>iM £«^. 8, 301-314.
McCiuinness. B.T.. Walter. G.. Fitzgerald, K., Schuler. P.. Mahoney. W.. Duncan, A.R.,
Hoogenboom, H.R., 1996. Phagc diabody repertoires for selection of large numbers of
bispecific antibody fragments. A/«fu/v fl/o/t'c7». 14, 1149-1154.
Mullcr, K M . . Amdt, K.M. and Pluckthun. A.. 1998b. A dimeric bispecific miniantibody
combines two specificities with avidity. F£flS/.t'//. 432.45-49.
Muller. K M . , Amdt, K M . , and Pluckthun. A.. 1998a. Model and simulation of multivalent
binding to fixed ligands. .4/w/ fi/m/it'/M 261, 149-158.
Neri. D., Momo, M.. Prospero. T., Winter, G.. 1995. High-affinity antigen binding by
ehelating recombinant antiKnlies (CRAbs). 7. A/r>/. flw/. 246. 367-373.
Pack, P.. Muller, K.. Zahn, R. and Pluckthun, A.. 1995. Tetravalent miniantibodies with high
avidity assembling in £.vrAenV/»a co//. 7. A/o/. S/o/. 246, 28-34.
Padlan E.A.. 1994. Anatomy of the antibody molecule. A/»/ /m/WM«o/. 31. 169-217.
Pavlinkova. Ci.. Bercsford. G., Booth. B.J.. Batra. S.K.. Colcher. D.. 1999a. Charge-modified
single chain antibody constructs of monoclonal antibody CC49: generation.
-102-
Design and application of Diabodics. Triabodics and Tclrabodies for cancer targeting
characterization, pharmacokinetics, and biodistribution analysis. A/MO/. A/«/. fiiW. 26, 27*
34.
Pavlinkova. G.. Booth, B.J., Batra. S.K.. Colcher, D., 1999b. Radioimmunothcrapy of human
colon cancer xenografts using a dimeric single-chain Fv antibody construct. (7m. C'uwcw
rte.v 5.2613-2619.
Pedley. R.B.. Boden, J.A.. Boden. R., Dale, R.. Begcnt, R.H., 1993. Comparative .MI¥
radioimmunothcrapy using intact or F(ab')2 fragments of 1311 anti-CEA antibody in a
colonic xenograft model, flr JCumrr 68, 69-73.
Pei, X.Y., Holliger. P., Murzin. A.G.. Williams. R.L., 1997. The crystal structure of a trimcric
antibody fragment with non-cognate VH - VI. domain pairs shows a rearrangement of
VH CDR3. Proc AW/ .4<W Sri l'S.4 94. 9637-9642
Perisic, O., Webb, PA.. Holliger, P., Winter. Ci.. Williams. R.L.. 1994. Crystal structure of a
diabody. a bivalent antibody fragment. S/rwc/M/v 2, 1217-1226.
Pluckthun, A.. Pack, P., 1997. New protein engineering approaches to multivalcnt and "
bispecific antibody fragments. /mmM/ioftr/ino/uKi'3, 83 105. « V
Power, B.E., Hudson. P.J.. 2000. Synthesis of high avidity antibody fragments (scFv
multimers) for cancer imaging. 7. /mmumi/. A/<7n<x/.v 242. 193-204.
Ricthmuller. G.. Schncidcr-Gadickc. F... Schlimok. G.. Schmicgel. W.. Raab. R . Hoffkcn, K.,
Gruber, R., Pichlmaier. H., Hirche. H., Pichlmayr. R.. Buggisch. P.. Witte. J.. 1994.
Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C
colorectal carcinoma. 77it' /Lancrf 343, 1177-1183.
Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffkcn, K., Gruber, R.,
Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., Pichlmayr, R. 1998.
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year
outcome of a multicenter randomized trial. 7. O/n. ^«f«/. 16, 1788.
Robert, B., Dorvillius, M., Buchegger, F.,Garambois, V., Mani, J.C., Pugnicres, M., Mach,
J.P., Pelegrin, A., 1999. Tumour targeting with newly designed biparatopic antibodies
directed against two different cpitopes of the carcinocmbryonic antigen (C'liA). /«/./
Cancer 81, 285-291.
Roovers, R.C., Henderikx, P., Helfrich, W., van der Linden, E.. Rcurs, A., dc Bruine, A.I'.,
Arends, J.W., de Leij, L., Hoogenboom, H.R., 1998. High-affinity rccombinant phage
antibodies to the pan-carcinoma marker epithelial glycoprotcin-2 for tumour targeting, flr
7 Ca/tcrr 78, 1407-1416.
Roux, K.H., Strelets, L., Brekke, O.H., Sandlie, I., Michaelsen, T.E., 1998. Comparisons of
the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune
complexes: a role for flexibility and geometry. 7. //www/w/. 161, 4083-4090.
Roux, K.H., Strelets, L., Michaelsen, T.E., 1997. Flexibility of Human IgG subclasses. 7
/mmw/jo/159, 3372-3382.
Segal, D.M., Weiner, G.J., Weiner, L.M. 1999. Bispecific antibodies in Cancer Therapy.
CWr. Opm. //mm/no/. 11, 558.
Souhami, R.L., Beverley, P.C.L., Bobrow, L.G., 1988. Proceedings of the First International
Workshop on Small-Cell Lung-Cancer Antigens. Lw/jg Cancer 4, 1-114.
Thouvenin, E., Laurent, S., Madelaine, M.F., Rasschaert, D., Vautherot, J.F., Hewat, E.A.
1997. Bivalent binding of a neutralising antibody to a calicivirus involves the torsional
flexibility of the antibody hinge. 7 A/o/ flio/ 270, 238-246.
-103-
Chapter 4
Turner, D.J., Ritter, M.A., George, A.J.T., 1997. Importance of the linker in expression of
single-chain Fv antibody fragments- optimisation of peptide sequences using phage
display technology. 7 //H/HM/IO/. A/e/AodS; 205,43-54.
Verma, R., Bolcti, E., George, A.J.T., 1998. Antibody engineering: comparison of bacterial,
yeast, insect and mammalian expression systems./ /m/wi/wo/. A/efAocfc 216, 165-181.
Viti, F., Tarli, L, Giovannoni, L., Zardi, L., Neri, D., 1999. Increased binding affinity and
valence of recombinant antibody fragments lead to improved targeting of tumoural
angiogencsis. C'amw/?e.v. 59, 347-342.
Watkins, S.J., Mesyanzhinov, V.V., Kurochkina, L.P., Hawkins, RE., 1997. The 'adenobody'
approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene 77ier. 4,
1004-1012.
Whitlow, M.. Filpula, D., Rollcnce, ML., Feng, S.-L. Woods, J.F., 1994. Multivalent Fvs:
characterisation of single chain Fv oligomcrs and preparation of a bispecific Fv. Profe/n
Ewy 7, 1017-1026.
Wickham, T.J., Lcc, G.M., Titus, J.A., Sconocchia, G., Bakacs, T.. Kovcsdi, I., Segal, D.M.,
1997. Targeted adenovirus-mediated gene delivery to T cells via CD3.7. K/>«/. 71, 7663-
7669.
Worn, A., Pluckthun. A., 1998. Mutual stabilization of VL and VH in single-chain antibody
fragments, investigated with mutants engineered for stability, fl/oc/ie/n/.vrrv 37, 13120-
13127.
Wu, A.M.. (hen, W , Riiubitschek. A.. Williams, LI-.. Neumaier. M.. Fischer, R., Hu, S-Z.,
Odom-Maryon, I., Wong, J.Y.C., Shively, J.E., 1996. Tumour localisation of anti-CEA
single-chain Fvs: improved targeting by non-covalent dimers. //n/MM/ior«/i/io/ogv 2, 21-
36.
Wu, A.M.. Williams. L.E., Zieran, L., Padma, A., Sherman, M.. Bebb, G.G., Odom-Maryon,
T., Wong, J.Y.C., Shively, J.E., Raubitschek, A.A., 1999. Anti-carcinoembryonic antigen
(CEA) diabody for rapid tumour targeting and imaging. TH/nowr 7arucf/wg 4, 47-58.
Zdanov. A., Li. Y., Bundle. D.R.. Deng, S-J.. MacKenzie. C.R., Narang. S.A.. Young. N.M.,
Cygler, M., 1994. Structure of a single-chain antibody variable domain (Fv) fragment
complexcd with a carbohydrate antigen at 1.7-A resolution. fVoc MJ//. /4raJ. Sr/'. t/S/4
91.6423-6427.
Zhu. Z., Prcsta, L.G., Zapata. G., Carter, P., 1997. Remodeling domain interfaces to enhance
hctcrodimcr fonnation. Prort'/// 5f/'. 6, 781-788.
-104-
• - - . « . * • >
Chapter 5
Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar
Binding Characteristics yet Structural Divergence Between the Original
Murine Antibody and its Human Equivalent
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Abstract
Antibody engineering provides an excellent tool for the generation of human
immunotherapeutics for the targeted treatment of solid tumours. We have engineered and
selected a completely human antibody to Epithelial Glycoprotein-2 (EGP-2), a transmembrane
glycoprotcin present on virtually all human simple epithelia and abundantly expressed on a
variety of human carcinomas. We chose to use the procedure of "guided selection" to rebuild a
high affinity murinc antibody into a human antibody, using two consecutive rounds of variable
domain shuf ing and phagc library selection. As a starting antibody the murine antibody MOC-
.11 was used. After the first round of guided selection, where the VH of MOC-31 was combined
in lab format with a human VL C'L library, a small panel of human light chains was identified,
originating from a segment of the Vklll family, whereas the MOC-31 VL is more homologous
to the Vkll family. Nevertheless, one of the chimaeric Fabs, C3, displayed an off-rate similar to
M(X -31 scFv. Combining the VL of C3 with a human VH library, while retaining the VH CDR3
of MOC-31, clones were selected using human VH genes originating from the rarely used VH
7 family. The best clone, 9H, shows over 13 amino acid mutations from the germline sequence,
has an off-rate comparable to the original antibody and specifically binds to the "MOC-31"-
cpitope on F.CJP-2 in specificity and competition ELISA, FACS analysis and
immunohistochemistry. In both VL and VH of antibody 9E, three germline mutations were found
creating the MOC-31 homologue residue. Structural modelling of both murine and human
antibodies reveals that one of the gennline mutations, 53Y in VH CDR2, is likely to be involved
in antigen binding. We conclude that, although they may bind the same epitope and have similar
binding affinity to the antigen as the original murine antibody, human antibodies derived by
guided selection may retain only some of the original key elements of the binding site chemistry.
The selected human anti-EGP-2 antibody will be a suitable reagent for tumour targeting.
Introduction
By the expression of tumour-associated antigens (TAA), colorectal carcinoma (CRC)
cells may be distinguished from their non-malignant counterparts. Among the identified surface-
bound TAAs is epithelial glycoprotein-2 (EGP-2), also known as CO 17-1A antigen, KSA,
EGP40 or Ep-CAM. The antigen, encoded by the GA733-2 gene, is a 38-kDa transmembrane
protein that is present on human non-squamous epithelia and is highly expressed on their derived
tumours. In the serum from patients suffering from carcinoma, EGP-2 could not be detected by
MOC-31 [ 1 ], one of the many murine monoclonal antibodies (mAbs) that have been generated
against the EGP-2 antigen. Thus the EGP-2 antigen is not shed into the circulation and is
regarded as a suitable target for imaging and immunotherapy of carcinomas. In radioimmune
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detection [2. 3], targeting of toxins or chcmotherapcutic drugs [4-6] and phase I and II clinical
trials (7-9), murine mAbs were successfully used. These studies show the large potential of
mAbs to EGP-2 in immunotherapy. In a previous study, we showed that the Mab M(X'-3I has
the lowest kinetic off-rate of a series of well-characterised anti-U(iP-2 antibodies [ 10). The V-
genes of this antibody have been cloned as single chain variable fragment (scFv) which competes
with the original hybridoma antibody for binding to the antigen. The off-rate of the scFv is better
than those of the bivalent 17-1A and 323/A3 anti-EGP-2 antibodies, providing it with an
essential characteristic for tumour retention in vivo [I I). Therefore, the V-genes of M(X'-3I will
be very suitable for the rational design and generation of human antibody-based
immunotherapeutics for the treatment of solid tumours.
A disadvantage of the use of murine antibodies for immunothcrapy of human carcinomas
is that during the repeated administration of the mAbs to patients, a human anti-mouse antibody
(HAM A) immune response can be induced. This may cause scrum sickness of the pntient and
rapid blood clearance of the mAbs, thereby reducing their eflkacy 112). It is expected that human
antibodies would evoke a more effective and compatible response with the patient's immune
system. Murine antibodies can be humanised by CDR-grafting [1.1] where the hyperviiriiible
loops of the mAb are transplanted to a human antibody, thereby retaining the epitope and
specificity. However, such CDR grafted antibodies retain a large proportion of non-human
sequences, which include the CDRs as well as framework residues, which arc sometimes retained
because they are involved (in)directly in antigen binding [14, 15]. Furthermore, humanisalion by
resurfacing [16, 17] involves the retention of non-human framework sequences in all but surface
located positions. In all instances some rodent antibody derived sequences are still included in
the humanised antibody and thereby may enable the mAb to provoke an immune response. In
particular, the transplantation of CDR-loops with "non-human" canonical forms, such as
canonical structures I and 5 of murine light chain loop LI [18] for which there is no human
homologue, may both assign a typical murine idiotypic structure to the antibody combining
surface, as well as provide unique T-cell epitopes for HAMA induction.
An alternative method termed guided selection has been developed, to convert murine
antibodies into completely human antibodies with similar binding characteristics [19]. In this
method the murine V domains are sequentially or in parallel replaced by human V domains,
using phage selection to derive the human antibody with the best affinity. Two published
examples demonstrate the power of this method. Figini et al. (1998) [20] shuffled the light chain
of a murine anti-hapten phenyl-oxazolone antibody, NQ10.12.5, with a repertoire of human
heavy chains. After a second shuffle of the selected VH s with a repertoire of human VL s,
entirely human antibodies were generated. In a similar approach, starting with the murinc VH ,
a murine anti-TNFa (tumour necrosis factor) antibody was converted into a human version [ 19].
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The combination of shuffling of V-genes and selection on antigen provides a means to direct the
isolation of a human V-gcne pair with largely similar binding characteristics as the starting
antibody.
In order to obtain a human anti-EGP-2 antibody with the same binding characteristics as
MOC-31, which may be used for immunotherapy, we chose the method described by Jespers et
al. (1994) forthehumanisationofthe MOC-31 mAb by guided selection. In two sequential chain
shuffles, the murinc VI. and VH were replaced by fully human antibody V genes, while
maintaining both specificity and affinity. The murinc and fully human antibodies were modeled
and structural analogies and differences arc discussed.
Materials and Methods
/;.v<7u77<7i/tf fw
Eschcrichia coli TGI: K12, A(/ac-/>r«A .vu/>£, r/», /i«/DJ/F'/raZ)36, /?roA*B\
/MC/.AMI5KI2.
««*/ //cwv c7i«/w.v
The V-gencs of MOC-31 were cloned in the phagemid pCESI Fab format vector [21].
The ApaLI-AscI fragment of the cloned VL CL was replaced by the VL-CL s from a library (9
• 106 clones), which was prepared from total RNA isolated from a human fresh spleen using
random primers (Promega) for the preparation of cDNA. For the 2nd round of chain shuffling,
the selected human VI.-CL was combined with a human VH library. To retain the heavy chain
CDR3 of MOC-31 the H3 MOC-31-for-primer (5' -ACT CGA GAC GGT GAC CAG GGT
ACC TTCi GCC CCA GTA GTC CCC CTT AAT AGC GAA TCT TGC ACA G(AT)A ATA
CAC GGC CGT GTC-3') was used with an equimolar mixture of VHBACKSfi primers [21 ] for
PCR amplification of the VH genes from cDNA derived from a human spleen [21]. The cDNA
was prepared from total RNA using random primers (Promega) as described [21]. The PCR
products wore cloned as a Sfil-Bstl-ll fragment in pCESI containing the selected human light
chain and a human gamma-1 CH 1 gene fused to filamentous phage gene III, as described by de
Huurd i>r«/. [21].
Rccombinant F.GP-2 was expressed in the baculovirus system as described (Strassburg
et al., IW2; a kind gift from Professor D. Herlyn (the Wistar Institute)) and was biotinylated with
NHS-SS-biotin (Pierce) according to the manufacturers descriptions. The biotinylated EGP-2 was
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tested with MOC-31 on a streptavidin-coatcd sensorchip in a BIAcorc2000 (Biacorc AB,
Sweden). Selections were performed on biotinylated EGP-2 as described by Hawkins et al.
(1992) with some modifications: phage were incubated on a rotator wheel for one hour in 2"o M-
PBST (PBS supplied with 2°o (wv) skimmed milk powder and 0.1% (v v) Tween-20).
Meanwhile, 100 ul Streptavidin-conjugated paramagnetic beads (Dynal, Oslo, Norway) were
incubated on a rotator wheel for two hours in 2% M-PBST. Different amounts of biotinylated
EGP-2 were added to the pre-incubated phage (for the VL -shuffle: lO'-'TU for round I, 10" TU
for subsequent rounds; for the VH-shuffle: 10'" TU) and incubated on a rotator wheel for 30
minutes. Next, beads were added and the mixture was left on the rotator wheel tor 15 minutes.
After 14 washes with 2% M-PBST and one wash with PBS, phage particles were eluted with 950
ul 0.1 M triethylamine for five minutes. The cluatc was neutralised by the addition of 0.5 ml
Tris-HCI (pH 7.5) and was used for infection of log-phase £.<•«// TO I cells. The TCi 1 cells were
infected for 30 minutes at 37°C and were plated on 2xTY (I6g Bacto-trypton, lOg Yeust-cxtruct
and 5g NaC'l per litre) agar plates, containing 2"o (w v) glucose and lOOmg ml ampicillin. After
overnight incubation at 30°C, the colonies were scraped from the plates and used for phage
rescue as described [22].
Soluble scFvs and Fabs were produced as described [IO|. IvLISAs and kinetic
measurements using SPR in a BIAcore TM 2000 instrument (BIAcore AB, Uppsala, Sweden)
were performed as described by Roovers et al. (1998). For the specificity EL1SA, wells were
coated with 10 mg/ml bovine serum albumin (Sigma) in PBS, 3 mg/ml hen egg white lysozymc
(Boehringer Mannheim) in 0.1 M NaHCO3 (pH 9.6), 10 mg/ml Tetanus Toxoid in 0.1 M
NaHCO3 (pH 9.6), or with 0.5 mg/ml EGP-2 in PBS. For the competition EUSA, Fab antibodies
expressed as pill fusions on the tip of bactcriophagc were detected in the presence of excess
whole antibody as described by Rooversetal. (1998). Approximately 10 13 colony-forming units
(cfu) of phage (and I in 2, I in 4 etc. serial dilutions hereof) were mixed with 50 ml of
hybridoma supernatant containing approximately 1 mg/ml whole antibody. For affinity
measurements, the non-biotinylatcd antigen was covalently coupled to a C'M-5 sensorchip
(BIAcore AB, Uppsala, Sweden), resulting in a surface of 500 resonance units (RU). All kinetic
measurements were performed on this antigen surface. Using TBS (20 mM Tris, pH 7.4, 150 mM
NaCl) containing 2 mM MgCI2 and 0.01 % (v/v) Tween-20 as a running buffer, the Fabs/scFvs
were passed over the sensorchip at a flow rate of 20 ml/minute at 25°C. The rate constant (k „,)
was obtained by direct fitting and fitted to the data according to a single-site model, using the
BIAevaluation 2.1 software (BIAcore AB, Uppsala, Sweden). The off-rates (koff ) of 9E and
MOC-31 are, respectively, an average of eight and five curves made with different antibody
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dilutions. Association rates (kon ) were determined from a plot of [ks = kon * C / koff ] versus
antibody concentration (C).
DM4 .
The nucleotidc sequences of the selected Fabs were determined using the dideoxy
sequencing method of Sangcr. Products of the sequencing reaction were analysed on a semi-
automated sequencer (Alf Express, Pharmacia). Oligonucleotides used were pUC-REVERSE:
50 -LAG CiAA ACA GCT ATG AC-30 and CHI FOR: 50 -GTC CTT GAC CAG GCA GCC
CAG GGC-30 . Alignments of V gene sequences were performed using V BASE on webpage:
http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/DNAPLOT.html. Canonical class assignments
were performed using webpage: http://www.biochcm.ucl.ac.uk/~martin/abs/chothia.html
1. Building the framework and canonical CDRs
The framework and canonical CDR backbones were modelled by an improved version (N.R.W.
& A.R.R., unpublished) of the original AbM algorithm [23]. As a result of studies which showed
thnl certain residue positions in canonical limps were conserved in chi-l angles, the side-chains
of those positions were built using maximum-overlap, rather than using the CONGEN iterative
side-chuin placement algorithm [24]. The non-conserved side-chains were not built at this point,
but were built simultaneously with the non-conserved H3 side-chains (see below).
2. Building non-canonical non-H3 CDRs
These were built using a modified version (Whitelegg, 1999; N.R.W. Searle & A.R.R.,
unpublished) of the combined antibody modelling algorithm (CAMAL; [23]). Of special note
are the force field modifications in which the stand-alone implementation of VFF [25] was used
to energy-screen the generated conformations, instead of Eureka. In addition, the candidate
conformations were energy-minimised using VFF.
3. Building H3 loops
Recent studies have shown that in the many instances, CDR-H3 loops exhibit a "kinked" C-
tcrminal region [26]; [27], The kink is determined by a number of sequence-based rules, and the
antibodies modelled here conformed to those rules. These features were added to CAMAL and
taken into account in the following way when modelling H3 loops. First, the C-alpha to C-alpha
database search [23] was performed, using only the set of kinked H3 crystal structures to derive
the C-alpha to C-alpha distance constraints (in order to bias the database hits in favour of kinked
structures). The database hits were then subjected to energy minimisation after grafting, to
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minimise poor loop/framework joins. Subsequently, the CONGFN (24] and the Go and Schcraga
chain closure algorithm [37] were used to rebuild a five-residue segment at the apex of each
database loop. Finally, each conformation was subjected to minimisation by VFF [25] to relieve
any residual high energy in the loops, and the lowest energy loops, as measured by VFF, were
clustered using RMSD as the criterion.
4. Final screen
To select the final H3 backbone conformation, a screen based on similarity ( m o w e d by RMSD)
to the known structures of the particular IB length being modeled was used. It has been observed
that certain length H3 loops have similar conformations in the majority of examples, notably
eight and ten residue loops A similarity score for each of the clustered conformations was
calculated: Score < all known structs (l/dx ) mx where dx is the RMS deviation between the
model and structure x. and mx is the sequence similarity (using the MDM matrix, [ 11. 28]
between the sequence of the model and structure x. The structure being modeled u ;is cxi-hided
from the list of known structures while performing this screen. Finally, side-chains wcic minified
using the dead-end elimination algorithm (see below). 113 and non-conserved side-chum
modeling The final stage was to build side-chains on the selected backbone model. Analyses of
antibodies have shown that for certain residue types, the chi-1 values of the four C-tcrminal H3
residues are conserved (N.R.W. & A.R.R., unpublished). Therefore, these were built using the
average observed chi-1 values. For the chi-2 of these residues, cither the extended conformation
was used or the mean of frequently observed (64-88 %) values was used, depending on whether
the chi-2 was conserved for that residue type and position. All remaining H3 and canonical non-
conserved side-chains (as well as all side-chains on the non-canonical non-H3 loops) were built
simultaneously on the final selected backbone, using a modified version of the dead-end
elimination algorithm [29]. In this procedure an attempt is made to find a global minimum by
successively eliminating rotamcrs from a rotamcr library which have a higher "lowest" energy
of interaction with their environment than the "highest" energy of interaction of the other
rotamers for that residue. The Connolly structures [38] were generated using the program Insight-
II 97.0 (MSI) and the images shown are of the solvent- accessible surfaces, as opposed to the van
der Waals surfaces.
Fabs and scFvs were tested by FACS analysis for specific binding to EGP-2 positive cells
as described by Henderikx e/a/. (1998) [30] with some minor modifications. The colon cell line
CaCo2 (American Type Culture Collection, Rockville. MD) was stained using scFv (M(X"-31)
or Fab (clones C3 and 9E) periplasmatic fractions. After the last incubation with FJTC-
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conjugated rabbit anti-mouse (DAKO, Glostrup. Denmark; diluted 1:50 in incubation buffer),
detection of bound scFvs or Fabs was performed by means of flow cytometry on a FACScalibur
(Becton Dickinson) and results were analysed with the CELLQuest program (Becton Dickinson).
Fabs were tested immunohistochemically as described for scFv by Roovers t7 a/. (1998).
Results
In the first guided selection step we aimed to replace the murinc light chain with a human
version. The variable heavy chain gene of MOC-31 was cloned into the pCES 1 Fab format vector
[21) and the obtained chimacric VH CH 1 was combined with k and I light chain libraries derived
from human spleen separately, yielding two libraries of 10* clones (k) and 2*107 clones (I). We
chose to use spleen as a source of human V-genes to access maximal germline and somatic
hypcrmutation diversity (of both igM and IgC! B cells). Phage were rescued and 8x10'*
transforming units (TU) of the k library were used for the first selection round. Schier <>/ a/. [31,
32] obtained highcr-affnity monomeric scFv fragments on phage only by selecting in solution
using limiting concentrations of biotinylated antigen, followed by screening the selected binders
for their koffin BIAcorc. In order to obtain high affinity antibodies to tumour antigen EGP-2,
selections were performed on biotinylated EGP-2 with concentrations varying from 1 nM down
to 10 pM (Table 1).
Table I
<r/)7)rorv
[Ag] used during selection (nM)
1 (rdl); 1 (rd2); 1 (rd3); 1 (rd4)
1 (rdl); 0.1 (rd2); 0.1 (rd3); 0.1 (rd4)
0.1 (rdl); 0.1 (rd2);0.1 (rd3);0.1 (rd4)
0.1 (rdl); 0.01 (rd2);0.01 (rd3);0.01 (rd4
1
4/30
4/30
0/32
0/32
Round of selection
2
36737
36737
36737
36737
3
12/16
11/16
7/16
6/16
4
nd
nd
12/16
36737
nd, not determined; rd, round
After each round of selection, polyclonal phage was prepared and the frequency of
binders to EGP-2 was determined in EL1SA. The ELISA results in Table 1 show that in all
selection rounds binders were retrieved. Clones positive in ELISA and selected in the third
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round, were tested for their affinity in BlAcore: some Fabs show an off-rate similar to the starting
antibody MOC-31 (Table 2). The VL gene nucleic acid sequence of these clones was
determined and submitted to Gen Bank (accession numbers: AF2O9862-AF21NX66). Alignment
using V-BASE. revealed that the light chains originate from the human Vklll family (Figure I).
No correlation can be found between the used antigen concentration and the off-rate of the
selected clones. For instance, clones Cl, C5 and 1-4. which by sequencing appeared identical.
were selected using an LGP-2 concentration of 1 nM (C1) and 0.1 nM (C'5) or a combination of
these (E4. see Table 2). To produce more reliable off-rates, the Fabs with the lowest off-rates
were produced in large amounts, purified and analysed in BlAcore. As shown in Table 2, the
purified Fabs show an off-rate in the same range as M(X'-31 (between 10'V'and 10 V ) . Clone
C3 was chosen to guide the selection of the human heavy chain. Compared to the sequence of
the gcrmline segment, C3 shows 16 nucleotidc and nine ammo acid substitutions.
Table 2
fti- W o#-rufef <V7*a//) toman Fa/w aw/wFv WOC-J/
Clone"
Cl
C5
E4
G5
E3
C3
C4
9E>
MOC-31 •
l"rd
1
0.1
1
0.1
1
1
1
100
na
[Ag]«(nM)
2""rd 3
1
0.1
0.1
0.1
0.1
0.1
0.1
100
na
"rd
1
0.1
0.1
0.1
0.1
0.1
0.1
100
na
**<IO-V)
1.5
1.6
1.2
1.8
1.8
0.84
34
nd
nd
*,,,,(ioV)<
nd
nd
4.4
3.6
2.1
3
nd
4.4
5.7
' AJIO'M's')*
0.9
0.86
1.2
" Clones selected in 3"* round
§ The Ag concentration used in the selection round 1, 2 and 3
* Off-rate of purified Fab's and scFv as determined by BlAcore
t Fab 9E is completely human
J scFv MOC-31 is completely murine
na, not applicable; nd, not determined; rd, round
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Figure I
am/ ami>ioaf/</ sequence a/ignmf«/ t»/ »tjn«/>/t' -J /
(a) DNA sequence: (b) amino acid sequence. The DNA sequences of the Y of of half human Fabs (mouse V,,,
human V,) and of MCX-31 arc aligned to Vg/38K, (he human gcrmline gene with highest homology u«he selected
human light chains as determined by V-BASe (http://www.mrc<pe.cam.ac.uk/im(Hloc/resiricted/l)NAI'l.()T.hlml)
Framework (FR) and C'DR regions arc indicated. Numbering and loop regions (I.I -L.I) are according to slnicUird
criteria defined by Chothia (Chothiart «/., 1992; Tomlinson c/ u/.. 1992. 1995; Williams.-/ <;/.. 1996). fDRs are
according to Rabat ?/ a/. (1991). Silent mutations from gcrmlinc arc indicated using small characters, t The DNA
and amino acid sequence of clone ( I arc identical to those of clones C'S and E4.
As shown in Table 3, the selected human VL s have a different canonical structure for
LI (fold 2) to that used by MOC-31 VL (fold 4). No differences in lengths or canonical loops
were observed for CDR2. Three of the selected light chains used the same canonical structure
for L3 (fold I) as MOC-31. The structure for L3 of the other selected VL s (having one extra
residue in L3) could not be determined, since these chains have a thrconinc at position 96,
whereas fold S (with seven residues in the L3 region) uses a proline at this position [IK].
Furthermore, no significant amino acid homology was found between the C'DRs of the human
VL s and those of the MOC-31 VL (Figure I). In parallel to the selections with the k library,
selections were performed with the 1 library. No enrichment could be found after three rounds
of selection and no EGP-2 binding clones were detected in ELISA. Most likely, for replacement
of the murine K chain, there was no VH or antigen binding-compatible I light chain available in
the human A. repertoire.
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Table 3
V-gcnc
VL-CV
VL-G5
VL-E3
VL-C3
VL-C4
VL-MOC-31
VH-9E
VH-MOC-31
Human
V-gcne
family*
VKIII
VKIII
VKIII
VKIII
VKIII
VKII
V,,7
V,,7
No. of mutations from
Germ line*
nuclcotidcs
11
II
II
16
16
109
23
70
amino acids
4
4
5
9
8
44
13
26
Canonical
structure"
LI
2
2
2
->
2
4
1
1
L2
1
1
1
1
1
1
T
2
L3
')
'>
•>
• )
1
1
NA
NA
Closest
human*
germ line gene
3A9
Vg/38K
Vg/38K
3A9
Vg/38K
DPKI3/OI1
Vl-4.1b
YAC-10/ld37
*V-gene families and closest human germlines (for MOC-31) were deduced from V BASE
^ Gcrmline genes used are Vg/38K for the light chains and VI-4.1b for the heavy chains
" Canonical structures were assigned according to Chothia cf c//. (1989 & 1992). Selected
human V, 's were assigned in combination with MOC-31 V,,. Selected human V^ (9E) was
assigned in combination with the V, of C3.
t The DNA sequence and therefore the V-gene classifications and structural predictions of
C'DR-loops of clone Cl is identical to clones C5 and E4
7 No canonical of the same loop length could be found using webpage:
http://www.biochem.ucl.ac.uk/-martin/abs/chothia.html. But according to Tomlinson e/ a/.
(1995) canonical structure 5 might be assigned to L3 of these clones.
/yumcjm.sYifion »/7/»i' A?<IVT c/ia/w
For the chain shuffling of the heavy chain, the selected human light chain of clone C3 was
first cloned into pCliSl not carrying any VH genes to avoid later contamination of the MOC-
31 VH Human VH genes were amplified from the RNA of human spleen using oligonucleotide
H3-MOC-31 -KOR. introducing the MOC-31 CDR3 in all sequences. This product was cloned
as indicated in Materials and Methods into the C3-light chain containing vector, to create a
library of 1.2x10' clones. This was subjected to three rounds of selection. Under stringent
selection conditions (decreasing phage input litres and decreasing antigen concentration, as
before), no human HGP-2 binding antibodies were identified. After three rounds of selection.
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EGP-2 binding antibodies were obtained using non-stringent conditions (phagc input 10 12 TU,
100 nM antigen). Figure 2 shows that all 11 clones tested arc specific tor EGP-2, but signals do
not reach values above 0.7.
8
08
0.6
02
0
I EGP-2
HEL
TT
BSA
7A 8A 8B 8D 8E 8F 9A 9B 9E 9F 10F
Clone name
Figure 2
,S/Hv///Vm- AY./S/4 o/V/ontw .ve/crf«/<i/?cr .VCCO/K/c/iain A7IM///<\
The specificity of the selected Fabs was tested in an ELISA using plastic-immobilised bovinescrum albumin (USA),
hen egg-white lysozyme (HEL), tetanus toxoid (TT) and epithelial glycoprotein-2 (EGP-2). Bound soluble Kfc
fragments from individual clones were detected with anti-myc tag antibody 91:10.
DNA sequencing of four EGP-2 specific clones (including clone 9E) revealed that these
clones all contained the same VH . This VH was completely human and its DNA sequence was
submitted to GcnBank (accession number: AF209860). V BASE sequence alignment showed it
originated from the small but discrete VH 7 family [33] with 23 nuclcotide and 13 amino acid
mutations compared to the germlinc sequence (Figure 3). As shown in Figure 3, the amino acid
sequence in the CDR3 and framework 4 regions of MOC-31 VH were retained during the
shuffling. BIAcore experiments with the representative clone, 9E, purified from 0.5 litres of
culture, show that it has an affinity in the same order of magnitude as M(X'-31 (Table 2). The
human Fab 9E specifically binds EGP-2 positive cells as shown by FACS analysis (Figure 4) and
competes with MOC-31 for binding to rccombinant EGP-2 in ELISA (Figure 5). The Fab was
also tested in immunohistochemistry and a similar staining was observed as shown by Roovcrs
ct al. (1998): the Fab reacts with normal and malignant non-squamous cpithclia and does not
stain, malignant tissue reported negative for the antigen (melanoma; data not shown; [34]. This
confirms the specificity. The variable chains of MOC-31 and 9E were modelled as described in
Materials and Methods. The coordinates of the V-gcncs of MOC-31 and 9E were deposited in
the PDB-database with the accession numbers Idx2 and Idx3, respectively. As shown in Figures
6 and 7 and discussed in more detail in the Discussion section, the structural modeling revealed
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large differences between the murinc and the human antibodies, in particular between their light
chains.
Discussion
We cloned the repertoire of human light chains into the phagemid pCESI containing the
MOC-3 I VH . Since MOC-31 scFvs have a tendency to dimcrisc [10], we used a Fab format for
the humanisation In this way we can screen the antibodies for affinity rather than avidity and
also select with less avidity mediated problems for high affinity binders. We selected on soluble
biotinylatcd antigen using stringent selection conditions (low Ag concentration and low phage
input). These selections yielded chimacric murine VH / human VL antibodies with comparable
off-rates as the parent scFv MOC-31. In contrast to the rapid and successful chain shuffling of
the light chain, the shuffling of the heavy chain was more difficult: only by increasing the antigen
concentration and the phage input could binders be selected. The lower expression yields of the
fully human Fab 9H (34 ug/l) versus the Fab C3 (80 ug/l) as well as its reduced affinity are most
likely responsible for the higher antigen concentration required to select the phage antibody. This
emphasises the importance of the empirical approach for determining optimal conditions for
affinity-selections. Sequence alignment using V BASE showed that MOC-31 VL has more
homology to the Vkll family than to the Vklll family from which the selected human light chains
originated. Thus unlike other examples [20]; Salfcld et al.. 1997), the light chain guided selection
did not yield the most homologous human counterpart sequence. Nevertheless, there are signs
of ami no acid conservation between the MOC31 VL and the selected human VL s. Remarkably,
the most abundant clones. Cl, C5 and [-4, which arc selected on different antigen concentrations
and are identical at the nucleotide level, are completely germline in sequence except for two
mutations in FR3. At both sites, the germline residues are replaced by equivalent residues present
in the original M(X'-31 VL sequence (A60D; S77R; Figure 1). The VL of another selected clone.
C3, shows the same mutations as well as a similar type mutation in FRI (T10S). Of all selected
human light chains, the VL of clone C3 has both the highest level of amino acid substitutions
from germline (Table 3) and the highest level of amino acid homology to MOC-31 VL . This
may well indicate the involvement of some of these residues in antigen binding. Structural
modelling of scFvs MOC-31 and 9E (which carries the C3 light chain; see Figure 6) revealed that
60D is quite close (6 A E) to 54R in the L2 loop, but faces the other way and hence cannot form
a salt bridge with it. The conformation of its side-chain, however, is similar to that in MOC-31.
-118-
SI
8
5
" 2 :
- S :
H O O
E " :
3 :»
§ : <
8 :S
8 : •
8 i^
H =2
I : •
S i :
s - g ; i
e ; •
, 5 : •»
o • <
8 : :
O - *J
5 : 3
u • <
g : :
55
- a
s -• s
>. 5
Chapter 5
10 20 Ml
VI 4 . 1 b OVQLVQSGSlLKXPCASVKVSCKASGYTrr SYAMN
»£ C A.V T . C I .
MOC-J1 . . K . Q . . . P I T . . I H . G . .
«0
I
MVDOAPGQGLZ1MC
. . K . . . . K . . K . . .
10 S« «O
N I K T H T G N P T Y A Q G r r G
Y G
Y..ES...DD.K.
I
•0 •> Me M
i l l I
V M . l b (rVrSLDTSVSTATLQISSUUUEDTAVYYCAII
9t .L N..E.A F . . . FMKGDY
MOC-31 ..A...C..A.A KM..II T.r... rAIKCDY
HGOGTLVTVSS
KGQGTTVTVSS
Figure 3
£W/f a no* limi'nn ar/a* . c/ia/n «n</ A/OC-i /q/'/Ae .ve/erfra" Aw/na/7
(a) DNA sequence: (b) ammo acid sequence. The DNA sequence of the human heavy chainfrom the selected anti-
EOP-2 clone and of M( X -11 arc aligned to VI-4 I b, ihchuman germiine gene with highest homology to the selectd
human heavy chain as deduced from V-BASF. (http:/'www.ma'-cpc.cam.ac.uk/'imt-doc/restricted/DNA-PLOT.html)
I-runic work (IR) und ('I)K regions arc indicated. Numbcnng and loop regions (111 -IB) arc according to structura
criteria defined hy ('holhiu (Cholhiacru/.. IW2; Tomlinsonj'/a/, 1992. 1995; Williams<•/ u/.. 1996). CDRs are
according to Kabal fi u/ (1991). Silent mutations from gcrmlinc are indicated using small characters.
10
tensity
Figure 5
Himlmg of Fab 9|- phage antibinly to
rccoinhinant l-'CiP-- in the presence of (A) no
coni|H.*tint! antirHHly. ( I ) an excess of an
irrelevant antibody (UIC'2. anti-P-glycoprotcii
hybridoma). or ( • ) the MOC-31 whole
antibody.
Q
O
Figure 4
q/'.w/u/)/f «'Fv A/OC-J/ Ci
// i
Thin line is negative control (9E10); thick line B
binding of scFv MOC-31; thin dotted line is half humai
Fab C3 and thin striped line is human Fab 9H.
20 40 60
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Figure 6
Co/ino//v .Yo//V/-.vwr/ace s/ruc/ure.v o/
The variable chains only are shown, (a) and (b|: the opposite views of (c) and (d) respectively, (c) and (f): lop view
showing the antigen-binding sites, (a), (c) and (e) MOC-31, (b), (d) and (0 9E. The Conolly structure* wee
generated using the program Insight-ll 97.0 (MSI)and show the solvent-accessible, rather than the van dcr Waak
surface.
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Figure 7
.VM/X77'»M/W.V/7/O/I o/7/ie a/trigf/i />/Wmg .s/'/es q/7Ae mowoc/o/ia/ A/OC-i / am/ r/ie /wmaw Fa/> 9£.
The variable chains only are shown. The (wo models were superimposed using least-square fitting on conserved
framework regions adjacent to the DC'Rs. Residues with similar positions are shown in red (9E) or green (MOC-31)
The other germline mutations are in the same conformation in both MOC-31 and 9E and appear
to be largely unimportant, being framework residues distant from the CDRs which, additionally,
point sideways or interact only with the framework. As shown in Figure 6(c) and (d), the exposed
residues 24R, 27 K, 31H. 931- present in the MOC-31 VL were not retained in C3-VL except for
24R, but this residue is projected from the side of the Fv and is therefore unlikely to be involved
in antigen binding. In the humanised C3 light chain the exposed residues are 24R, 50D, 54R, 91R
and to some extent 28S, 30S and 32Y. Residue 54R is projected downwards and sideways, away
from the binding site (not shown in Figure 6). When we compare the side views of both Fvs, we
observe the bulky residue 94W in the centre of 9E (sec Figure 6(b) and (d), which is absent in
MOC-31 (Figure 6(a) and (c)). These observations suggest that for the light chain guided
selection, sequence homology is not required to maintain an antigen-antibody interaction with
the same or similar kinetics of binding. This may be caused by the often-dominant role of the
heavy chain in antigen binding. Sequence alignment using V BASE of the VH of MOC-31
showed that this chain has the highest homology with germline YAC-0/ld37 of the human VH
7 family. Indeed, the selected human heavy chain of clone 9E originated from the VH 7 family,
albeit from a different germline segment (VI-4.1b). It differs only moderately from the murine
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MOC-31 VH (Table 3), in total in 29 % (26/90 amino acids, in which the 90 aa arc encoding the
region after the FRl-part encoded by the PCR-primers and up to and including FR4). The
antibody models were used to investigate possible common features around the antibody
combining site. The main structure of the heavy chain CDR3 was. as expected, maintained. For
example, from Figure 6(e) and (0 it is clear that the heavy chain residues 98 K uiul 1001) arc
buried in both antibodies. Of the 13 amino acid germ line mutations found in 91-, three are
mutations that create the MOC-31 homologue residue (A33G in CDR1. N53Y in CDR2 and
S82aN in FR3). As shown in Figure 6. of the exposed residues 53Y. 56K and to some extent 28T
in MOC-31 VH . only 53 Y is retained in 9F.-VH , suggesting the involvement of this residue in
antigen binding. The superimposition of the binding sites of both antibodies, shown in Figure 7.
reveals that some residues have very similar positions and that they arc actually in corresponding
positions in the CDR loops. In particular, this is very obvious for the VH residues at positions
53 and 56. The pattern of mutations and the fact that a non-homologous human VL and a human
heavy chain with close homology to its MOC-31 counterpart were selected, suggest that the
heavy chain of MOC-31 is more essential for the specific binding of the antibody to liCiP-2 than
the light chain. Thus, the guided selection procedure yields a human antibody with similar
binding characteristics as the original murine MOC-31 antibody, yet with minimal structural
conservation. This contrasts with the data from Figini et al. (1994), in which an anti-phenyl-
oxazolone antibody was humanised with the same procedure; in this case, 6/7 of the putative
contact residues were retained in the fully human version. The structural solution to the
recognition of a particular epitope within a larger protein antigen is less stringent. For example,
minimal structural homology has been noted in two anti-influenza virus ncuraminidasc
antibodies binding to overlapping epitopes [35]. This reduced stringency on conservation of
critical binding site residues within the antibody-protein antigen interaction, apparently allows
structural divergence of antibodies obtained by guided selection. Using humanisation technique
of guided selection, we have isolated a fully human antibody directed to l;(iP-2. Since 1994,
several groups have used the guided selection technique to obtain human antibodies by sequential
chain shuffling (Salfeld et al., 1997; [20, 36, 37]. Watzka et al. (1998) described that the second
shuffle (of the VH ) led to the selection of a humanised antibody, which recognised an epitope
present only on the immobilised (coated) antigen. In principle, the modulation of flnc-spccificity
may be caused by the possible different chemical interactions with a similar area on the antigen.
However, in this case it appears that a suboptimal selection procedure has interfered with the
structure of the epitope, causing failure of the guided selection procedure, and selection of
antibodies to completely different epitopes on the antigen. Since the heavy chain CDR3 is the
main loop involved in antigen binding and its species origin cannot be traced easily due to its
highly diverse nature anyway, several groups have opted to maintain this loop in the guided
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selection procedure. Similarly, we have succeeded in humanising an anti-CD30 antibody, which
had the same cpitopc specificity as the original murine Ki^l antibody, by retaining only the
murinc heavy chain CDR3 (Klimka c/ a/., unpublished results). Rader et al. (1998) humanised
the murine antibody LM609 (directed to human intcgrin av^3 ) by guided selection, retaining
the murine CDR3 s of both heavy and light chain. In contrast, our data suggest that it may not
always be necessary to maintain the CDR3 of the murinc light chain during the guided selection
as was suggested by Rader et al. (1998). Thus, guided selection of rodent antibody V-genes
provides a powerful tool for interspecies conversion of antibodies. Due to the different chemistry
of the human antibody-antigen interaction, it can be envisaged that in some cases guided
selection may alter the antibody-mediated triggering or signal transduction of the starting rodent
antibody (i.e. antibody intcmalisation. receptor crosslinking). Therefore, any resulting antibody
will need to be screened for loss (or gain) of such secondary binding feature.
In conclusion, we have obtained a high affinity antibody which specifically binds EGP-2
as confirmed by FACS analysis, immunohistochemistry and specificity ELISA and may be useful
for tumour targeting studies. For instance, hispecific antibodies can be generated by combining
the isolated human a-EGP-2 antibody with an a-CD3 antibody. Together with co-stimulatory
signals, these bispecific antibodies can be used to provide T cells with tumour specificity and
cytotoxic potential (Kroesen et al., 1994). Recently, such a bispecific molecule was synthesised:
the V-genes of MOC-31 were combined with those of an a-CD3 antibody. This diabody was
capable of retargeting T cells to lung cancer cells in vitro [38]. Thus, the human a-EGP-2
antibody may be suitable as a building block for the generation of immunotargeting therapeutics
such as immunotoxins, immunocytokincs or bispecific. whole or radiolabellcd antibodies.
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Abstract
Antibodies to tumour-associated antigens are increasingly being used as targeting vehicles
for the visualisation and also therapy of human solid tumours. The Epithelial cell adhesion
molecule (Ep-CAM) is an antigen that is ovcrexprcssed on a variety of human solid tumours and
constitutes an attractive target for immunotargeting. We have set out to obtain fully human
antibodies to this antigen by selection from a large antibody repertoire displayed on
bactcriophagc. Two single-chain variable antibody fragments (scFv) were identified that
specifically bound rccombinant antigen in v/7ro. One of the selected antibodies (VEL-1) cross-
reacted with extracellular matrix components in immunohistochemistry of colon carcinoma,
whereas the other scFv (VEL-2) specifically recognised colon cancer cells. The latter antibody
was further characterised with respect to cpitope specificity and kinetics of antigen-binding. It
showed no competition with the well-characterised anti Ep-CAM MOC-31 monoclonal antibody
and had an off-rate of 5 x 10'* s '. To obtain an antibody format more suitable for in vivo tumour-
targeting and to increase the apparent affinity through avidity, the genes of scFv VEL-2 were re-
formatted by fusion to a human (y l ) hinge region and CH3 domain. This "minibody" was
expressed in /•.'<<)//. specifically bound the Ep-CAM antigen and showed a 20-fold reduced off-
rate in surface plasmon resonance (SPR) analysis. These results show that phage antibody
selection, combined with antibody engineering may result in fully human antibody molecules
with promising characteristics for in vm> use in tumour targeting.
Introduction
During nuilignant transformation, a number of cellular (self-) antigens is upregulated or
mutated, providing targets for immunotherapy of human cancer. The Epithelial Cell Adhesion
Molecule (Ep-CAM, also known as EGP-2, EGP40, KSA, CO17-1A antigen or GA733-2
antigen) is a type I transmembranc glycoprotein which is abundantly expressed on a variety of
human carcinomas, notably on colorectal carcinoma (CRC). The protein is present on almost all
cell types derived from the ectoderm and endodenn gcrmlineages [ I ] and has been reported to
function as an intercellular adhesion molecule [2]. Recently, Ep-CAM was shown to modulate
cadherin-based intercellular junctions, causing a redistribution of E-cadherin and catenins and
a downrcgulation of a-catenin in transfected L-cells and epithelial cells [3]. This suggests a role
for the antigen in tumour metastasis: increased expression of Ep-CAM may lead to a decrease
of the number of cadherin-based junctions, thereby possibly destabilising intercellular contacts
and promoting metastasis (for review, see [4]). In CRC, adenomas show a low, heterogeneous
expression of the antigen, whereas carcinomas are found to be homogeneously positive [S],
providing the antigen with an essential characteristic for use as target in immuno-targeting. In
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addition, it is not shed into the circulation [6], which further increases its usefulness. — -
Ep-CAM has been widely used as a target for immunotargcting of solid tumours. In most
clinical trials, murinc monoclonal antibodies have been used, either for visualisation [7, 8], or
for treatment (9-12). However, the therapeutic use of most murinc antibodies in humans is
limited by the induction of a MAMA (human anti-mouse antibody; 113)) response. And although
part of this response may consist of an anti-idiotype antibody network which is expected to
augment the therapeutic effect, the induction of this cascade has been reported not to correlate
with the response of patients treated with the 17-1A anti-Hp-C AM antibody [14). On the other
hand, therapeutic strategies designed on anti idiotype antibodies and the induction of the anti-
idiotype network have been shown to induce clinical responses 115-17|.
To partially overcome the problems inherent to the use of murinc antibodies in humans,
chimene and humanised versions of murine antibodies to l-p-C'AM have been developed | IK.
19]. To date, only very few fully human antibodies have been described that recognise the native
antigen [20.21].
Therefore, to improve on existing modalities for antibody targeting of Ep-('AM
expressing solid tumours, we have used the power of phage display to select fully human
antibodies to the antigen. From a large, non-immune single-chain Fv (scFv) phage antibody
repertoire [22], two clones were selected that recognised recombinant antigen <« vi/ro. However,
one of these antibodies also reacted with extracellular matrix components in
immunohistochemistry of colon carcinoma, which made the antibody unsuited for in \ /m use.
The second antibody specifically bound the antigen in several //i n7r« tests, but showed a
relatively fast dissociation rate in kinetic analysis. Therefore, to improve the apparent affinity by
means of avidity and to obtain a suitable antibody format for /w v/vo use, the genes of scFv VEL-
2 were re-formatted as minibody. This fully human VEL-2 minibody is shown to be a promising
candidate for further evaluation as tumour-targeting vehicle.
Materials and Methods
TG1: K12,Atfaopro), wpf, //», WD5/F' fra£>36,/?ra4B\
gf anf/fcx/v .ve/«7ion on recomfcirtawf £p-C4A/
A large phage antibody repertoire in scfv format [22] was used for selection. The library
was rescued with helper phage M13K07 and phages were panned for binding to antigen. Two
selection methods were used: panning on antigen coated to immunotubes ( |23|) . or panning on
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biotinylatcd antigen in solution (lOOnM concentration), followed by retrieval on streptavidin
coated magnetic beads, as described ([24]). Three selection rounds were performed on purified,
recombinant, baculovirus-expressed Ep-CAM ([25]; a kind gift of Prof. D. Herlyn. the Wistar
Insitutc, Philadelphia, Pennsylvania, U.S.A.). After the second and third round of selection,
individual clones were tested for binding to antigen in ELISA.
Individual bacterial clones were picked and expression of soluble scFv fragments was
induced by activation of the upstream Z^ *tZ promotor with isopropyl-f}-D galactopyroside (IPTG)
as described [23|. The assay is further described by Roovers ef a/. [26]. Recombinant minibody
was detected with a polyclonal antiserum to human Fc regions (Jackson ImmunoRcsearch
Laboratories, West (irovc, Pennsylvania. U.S.A.: 0.1% (v/v)) and peroxidase-conjugated rabbit
anti goat immunoglobulincs (Dako, Glostrup, Denmark: 0.1% (v/v)). Staining was performed as
described [26|.
For competition experiments, individual clones were rescued with helper phage M! 3KO7
as described 123 J. Phagcs expressing the respective scFv were then mixed with a 10-fold molar
excess of M O O I monoclonal antibody |27| or an irrelevant control antibody (the Ki-4 anti-
CD30 antibody: [28]) and added to antigen-coated wells. Phages were then detected with a
polyclonal sheep antiserum to fd phagc (Pharmacia. Uppsala, Sweden) and peroxidase-
conjugated rabbit anti goat immunoglobulincs (Dako). Staining was performed as described [26].
Colorcctal cancer cell line CaCo2 (ATCC number HTB37) was cultured in Dulbecco's
Modification of Eagle's Medium (DMEM; Dulbecco, Life Technologies) supplemented with
10% (v/v) fetal calf scrum and 2mM glutamine at 37°C in a humidified atmosphere containing
5% (v/v) CO,. Cells were harvested by a short treatment with trypsin/EDTA, washed in
phosphate buffered saline (PBS) and aliquots of approximately 500,000 cells were made in
polystyrene FACSscan tubes (Falcon: Bccton & Dickinson, Heidelberg, Germany). All
incubations were carried out during one hour at rt in 2% (w/v) skimmed milk powder (Marvel)
in PBS, containing 0.05% (w/v) NaN, (2%MPBS/N,). Three washes, each consisting of
eontri filiation of the cells (400g, V, rt) and resuspension in 1ml of 2%MPBS/N»were performed
between every incubation step. Cells were stained with recombinant scFv fragments
(approximately lOOjig/ml concentration), the 91:10 monoclonal antibody [29] directed to the C-
terminal c-myc-derived epitope tag (0.1% (v/v) in 2%MPBS/N,) and FITC-labeled rabbit anti-
mouse immunoglobulines (Dako, Glostrup, Denmark; 2% (v/v) in 2%MPBS/N ,). Finally, cells
were washed three times with 2%MPBS/N,, once with PBS, resuspended in 500ul PBS and
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analysed by flow cytometry using a FACS-Calibur (Becton & Dickinson. Heidelberg, (.icnnany).
Data were analysed using the Cellquest software program (Becton & Dickinson. Heidelberg,
Germany). , .ij
Table I
Name Sequence
CLASS-BACK
Hinge-CHI-FOR
Hinge-L-CH3-
BACK(l)
His6-CH3-FOR
Hinge-L-CH3-
BACK(2)
MI3-FOR
V TAA TAAOtit IKtilfClKiTCKiAtitiOKiT AATTtT ATT Tl'A A(Ri AUACACI TV
S-CCA CCG r AC GOT GOG CAT GTO TGA OTT TTG TCA CAA GAT TT<! (H K «• A ACJ'
5-CACACATGCCCACCGTOCGGTOOAOOCOOTTCAOOrOOAl.ul >.<,t U'TOOO
CAG CCC CGA GAA CCA CAG O-J'
5' TTC TOG ACT GAA TTC TTA TTA OTO ATO OTO ATO ATO ATO TTT ACT COO AOA CAO
GOA GAG-J'
5' TTC TCG ACT GCO OCC OCA OAC AAA ACT CAC ACA TOC CCA-J'
5'-CGC CAO CXiT TTT (TC AGT CAC GAC-.V
C/o/i/wg o/a«
PCR was performed using Expand™ High Fidelity Taq polymcrase (Bochringer
Mannheim, Mannheim, Germany) together with the buffer supplemented by the manufacturer
in a 50ul reaction containing l,25mM MgCK, 25()uM of each of the 4 different
desoxyribonucleoside triphosphates (dATP, dTTP, dCTP, dGTP). 5(K)pM of both primers
(BACK and FOR), lOOpg of DNA template and 0.1U of DNA polymerasc. PCR was performed
by 25 cycles of (94°C, 45 sec; 55°C, 45 sec and 72°C, 1 min 30 sec) and products were analysed
by agarose gel electrophoresis with ethidium bromide staining using standard techniques [30].
The human (IgGl)CHl gene, present in vector pCESI [31] was amplified with primers
CL-ASS-BACK and Hinge-CH I -FOR (Table I), which introduces the human IgG I hinge region
at the 3' end of the CHI gene. The human (IgGI) CH3 gene was amplified from vector VH-
Express [32] with primers Hinge-L-CH3-BACK(I) and His6-CH3-FOR (Table 1). This
introduces part of the hinge region and a flexible (Gly^Ser>2 linker at the 5' end of the CH3 gene
and a hexa-histidine (His6) tag, two stop codons and an fc-o/fI restriction site for cloning at the
3' end of the CH3 gene. Both fragments (CHI -Hinge and Hingc-L-CH3-His6) were purified from
the PCR mix with the Wizard PCR prep purification kit (Promega, Madison, U.S.A.).
Approximately 75ng of both DNA fragments were then joined using 10 cycles of Splice Overlap
Extension PCR (SOE-PCR: [33]) without primers and re-amplified by 20 cycles using outer
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primers (CL-ASS-BACK and His6-CH3-FOR). The re-amplified PCR product was then purified
from the reaction mixture using the Wizard PCR prep purification kit. cut with the restriction
enzymes AV«/?I and AvrAll and ligated into pCES 1, thereby replacing the bacteriophage gene III
and creating vector pCESI/CH3.
To synthesise a minibody of scFv VEL-2, the human IgG I hinge region, linker sequence
and CHI domain, present in pCESI/CH3, were amplified with primers Hinge-L-CH3-BACK(2)
and M13-FOR (Table 1). This introduces a AW/1 restriction site at the 5' end of the hinge region
and removes the first five residues ('EPKSC amino acid sequence) of this domain. The PCR
product was cut with restriction enzymes Afo/I and £t-o/?l and cloned into pCANTAB6 [34],
creating PC6/CH3. This removes the bacteriophage gene III from the vector. Antibody V-genes
of VEL-2 in scFv format were excised from plasmid DNA of VEL-2/pCANTAB6 using
restriction sites ,S'/;I and <W>/I and cloned into PC6/CH3, resulting in minibody VEL-2. Both
vectors pCLSI/C'M3 and PC6/CH3 were sequenced using the dideoxy chain termination method
[35] to ensure that no mutations were introduced in the genes due to amplification.
For large-scale purification, the selected scFv antibody fragment VEL-2 was rc-cloncd
in an expression vector lacking the bacteriophage gene III (as 5/; I / M>/1 fragment in pUCI 19-
polylllSftMYC. a kind gift of Dr. Andrew Griffiths, MRC Laboratory of Molecular Biology,
Cambridge, U.K.) This method ensures less toxicity to the £.«>/» host due to expression of the
bucteriophage gene III during induction and thus a higher yield of protein. Production of soluble
scFv and minibody fragments and purification from the £.<:•«/; periplasmic space using
immobilised metnl ion affinity chromatography (IMAC) and fast protein liquid chromatography
(FPLC) were pcrfonncd as described for scFv by Roovers e/ a/. [26].
After purification of recombinant minibody fragment, different samples were analysed
by means of SDS-polyacrylamide gel electroforcse (SDS-PAGE; [36]). Samples were either
dissolved in reducing loading buffer (containing dithiothreitol: DTT) or in non-reducing loading
buffer (lacking DTT) and loaded onto a 10% (w/v) polyacrylamide gel. Proteins were separated
according to size, electroblotted to nitrocellulose using standard techniques [30] and blots were
dried on air. Minibody was then visualised with a polyclonal antiserum to human Fc regions
(Jackson ImmunoResearch Laboratories, West Grove. Pennsylvania, U.S.A.: 0.1% (v/v/)) and
peroxidasc-conjugated rabbit anti goat immunoglobulines (Dako: 0.1% (v/v)). Staining was
performed with diaminobcnzidinc/H,O;.
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To determine the kinetics of binding of different antibody fragments, rccombinant Fn-
CAM [25] was covalcntly coupled to a CM5 sensor chip via aminc coupling. resulting in an
antigen surface of 900 resonance units (RU). IMAC- (and for scFv: FPLC-) purified antibody
fragments were then run over the surface at high (20ul/min) tlow rate to saturation of binding.
From the obtained sensorgrams. off-rates were determined by curve-fitting on the first 10 sec.
of the dissociation phase using the BIAevaluation (version 2) software (Pharmacia, Uppsula,
Sweden).
Cryoscctions of different tissues (normal colonic epithelium and colon carcinoma) were
cut and mounted on 3-aminopropyl-2-cthoxysilanc (APTS-) coated glass slides. Sections were
subsequently stained with rccombinant antibody fragments, an antibody to the hexallislidinc tug
(SeroTec, Raleigh, U.S.A.; 0.1% (v/v)) and pcroxidasc-conjugatcd rabbit anti mouse UIHIIHKIICS
essentially as described [26].
Results
Se/erf/on a/»</ m Wfro / /
We set out to select fully human antibodies to the tumour antigen lip-C'AM for the
purpose of immunotargcting of human cancer. To this aim, we first performed phagc antibody
selections on rccombinant antigen coated in immunotubes, using a large, non-immunised single
chain Fv (scFv) phage antibody library [22]. After three and four rounds of selection, individual
clones were picked and DNA-fingerprinted as described [23]. One predominant clone was found
(data not shown) and selected for further analysis. Soluble scFv was then expressed as described
[37], and shown to specifically recognise recombinant antigen in ELISA (Fig. I).
i.s
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Figure 1
£/,/5/f »/
ScFv VEL-I (vertically striped bars), s:Fv
VEL-2 (horizontally striped bars) and
minibody VEL-2 (diagonally striped bant)
were tested on the anligcns I.p-C'AM
(epithelial cell adhesion molecule) Tct
Tox (tetanus loxoid) and USA (bovine
serum albumin). Negative controls for scFv
(open bars) and minibody (solid black bant)
arc also indicated.
Ep-CAM Tel Tox BSA
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However, when the antibody was used to stain cryosections of primary colorectal
carcinoma, staining of fibroblasts and extracellular matrix components was also observed, apart
from the (expected) epithelial cell reactivity (Fig. 2).
B
<jn/;/xx/y
Staining of primary colorectal carcinoma
with A) an irrelevant scFv as negative
control; B) clone scFv VEL-I and Q
clone scFv VF.L-2. Bound antibody
fragments were detected with the 9EI0
antibody and pcroxidase-conjugated
rabbit anti-mouse immunoglobulines.
When the epitope specificity of the
scFv fragment was compared to
that of the well-characterised
MOC-31 antibody [27] in a
. '< competition ELISA, clone VEL-1
did not compete with this antibody
• ,; (data not shown). Measurement of
" the kinetics of antigen binding of
\ Vv, « '"" scFv VEL-1 was performed using
surface plasmon resonance (SPR)
'" * BIAcore. The off-rate of the
•: "•C^ monomenc scFv was measured to
"f»;.,»*. be 8.4x10' s ' under the
• ' ' ' conditions used (Table 2). To
further characterise the epitope recognised by the VEL-1 antibody, the Ep-CAM antigen was
treated with NalOj (as described by [38]). which cleaves carbohydrate vicinal hydroxyl groups
under mild acidic pH [39]. The reactivity of scFv VEL-1 with the antigen in ELISA was slightly
inhibited by Nal(\-trcatment (data not shown), revealing that the epitope recognised by this
selected antibody fragment could be partially composed of a carbohydrate structure. This may
explain (part of the) cross-reactivity with different cell types and extracellular stroma. observed
in immunohistochemical analysis (Fig. 2).
To possibly overcome the problem of selecting antibodies to cross-reactive epitopes of
the Ep-CAM antigen, which may be caused by the partial denaturation of the antigen upon
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coating the antigen to immunotubes. a different selection procedure was chosen. Selections were
performed on biotinylated antigen in solution using retrieval with strepta\ idin-coated magnetic
beads [24]. Again, one predominant clone was found after three rounds of selection, as
determined by DNA-fingerprint analysis (data not shown). This scFv (VEL-2) was also shown
to specifically recognise the Ep-CAM antigen in EL1SA (Fig. I). In addition, it specifically
stained Ep-CAM positive epithelial tumour cells in immunohistochemical analysis of primary
colorectal carcinoma; it did not show the cross-reactivity observed with scFv VEl.-l (Fig. 2).
However, the off-rate of the monovalent scFv was higher than that of the VHL-1 antibody:
5.0x10" s' (Table 2).
Table 2
CAarur/eruf/cv o/VAf />//u/i/i£ Ai/if/irc oAf/crW an//' £/>-
Antibody:
VEL-1 scFv
VEL-2 scFv
Minibody (VEL-2)
MOC-31 scFv
k,,n•> - S E ( I O ' s ' )
8.4+/-0.145
50 +/- 4
2.2 +/- 0.3"
0.34 +/- 0.05
t,,(s)*
83
14
315
2039
' t,,j calculated as t, ? = I
" apparent (bivalent) dissociation rate constant
For comparison: the off-rate of the high affinity monovalent MOC31 scFv has been
reported to be 3.4 x 10^ * s ' [26] (Table 2). As was determined for the VEL-1 antibody, the VEL-
2 scFv did not cross-react with the MOC-31 antibody in competition ELISA (data not shown).
In addition, the reactivity of the VEL-2 antibody was not affected by NalO., treatment of the Ep-
CAM antigen (data not shown), showing that the epitopc recognised is most probably composed
of a protein sequence. The amount of scFv purified from £.cti// was measured to be between 100
and 200ug per liter of bacterial culture.
Sequencing of the V-genes of both scFv's VEL-1 and VEL-2 and alignment of the genes
to their closest germile V-segment using V-base (http://www.mrc-cpc.cam.ac.uk/imt-doc
/restricted/DNAPLOT.html) revealed that they originated from commonly used VH and VL gene
families: the VH- and VL-gene of scFv VEL-1 are both derived from the largest VH (VH3) and
VA. (VA.3) V-gene families (Table 3). Only a few mutations were found in the non primer-
encoded VH-gene segment and the VA. gene showed no mutations at all (Table 4). Mutations in
the VH gene were largely confined to the CDR1, except for two mutations in FR3 (E(85)~»G and
K(94)-»R). The observed mutations in VA.-CDR3 are probably due to the J-scgment usage and
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junctional diversity (Table 3 and 4).
Table 3
(icrmlinc segment usage of selected anti Ep-CAM antibodies:
Antibody
VEL-I
VEL-I
VEL-2
VEL-2
V-gcne
VH
VL
VH
VL
V-gene
family
VH3
VX3
VHl
VX3
Used V-segmcnt
DP-47/V3-23
DPL16/VL3.1
DP-7/21-2
DPL16/VL3.I
rv ,
Used D-segment
D6-25
n.a."
D6-I9
n.a.'
Used J-segment
JH3a
A2/U3a
JH3b
JA.2/JX3a
' n.a. not applicable
The V-gcncs of scFv VEL-2 belonged to the VHl and VA.3 V-gene families (Table 3). Strikingly,
the VH gene of scFv VEL-2 is different from that of scFv VEL-1, but the VL gene shows a
murked homology to that of scFv VEL-1. Both VL genes are derived from the same germline VA.
segment, show no mutations compared with this segment, but have a different CDR3 (Table 4).
In uddition, both VL. genes also use the same J-scgment (JA.2/JA.3a: Table 3). The VH gene of
scFv VbL-2 also shows no mutations compared with the germline V-segment (Table 4).
Figure 3
r cvtome/ric ana/vs« o/"
Number of events (counts) as function of
the fluorescence intensity of the cells (FL1-
H). Thin line: negative control: dotted line:
scFv VEL-1 and striped line: scFv VEL-2.
Finally, both scFv antibodies were
tested for their ability to bind to cell
surface-expressed antigen by means
of flow cytometry and only scFv VEL-2 was shown to recognise the Ep-CAM positive CRC cell
line CaCo2 (Fig. 3). This made only the VEL-2 antibody suitable for development as vehicle to
target Ep-CAM positive malignancies.
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To increase the apparent affinity of the specific anti Ep-CAM scfv VI-1-2 through avidity
and to obtain a suitable antibody format for use in 1/1 vm> targeting of tumours, the "iniiubody"
format (40] was chosen. In this format, the scFv cassette is genetically linked to a human hinge
region, a flexible peptidc linker and human CH3 domain that causes dimerisation of the
monovalent scFv moiety. In addition, it causes an increase of the molecular weight to
approximately 90kDa, which is a suitable size for radio-immuno imaging purposes using the
commonly used T c radionuclide [41 ]. The VEL-2 scFv was linked to an engineered human
IgGI hinge region that was truncated at the 5'end of the gene, as described by Alt i7<i/. |42|. In
contrast to the sequence originally described by Hu ct a/. [40]. the first five amino acid residues
'EPKSC were omitted to avoid the presence of an unpaired cystcine in the final construct (Fig.
4). In addition, three extra alaninc residues were introduced between the ('-terminus of the VI .
domain and the N-terminus of the hinge region, to encode the /VWI restriction site (Tig. 4).
Not I
--VL gene-- ACC GTC CTA GGT GCG GCC GCA GAC AAA ACT CAC ACA TGC CCA CCG TGC
T V L G A A A D K T H T C P P C
—VL gene— —IgGI Hinge—
GGT GGA GGC GGT TCA GGC GGA GGT GGC TCT GGG CAG CCC CGA --IgGI CH3 gene—
G G G G S G G G G S G Q P R
—Linker— —CHS gene--
_ _
--- CCG GGT AAA CAT CAT CAT CAC CAT CAC TAA TAA GAA TTC
P G K H H H H H H * *
—CH3 gene-- --Hexahistidine Tag— Stop
Figure 4
Nucleotide sequence and aminoacid translation of the engineeredscFv-Hingc-L-CH3 region and ('-terminal rcgicn
of the CH3 domain. The construct contains a C-terminal hexahistidine (116) tag for Immobilised Metal ion Aflinif
Chromatography (IMAC).
Expression of this cassette in £.cW/ resulted in dimcric molecules of the expected
molecular weight (+/- 90kDa), as determined by Western blotting using a polyclonal anti human
Fc(y) specific serum (Fig. 5). Under reducing conditions, a 45kDa band was found,
corresponding to the scFv-hinge-linker-CH3 cassette and a 15kDa band, corresponding to free
CH3 domains. This indicated that proteolytic cleavage occurred in the linker between the scFv
moiety and CH3 domain. Under non-reducing conditions, several bands were found that
corresponded to various degradation products of the minibody (Fig. 5). Most probably due to its
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increased size, the expression level of minibody VEL-2 was only between 50 and lOOng per liter
bacterial culture. Minibody VEL-2 bound avidly to antigen, as witnessed by the ofT-rate of this
antibody format which was reduced by a factor of approximately 20 compared with the parental
scFv (2.2x10"' s ' verfia 50x1 Q' s': Table 2) in SPR analysis. As expected, it bound specifically
to the Ep-CAM antigen in ELISA (Fig. 1) and immunohistochemistry, showing a staining pattern
comparable to that of the VEL-2 scFv (Fig. 2). Furthermore, by using a human Fc-specific
antiscrum as detecting antibody in ELISA, the physical link between the scFv moiety and Fc tail
(CH3 domains) could be demonstrated (Fig. 1). As was shown for the scFv. minibody VEL-2
also recognised cell-surface expressed Ep-CAM antigen, demonstrated by flow cytometric
analysis using the CaCo2 cell line (data not shown).
MW(kDb):
97.4—
66—
46—
30-
21.5-
#;-
'?•>. • •
a
Figure 5
express/ow fty K o /
IMAC-purified VEL-2 minibody
was loaded onto a 10% (w/v)
polyacrylamidc gel in cither
reducing (lane I) or non-reducing
(lane 2) loading buffer. Proteirt>
were separated according to size,
blotted to nitrocellulose and
visualised by means of a polyclorwl
goat antiscrum to human Fc
regions, peroxidasc-conjugatcd
rahbbil and goal immunoglobulincs
and staining with DAB H,O,.
Molecular weight markers arc
indicated on the left. Antibody
formats corresponding to the
respective bands arc depicted on
the right. Open ovals: VH and VL
domain of scFv moiety;
horizontally striped ovals: CH3
domains.
Discussion
To improve on existing modalities for immunotargeting of solid tumours expressing the
Ep-CAM antigen, we have used phage display to select fully human antibody fragments specific
for the antigen. Two different selection procedures were used to obtain anti Ep-CAM antibodies:
whereas panning on antigen coated in immunotubes only resulted in an antibody that cross-
reacted with extracellular matrix components, selection on biotinylated antigen in solution did
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result in a specific anti Fp-CAM scFv. Since this scFv antibody showed a relatively fast
dissociation rate from antigen and since the scFv antirxnly format is not optimal for use in »"« vhv
tumour targeting, the genes of scFv VEL-2 were re-formatted into the mimhody format. This
engineered minibody was expressed in £.«»//, showed specific binding to antigen in several lit
vj/ro tests and had a markedly reduced off-rate compared with the parental scFv. Therefore, this
fully human minibody is a promising candidate for further evaluation as tumour targeting vehicle.
In agreement with a recent report |20), we were unable to select an antibody that was truly
specific for the Ep-CAM antigen by panning a large phage antibody library |22| on reconibinant
antigen coated in immunotubes. This selection procedure may have the disadvantage of selecting
antibodies directed to otherwise cryptic epitopes of an antigen that may become exposed upon
coating the protein in immunotubes. In this respect it is noteworthy that the VI-1 -I and Vl-L-2
scFv antibodies differ mostly in their VH domain and use very similar VI. domains (Table .1 and
4). This emphasises the importance of the VH domain lor the exact epitope specificity, a
phenomenon that has also been noted by others [21].
It is surprising that neither the VEL-1, nor the VEL-2 antibody compete with the MOC-31
murine anti F.p-C'AM antibody. Most of the well-characterised anti Ep-CAM antibodies made
via the hybridoma technology (e.g. 17-1 A: [43]; 323/A3: |44| and M(X'-3I: |27|) all recognise
an overlapping epitope on the antigen that is apparently immunodominant m Ww» but is not
targeted during /n v/7ro phage antibody selection. However, this possibility of selecting
antibodies directed to non-immunogenic epitopes of an antigen is a known feature of the phage
display technology [45, 46] and is not uncommon. Whether the epitope specificity of the anti
Ep-CAM antibody VEL-2 will have an effect on its in vivo targeting properties remains to be
determined.
The off-rates of the scFv fragments we measured are typical for phage antibodies selected
from large, non-immunised repertoires [22, 31,47], except for the VEL-2 scFv (Table 2). It may
seem surprising that this scFv was selected, despite of its relatively fast off-rate. This may be
explained by multivalcnt expression on phage, even in the phagemid system used, which
compensates the fast off-rate through rcbinding (avidity).
Since there is a clear correlation between the off-rate of an antibody and its /« vivo tumour
targeting [48] performance and since differences in off-rate measured by SPR in a BI Acorc can
be correlated with different retention times on the surface of tumour cells [48], we decided to
improve the apparent affinity of scFv VEL-2 for the Ep-CAM antigen by increasing the valency
of the molecule. Indeed, the off-rate of the VEL-2 minibody was approximately 20-fold lower
than that of the VEL-2 scFv (Table 2).
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1. VH sequences:
™i _5*i ^ _.S??? **^  COM nw
123456789012345678901234567890 I*b2345 67890123456789 012abc3456789012345 6789O12345678loi2atoc34S6789O1234
DP-47/V3-23 «vqll«»gGGLVOPGGSLRLSCAASGrrrS S—YAMS HVROAPGKGLEWVS AISG—SGGSTYYADSVKG RFTISROHSKMTLYtOMlSLRAEDTAVYYCAK
'/EL-1 VH q . . . v —ro.B — Q R DMRAVATUGGWMDV HOQgttvt»»«
DP-7/21-2 qvqlvq»9A£-/KKPGASVKVSCKASGYTFT S—YYKH WVBOAPGQGLEWC IIHP—SGGSTSYAQKFOG RVTMrRDTSTSTVYWLSSLRSEDTAVYYCAR
^"•"* ^" '" — GYNSAFDI 1
2. VA. sequences
™i =»i [^  CDR2 ni3 cw»3 nt4
1234567891234567890123 45678901«bc234 567890123456789 01abcde23456 789012345678ab90123456789012345678 9012345ab
VEL-l'vL^ '^  "•"<*"WSVALGQTVRITC QG-DS-LRSY-YAS WYQOKPGQAPVLVIY GK NNRPS GIPDRFSGSSSG—NTASLTITGAQAEDEADYYC NSRDSSGMH
vtt-2 VL !!!!! . ' !! ! ! - ! ! - ! ! ! ! - ! ! ! ! ! ! ! ! ! ! ! . ' ! ! ! ! ! ! !! ! ! ! ! ! !! II
Primer-encoded sequences are indicated with lower case letters.
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This effect of bivalency is in good agreement with what has been r eporied for the C6.5
scFv antibody directed to the c-erB-2 antigen [49], but is larger than the avidity effect reported
for triabodies [50, 51]; for review, see [52], Although this effect of nuiltivalency heavily
depends on the particular antibody used and on the density of the target antigen on the ecl I
surface, the flexibility of both antigen-binding sites in a minibody will increase the likclihoo d
of rebinding of one arm when the other has dissociated from antigen, which may partially explai n
these contradictory data.
As judged by Western blotting using non-reducing conditions, not all of the expresse d
minibody was disulphidc-bndged (Fig. 4). but the majority (approximately b()-70"o) of the
product contained one or two s-s bridges between the two chains. Proteolysis of the minibod y
was evident and was mostly confined to the flexible linker between the scFv moiety and CM 3
domain (Fig. 4). This constitutes a problem for the synthesis of protein to be used in i/t vivo
tumour targeting studies. However, this may be solved by c hoosing a protcasc-dcficicnt £.(•»//
strain for expression, or by expressing the genes in a suitable eukaryotic expression system [40].
The different cpitopc specificity of the VEL-2 antibody compared with that of most o f
the munne anti Ep-CAM antibodies offers possibilities for the design and engineering o I
targeting molecules directed to the Ep-CAM antigen. We have recently reported on the successfu I
cloning and humanisation of the murine MOC-31 antibody [21, 26]. The combination of hot h
of these specificities into one molecule to develop a chclating antibody or "CRAb" [ 53 ] would
significantly enlarge the targeting potential of these molecules.
We conclude that minibody VEL-2 is a promising candidate for further evaluation a s
tumour targeting vehicle. It is an engineered form of one of the first fully human anti F.p-CA M
antibodies described to date and it combines a suitable antibody format for /« Ww tumour
targeting with increased affinity compared with the parental scFv.
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Abstract
Phagc antibody display technology offers a powerful tool for the isolation of specific
antibodies to defined target antigens. Most selection strategies described to date have relied on
the availability of purified -and often recombinant- antigen, providing the possibility to perform
selections on a well-defined antigen source. However, when the target antigen is non-purifiable
(e.g. an integral membrane protein), or if the antigen is unknown (e.g. when searching for novel
markers on cells or tissues), panning of phagc antibody libraries has to be performed on complex
antigen sources such as cell surfaces or tissue sections, or even by /« v/vo selection methods. This
provides a scries of technical and experimental challenges.
A main focus of our research is to select antibodies directed to novel cancer-induced
antigens expressed by tumours and by the tumour vasculaturc. To understand the parameters
governing selections on complex antigen sources and to assess the efficiency of these phagc
library selections, we have set up two model selection systems in which both tumour cells and
vascular endothclial cells serve as target "antigen". We describe a model based on phage
antibodies directed to the tumour antigen epithelial glycoprotein-2, to compare phage antibody
selections on a range of different antigen sources, including purified-, recombinant antigen,
whole live cells, tissue cryosections and m vivo grown solid tumours. Secondly, we describe a
model based on a phage antibody directed against the cndothelial cell inducible adhesion
molecule li-sclectin. We compare selections on cultured cell monolayers with selections on cells
suspensions immobilised on columns, to determine which selection approach is most suitable for
the identification of novel tumour endothelial cell markers.
Our data provide insight into the efficiency and thus potency of different selection
strategies and show that there arc very large differences regarding recovery and enrichment of
binding phage between the different methods tested. Our results further demonstrate the
feasibility oI phagc antibody selections on whole, intact cells and show that these may sometimes
compare favourably to selections on purified antigen. Selections on endothelial cells immobilised
on columns compare favourably with selections on cell-monolayers; the most favourable
conditions for both selection procedures are described. The implications of our data for phage
antibody selections on these different complex antigen sources using either non-immune or
immune phage antibody repertoires are discussed. The use of model systems such as the ones
described here will help to determine optimal experimental conditions for phage library
selections on complex antigens and aid in developing more powerful selection procedures for
target discovery.
Introduction
liver since its first description [ I ], antibody phage display has been a powerful tool for
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the selection of antibodies to defined target antigens. Large (non-immune or synthetic) "single-
pot" antibody repertoires have been made and displayed on phage from which specificities to a
whole range of antigens have been be obtained (2, 3); for review, sec | 4 | and |5). Most phagc
antibody selection strategies have relied on the availability of purified and/or recomhinant
antigen. This permits the immobilisation of antigen onto solid supports and thus permits phagc
antibody selections to be performed under well-defined conditions. Proteins are often non-
covalently coated to immunotubes and phage antibody repertoires arc panned for binding to
antigen. After extensive washing w ith detergent supplemented-buflers, phage antibodies that are
specifically bound to antigen can be retrieved, for example by a change in pll (2], by the use of
chaotropic agents [6] or by proteolytic digestion (7). ?
If, however, a protein requires the presence of a lipid bilayer for its native structure (as
e.g. in 7-transmembrane receptors), or if the aim of selections is to identify novel cell surface
markers specific for certain tissues, cell types, or cells at specific differentiation or disease-
induced states, phagc antibody selections have to be pertbmied on a much more complex source
of antigen [8-10]. The outcome of selections on complex antigens is governed by a number of
parameters that can roughly be divided into antigen-related factors and selection-related factors.
Important antigen-related factors include the amount (and thus concentration) of antigen, the
quality of the antigen (integrity during the selection procedure), the nature of the antigen
(intemalisation, accessibility, glycosylation, presence of immunodominant epitopes, expression
profile on different cell types, environment-dependent expression) and generation of nco-epitopes
due to preparation of the antigen. Selection-related parameters include the phagc library used
(e.g. V-gene source of the library, antibody display format, size of the library, ...), method of
phage preparation, conditions and time of incubation of phagc with the antigen, blocking and
washing during selection, method of elution and the use of subtraction and depletion strategics
or 'directed'-selection procedures (specific elution, Proximol"* selections or surface cpitopc
masking: [11-13].
The main focus of our research is to develop antibody-based immunotherapeutics for use in
cancer treatment. Tumour targeting may be based on antibodies with specificity for tumour
associated antigens [14], or for antigens on the cndothelium lining the tumour vasculaturc [15].
To date, however, only a limited number of antigens expressed by tumours or by the tumour
vasculature have been described as possible target molecules. Novel tumour antigens may
possibly be identified by differential cell selection using large 'single pot' phagc antibody
repertoires. Since phagc display works outside the immune system [2], these repertoires will also
contain antibodies to non-immunogenic and self-antigens, thereby avoiding possible restrictions
induced by wi v/vo tolerance mechanisms. Thus, by using a powerful selection procedure for
phage library selection on cell surfaces, it may be possible to identify novel tumour antigens by
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virtue of the antibodies that recognise them.
To isolate antibodies with these desired specificities, phage library selections have to be
performed on tumour- or tumour vasculature-derived antigen sources. However, it is unclear
how efficient phage library selections on these complex antigens are when compared with
selections on purified targets, in terms of enrichment of specific phage antibodies over non-
relevant clones and of recovery of phage. To better understand the parameters governing phage
library selections on complex antigens, we have set up model selection systems for the
enrichment of phage antibodies specific for the tumour antigen epithelial glycoprotein-2 (EGP-2)
and the endothclial cell inducible adhesion molecule E-sclcctin.
EGP-2 is a transmembrane glycoprotein abundantly expressed on a variety of human
carcinomas [16, I7|. We have previously reported on the isolation and characterisation of high
affinity single-chain variable antibody fragments (scFv, called MOC-31 and MOC-161) to this
tumour antigen [ IK|. In the present study, we set out to use these MOC phage antibodies in a
model for the selection of phage antibody repertoires on tumour material, including purified
rccombinant protein, cell surfaces, tissue cryosections and 1/1 v/vo grown solid tumours.
The second model is based on the selection efficiency of a phage displayed scFv derived from
E M - / //V/. .Y« tfMJxKty d/rected aga/ntf fte /nduc/We endoJ te^ reM-su/fao" adtesJw?
molecule E-sclcctin. li-sclcctin is a 116kl)u membrane glycoprotein, which plays a role in the
recruitment of leukocytes into sites of inflammation. It is largely absent from the endothelium
of normul tissues |20] and is transiently expressed on activated cndothelial cells in several
conditions, such as tissue regeneration and wound healing, as well as on the endothelial cells of
some ncoplustic tissues [21-23). E-sclcctin expression can be induced by a variety of
inflammatory mediators such as intcrleukin-l (1L-1), intcrferon gamma (IFN-y). and tumour
necrosis factor alpha (TNF-a). This model system allows us to estimate the feasibility and the
efficiency of selection of phage antibodies directed to antigens differentially expressed on
activated endothelium.
In our model experiments, the enrichment of specific phage was determined after a single
round of selection on different antigen sources. Our results demonstrate the feasibility of phage
antibody selections on these 'alternative' complex antigen sources and demonstrate the
differences between various selection regimens, as well as the differences between the two target
antigen sources. This study has implications for the design of experiments aimed at targeting
particular (integral) membrane proteins or at identifying novel (disease-induced) antigen
structures on cells and tissues. Knowledge of the applicability and relative potency of different
selection procedures and of the effect of the different parameters governing the efficiency of
these selections is now being used for the isolation of phage antibodies for tumour-cell or
tumour-vasculaturc targeting.
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Materials and Methods
The V-genes of the anti EGP-2 murine hybridomas MOC-31 and MCXM6I were cloned in
scFv format for the expression on bactcriophage as described [18]. The vector pCOMB3,
containing the cloned V-genes of the murine anti human E-selectin antibody FNA-I 119) in Fab
format was kindly provided by Dr. van Zonncvcld (Dept of Biochemistry. Academic Medical
Center, University of Amsterdam, the Netherlands). The variable domains of both heavy- and
light chain of EN A-1 were PCR-amplified from purified plasmid DNA und cloned for display
in scFv format containing a flexible 15-residuc Gly-Scr linker as described 118. 24). Phage fd-
DOGI has previously been described [24]; fd-DCXil-DI .3 contains the V-genes of the anti hen
egg lysozyme(HEL) antibody D1.3 [25], cloned as scFv in fd-IXXil [l|. M(X'-3I.-Ihl and
ENA-I expressing phage confer ampicillin (AMP) resistance to the bacterial host upon infection,
whereas fd-DOGI and fd-DCXJI-D1.3 phagc confer tctracyclin (TET) resistance to bacteria.
E.co// sfram
TGI: KI2, Af/ac-pro), supf, /Ai, *.«/D5/F'/raD36,prr>A'B\ /«</". teZAM15
Ce// /me*
Colorectal cancer cell lines CaCo2, LSI74T and SW480 were obtained from the American
Type Culture Collection (ATCC; numbers HTB37, CL188 and CCL228 respectively). Cells were
cultured in Dulbecco's Minimal Essential Medium (DMEM: Dulbccco, Life Technologies)
supplemented with 10% (v/v) fetal calf scrum and 2mM glutaminc. Primary human umbilical
vein-derived endothelial cells (HUVEC) were isolated as described [26) and cultured in RI'MI
1640 medium (Dulbecco. Life Technologies), supplemented with 20% (v/v) heat-inactivated
human serum, 2mM glutamine, O.lmg/ml streptomycin and 100 U/ml penicillin. E-sclcctin
expression was induced on subconfluent monolayers of HUVF.C by a 4 hours incubation with
lOng/ml TNF-a (Pcpro Tech EC Ltd.. London, England) in fresh RPMI medium. Non-activated
(control) cells were incubated with fresh medium only. All cells were kept at 37"C in a
humidified atmosphere containing 5% CO,. Since mycoplasm infection has been reported to
influence the level of antigen expression on the cell surface [27], all cell lines used were
regularly tested for mycoplasm infection and consistently found to be negative.
Recombinant EGP-2 was expressed in the baculovirus expression system and purified as
described [28]. The protein was a kind gift from Prof. Dr. Dorothec Herlyn, the Wistar Insitute
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of Anatomy and Biology, Philadelphia, Pennsylvania, U.S.A.
/4/ia/y.vw q//?/ia#f anf;Ao</y />/W/>»g /»y /weans o//7ow cytomefry
Phagc antibodies MOC-31 and ENA-1 were rescued with helper phagc M13KO7 as described
[2]. £.c«// T(i I, infected with phagc fd-DOG I or fd-DOG 1 -Dl .3 were grown for 24hrs at 30°C
in 2xTY medium (1.6% (w/v) tryptone; 1.0% (w/v) yeast extract; 0.5% (w/v) NaCI),
supplemented with 25ug/ml tetracyclin. All phage were purified and concentrated by
precipitation from the bacterial culture supernatant with polyethylene glycol (PEG)/NaCI as
described [29J. Cells were harvested by trypsinisation (CaCo2) or EDTA treatment (HUVEC)
and uliquots of approximately 5x10^ cells were made in polystyrene FACSscan tubes (Falcon:
Bccton & Dickinson, Heidelberg, Germany). HUVEC were fixed with 1% (w/v)
paraformaldchydc in PBS for 30 minutes (30') at room temperature (rt) and blocked with 2%
(w/v) skimmed milk powder (Marvel) in PBS (2% MPBS) for 30 minutes at rt before staining.
All further incubations wcrc carried out for one hour at rt; three washes, each consisting of
ccntrifugation of the cells (400g, 3', rt) and resuspension in I ml of 2% MPBS. were performed
between every incubation step. Cells were stained with approximately 10" colony forming units
(cfu) of phagc in 50()ul 2% MPBS, a polyclonal sheep antiscrum to fd phagc (Pharmacia,
Uppsala, Sweden: 0.02% (v/v) in 2% MPBS) and FITC-labeled rabbit anti-goat
immunoglobulines (Dako, Glostrup, Denmark; 2% (v/v) in 2% MPBS). Finally, cells were
washed four times with PBS, resuspended in 500ul PBS and analysed by flow cytometry using
a FACS-Calibur (Bccton & Dickinson, Heidelberg, Germany). Data were analysed using the
Ccllqucst software program (Becton & Dickinson, Heidelberg, Germany).
/ .vr/tt'/ions /»v /Min/iinx on </i/fcrt7i/ £GP-2 /Muifi ve a/i/igew sow/res
Phagc wcrc prepared as described (sec section 2.5). An excess of fd phage (fd-DOG 1 or fd-
IXXil-DI.3) was then mixed with cither M(X'-31 or -161 phagc and the resulting mixture was
panned for binding to antigen. A schematic representation of the model is depicted in Fig. I. All
selections were performed in 2%MPBS as blocking agent for non-specific interactions. For all
selections, the total amount of input phage used was between 10'° and 10'* cfu.
Selections on purified EGP-2 were performed by panning in antigen-coated (at lOug/ml)
immunotubes as described [2|. All selections on cell lines were performed in suspension with
Ix 10' cells in a volume of 5ml 2% MPBS. Briefly, cells (4ml) and phage (Iml) were blocked in
2% MPBS for Ihr at rt; phage were then added to the cells and incubated for two hours at rt with
gentle shaking. Cells were pelleted (40()g, 3', rt), washed ten times with 5ml of 2% MPBS and
twice with 5ml of PBS (by resuspension and ccntrifugation) and phagc wcrc clutcd with different
elution butlers (IGniM HC1; lOOmM HCI; lOOmM TEA or by directly adding exponentially
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growing £.co/» TGI to the selection mixture). Incubations ot'phage in these strong acidic or basic
solutions for 10 min. have been shown to have a ncglcgible effect on phagc infectivity |30, 31).
HCI or TEA-containing elution buffers were then neutralised with half a volume of 1M Tris-HCI
(pH 7.4) and phage were titrated by serial dilution in 2xTY medium, followed by infection into
exponentially growing £.<?>// TGI and parallel plating on AMP and ITT containing tigar plates.
For selections on tissue cryoscctions. u patient-derived primary colorcctal tumour (obtained
after surgery) was used. Five urn cryoscctions were cut. mounted on 3-uminopropyl-tri-cthoxy
silane (APTS) coated glass slides, air-dried and fixed with 1% (w/v) paratbnrtaldchydc in PBS
for lOmin. at it. The tissue was then blocked with 2% MPBS for 30min. at rt, phage were applied
in 500ul 2% MPBS and incubated for 1.5 hours at rt. Slides were washed ten times with 4ml of
2% MPBS. twice with PBS and phage were eluted with 500ul lOOmM TliA. Titralion of input
and output phage were as described.
Titers of input and output phagc were corrected for different volumes and expressed as the
total amount of colony forming units (cfu). Recovery of specific phagc was calculated as the
percentage of AMP-resistant colonies (cfu) recovered after one round of selection, Enrichment
factors were calculated as the product of ratios of AMP and TET-resistunt colonies before and
after selection, according to the formula:
enrichment factor = (('"cfu,,, / '"cfu^) * (""cfii^, / ""cfti*,)).
(in = input titer; out = output liter)
A/oaW se/ec/ions ftv /»a/m//i# »n 77V/-"- ar -ar/i varca* //£/>'£(' iH»n«/awr.v
HUVEC were cultured in 24-well or 6-well culture dishes (50.000 and 140,000 cells/well
respectively) and activated by pre-incubation with TNF-a or used without activation (sec section
2.3). Cells were washed twice with PBS/0.1% (w/v) bovine serum albumin (BSA) and cither
used directly for selection, or fixed with 1% paraformaldehyde prior to selection. Fixed cells
were blocked with PBS (PBS. containing ImM MgSO, and CaCl,)/l%BSA or 2% MPBS for
30' at rt. Cell panning was performed by incubating HUVEC with I ml of a prc-blocked phage
mix (as in section 2.6, but alternatively blocking was also performed in PBS' /1%BSA) for one
hour at rt. Phage bound to HUVEC monolaycrs were then subjected to different washing (5, 10,
or 20 washes with lml of either PBS /1%BSA, or 2% MPBS ') and elution conditions (lOOmM
HCI or lOOmM TEA) and ratios of AMP and TET resistant cfu were determined before and after
selection as described.
A/odW sWec//o/« on acriva/ea" //(7^£C i«mg a A/gA ^rat/ie/j/ /wagne/;c .veparaf/ow cu/urn/i
For column selections, TNF-a-activated HUVEC were harvested by EDTA treatment, washed
twice with PBS/0.1% BSA, fixed with 1% paraformaldehyde and blocked with PBS/l%BSA as
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described. Approximately 5x10' cells were then incubated for 30" at rt in I ml PBS/0.1%BSA
containing a 1:50 dilution of the anti CD31 mouse monoclonal antibody EN4 (Monosan, Uden,
the Netherlands). Cells were washed twice with PBS/0.1%BSA and either magnetically labeled
by resuspension in lOOul PBS/0.1%BSA, containing 20ul of goat anti-mouse IgG MACS
magnetic microbcads (Millenyi Biotec, Bergisch Gladbach, Germany), or first incubated with
I ml of prc-blockcd phage mix (for one hour at rt) before labeling. Unreacted beads were removed
by two washes with I ml PBS/0.1 %BSA and labelled cells were resuspended in lOOul degasified
PBS/0.l%BSA. Cells were loaded onto a MiniMACS-MS column pre-equilibrated with lml
PBS/0.1%BSA and placed in a magnetic field (Miltcnyi Biotec, Bergisch Gladbach, Germany).
For phage panning on the column, I ml of prc-blockcd phagc were passed five times through the
MACS column (equiped with a flow rate restricting needle) retaining magnetically labeled
HUVIvC. The column was washed ten times with 2ml of PBS/1%BSA and subsequently drained
by removal from the magnetic field. For phagc panning on the column, cells were washed twice
again with lml of PBS/0. l%BSA to equal the amount of washing steps. Bound phage were
clutcd from HUVKC by TEA elution (see section 2.6) and titrated before and after selection as
described.
/« v/vo .v
Athymic (nude) mice were xenografted with the HGP-2 positive human colorcctal carcinoma
cell line LSI74T. When tumours reached a diameter of approximately 0.5cm, mice were
anaesthetised and 200ul phage mix (in PBS) was injected into the tail vein (intravenously: i.v.)
or directly into the intcrstitium of the tumour. After 5 or 30 minutes, mice were sacrificed and
organs were removed and snap-frozen in isopentane at -70°C. Phagc were then clutcd from
different organs essentially as described [32]. Briefly, organs were weighed, thawed and
mechanically sheared by blending with a Polytron PT1200 (Kinematica AG, Switzerland) in five
ml of R I'M I medium (Dulbecco. Life Technologies) containing lmM of the protease inhibitor
phenylmcthylsulfonvi fluoride (PMSF). Five ml of exponentially growing £.tWi TGI were then
added and the suspension was incubated for 30' at 37°C. Phage were then titrated by serially
diluting the mixture in 2xTY medium and plating in parallel on AMP and TET containing agar
plates. Output phage liters were corrected for the weight of the organ and expressed as cfu/mg
of tissue; input phage liters arc given as the total number of cfu injected. Enrichment factors and
recovery of specific phagc were calculated as described (see section 2.6).
Results
To better understand phage antibody selections on complex antigen sources such as whole live
cells, we set out to develop models that would permit us to compare various selection strategies
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and assess the most important parameters for selection. As a model for tumour-cell selection, we
used the high affinity M(X"-3I and MCXM6I scFv phage antibodies directed to the pan-
carcinoma marker EGP-2 [18] and fd-DOG 1 or fd-DOG t -D1.3 phage as non-binding controls.
The two anti EGP-2 scFv antibody fragments recognise at least partially overlapping cpilopcs
on EGP-2. which permits their direct comparison in these model experiments. As a model for
tumour endothciial-eelI selection, we cloned the anti E-sclecttn antibody 1-NA-l 11«>| as scFv for
the expression on phage and used it in combination with fd-IXXil and fd-IXXil-l)U for
selection on TNF-o-activated endothelial cells. In a typical model experiment, phage mixtures
of an excess of (non-binding) control phage over specific phage were selected on antigen. Sine*
antigen-specific and control phage confer a different antibiotic resistance to the bacterial host
upon infection, enrichment and recovery of binding phage can easily be determined by titrntion
and parallel selection on both antibiotics (Fig. I).
MOC / F.NA phage
(confer AMP resistance)
Titrate on AMP:
PhllfT ITliil
Titrate
^ - - ^
ratio 1: AMP/TET
fd-tet/D 1.3 phage
(confer TET resistance)
Enrichment:
ratio 1 / r»tio2
--— _^
^ ^ ^ ^
Titrate on TET:
Figure I
i'r rutf/frtf o/'a mm/(7
MOC/ENA phage i fd/DI.3 phage
Selection by panning on different antigen sources
Recovery Titrate
AMP ratio 2: AMPfTET TET
A phage mix of M(X or I'N
with an excess of fd-IXKil or I'd-
IXXil-DIJ phage was panned for
binding to different antigen source.
Enrichment of specific phugc was
calculated from the input mul output
ratios of AMP and I I I rcsistail
colonies (cfu). Recovery of specific
phage was determined as I he
percentage of AMP resistant
colonies recovered after a single
round of selection.
Cell binding of all phage antibodies was first demonstrated by means of flow cytometric
analysis using the target cell lines CaCo2 (expressing EGP-2) and TNF-a-activatcd (expressing
E-selectin), or non-activated HUVEC (Fig. 2). As expected, MOC-31 or -161 scFv expressing
phage bound the EGP-2 positive cell line CaCo2 (shown for MOC-31 only) and F.NA-1 scFv
expressing phage stained TNF-a-activated HUVEC, but not the non-activated cells. Fd-IXXJl
and fd-DOG 1-D1.3 phage were negative on all cells tested (Fig. 2).
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Figure 2
y g to
ftvy7ow cvto/we/ry
A: Colorectal cancer cell line CaCo2 was stained with MOC-31
scFv expressing phage (thick line) and fd-DOGl phage as negati\e
control (thin line).
B: TNF-o activated HUVF.C were stained with ENA-I scFv
expressing phage (thick line), or fd-DOGl phage as negati\e
control (dashed line).
C: Non-activated HUVF.C were stained with ENA-1 scFv
expressing phage (thick line), or fd-DOGl phage as negative
control (dashed line).
In all experiments, bound phage were detected with a polyclond
sheep antiserum to fd phage and FITC-conjugatcd rabbit anti goat
immunoglobulins.
In the first model experiments, we selected a mixture
of specific (M(X"-31 or MOC-I6I) and control phage
(fd-DOGl) on recombinant EGP-2 antigen by panning
in immunotubes (Table I). Our results confirm the very
low recovery reported for selections on recombinant
antigen [30]. This may be largely due to very inefficient
coating of the antigen, thereby decreasing the effective
antigen concentration during selection, or due to
modification of the cpitope upon coating. A consistent
difference in enrichment factor was found between the
MOC-31 and MOC-161 phage antibodies, although
recovery of specific phage was similar. Expression of a control scFv (anti hen egg lysozymc
(Illil.) antibody 1)1.3) on the non-specific phage (fd-DOGl) did not significantly alter the
enrichment, nor the recovery of specific phage (Table 1). Apparently, the non-specific binding
of phage to the antigen-coated solid phase was independent of antibody expression.
As a first step in the study of cell-based selection strategies, we compared different elution
conditions to retrieve MOC-31 phage after selection on the colorectal cancer cell line CaCo2.
Cells were harvested by short trypsinisation before selection, as immunocytochemical analysis
showed no influence of this treatment on the recognition of EGP-2 by the parental hybridoma
antibodies (data not shown). However, we cannot exclude that part of the antigen expressed on
the cell surface was lost because of the preparation method. We determined the viability of
CaCo2 cells before and after one round of selection (with 12 washes) to be 90°o and 70%
respectively (by trypan blue exclusion: data not shown). This indicates that in our model
experiments, loss of antigen through cell lysis before elution probably docs not significantly
influence the selection efficiency.
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Table! T
Spec. *
Non-rel. <&
MOC-31/
fd-DOGI
MOC-31/
fd-DOGl-
D1.3
MOC-161/
fd-DOGI
MOC-161/
fd-DOGI-
DI.3
Elution
lOOmM
TEA
lOOmM
TEA
lOOmM
TEA
lOOmM
TEA
Input
titers*
7.5*10"
6*10"
7.5*10"
4.75*10'°
1.5*10'
6*10"
1.5*10"
4.75*10'"
Output
titers
1.5*10*
2.7*10'
4.68*10'
2.4*10'
3.15*10'
1.2*10'
8.4*10'
3.6*10'
Input
ratio* *
1 :800
1:63
1 :400
1 :32
Output
ratio
5.55 : 1
19.5 : 1
1 : 3.81
2.33 : 1
Enrich-
ment
factor
4440
1229
105
75
Recovery
("o total)
2
62
21
56
* Titers are given for AMP resistant cfu (top) and TFT resistant cfu (bottom)
** ratios are given for (AMP : TET) resistant cfu
Very harsh elution conditions (1 OOmM HCI or I OOmM TEA) were shown to be necessary to
retrieve all MOC-31 phage, which is probably due to the relatively high affinity of the scFv
(Table 2; for simplicity and clarity, phagc titers have been omitted from this and subsequent
tables). Indeed, it has been reported that such conditions are sometimes necessary to retrieve
phage antibodies with high affinity [31,33]. When £.co// TGI were used as the "elution" moiety
(adding exponentially growing bacteria to the selection mixture), the selection efficiency was
roughly equal to that using strong basic or acidic elution (Table 2). This probably reflects MOC-
31-expressing phagc detaching from antigen during the incubation with bacteria. The majority
of scFv-expressing phage will be monovalent [34] and in theory, 50% of monovalcnt phage
bound to antigen would detach over 30 minutes (calculated from the off-rate of the antibody:
[18]. The fact, however, that the enrichment factor and recovery of MOC-31 phagc were similar,
hints towards the possibility that MOC-31 phage still bound to antigen arc also capable of
infecting £.ro//\ The addition of an excess of non-binding helper phagc M13K07 (confering
kanamycin resistance to the bacterial host) to block non-specific interactions of phage with the
cell surface did not result in an improved enrichment of specific phage (data not shown).
Apparently, a low level of background binding of phagc to cell surfaces cannot be prevented in
this way.
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Table 2
A/oaW se/ec/iww on £CP-2 expressing co/on cancer ce// ///ies.-
#ty e#ecf o/a7#erence.? m anf/feoa'.y o#"-ra/e
A
e#ecte o/e/u/io/j Z>u#er ana"
S p e c *
Non-rcl. <D
MOC-31
fd-IXXil
MOC-31
fd-DOGI
MOC-31
fd-IXXi l
M(X'-3I
fd-DOGI
Cell line
used:
CaCo2
CaCo2
CaCo2
CaCo2
Elution
condition
lOmM
HCI
IIKImM
HCI
KKImM
TEA
E.cW/
TGI
Input
ratio
1:100
1:30000
1:30000
1:8600
Output
ratio
90: 1
1 : 2.5
1 :3
1 : 1
Enrichment
factor
9(XX)
12000
10000
8600
Recovery
(% total)
24
6
5
37
B
Spec. <J>
Non-rcl. *
M(X'-3I
fd- IXXi l
MOC-31
fd-LXXH-DI.3
M0C-I61
fd-IXXi l
MCX-I6I
fd-IXXi l-DI.3
Cell line
used:
I.S174T
ISI74T
LS174T
LSI74T
Elution
condition
lOOmM
TEA
lOOmM
TEA
lOOmM
TEA
HK)mM
TEA
Input
ratio
1:2417
1:292
1:3125
1:283
Output
ratio
6.4 : 1
54.7 : 1
1 : 1.15
10: 1
Enrichment
factor
1 5469
15972
2717
2830
Recovery
(% total)
425
205
89
88
To assess the effect of diflerences in antibody off-rate on the outcome of cell-based selections,
we compared MCX-31 scFv to MOC-161 scFv (which has a six-fold higher off-rate than MOC-
31) in our model selection system. First, three different colorcctal cancer cell lines (CaCo2,
LSI74T and SW480) were used as 'antigen' in model selections to compare selections on
different loloiwial cancer cell lines. Results from these selections indicated that LS174T has the
highest c\pics.Mon level of EtiP-2, resulting in an enrichment factor of approximately 15,000 and
recovery of MOC-31 phage of 6° «(data not shown). When comparing MOC-31 to MOC-161 in
selections on whole cells (Table 2). a consistent difference in enrichment and recovery was
found, showing that a faster ofl'-rate not only reduces the enrichment of specific over non-specific
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phage. but also dramatically decreases the recovery (Table 2). The observed ditYerencc in
selection efficiency cannot be attributed to differences in expression level between the two scFv
phage antibodies, because Western blot analysis of total phage using a monoclonal anti-
bacteriophagc pill antibody [35] revealed that, on the contrary. MOC-I6I scFv was expressed
to a higher level on phage (27.5% of all pi 11-containing protein was scFv-pltl fusion) than MOC-
31 scFv (14.2% of scFv-plll fusion, based on densiomctry: data not shown).
Since it has been shown that antigen expression on solid tumours can vary as u result of
external signals {36}. cell lines may not reflect the antigen expression of that particulur cell type
i» ww. As an alternative antigen source that mimics the MI viw antigen expression more closely,
tissue cryosections of patient-derived material may be used, provided a suitable selection
procedure can be established. We first analysed several patient-derived primary tumours by
means of immunohistochemtstry for their EGP-2 expression; a tumour was then chosen that
homogeneously stained positive with the MOC-31 parental whole antibody (data not shown).
Since EGP-2 is a membrane antigen, the amount of protein available in these cryosections will
be very limited, although some intracellular antigen will also be exposed. As expected, the
selection efficiency dropped dramatically compared with panning on whole live cells expressing
EGP-2: the enrichment factor was decreased by a factor of 100-200; the recovery by a factor of
20-50 (Tables 2 and 3). No difference in enrichment or recovery between MOC-31 and 161 was
observed.
Table 3
K o/i
S p e c *
Non-rel. *
MOC-31
fd-DOGI
MOC-31
fd-DOGl-DI.3
MOC-16I
fd-DOGI
MOC-161
fd-DOGl-D1.3
Elution
condition
lOOmM
TEA
lOOmM
TEA
lOOmM
TEA
lOOmM
TEA
Input ratio
1:2000
1:200
1:3000
1:300
Output
ratio
1:37.6
1:11.8
1:37.5
1:7.94
Enrichment
factor
53
17
80
38
Recovery
(% total)
25
2
24
2
To preserve the m v/vo antigen expression even better, />» v/Vo selection strategics could also
be considered (as first described by [32]). Therefore, we determined if MOC-31-expressing
phage could be enriched in an />» v/vo selection model using athymic mice xenografted with the
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human colorectal cancer cell line LSI74T. We determined the number of phage present in the
tumour and in muscle as antigen-negative control organ. No enrichment of specific phage could
be observed in the tumour compared to muscle, when phage were injected intravenously (i.v.)
into the tail vein of xenograftcd mice (Table 4). When using the rescued "empty" phagemid
vector pC'ANTAB6 in a control experiment, no difference between this control phage and MOC-
31 expressing phage could be observed with regard to preferential retention in the tumour (Table
4). However, when a phage mix of MOC-31 and fd-DOGl was injected directly into the tumour,
an approximate 10-fold enrichment of MOC-31 phage was observed (comparing tumour with
muscle), proving that antigen-binding phage were specifically retained in the tumour. Recovery
of phage was approximately 0.001% of the input, per mg of tumour.
Table 4
/n .vWtr/7'on.v
Spec. *
Non-rel. <X>
M(X-3I
fd-IXXil
pCANTAB6
fd-IXXil
MOC-31
fd-IXXil
MOC-31
fd-IXXil
Selection
condition
30'
i.v.
5'
i.v.
5'
i.v.
5'
intratumoural
Input ratio
(AMPTI-T)
1:10000
1:16.5
1:41
1:100
Output ratios
(AMP:TF.T)»
tu. 1.3400
mu: 1:4285
tu: 1:5.8
mu: 1:3.4
tu: 1:15.3
mu: 1:10.8
tu: 1:2.57
mu: 1:24
Enrichment
factors
tu: 2.94
mu: 2.33
tu: 2.84
mu: 4.85
tu: 2.68
mu: 3.8
tu: 38.9
mu: 4.17
• Output ratios arc given lor tumour (tu) and muscle (mu): phage liters were corrected for the weight of the orga
and expressed as cfu/mg.
In a second model, we have investigated the use of more refractive endothclial cells for phage
punning. We cloned the ami E-sclcctin antibody ENA-1 into scFv format containing a flexible
15-residuc Gly-Ser linker using a cloning procedure and primers as described by [ 18]. For model
selections on activated »vra« non-activated endothelium, we first selected mixtures of anti-E
selcctin seKv expressing phage and control phage (fd-DOGl) on human umbilical vein
endothclial cells (UUVEC) monolaycrs. E-selectin expression on HUVEC was induced by a 4
hr incubation with TNF-o.
Different phage mixtures of control and E-selcctin specific phage were selected on TNF-o
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stimulated and non-stimulated human endothelial cells, grown either in 24- or 6-well plates
(Table 5A and B respectively). As expected, phagc could not be enriched by panning on E-
selectin negative, non-activated endothelial cells (Table 5A). However, after a single selection
round on E-selectin-expressing. activated endothelial cells, different degrees of enrichment of
EN A-1 displaying phage were obtained, with an average of 44 fold enrichment for all selections
performed, and a maximum enrichment of 72 fold (Table 5B).
Table 5
A/tx/e/ ce// .ve/ecf/o/ts o«
A
Treatment
Fixed
cells
Fixed
cells
+ AZIDF.
+ TNFa
24 wel
Fixed
cells
Fixed
cells
+ TNFa
Washing
Blocking
I OX
MPBS
10X
MPBS
I0X
MPBS
I0X
MPBS
10X
PBS-BSA
Elution
condition
lOOmM
MCI
lOOmM
TEA
lOOmM
TEA
lOOmM
HCL
lOOmM
HCL
Input
Ratio
1:53
1:53
1:53
1:53
1:53
Output
Kutio
1:54
1:6
1:7.9
1:5.3
1:7
Enrichment
factor
No
Enrichment
K.S
6.7
10
7.6
Recovery
Co)
0.013
0.057
0.049
0.045
0.06
In order to prevent intemalisation of E-selectin [37], cells were treated cither with
azide or mildly fixed with 1% paraformaldehydc Fixation of the cells generally resulted in
increased enrichment and recovery. This is probably due to the higher integrity of fixed v.v
azide-treated cell monolayers during selection. Both MPBS or PBS/BSA were tested as
blocking/washing agents during selections. Both agents demonstrated similar
blocking/washing capacity, but MPBS was overall a better agent. We also compared clution
of binding phage using lOOmM HCI or lOOmM TEA, since it has been reported that clution
buffers can have an effect on overall recovery of phage [38]. Both methods are efficient in
eluting specific phage; however, HCI elution resulted in higher enrichment factors.
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B
Treatment
Fixed
cells
Fixed
cells
+TNF-0
Fixed
cells
Fixed
cells
Washing/
Blocking
MIX
MPBS
IOX
MPBS
5X
MPBS
20X
MPBS
Elution
condition
lOOmM
TEA
lOOmM
HCL
IO()mM
HCL
lOOmM
HCL
Input
ratio
1:60
1:60
1:914
1:914
Output
ratio
1:1.8
1:1.2
1:16
1:14
Enrichment
factor
33.3
72
57.1
65.3
Recovery
(%)
0.14
0.123
0.34
0.094
To test the effect of the amount of antigen on selection efficiency in this model, selections
were performed on cell monolaycrs grown in both 24 and 6-well plates. After 10 washes,
enrichment on ft well plates was, on average, 6.4 fold higher than on 24 well plates. Recovery
of specific pluigc was also higher, increasing with (on average) 0.08% for selections on 6 well
plates (Table 5A and B). Variations of the washing procedure were then tested to increase the
selection efficiency. Extensive washing decreased phage recovery, but did not have a significant
effect on the enrichment of specific phage (Table 5B). Phage recovery was dependent on the
number of washes: recovery of ENA-1 phage was found to be reduced from 0.34%, after 5
washes, to 0.09% after 15 additional washes. Therefore, as can be calculated from the data in
Table 5, an average of 13% of the phage input was lost per wash during the first 5 washes, and
an average 1.6% per wash during the subsequent 15 washes. After the first 5 washes, additional
washing increased the enrichment only 1.14 fold (Table 5B).
Selection on endothelial-cell monolaycrs was then compared with selection on column-
immobiliscd cells, since this method can be simultaneously used for library selections on
etulotheliul cells isolated from tumors by magnetic activated cell sorting (MACS). For the first
column selections, cells were magnetically labelled via anti-CD31 and anti mouse microbeads
and caught onto a MACS column. Cell panning was then performed by running the phage mix
through the cell-loaded column. This method resulted in enrichment factors similar to the average
enrichment obtained after selections on monolaycrs. most likely because it does not allow
extensive interaction between phage antibodies and cell surface antigens (Table 5 and 6).
However, incubation of phage with cells for I hr prior to loading the cells on the MACS column
and extensive washing of the column gave a 460 fold enrichment, which was far superior to any
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selection on cell monolayers (Table 5 and 6). In this model, column-iminohilised cell selection
appears therefore to be more effective than selections on monolayers. This is probably due to a
more efficient washing procedure, since the number of phage recovered in the washes from
columns was on average over 10 fold higher than the number of phagc recovered from monolayer
washes (data not shown). The increased stringency of washing also correlates with the low
recovery of specific phagc after selection on MACS columns (Table 6).
Table 6
ow / / t /^£C using a A/'gA gra</»'fwf mag/if/ic .vc/Nirur/o/t co/Minn; f/0
fne co/umn. fS; panning on ce/& in .vu.v/wi.v/on. prior to /oaJ/'ng on //if co/umn
Treatment
+ TNF-a
- TNF-a
Elution condition
lOOmM TEA
lOOmMTEA
Input
Ratio
40: 1
4 0 : 1
Output
Ratio
1.2 : 1
220: 1
Enrichment
-5.5
Recovery
(%)
O.OOO33
0
B
Treatment
+ TNF-a
- TNF-a
Elution condition
lOOmMTEA
lOOmMTEA
Input
Ratio
100: 1
100: 1
Output
Ratio
1 : 4.6
69: 1
Enrichment
460
1.4
Recovery
(%)
O.OOO58
0
Discussion
In the present report, we describe the design and use of model systems to study the enrichment
of phage antibodies on a number of complex antigen sources, including cell surfaces, tissue
cryosections and /n vivo grown solid rumours. This is the first report to directly compare these
different selection strategies with regard to enrichment and recovery of specific phagc.
Furthermore, we have compared selections on tumour cells expressing high levels of EGP-2 to
selections on vascular endothelial cells that can be stimulated to express physiological levels of
E-selectin.
Antibody phage display has proven to be a very powerful method for the isolation of
antibodies to defined target antigens [2, 39, 40], for review see [4, 5]. However, many
applications of the technology require selections on non-purifiable (integral membrane-) antigens
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[41 ], while in other cases, the target antigen is unknown [8,42]. We are using the phage display
technology to identify novel tumour-cell and rumour endothelial cell-markers by selecting large
'single pot' repertoires on these two cell types. Phage antibodies specifically recognising one of
these two cell types then may define novel antigens. In all of these cases, selections have to be
performed on complex mixtures of antigens, which makes retrieval of the desired specificity
much more complicated for a number of reasons.
The antigen concentration (e.g. the density on the cellular surface) may be very low, thereby
dramatically decreasing the chance of selecting antibodies, in particular those with lower affinity.
In our model experiments, we found large differences in enrichment and recovery of specific
phage, depending on the cell type, and antibody, and the selection strategy used (Table 2, 5 and
6).These differences may be caused by the antigen density on the cell surface and/or the nature
of the antigen [ 38 J. The expression level of C-selectin on HUVEC, induced by TNF-ot activation
of these cells, has not been described, but EGP-2 is present in high copy numbers on colorectal
cancer cell lines (10" copies/cell: [27]. Our model antigens EGP-2 and E-selectin both have the
same overall architecture, being type 1 transmembrane molecules. Thus, their accessibility on the
cell surface is most likely comparable. Indeed, both antigens are accessible for binding of phage
Hnlihixlii"; ;>>; <1<*miin«lrativl hy f-'Af "*J iinnlyviw nciny P N A I and M O T ' 11 ovpreuuiny phuyo (Fig.
2). The large difference in FACS staining obtained using comparable amounts of phage (Fig. 2)
is probably due to di (Terences in expression level between the two antigens: however, it may also
be explained by diffenecs in the level of antibody display and/or differences in antibody affinity.
As expected, enrichment on whole cells was clearly dependent on the affinity of the antibody,
as shown by the reduced selection efficiency of MCX'-161 compared with MOC-31. Both scFv
antibodies recognise at least partially overlapping cpitopes on EGP-2, which excludes possible
effects of cpitopc inaccessibility on the selection efficiency. They differ in off-rate by a factor of
approximately six [IS), resulting in a six-fold lower enrichment factor and a two-and-a-half fold
lower recovery of M(X'-1M (Table 2). As shown, this factor is an understimatc. since MOC-161
scFv was expressed to a higher level on phage than MOC-31. giving MOC-161 some avidity
advantage.
Antigen expression on cells is highly dependent on the cellular environment and on cell-cell
and cell-matrix interactions [36]. The antigenic expression of endothelium e.g. is dependent on
its microenvironment: factors such as cell-cell interactions, cell-matrix interactions and other
exogenous factors such as mechanical forces, soluble growth promoters and inhibitors, cytokines
and plasma lipids and -proteins all influence the endothelial cell phenotype. Therefore, we
decided to use primary endothelial cell monolaycrs directly for selection, maintaining cell-cell
and partial cell-matrix interactions. In addition, this endothelial cell culture induces a
proliferative phenotype [43], which can further be modulated to mimic the tumour-endothelial
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phenotype e.g. by the addition of soluble growth factors, cytokines and tumour conditioned-
medium. However, the low enrichment and recovery obtained from the selections on monolaycrs
indicated that this procedure needs optimisation. By optimisation of washing, blocking and
elution and increasing the amount of antigen, we could achieve enrichment factors up to 72 on
HUVEC monolayers (Table 5), indicating the importance of these selection parameters for more
efficient phage library selections.
Highly pure cell populations may be isolated from complex cell mixtures (c.g tumour
homogenates) by the use of MACS for selection purposes. This method allows simultaneous
selection and depletion, since the phage library can be incubated with the cell mixture prior to
the column isolation, resulting in the loss of phage antibodies binding to nun target cells. As a
first test for column based selections, we decided to use indirect labeling of HI IVI-C with un and
CD31 antibody and magnetic beads for model selections on a high gradient magnetic separation
column. Panning on cells in suspension prior to loading on the column resulted in an improved
enrichment factor (460-fold) compared with selection by direct panning on column immobilised
cells or with selection on HUVEC monolayers (Table 5 and 6). This may be attributed to the
improved interaction between cells and phage and to the efficient elimination of background
phage by washing on the column. However, because of the nature of the washes on columns,
mild for the cells and stringent for removal of unbound phage, recovery of EN A-1 phage was also
dramatically decreased (Table 6). This effect will be most pronounced for lower affinity
antibodies, thereby decreasing their chance for selection. These column-based selections appear
to be particularly suitable to combine with subtractivc selection strategics.
As an alternative to selections on cells, other antigen sources may be used that faithf'uly mimic
the /n v/'vo antigen expression profile and that allow appropriate /n v/7ro selection procedures to
be used. Selection on tissue cryosections has been described (44], but this has not yet been
compared with selection on other complex antigens. Our comparative analysis shows that
enrichment and recovery of phage were reduced compared with selection on whole live cells
(Table 2 and 3), most likely due to the limited amount of antigen present. Despite the fact that
we used primary, patient-derived tumours instead of artificially grown Colo205 xenografts for
selection, recovery of specific phage (0.02% of input: Table 3) was similar to what has been
descibed for selections on cryosections (output/input ratio lO'': [44]. However, the presence of
extracellular matrix components and other (antigen-negative) cell types in the sections we used
for selection may have caused increased recovery of background phage. thereby explaining the
lower enrichment factors we found in our model system (80-fold wrvw.v 1500 fold). Indeed,
recovery of background phage was more than 50-fold higher than reported (output/input ratio
5x10"* versus <10~', [44]. Furthermore, the abundance of intracellular antigens in such tissue
sections may hamper the selection of cell-surface reactive antibodies, making subtractive
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selection strategies necessary.
A novel strategy to identify tumour specific antibodies is the in v/vo selection method. The
feasability of this selection strategy, first described for the selection of peptide phage [10, 32],
was first tested in our model for the selection of tumour cell-specific markers. In this model, no
enrichment of MOC-31 expressing phage could be observed in the tumour (compared to muscle)
of LS 174T-xenograftcd mice, by injecting phage mixtures into the tail vein (Table 4). This may
be explained by limited contact with antigen, since during the 5' circulation, phage do not cross
the cndothelial lining of blood vessels and penetrate into the organ interstitium to encounter
antigen [32]. This hypothesis was strengthened by injecting a phage mixture directly into the
tumour, which did result in a ten-fold enrichment of MOC-31 expressing phage (comparing
tumour to muscle: Table 4). Therefore, this selection procedure seems more suitable for the
isolation of tumour cndothelial cell-specific markers. In a preliminary experiment using a model
of human skin grafted onto athymic mice (as desribed by [45], activation of endothelial cells
through local injection of TNF-a and i.v. administration of a phage mix, ENA-I expressing
phage could indeed be enriched in the skin graft. Phage were allowed to circulate for 10' or4hrs
/« v/Yo, resulting in a 39-fold and 141-fold enrichment of EN A-1 expressing phage respectively
(data not shown). This also shows the beneficial effect of longer circulation times on the in vivo
selection efficiency in this model. However, the very large quantities of unbound phage present
in blood, which arc only slowly cleared, still limit the chances for successful m v/vo selections.
Other possibilities to decrease the recovery of background phage than the prolonged incubation
time (allowing physiological removal of unbound phage). include e.g. i/i Ww perfusion of the
animal and washing of the homogenised tumour after removal from the animal.
The enrichment factors and recoveries of specific phage antibodies found for the different
selection methods described in this report have implications for the design of selections on
complex antigen, such as tumour cells or endothelial cells of the tumour vasculature. The
enrichment factors reported here for selections on whole live cells compare very favourably with
those previously reported [46, 47|; 25- and 12-fold respectively VCV.VM.V the 60 to 10,000-fold
reported here, for a single round of selection). These enrichment factors are particularly important
when using very large libraries, containing 10"to 10'"different antibodies [40,48.49]. Due to
the large diversity of these repertoires, only a limited number of phage particles per clone is
generated after rescue of the unselected library. To retrieve the total population of binding
antibodies after the first, critical round of selection, the efficiency of selection must be high
enough to bridge the difference in input and output phage numbers. If selection efficiency in the
first round is low, then even high affinity clones like MOC-31 might be lost from such large
repertoires. For example, when the output titer of phage is 10" for the first round of selection and
the diversity of the repertoire is 10'", MOC-31 would most likely be retrieved by panning on
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whole live cells in suspension (with enrichment factors >IO*). However, when using less efficient
selection regimens, even this high affinity clone may be lost. Lower selection efficiencies then
mean that only a fraction of the total binding population will be retrieved, resulting in different
selected antibodies every time a series of selections is repeated.
A difficulty of the use of large, non-immune or synthetic repertoires for selection on complex
antigens is that they contain antibodies to a whole range of epitopes expressed on the antigenic
surface [2, 50]. Therefore, antibodies with the desired specificity may be largely obscured by
clones binding to irrelevant epitopes. To direct the selection of phage antibodies towards specific
epitopes. subtraction and depletion strategies have been devised und successfuly used (42. 51 -
55]. The removal of non-relevant clones can also be achieved by alternating selection on ditVcrent
antigen sources to home in on antigen-binding clones [56].
Alternatively, phage antibody repertoires may be used in which the starting frequency of
antigen-specific clones in the primary library is increased by immunisation with the antigen of
interest (in those cases, where the antigen is known: [51. 57] or by using patient-derived
repertoires (in case the antigen is unknown: [42]. Since these repertoires arc shaped by the
immune system, they contain a higher starting frequency of binding antibodies that will have
overall higher affinities, which will increase the chances of selecting those with the desired
specificity.
We conclude that these model systems are valuable tools to study phage antibody selections
on different complex antigen sources. This is the first report that directly compares selections on
recombinant antigen to cell-based panning, selections on tissue cryosections and lo an /« v/vo
model. Our data clearly demonstrate the feasibility of using complex antigen sources for
selections, but also indicate that part of the total binding population may be lost, if the procedure
is not carefuly designed. This report provides valuable information for the application of phage
display technology in the search for novel tumour associated-antigens. Recently, we have used
the experimental conditions derived from our model experiments to design and perform
selections on HUVECS and CaCo2 cells. Indeed, by direct panning without subtraction or
depletion strategies, we were able to identify a large number of antibodies directed to both cell
types and some antibodies selected on activated HUVEC display tumour endothclial cell
specificity. The latter may serve as novel anti-cancer targeting moieties.
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Abstract
Immunotargcting of solid rumours using antibodies has become a valuable tool for the
detection of cancer metastases and the treatment of minimal residual disease. However, only few
tumour antigens useful for targeting have been described to date. To identify cell-surface targets
on colorcctal carcinoma, we selected a large, human phage antibody repertoire on freshly isolated
colon tumour cells. Two antibodies were identified that reacted with epithelial cell-restricted cell-
surface antigens, whereas one clone preferentially reacted with stromal cells. These antigens are
tumour-associated antigens, as shown by their uniform expression in tumours of different
patients and of different differentiation stages and their limited expression on normal tissues. The
pattern of reactivity in immunohistochemistry and ELISA suggests that these antigens are
different from previously identified tumour-associated antigens (e.g. Ep-CAM orc-ERB-2). This
phage antibody-based method may lead to the cloning of novel tumour antigens that are useful
for immunotargcting of solid tumours.
Introduction
Colorectal cancer (CRC) is the second most prevalent cancer in western world. The
principal treatment modality is surgical removal of the primary tumour and adjuvant
chemotherapy (at present, 6 months of fluorouracil (5-FU) plus leucovorin (folinic acid) can be
considered standard therapy) for metastatic disease. However, especially for minimal residual
disease, immunothcrapy using monoclonal antibodies directed to tumour-associated antigens has
proven to be a promising new treatment modality [1, 2]. However, most of the target antigens
described to date for colon cancer (e.g. CF:A, c-HRB-2, TAG72. Ep-CAM) are tumour-associated
and thus arc also expressed on normal colon. This may give rise to toxicity problems when these
antigens arc used as target for the treatment of patients [3].
The search for new target antigens expressed on cancer has traditionally involved the
immunization of mice with cancer cells, cell lines or cell-extracts and the subsequent screening
of hyhridomas for antibodies that bind the target cell [4], In addition, tumour antigens have been
identified by the cloning of T-cells that recognise MHC-I restricted peptides derived from the
antigen [5|. More recently, genetic approaches are increasingly being used to define genes that
arc associated with malignant transformation [6] or to define distinct genetic subtypes of
malignancies [7] at the transcriptional level.
Antibody phage display (reviewed in [8]) has also been used as a means to quickly select
antibodies specific for certain cell types or tissues [9, 10] or known tumour antigens [11. 12].
This strategy may be used to identify cell-surface structures on cancer cells: novel antigens can
then be defined by means of the antibodies that recognise them. Although this approach has
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already been successfully applied to melanoma [13. 14] and to a lesser extent also to lung
carcinoma [15]. untill now, only one study has been reported that describes the selection of
antibodies reactive CRC antigens [ 16].
t J ; f The success of this approach depends on many parameters, including the phagc antibody
library size and quality and particularly on the selection method used. We have previously
described a study of phagc antibody selections on complex antigens, such as cell surfaces, in
which we investigated the parameters important for successful selection 117|. These models were
used to define selection criteria for efficient selection on whole tumour cells. Here, we describe
the use of these protocols for the selection of human antibody fragments reactive with colon
cancer. By direct panning of a large, non-immunised phuge antibody repertoire | IK| on freshly
isolated colon tumour cells, we retrieved antibodies that recognise patient-derived tumour
material in immunohistochemistry (IHC). The antigens recognised by these selected antibody
fragments proved to be tumour-associated antigens by their uniform expression in tumours of a
number of different CRC patients. On the basis of their expression pattern in normal tissues, they
cannot be classified as any of the colon tumour-antigens known to date. However, the selected
antibodies failed to recognise the native antigen, revealing that the target epitopes were
dependent on chemical modification of the proteins.
This study shows that phage antibody technology may successfully be used to select
antibodies with reactivity to possibly novel colon tumour antigens.
Materials and Methods
TGI: K12, Af/ac-/woA s«p£, /*/, fa</D5/F'/raD36,/woA*B\ /ac/", /«<ZAM15
Ce// //ne
Colorectal cancer cell line CaCo2 was obtained from the American Type Culture
Collection (ATCC; number HTB37) and was cultured in Dulbeccos Modified liagle Medium
(DMEM; Dulbecco, ICN Pharmaceuticals. Costa Mesa, CA-USA) supplemented with 10% (v/v)
fetal calf serum and 2mM glutamine. Cells were kept at 37°C in a humidified atmosphere
containing 5% CO,.
.se/ec/»o« on /vwia/r co/orw/a/ carc7/i»ma
A large, non-immunised phage antibody repertoire [18] was used for selection. The
library was rescued with helper phage M13KO7 and phages were purified and concentrated from
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the bacterial culture supernatant by polyethylene glycol (PEG) precipitation as described [19].
After each selection round, the percentage of bacterial clones containing complete (Fab) insert
was also determined, since a loss of clones containing V-gene insert is representative of
inefficient selection.
After surgery, primary colorectal cancer tissue was obtained from the department of
Pathology. Tissue was rinced three times with 20ml of PBS (50mM phosphate buffer
(KHjPO/NajHPO.,: pH 7.4); 150mM NaCI), cut in small pieces using a sterile scalpel blade and
rinced again with PBS. Tissue pieces were allowed to settle and buffer supernatant was removed.
Cells were detached by overnight incubation at 4°C in isolation buffer (PBS, containing imM
EDTA, ImM FiGTA and 0.5mM DTT) with gentle shaking. Next day, cells were harvested by
centrifugation (lOOg, 3min, 4°C), washed three times with 10ml of PBS by centrifugation and
resuspension and fixed in 5ml 0.25% (w/v) paraformaldehyde in PBS for 20min at 4°C. Cells
were washed three times again with 10ml of PBS, pelleted (lOOg, 3min, 4°C) and resuspended
in I ml of PBS. Phages were blocked for I h at rt in lml of 4% (w/v) Marvell (skimmed milk
powder) in PBS (4%MPBS), added to the cell suspension and incubated for I'/ih at room
temperature (rt) with gentle shaking. Cells were washed five times with 5ml of PBS by
centrifugation and resuspension and phages were eluted with lml of lOOmM tri-ethylamine
(TEA) for lOmin ut rt. The cluate was neutralised with 0.5ml 1M Tris-CI (pH 7.5) and phages
were allowed to infect exponentially growing i'.co// TGI and titrated as described [19J.
Ay DM4-_/mge/ywi/if/>ig am/
After selection, antibody-encoding V-gcncs of selected antibody fragments were
amplified by PCR from a single bacterial colony using primers pUC-reverse (5'-AGC GGA TAA
CAA TTT CAC ACA GG-3') and fd-TET seq (5-TTT GTC GTC TTT CCA GAC GTT AGT-3). The
percentage of bacterial clones containing complete (Fab) insert was then determined, since a
decrease of clones containing V-gcne insert is representative of inefficient selection. Finally,
antibody V-gcncs were DNA-fingerprinted as described [19].
For iinmunohistochcmistry (1HC). five micrometer cryosections of different cancerous
and normal tissues were cut and mounted on Starfrost Adhesiv (Klinipath. Duiven. the
Netherlands) glass slides. Slides were dried overnight at room temperature (rt) and stained with
rccombinunt Fab antibody fragments as described for single-chain Fv (scFv) by Roovers e/ a/.
|20|. I .urge scale production and purification of antibodies reactive in 1HC using immobilised
metal ion affinity chromatography (1MAC) and fast protein liquid chromatography (FPLC) were
as described for scFv by Roovers t7 a/. [20].
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Adherently growing CaCo2 cells were harvested at subeonfluency by trypsin/l-DTA
treatment and washed once with PBS. Cells were either used directly, or fixed with l"o (w/v)
paraformaldchyde in PBS for 20min at rt. Subsequently, cells were washed twice with 2% (w/v)
bovine serum albumin (BSA) in PBS and aliquots of approximately 5x10* cells were made. All
incubations were carried out for one hour at rt in either 2%MPBS containing 0.05% (w/v) NaN j
(2%MPBS/N,) for untreated cells, or tn 2"oMPBS for parafomwldehyde-fixed cells, ("ells were
washed twice with 0.5ml of the respective bufler between every incubation step. Staining was
performed with purified, recombinant antibody fragments (lOOnM), the 91:10 antibody ( | 2 I ) ;
50%(v/v) hybridoma supernatant) and FITC-conjugatcd rabbit anti mouse immunoglobulines
(Dako, Glostrup, Denmark; 2% (v/v)). Cells were finally resuspended in 0.5ml of PUS and
staining was visualised by flow cytomctry using a FACS-Calibur (Bccton & Dickinson,
Heidelberg, Germany).
Results
To identify possibly novel cell-surface antigens on colorectal carcinoma, we set out to
select phage antibodies with specificity for colon tumour cells by panning a very large Fab phagc
antibody repertoire [18] against freshly isolated tumour cells. For practical reasons, «i new
tumour-cell isolation from a tumour of a different patient was performed for every round of
selection; therefore, the amount of cells differed between selections. Table 1 shows the results
of selections: there is no clear increase in phage titer, but this may be explained by the di (Terences
in cell number used for selection. However, the percentage of clones containing full-length Fab
insert did increase with every selection round, hinting towards successful selection (Table I).
After four and five rounds of selection, the diversity of the selected phage antibody
population was examined and clones having a distinct fingerprint pattern (25 after round four and
17 after round five) were subsequently tested for their reactivity towards colorectal cancer tissue
in immunohistochemistry (IHC). After four rounds of phage selection, no positive signals were
observed in the screening of different selected antibodies by means of IHC on colon tumour
tissue of a different patient. However, after five rounds of selection, three out of 17 different
Zfa/M fingerprint patterns tested were scored positive in IHC (Fig. 1).
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Table 1
o/c/ones
wiser/
Selection
round:
1
2
3
4
5
Input
(i)
4.2 x
2.4 x
I.Xx
8.0 x
2.5 x
titcr*
10"
10"
10"
10"
10"
Output
(o)
2.6 x
5.0 x
3.3 x
4.9 x
4.1 x
titer*
10'
10'
10"
10'
10"
Ratio
6.2
2.1
1.8
6.1
1.6
o/i
x 10-*
x 10*
x 10'
x 10*
x 10'
Enrichment
factor* *
n.a.
0.34
8.57
0.34
2.62
% full-length
clones
n.d.
n.d.
83
94
100
• tilers arc given as colony-forming unit (cfuVml
** enrichment factor is defined as:
(Ratio o/i selection round n+1) / (Ratio o/i selection round n)
n.a. nor applicable
n.d. not determined
> • *
Figure I
/mmu/ioA/.v/wAemica/ .v/a/'/iwig
«/ 'i.v.vMt' fn'o.vft'/ion.v »/ co/ow
/ u.v/ng
R.
&
Hound antibody fragments were
delected with the 9FI0 antibody
recognising a C'-myc-derivcd cpitopc
1*8 *"^ pcroxydase-labeled anh
mouse antibodies.
A: negative control (a Fab antibody
directed to tetanus toxoid); B: clone
B5; C: clone BK and D: clone C8.
D
Two of the antibodies exclusively stained malignant epithelial cells (clones B5 and C8):
the observed staining pattern was mostly membranous, but also partially cytoplasmic (Fig. lb and
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Id). The remaining clone (B8) reacted very slightly with epithelial cells, but strongly stained
stromal cells (e.g. tlbr\>blasts: Fig. Ic). The V-genes of these selected antibodies were sequenced
and shown to originate from different, but commonly used V-gene families (Table 2) VII genes
were all derived from the largest (VH3) gene family and light chain genes originated from both
isotypes (VK2 and 3 and VA3 families: Table 2). Production of the antibodies us soluble Kab
fragments in E.i-o/i revealed that all antibodies were expressed as disulfidc-bridged hcterodimers
of light and heavy chain of approximately 45kDa. All antibodies could be purified to more than
90% by one-step immobilised metal-ion affinity chromutography (IMAC: Fig. 2a). In addition,
fast protein liquid chromatography (FPLQ analysis of IMAC-purified Fab showed u single peak
at the retention time expected for a protein of approximately 50kDa (Fig. 2b). The yield of
purified antibody fragment varied between 600 and KOOug per L of bacterial culture.
Table 2
-^. P-
V-gene:
VH (clone B5)
VL (clone B5)
VH (clone B8)
VL (clone B8)
VH (clone C8)
VL (clone C8)
V-gene
family
VH3
VK3
VH3
VK2
VH3
VX3
Closest gcrmline
V-gcnc segment
DP-77/WGH16+
Vg/38k
VHGL3.7/DP-82
DPK27/A29+
cos-8/hv3005f3
DPLI6/VL3.I
D-scgment used
D5-5
n.a.
D6-25
n.a.
D6-I3/DNI
n.a.
J-segmcnt used
JH4b
JK2
JH6b
n.d.
JII4b
JL2/JL3a
n.a.: nul applicable
n.d.: using the sequence alignment software of V-base: (http://www.mrc-cpe.cani.ac.uli/inil-doc/rcstrictcd
DNAPLOT.html), the segment could not be determined
To validate the antigens recognised by the selected antibody fragments as putative colon
tumour antigens, their presence on several different colon tumours (n=IO) of various
differentiation (Dukes' A through C) was tested by immunohistochemical analysis. All three
antigens were expressed in all tumours tested, giving the same staining pattern as shown in Fig.
1. To examine whether the target antigens were also expressed in different adenocarcinomas than
CRC, staining of carcinomas the stomach, lung and breast was performed. Clone C8 showed
strong homogeneous positivity for all tumours; Fab B5 showed strong positivity for breast and
lung carcinoma, but was more heterogeneous reactive with stomach carcinoma and clone B8 was
negative on all tumours.
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of the antigen (data not shown). In addition, immunoprccipitation using capture of native antigen
in solution did neither result in the precipitation of a specific protein (data not shown). These
results show that the epitopes recognised by the antibody fragments could well be dependent on
chemical modification of the antigen expressed on the cell-surface.
•-'"' Indeed, flow cytometric analysis of CaCo2 cells using Fab fragments B5 and C'8 showed
that antibody reactivity was abolished when cells were not fixed with paraformaldehyde (Kig. 3)
or treated with a reducing agent (dilhiothrcitol (DTT): data not shown) However, both antibody
fragments did strongly stain paraformaldehyde-fixed whole C'aC'o2 cells, proving that the
antigens recognised by antibodies BS and C'8 arc cell-surface markers.
Figure 3
(W/-.VMr/<MV
a.v
ami/v.vi'.v /At'
Histogram plots showing the number
of gated whole cells (counts) us a
function of their fluorescence
intensity (Fl. I-H). Cells were cither
untreated, or fixed wilh 1% (w/v)
paraformaldehyde prior to staining.
Negative control staining (an
antibody to the antigen tetanus
toxoid) is shown in all panels by a
dotted line.
A: the anli I-p-CAM antibody M ( X -
31 (thin line) as positive control; B:
Fab B5 staining of untreated eelk
(thin line) and fixed cells (thick
line); C: Fab CX staining of
untreated cells (thin line) and fixed
cells (thick line).
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Table 3
Tissue
Breast
Colon
Ilcum
Kidney
Larynx
Liver
Lung
Lymph node
Muscle
Ovarium
Pancreas
Skin
Spleen
Stomach:
nntnim
Thyroid
Uterus
7feo/fln/isCT*rm>KF!iW/
Staining by Fab B5
membranous and
cytoplasmic + on
epithelial cells
membranous + on
epithelial cells
mostly membranous + on
epithelial cells only
only distal tubuli +
glomcruli —
—
only bile ducts slightly +
hepatocytes
bronchial, kubic
epithelium +
—
—
—
exocrine part +
endocrine part —
—
—
membranous and
cytoplasmic ^ on
epithelial cells
(focal ly) very slightly +
—
Staining by Fab B8
n.d.
smooth muscle cells
and endothelial cells
slightly +
—
—
—
—
—
endothelial cells
slightly +
—
n.d.
—
—
very locally +
mostly —
some smooth muscle
cells slightly +
—
Stainint: bv Fab C8 ;
—
membranous + on
epithelial cells
membranous and
cytoplasmic + on
epithelial cells only
proximal/distal
tubuli +
glomeruli —
—
bile ducts and
hepatocytes +
bronchial, cubic
epithelium +
—
—
inclusion-cysts +
exocrine part +
endocrine part —
—
—
membranous and
cytoplasmic * on
epithelial cells
strongly
membranous + with
apical accentuation
epithelium of basal
parts of tubules +
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Discussion
In this report, we describe the successful isolation of antibodies with specificity for
antigens expressed in colorectal carcinoma by panning a large, non- immunised phage antibody
library on colon tumour cells isolated from patient-derived tissue. Antibodies M5 and C8
recognise epithelial cell-specific antigens and antibody B8 prcfercntially reacts with stmmal cells
in colon tumours only. These antigens are of interest, because they arc expressed in sections of
all (n-10) colon tumours tested and in only a limited panel of normal epithelial tissues. They are
not tumour-specific in the strict sense, but may be classified as tumour-associated antigens.
Future quantitative expression studies arc needed to further validate these antigens as tumour
markers. '
The selection protocol used for phage antibody selection was clmignrnl to direct the
selection towards epitopes common to different tumours and to avoid possible selection of
antibodies directed to antigens unique for one patient (e.g. HI.A molecules). Therefore, tumours
used were not matched or selected for any stage or differentiation stage. Indeed, the three phage
antibodies selected showed reactivity towards CRC tissue of all different patients tested (n"IO).
However, the abundance of clones that did not react in NK' (14 out of 17 different antibodies
tested after five rounds of selection) may indicate that numerous antibodies specific for a subset
of patients were selected. Since the selected pool of antibodies after five selection rounds was
still diverse and only a limited number of the selected clones was sampled, it is expected that
many more specificities may be identified by additional screening.
Selections were performed on patient-derived tumour material which was treated with
DTT to extract tumour cells from the surrounding extracellular matrix and tumour cells were
fixed with paraformaldehyde to preserve the cell surface during the selection procedure.
Therefore, it is no surprise that the epitope recognised by all three selected antibody fragments
depends on modification of the cell surface. These antibody fragments themselves arc therefore
not useful for m vivo targeting of CRC, but may be of value for immunodiagnosis of CRC. In this
respect it is noteworthy that Fab C8 recognises its antigen in formaline-fixed, paraffin-embedded
tissue sections, which may enlarge its usefulness for diagnostic applications.
The use of a direct selection strategy without depletion or subtraction docs not avoid the
retrieval of antibodies that cross-react with normal tissue, as witnessed by the reactivity of the
selected clones towards a subset of normal tissues (Table 3). To direct the selection towards
tumour-specific epitopes, depletion and/or subtraction strategies should be used [9, 13, 16). In
addition, future experiments should be designed such that the selection of antibodies reactive
with modified antigens is avoided. A number of different selection strategies may be envisioned,
including selections on labelled cell lysates or membrane preparations, or the use of tissue
sections. Phage antibody selections on tissue cryosections of patient material have already been
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successfully used [22]. Indeed, in the model system we have described before [ 17], we also found
that moderate enrichment factors of specific phage can be achieved on this source of antigen.
Therefore, we have explored this selection strategy for the selection of antibodies to colon
tumour antigens. However, after multiple rounds of selection, a loss of phage clones containing
Fab insert was observed, indicating that the selection pressure was not sufficient for the selection
of binding phage (data not shown). This was probably caused by the limited amount of antigen
present in tissue cryoscctions.
Expression of tumour-associated antigens in normal tissue may cause toxicity in patients
when an antigen is used as target for immunothcrapy [3]. However, for radio-immunodiagnosis,
low-level expression in normal tissue may be less of a problem [23,24]. In the latter setting, less
antibody is given to patients causing less toxicity problems in antigen-positive normal tissues,
even when the antigen is shed into the circulation [25]. The normal tissues that arc important for
dose-limiting toxicity are blood cells when radio-immuno targeting (RAIT) is used [26] and
mainly the liver and kidney when unconjugated antibody is used. The antigen recognised by
selected antibody B5 is not present on hepatocytes and only on the distal tubuli in the kidney,
thereby probably avoiding an important cause of toxicity in patients. In addition, none of the
target antigens was expressed on lymphocytes, as witnessed by the absence of staining in lymph
node tissue. This shows that by direct phage antibody selection on primary CRC, antigens with
promising tissue distribution for immunotargcting of cancer may be identified.
On the basis of their expression pattern, the antigens targeted by the selected antibody
fragments do not correspond to any of the known colon tumour-antigens c-ERB-2 [27], CEA
[28] or lip-CAM |29]. This was con tinned in EiLISA using the purified proteins (data not
shown). Whether the exact epitopc recognised by the selected antibodies is composed of a
carbohydrate structure was not yet assessed. Therefore, it cannot be excluded that the selected
antibodies arc directed to a cancer-associated carbohydrates (e.g. TAG-72 / Sialyl-Tn [30]).
However, this seems very unlikely since the immunoreactivity of selected antibodies could be
restored by treatment with a reducing agent (data not shown), which does not affect carbohydrate
structures. Further characterisation of these antigens using appropriately treated cell preparations
is expected to reveal the molecular nature of these antigens.
In conclusion, we have shown that phage antibody display provides a powerful means to
quickly select unti-tumour antibodies which show limited cross-reactivity with normal tissues
und may identify suitable targets for immunotargeting of CRC.
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Evidence for a bias towards intracellular antigens in the local humoral
anti-tumour immune response of a colorectal cancer patient revealed by
phage display
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Abstract
Many patients with colorectal carcinoma (CRC) mount a cellular as well as a humoral
immune response to the tumor. To investigate the nature and specificity of the humoral immune
response in a CRC patient, lymphocytes infiltrating the primary colorectal rumor and lymph
nodes draining the tumor were used as antibody variable (V)-gene pools for the construction of
phagc antibody repertoires. These libraries were first validated by selection on the antigen tetanus
toxoid and shown to contain antibodies that were probably derived from both naive and memory
B-cclls. The repertoires were then screened for the presence of antibodies directed to CRC by
selection on the cell line CaCo2. For comparison, the same selections were performed with a
phagc antibody repertoire made from Ei-cclls of healthy donors. Striking differences were
observed in the panel of specificities selected from these different repertoires: although a large
panel of antibodies reactive with patient-derived primary tumors was obtained from the immune
repertoires, none of these were reactive with cell-surface antigens. However, selections using the
non-immune library did result in numerous antibodies that recognised cell-surface markers on
CaCo2. These data suggest a bias in the local humoral immune response in this CRC patient,
directed primarily towards intracellular epithelial-cell specific target antigens.
Introduction
In patients with cancer, a humoral immune response directed to known tumor (associated)
antigens has been demonstrated by the presence of circulating antibodies in serum [1-5].
Therefore, lymphoid tissue obtained from patients with cancer may constitute an enriched source
of B-cclls secreting antibodies to tumor antigens. In addition, it may be particularly useful for the
development of immunotherapcutic protocols to know what antigens are target of an immune
response in cancer patients [6].
Phagc display of antibody fragments [7] has proven to be a powerful tool to select
antibodies with a desired specificity from 'immune' or non-immune repertoires [8-12]. The
technique hus been used as a tool to synthesise 'artificial" antibody repertoires of high diversity
in vim> for the selection of high affinity ligands [13, 14]. Alternatively, it may also be exploited
to study /« vivo humoral immune responses to particular antigens [5. 15, 16].
We set out to study the humoral immune response in a colorectal cancer (CRC) patient
by screening phage antibody repertoires made from patient material for the presence of antibodies
reactive with colon tumors. Since lymph node tissue has proven to be a valuable source of
variable (V)-genes for the construction of phage antibody repertoires [ 17] and since this tissue
has also been shown to be a rich source of antibodies to known tumor antigens [5], we decided
to use patient-derived lymph nodes (LN) draining a CRC for the construction of'immune' phage
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antibody repertoires. In addition, as has successful} been described tor melanoma [ 18], we used
the lymphocytes infiltrating the tumor (tumor infiltrating lymphocytes: TIL) as a source of anti-
tumor antibodies.
The phagc antibody repertoires constructed from these two tissues were subsequently
screened for antibodies reactive with colon tumors by selection on the colorcciul cunccr cell line
CaCo2. To assess whether these immune repertoires were biased in the spectrum of specificities
they contain, thereby revealing possible /n vivo tolerance mechanisms, we performed a
comparative analysis by selecting a large, non-immtnine phage antibody repertoire (111 on the
same cell line. Large differences were observed in the specificities of antibodies selected from
immune and non-immune libraries. From both V'-gene sources, antibodies that were reactive with
patient-derived primary CRC could be obtained. However, all antibodies selected from the local
immune sources were directed to intraccllular (cytoplasmic and nuclear) targets only, whereas
non-immune phage antibody repertoires yielded a diverse scala of specificities to cell-surface
markers. These data points towards the presence of a humoral immune response in this CRC
patient that is strongly biased towards intraccllular and epithelial cell-specific target antigens.
Materials and Methods
TG1: K. 12, A(7ac-/>ro), 5«/>£, /Ai, A.«/Z).5/F'/ra£>36,/woA'B', / ac / \ /acZAM 15
Colorectal cancer cell line CaCo2 was obtained from the American Type Culture
Collection (ATCC; number HTB37). Cells were cultured in Dulbecco's Modified Lagle's
Medium (DMEM; Dulbecco, Life Technologies) supplemented with 10% (v/v) fetal calf serum
and 2mM glutamine in a humidified atmosphere containing 5% COj.
Total RNA was isolated from two lymph nodes (LN, obtained after surgery) draining a
colorectal tumor, or from part of the primary tumor (TIL), by means of the RNazol method
(Cinna Bioteckx Laboratories, Houston, U.S.A.). RNA was dissolved in water; possibly
contaminating chromosomal DNA was digested with (RNase-free) RQl-DNasc (Promcga,
Madison, U.S.A.) for 30 minutes at 37°C and RNA was extracted again with RNAzol. lOug of
total RNA was then reverse transcribed (RT) using random hexamcr primers (Promcga, Madison,
U.S.A.) and MMLV reverse transcriptase (Boehringer Mannheim. Mannheim, Germany) in a
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50ul RT-reaction according to standard procedures [19]. For the LN-derived RNA, a CHl(yl)-
specific primer (CHI-FOR: 5"-GTC CTT GAC CAG GCA GCC CAG GGC-3') was used in
parallel forcDNA synthesis. Variable domains of immunoglobulin heavy chain genes (VH) and
complete (variable- and constant domain) light chain genes (VLCL) were then amplified by PCR
from cDNA (5ul cDNA was used as template) using a mixture of family-based forward (FOR)
primers with one of the family-based backward (BACK) primers in a separate reaction.
Oligonuclcotidcs used contained restriction sites for cloning and were as described by [12].
Amplification conditions for VH were: 30 cycles of 94°C, 1'; 55°C, 1" and 72°C, 2'. Light chain
genes (K and X) were amplified separately by 30 cycles of 94°C, 1"; 60°C. 1' and 72°C, 2'. The
primary PCR products (VH(RP; obtained from random primed cDNA), VH(IgG; obtained from
CHKIgGyl) primed cDNA). VKCK and VA.CX) were pooled per V-gene, digested with the
appropriate restriction enzymes (S/iI and fl.v/A'II for VH; -4/raZ.I and Avd for VLCL) and ligated
into the pCLSl vector to yield different 'single-domain'-repertoires (VH(RP), VKCK and VXCA.
for both the LN- and TIL-derived RNA and VH(IgG) for the LN-derived RNA only). Ligated
DNA was purified by phenol extraction, precipitated with ethanol, electroporated [20] into f.co/i
TGI and bacteria were plated on 2xTY/A/G plates (2xTY medium plates (1.6% (w/v) trypton;
1% (w/v) yeast extract: 0.5% (w/v) NaCI; 1.2% (w/v) bacto-agar). supplemented with 2% (w/v)
glucose and lOOug/ml ampicillin). Bacteria were harvested after overnight growth at 30°C in
2xTY/A/G medium and frozen in 2xTY/A/G, supplemented with 15% (v/v) glycerol at -80°C.
Plasmid DNA was then extracted from 500ul of glycerol stock (of OD^,= 100, corresponding
to approximately 10'" bacteria) of each of the 'single-domain'-repertoires using the QIAgen midi
plasmid isolation kit (Qiagcn. Hilden. Germany) and digested with 4/wZ.l and ,4.srl. The resulting
750 base pair (bp) VKCK and VA.CA. restriction fragments were gel-purified, pooled and ligated
in the (.4/></£l and .4wl-) digested heavy chain (VH) repertoires to yield full length Fab libraries.
After transformation to £.iWi TGI and overnight growth, individual bacterial clones were picked
and analysed for the presence of full-length insert by means of PCR using the primers pUC-
BACK. (5-A(K (KiA I AA CAA TTT C AC AC A IKi-.V) and fdTET-FOR (5-TTT GTC GTC TTT CCA GAC GTT
AGT-3).
.vf/ct'fion on />nn//«/ 7<7<inu.v
The two different lymph node repertoires (VH(RP) and VH(lgG)) were rescued separately
with helper phagc M13KO7 and phages were panned for binding to purified tetanus toxoid (TT:
Behringwcrkc. Marburg, Germany) in immunotubes as described [10]. The antigen was coated
at 10ng in! in lOOniM carbonate buffer (pH 9.6); during the second selection round, the antigen
concentration was lowered to 5ug/ml. After two selection rounds, individual bacterial clones
were tested for binding to antigen in ELISA.
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After selection, individual bacterial clones were picked and expression of soluble Fab
fragments was induced by activation of the upstream /.ar/ promoter with isoprupyl-P-1)
galactopyranoside (IPTG) as described [10], (21). After overnight growth at 30"C\ bacteria were
pelleted (4000rpm. 15', rt> and the resulting supernatant was used in the assay. Antigens were
coated overnight at 500ng ml and 4°C in lOOmM carbonate buffer (pH 9.6) to flexible %-wells
ELISA plates (Falcon: Becton & Dickinson. Heidelberg. Germany). The assay was further earned
out as described for scFv by Roovers <*/«/. (22 J.
For serological analysis, patient scrum and serum of a healthy donor were
decomplemented by heat-inactivation (30 minutes at 56"C") and serially diluted in 2"oMurvell
(skimmed milk powder) in PBS (2%MPBS). Diluted sera were then added to antigen (TTH'ouled
wells and incubated for one hour at rt. Bound IgG was then detected with a polyclonal rabbit anti-
human igG antiserum (Dako, Glostrup, Denmark; 0,1% (v/v) in 2°oMPBS). peroxidasc-coupled
goat anti-rabbit immunoglobulines (Dako, Glostrup, Denmark; 0.1% (v/v) in 2%MPHS) and
Trirnethylbenzidin (TMByHjOj staining.
/io/i on co/orecfa/ cancer ce// /ine CaCY>.2
Approximately 10' CaCo2 cells were harvested at subconfluency by trypsine/F.DTA
treatment and cells were washed once with PBS. Constructed 'immune' phage antibody
repertoires were rescued with helper phage M13KO7 as described Marks <•/ <//. [ I ()|. In parallel.
a large, non-immune phage antibody repertoires was used [II]. Phages were panned for binding
to live cells in suspension as described by Mutuberria ef a/. [23]. Four rounds of selection were
performed using either the immune (LN- and TIL-derived) or non-immune libraries.
q/"anr/7>cw/v £>in</i/ig to ce//s fcv means o/y7oH' cy/o/wrtrv
Phage antibodies were rescued with helper phage M13KO7 as described [10] and phage
were purified and concentrated by precipitation from the bacterial culture supernatant with
polyethylene glycol (PEG)/NaCI as described [19]. CaCo2 cells were harvested by trypsinisation
and aliquots of approximately 5xl0'cells were made in polystyrene FACSscan tubes (Falcon:
Becton & Dickinson, Heidelberg, Germany). The assay was further carried out as described by
Mutuberria e/ a/. [23].
o/ K-gewes
V-genes of selected antibody fragments were sequenced according to the dideoxy chain
termination method [24]. DNA was extracted from plasmid-containing bacteria by means of the
QIAgen mini plasmid purification kit (QIAgen. Hilden, Germany) and used as template for
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sequencing reactions using the thermo sequenase fluorescent labeled primer cycle sequencing
kit (Amersham Pharmacia Biotech, Buckinghamshire, England) with 5-Cy labeled primers CH1-
FOR en pUC-BACK. Products of sequencing reactions were then analysed on a semi-automated
sequencer (AlfExpress: Pharmacia, Uppsala, Sweden); obtained sequences were aligned to their
closest germline match by alignment to V-base: http://www.mrc-cpe.cam.ac.uk/imt-doc/
rcstricted/DNAPLOT.html.
/mmuno/i/.vroc'/tfm/ca/ arta/y.w.9 of a
Cryosections of different tissues (normal colonic epithelium, colon carcinoma and
melanoma) were cut and mounted on APTS coated slides. Sections were dried, fixed with 1%
(w/v) paraformaldehyde in PBS and blocked with 1% (w/v) bovine serum albumin (BSA) in
PBS. Slides were then stained with recombinant antibody fragments, the 9E10 antibody and
peroxidase-coupled rabbit anti mouse immunoglobulines (Dako, Glostrup, Denmark) as
described for scFv by Roovers e/ a/. [22]. Diaminobenzidin (DAB)/H,O, staining was finally
used to visualise bound antibody fragments.
Results
Cwi.v/rwff/ow o/7mmM/ie Fa/> />/ia#e
To study ihe spectrum of antibody specificities secreted by B-cells of a CRC patient, we
set out to construct Fab phuge antibody repertoires cither from the lymph nodes (LN) draining
the colorcctal carcinoma or from the Tll.s of that same carcinoma. First, tumor morphology of
a number of different cases was examined histologically. For the construction of'immune' phage
antibody repertoires, a tumor localised in the rectum of a 62-year old male was selected.
Histology of this case showed an adenocarcinoma with two important features: a wide
diffcrcntiution spectrum of the tumor itself and a very dense mononuclear inflammatory infiltrate
in the tumor stroma (Fig. 1A). The former theoretically ensures the presentation of a large
diversity of tumor antigens to the host immune system and the latter reflects the immune
response of the host. Morphologically, the carcinoma was on the one hand relatively poorly
differentiated, showing extensive mucous production and a considerable signet ring-cell
component (Fig. I A. I). However, in other areas, the process was relatively well differentiated
and consisted of well-formed glandular structures lined by tumor cells with columnar- and
goblet-cell features (Fig. 1A. 2). The stromal infiltrate (Fig. 1A. 3) contained histiocytes,
lymphocytes and numerous plasma cells that were further characterised by IHC. They consisted
of a polyclonal mixture of IgCl, lgA and IgM containing cells that expressed both isotypes of light
chains (K and A.). There was a slight preponderance of lgA positive cells (data not shown). Tumor
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stage was pT3N2MO with 8 lymphnode metastases (Fig. IB). The presence of lymphocylic
infiltrates in tumors from various sites is considered a good prognostic factor and can be
correlated to a less advanced stage of disease and increased recurrence-free survival (25. 26].
Therefore, the presence of lymphocytic infiltrate probably indicates an active ongoing immune
response to the autologous tumor in that patient and this prompted the selection of this tumor for
the construction of phage antibody repertoires.
Figure 1
' /?r;wi«n- ro/orec/a/ ewe/mwm
• v . ••_-»
& > ; . • • • • ' • • •
•V> , - A: primary tumor of the selected putient
containing various differentiation patterns: (I) a
signet ring<ell/mucinous component; (2) a wclt-
„ . -, . differentiated component and (3) a heavy
«'(• >4/, / ' I lymphocytic inliltratc (bar: lOum). B: pericolic
^ jj ' • , - ^ .V • r-» 7. • lymph node containing (4) tumor metustash
• • > / "%ftl7 ••' (bar:
For the construction of phage antibody repertoires, total RNA was extracted from cither
two lymph nodes (LN) draining the tumor, or from part of the tumor itself (TIL).
Immunoglobulin genes were then amplified by means of RT-PCR and rab phage antibody
repertoires were made in a two-step cloning procedure, analogous to the procedure described by
de Haardefa/. [12]. However, the order of cloning heavy-and light chain genes was reversed:
complete light chain genes (VLCL) were cloned as /<paZ.I - Avcl restriction fragments in the
heavy chain-containing 'single domain' VH repertoires. Since these two restriction sites arc only
present in 2 out of 51 functional VH segments (http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted
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/RESTRICTION.html), this strategy largely avoids restriction-biases of the libraries. To be able
to discriminate between those antibodies that had arisen from a secondary immune response in
v/vo and that had thus undergone an isotype class-switch to IgG and antibodies of different
isotype, we constructed repertoires in which either CH1 (y 1) isotype-specific priming or random
priming (RP) was used for cDNA synthesis and subsequent amplification of VH genes. This
resulted in two different LN-derived Fab repertoires (called 'RP' and 'IgG' hereafter). For the
construction of the TIL-derived library, only random priming (RP) was used. The total size
(diversity) of single-domain and full-length Fab repertoires is listed in Table 1.
Table 1
S/rp/y/ver.v/'fv (7n frj/«/ wi
V-genc
source
LN*
TIL**
VH(RP)'
library
1.5x10"
n.r.
5.4x10'
VH(IgG)-
library
n.r.
6.0x10'
n.r.
/ con/a/m'ng /nsei
VKCK library
2.5x10"
2.5x10*
1.2x10*
VXCA. library
1.3x10*
1.3x10*
1.7x10"
Full-length Fab
repertoire (K and A.)
6.88x10" (LN-RP)
2.88x10* (LN-IgG)
6.80x10* (TIL)
• Lymph Node
• • Tumor Intlllruting Lymphocytes
' obtained I'min Kanulom Primed (RP) cDNA
' obtained from t i l l (y I • lgU)-pnmed cDNA
n.r. not relevant
Ten randomly picked, full-length Fab clones from both LN-derived libraries were then
shown to be all different as judged by DNA-fingerprinting (as described by [10]). Furthermore,
these clones were rescued separately with helper phage M13KO7 and were all shown to express
Ig heavy- and light chain of the correct molecular weight on phage by means of Western blotting
(data not shown).
v re/xv/o/res
To determine whether the immune system of the selected patient had previously been
exposed to a 'model' antigen, his scrum was tested for the presence of circulating antibodies
directed to tetanus toxoid (IT) by means of ELISA. Both scrum of the patient and control serum
of a healthy donor showed strong immunoreactivity towards TT (Fig. 2).
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ICx, values (defined as the dilution at which the LLISA signal dropped to 50% of the
maximum value) for the sera were 1:32OO for the serum of the patient and 1:800 for the control
serum. This indicates that the immune system of this patient had previously mounted a response
to the antigen (most probably because of immunization), which made this antigen a good target
for validation of the constructed immune repertoires. Since memory B-cells generated as a result
of an immune response are expected to frequent secondary lymphoid tissue, the antibody
repertoires constructed from the pericolic LNs can be expected to contain antibodies to the TT
antigen. The LN-derived libraries were therefore selected on purified TT antigen; the input and
output titers of phage are listed in Table 2.
The percentage of clones containing full-length Fab insert increased to almost 100% after
the second selection round, indicating that selection enriched phage specifically binding to
antigen. From both libraries, numerous specific antibodies could be obtained, as determined by
ELISA (in a frequency of 13/45 tested for the VH(RP) library and 18/45 tested for the VH(lgG)
repertoire). Ten randomly picked positive clones (five from each repertoire) were then fl.v//VI-
fingerprinted and shown to consist of seven different antibodies (4 for the VH(RP) repertoire and
3 for the VH(IgG) library), proving that a diverse set of antibodies was selected. The V-genes of
these anti-TT antibodies were sequenced and shown to originate from different germline
segments of different V-gene families: VH genes were derived from the VHI and VH4 (RP) or
VH1 only (IgG) family; light chain genes originated from the VKI and VKIII (RP) or VXl and
VKIII (IgG) subgroups.
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Table 2
reperto/res O/J
Library
RP
RP
IgG
IgG
Selection
round
1
1
2
[Agl*
<ug/ml)
10
5
10
5
Input titer
i ( C F U ) "
3.0x10"
2.6x10"
3.0x10"
2.4x10"
Output tiler
o(CFU)
7.2x10'
5.1x10'
6.0x10'
1.7x10*
Ratio o/i
2.4x10'
2.0x10*
7.2x10*
Enrichment
factor" '
n.r.
82x
n.r.
3404x
% full-
length
clones
22.2
100
7.7
100
* concentration ol antigen used for coating of immunotubes
•* liters arc given as total amount of colony forming units (CFU)
*** enrichment factor was defined as (ratio o/i E2) / (ratio o/l El)
As has been observed previously [27], light chain promiscuity was seen for two of th e
antibodies selected from the IgG repertoire, where the same VH segment was found i n
combination with two different VL genes. The frequency of somatic mutation in the V-genes of
these selected antibodies (as determined by alignment of the sequences to their closest germ line
match) was high: overall, 2I.S mutations were found in the selected VH genes, of which 1 5
caused an amino acid change in the expressed protein. In VL-genes this frequency was, o n
average, 7.3 mutations of which 4.4 caused an amino acid change.
SWivfton «/7>/irt£t' fl/»fi7wx//c.v on co/orroftj/ rancer re// //«<• CaCo.?
To screen the constructed immune phagc antibody repertoires for the presence o f
antibodies to the tumor, the primary CRC of the selected patient would have been the first choice
as 'antigen' target for phagc selection. However, due to limitations in the quantity and qualit y
of the patient-derived tumor material and to the technical requirements for phage selection, w e
chose to use an unlimited, but surrogate source of tumor antigens, i.e. the CRC cell line CaCo2.
The patient-derived repertoires were selected on CaCo2 using conditions that were previously
described for selections on whole, live cells [23]. The phage titers as well as the percentage of
clones with complete Fab insert increased markedly after the third and fourth round of selection ,
again indicating successful selection of phage antibodies (Table 3). After three and four rounds
of selection, individual antibody clones were DNA-(ftvfM-) fingerprinted and clones having a
distinct fingerprint pattern were tested for their reactivity towards allogcncic primary colorectal
cancer tissue in 1HC.
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Figure 3
/mm« ni
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I ). using antibodies selected
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tlcn\etl immune libraries A:
ncgutivc control (o); H: clone
I \ KP7; (': negative control
i i. I): clone I Nlg( i l , I-:
J.mc TIL-8 (bar: l(Vm)
Surprisingly, all different clones that were selected from the I.N-derived immune libraries
(15 different antibodies on the basis of fingerprint patterns: 6 for the RP library and 9 for the IgCJ
repertoire) were reactive in IHC towards allogeneic primary colorectal carcinoma (examples ar e
shown in Fig. 3). All clones selected from these libraries were epithelial cell-specific but none
distinguished CRC from normal colonic epithelium (Fig. 3B and 3D). The observed stainin g
pattern was always cytoplasmic. Strikingly, none of the antibodies recognised the C'aC'o2 cell line
in flow cytometric analysis (shown for LN-RP7 in Fig. 4), meaning that the antigens recognised
were all intracellularly expressed. The TIL-derived repertoire yielded only one predominant clon e
(TIL-8) after three selection rounds; this clone also was reactive in IHC and showed pronounce d
nuclear staining that was not restricted to epithelial cells (Fig. 3E). Like all antibodies s elected
from the LN-derived libraries, this clone did not stain whole, live CaCo2 cells in (low cytomctri c
analysis (data not shown). The VH genes of 4 different antibodies selected from both I.N-dcrive d
repertoires and of the antibody isolated from the TIL-derived library were sequenccd and show n
to be derived from the three largest VH families: the VHI and VH4 subgroups for the LN-
derived antibodies and VH3 subgroup for the TIL-derived antibody.
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Table 3
Library
LN-RP
LN-IgG
TIL
Selection
round
1
2
3
4
1
2
3
4
1
2
3
4
Input titer
i (CFU)*
3.5x10"
1.6x10"
9.0x10"
2.8x10"
2.8x10"
1.5x10"
1.3x10"
3.7x10"
1.3x10"
3.0x10"
2.8x10"
2.2x10"
Output titer
o(CFU)
4.4x10'
9.6x10"
2.4x10'
1.8x10"
4.8x10'
1.7x10'
1.7x10"
8.1x10'"
4.4x10"
1.5x10'
4.8x10'
2.0x10"
Ratio o/i
1.24x10"*
6.19x10'
2.67x10"
6.43x10'
1.71x10*
1.14x10*
1.37x10"
2.19x10'
3.40x10'
5.00x10'
1.70x10*
9.10x10*
Enrichment
factor**
n.r.
none
430.8x
24.07x
n.r.
none
120x
15.98x
n.r.
1.47x
3.4x
5.3x
% full-length
clones
22.2
33.3
100
n.d.
7.7
23
93.8
n.d.
52.2
80
86.7
86.7
• liters urc given us total amount of CFU
** enrichment was defined as (ratio o/l E(n+1) / (ratio o/i En)
n.r. not relevant
n.d. not determined
Furthermore, these selected VH genes contained somatic mutations: on average, 12 mutation s
were found in the LN-IgG derived VH-genes. of which 8.8 caused an amino acid change in th e
protein. Surprisingly, this frequency was higher for the clones selected from the LN-RP library:
24.7 mutations per VH-gene. of which 17 caused an amino acid difference. The VH gene of th e
TlL-dcrivcd antibody contained 12 mutations, of which 8 resulted in an amino acid difference.
To compare the specificities selected from the constructed 'immune" libraries with those
of clones selected from a phage antibody library made from non-immune V-gcne sources, a non -
immune repertoire [II] was used in parallel for selection on the CaCo2 cell line. Selections using
this scFv library yielded 17 different antibodies that recognised patient-derived primary CRC i n
IHC. Within (his group, two specificities could be distinguished: (1)5 antibodies recognised pan-
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cell markers common to different cell types and (2) 12 antibodies recognised epithelial cell •
restricted antigens (examples of these are shown in Fig. 4). The latter group of antibodies did no t
discriminate between malignant CRC and normal colonic epithelium (Fig. 4H and 41")). I low ever,
3 out of 5 antibodies tested did stain whole, live CaCo2 cells in How cytometnc analysis (shown
for ces31 in Fig. 5), showing that most of the antigens recognised were expressed on the cell -
surface of CaCo2 cells. In addition, this confirms the possible selection of antibodies t o
intraccllular targets. Finally. 6 different antibodies were selected that did recognise cell-surfac c
antigens on the CaCo2 cell line (shown for clone ces9 in Fig. 5) but that did not show an y
reactivity in 1HC towards patient-derived tumor material (data not shown).
< • » » ( ( / / </M(»/l'.VI.V
M.VI«f{
« %>P»V ' ^ ^ A: negative control
* * ^ "^ / . (o);B:clonece»3l;
» J ^ M - / • • » • ' " ' (: clone ces27; D:
5 ^ ' *** clone ccs30 (bar:
Discussion
In this report, we describe for the first time the analysis of phagc antibody repertoire s
made from different, CRC patient-derived, immune V-gene sources, to study the local humoral
immune response to the tumor. Human 'immune' Fab libraries were made from the tumo r
draining lymph nodes and lymphocytes infiltrating the tumor; this tumor was an adenocarcinoma
selected on the basis of a high level of lymphocyte infiltration. Two of the immune libraries were
first validated by the successful isolation of antibodies to the 'model' antigen tetanus toxoid .
Upon selection of the immune libraries on the CRC cell line CaCo2, a striking panel o f
specificities was obtained: only antibodies to intracellular target antigens were selected.
However, parallel selections using a non-immune library yielded many different antibodies tha t
recognised cell-surface structures on CaCo2.
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These results point towards in viV« tolerance mechanisms that bias the specificity of a local
humoral immune response towards intracellular targets.
Figure 5
lo
mean.? 0//7ovf
A: dot-plol showing forward scatter
(FCS-H) ivrmv sideward scatter
(SSC-H) of CaCo2 cells; the gate
selecting whole, live cells is indicated
(Rl). B: number of cells (events) as
function of fluorescence intensity
(FLI-H). Thin line: negative control
(an antibody to TT); thin striped line:
clone LN-RP7: thin dotted line: clone
scFv ces9; thick solid line: clone scFv
ces31.
To vulidatc two of the constructed immune repertoires as representative pools of V-gene s
thut had been selected during />i Wro immune responses, selections were performed on the
'model' antigen TT, of which the scrum antibody titer of this patient was evidence of an activ e
or previous immune response (Fig. 2). Although there is no linear correlation between the seru m
tiler of unti-TT antibodies and the frequency of circulating IgG positive memory B-cells [28],
the presence of a serum liter docs indicate previous exposure of the immune system to th e
antigen. Several antigen-specific antibodies were retrieved that were shown to be somaticall y
mutated. Random mutations in a V-gcnc arc estimated to result in a ratio of replacement (R )
versus silent (S) mutations of 1.5 for framework (FR-) regions and of 2.9 for
complementarity-determining regions (C'DRs) [29, 30]. Higher R:S ratios for the CDRs indicate
that the antibody has been positively selected for binding to antigen. The R:S ratio for the CDRs
were very high for selected VH segments, but did not exceed the 'background' value of 2.9 fo r
VL segments (Table 4). This indicates that at least the VH genes had been selected during an m
vmi response, in which they were mutated and subsequently selected for their increased affinity
for the antigen. Indeed, measurement of the kinetics of binding of one of the anti-TT antibodies
selected from the lg(i repertoire by surface plasmon resonance (SPR) [31] analysis using a
BlAcore 2000, revealed an off-rate of 4.5 x 10** s' , which is typical for high affinity antibodies
generated after a secondary immune response. These data validate the constructed immun e
repertoires as a source of antibodies that have arisen from local HI vm> immune responses.
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Table 4
/?tf/7av q/'rty>/ac'<
genes o/"se/e<7ed
Library
source
LN-IgG*
LN-RP**
LN-IgG
LN-RP
TIL***
*mtvi/ f/?>
' <inri7V*/i<
Antigen
TT
TT
CaCo2
CaCo2
CaCo2
to .vi/enf (5)
;•.? </im7t>J /(
V-gcnc
VH
VL
VH
VL
VH
VL
VH
VL
VH
VL
mu/af/on.f in CD/f- <in<//htmeHwft
> /At' 7Tiifl/ij»«7i nn<y /o C/fC ct7/ //«(
Number of V-
genes sequenced
2
3
4
4
4
n.d.
4
n.d.
1
n.d.
R:S (CDR)
17
2.2
4.8
1.8
3.5
n.d.
S.2
n.d
1
n.d.
R:S (FR)
1
0.6
1.3
2.3
2.3
n.d.
1.2
n.d.
2.3
n.d.
n.d. not determined
* Lymph Node-derived, IgG-primed repertoire
** Lymph Node-derived, Random-Primed repertoire
*•• Tumor infiltrating lymphocytes-derived (random-primed) repertoire
From all three immune phage antibody repertoires (LN- and TIL-dcrived), only antibodies
that recognise intracellular (cytoplasmic or nuclear) targets were selected (Fig. 3 and 5), despite
the use of whole, live cells in the selection procedure. We have previously determined th e
integrity (and viability) of CaCo2 cells before and after one round of selection (with 12 washes)
to be 90% and 70% respectively [23]. Thus, the cell surface remains largely intact during th e
whole procedure. Indeed, after selection of the non-immune library, many different CaC'o2 cell -
binding antibodies were retrieved (Fig. 4 and 5). However, a small amount of intracellular protein
is liberated during the selection procedure, which also serves as 'antigen' in the selection. Fo r
this reason, antibodies directed to cytoplasmic and nuclear antigens were retrieved from th c
immune libraries. The lack of retrieval of antibodies that react with the cell-surface therefor e
strongly argues for a bias in the specificities present in the immune repertoires and thus in th e
local />; v/Vfl antibody response of this CRC patient. To further confirm this bias toward s
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intaccllular target antigens, selections were performed on the tumor antigen epithelial eel 1
adhesion molecule (Ep-CAM), which is known to mount a humoral immune response i n
approximately 15% of CRC patients [32]. No specific phage antibodies could be retrieved after
four rounds of selection on purified, recombinant antigen (data not shown). In addition,
scrological analysis of the patient's serum neither revealed any immunoreactivity towards the Ep-
CAM antigen (data not shown).
The VH genes of a subset of anti CRC antibodies selected from the 'immune' repertoire s
were scquenced and shown to be somatically mutated; the R:S ratios for CDRs and FRs of these
antibodies are listed in Table 4. Although the R:S ratio of CDRs of VH genes isolated from the
LN-IgG repertoire indicates that they did undergo somati c mutation, the ratio is far lower than
that observed for the anti-TT antibodies (Table 4). This may indicate that the B-cells from whic h
these anti-CRC antibodies arc derived were hampered in their development to plasma- o r
memory cells through the lack of T-cell help or through a tolerance mechanism, e.g. by
encountering soluble antigen (reviewed in [33, 34]). The VH genes of anti-CRC antibodies
isolated from the LN-RP library were also somatically hypermutated (as indicated by the R: S
ratio of CDRs: Table 4), to a similar level as the genes of the anti-TT antibodies selected from
this repertoire. This indicates the presence of somatically hypermutated antibodies of non-IgG
isotype. Indeed, immunohistochemical analysis revealed that in the lymph nodes draining th e
tumor, B-cells secreting antibodies of the IgA isotype were abundantly present (data not shown).
This result is not surprising, since the presence in CRC patients of circulating IgA antibodie s
directed to intraccllular antigens has already been described [35]. Although the number o f
antibodies retrieved from the Til.-derived repertoire is very limited, it is striking that the VH of
selected clone TIL-8 has an R:S ratio of the CDRs that is lower than the 'random' threshold o g
2.9 This more 'naive' pattern of mutation may be caused by a lack of local T-cell help. Thes c
data indicate that the B-ecll from which this antibody is derived probably is not part of th e
memory pool of B-cclls.
Differences between the l.N-derived RP and IgG repertoires were observed in the pane I
of antibodies selected on both the 'model' antigen TT and on the CaCo2 cell line. The pattern o f
somatic mutation observed in the VH genes of anti-TT antibodies selected from the Ig G
repertoire suggests that these genes arc probably derived from the memory pool of B-cells ,
whereas the VH genes of antibodies selected from the RP repertoire had a more 'naive'
(IgM-likc) pattern of mutation [29, 30] (Table 4). Interestingly, although both repertoires yieldc d
antibodies reactive with patient-derived primary CRC. the panel of selected antibodies wa s
completely different (as judged by DNA fingerprint analysis (data not shown) and sequencing
of the selected V-genes). Theoretically, the same antibodies found in the IgG repertoire shoul d
also be present in the RP library, in which all different antibody isotypes should be represented.
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However, many parameters (including mRNA levels, number of B-cclls and efficiency of V-gcnc
amplification) affect the contents of these two (RP and lg(i) random combinatorial phage
antibody libraries, which may explain the retrieval of a different panel of antib odies from both
repertoires.
One possible disadvantage of the combinatorial phage antibody approach is thai ih c
original pairing between VH and VL in antibodies is disrupicd. This disnipls the originu I
specificity of the antibody and may also create new specificities. However, if the antibod y
repertoire is sufficiently large, the original combinations of V-gencs should also be present. Th e
sizes of all immune repertoires (largely over 10 "clones for all libraries: Table I) compare very
well to those of immune repertoires that have been described [5. •*. 36|. However, since the exact
number of B-lymphocytcs present in the tissues used for construction of the immune repertoire s
is unknown, the possibility remains that certain original specificities were nol represented in the
immune libraries.
The analysis of autorcactivc antibodies and of the rumor antigens they recognise ha s
recently been performed by means of the SF.RF.X technology, a scrological analysts of th c
humoral immune response in cancer patients [37]. Using this technique, both cytoplasmic und
nuclear [38, 39] antigens have been identified as immunogenic targets. We show that in the CR C
patient studied, such antibodies are being produced by the B-cells present in LNs draining th e
tumor and in the tumor itself and that most of these antibodies arc somatically hypcrmutatcd .
However, by using this V-genc cloning procedure, we arc likely to select antibody genes derived
both from memory B-cells and from plasma cells, which m ay not always contribute equally to
the serum titer of anti-tumor antibodies [28]. Therefore, it remains to be seen whether th e
intracellular antigens recognised by our phage antibodies are identical to the antigens described
for the SEREX procedure [38]. Our data do not rule out the existence of humoral responses to
certain cell-surface antigens, as has been reported by others [32,40, 41 ], but they do show lha t
there is a large bias towards intracellular [4, 35, 42, 43) targets. It remains to be determined
whether such epithelial cell-specific, somatically hypcrmutatcd antibodies arc also found in other
CRC patients.
As has been observed before for auto-antibodies directed to the p53 proto-oncogenc [44,
45], the selected antibodies presented here are directed to the native antigen that is also expressed
in non-malignant tissue (Fig. 3). Such a non-specific humoral immune response may be only a
consequence of the breakdown of immune tolerance checkpoints in the patient. However, it wil I
be interesting to study the possible biological significance of the presence of the B-cclls tha t
produce the selected antibodies and the role of these antibodies in tumor eradication or tumo r
escape from immune surveillance.
We conclude that the combinatorial phage antibody approach is a rapid and valid way to
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study local humoral immune responses to defined and unknown target antigens in CRC patients .
Such studies will aid in an understanding of the immune response to the autologous tumor i n
CRC patients, which will eventually lead to improvements in immunotherapy of minima 1
residual disease.
References
1. Shiku II, Takahashi T, Resnick LA, Oettgcn HF, Old LJ (1977) Cell surface antigens o f
human malignant melanoma. III. Recognition of autoantibodies with unusua I
characteristics. 7. Exp. A/tv/. 145: 784-789
2. (iarrett TJ, Takahashi T, Clarkson BD, Old LJ (1977) Detection of antibody to
autologous human leukemia cells by immune adherence assays. /Voc. <Va//. /icaJ. Sex {/.
S. /}. 74: 4587-4590
3. Lubin R. Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, de Fromentel
CC, Preudhomme (', Fcnaux P, Fournier G. et al. (1993) Analysis of p53 antibodies in
patients with various cancers define B-cell cpitopes of human p53: distribution o n
primary structure and exposure on protein surface. Ca/itw /?«. 53: 5872-5876
4. Imai II, Furuta K, Landberg G, Kiyosawa K, Liu LF, Tan EM (1995) Autoantibody t o
DNA lopoisomcrase II in primary liver cancer. C7/'n. Camrr rtt'.v. 1: 417-424
5. Coombcr I)W. Hawkins NJ. Clark MA. Ward RL (1999) Generation of anti-p53 Fab
fragments from individuals with colorectal cancer using phage display. 7. //w/ww/u>/. 163:
2276-2283
6. Turcci (). Sahin U, Pfrcundschuh M (1997) Serological analysis of human tumor
antigens: molecular definition and implications. AYr>/. AY«/. 7Wav3: 342-349
7. Mc( 'nfferty J. (iriffiths AD. Winter G, Chiswell DJ (1990) Phage antibodies: filamentou s
phage displaying antibody variable domains. .V<;/i//r 348: 552-554
8. Clackson T, Hoogenboom IIR, Griffiths AD, Winter G (1991) Making antibody
fragments using phage display libraries. Mi/urt'352: 624-628
9. Chester KA, Begcnt RM. Robson I.. Keep P. Pedley RB. Boden JA, Boxer G, Green A,
Winter G. Cochct O, et al. (1994) Phage libraries for generation of clinically usefu I
antibodies. 77ir /.umrf 343: 455-456
10. Murks Jl). Hoogenboom HR. Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991)
By-passing Immunization; Human Antibodies from V-gene Libraries Displayed o n
Phage../ A/<»/. «/(>/. 222: 581-597
11. Vaughan TJ. Williams AJ. Prilchard K. Osboum JK. Pope AR. Eamshaw JC. McCaffert y
J. Hodits RA. Wilton J. Johnson KS (1996) Human Antibodies with Sub-nanomola r
Affinities Isolated from a Large Non-immunized Phage Display Library. A'af. S/o/fcA/io/.
14:309-314
12. dc Haard HI. van NeerN. Reurs A. Hufton SF. Roovers RC. Henderikx P. dc BruTnc AP,
Arcnds J-W. Hoogenboom HR (1999) A large non-immunized human Fab fragment
phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.
7. «/<)/. C/i.m 274: 18218-18230
13. Nissim A, Hoogenboom HR, Tomlmson IM, Flyn G, Midgley C. Lane D. Winter G
-208-
Evidence for a bias towards mtracelhitar antigens in the local humoral anti-tumour immune response ot'a colorcctal
cancer patient revealed by phage display
> (1994) Antibody fragments from a 'single pot' phage display library as immunochemica 1
reagents. £A/BO/ 13: 692-698
14 Griffiths AD, Williams SC\ Hartley O. Tomiinson 1M. Waterhouse P. Crosby WL.
Kontermann RE, Jones PT, Low NM, John Allison T, Prospero ID, Hoogenbootn HR,
rfs^i Nissim A,Cox JPL, Harrison JL,Zaccoio M, Ghcrardi li. WinterG (1994) (solutionof
s;»;.,' high affinity human antibodies directly from large synthetic repertoires. £Afl!HJ./, 13;
,,n 3245-3260 ' a
15. Clark MA. Hawkins NJ, Papaiounnou A. Fiddcs RJ. Ward RL (1997) Isolation of human
ami c-erbB-2 Fabs from a lymph node-derived phage display library. C7i«. £*/>. /m/nuno/.
,.«,,. 109:166-174
16. dc Haard HJ, Kazcmicr B, Oudshoorn P, Bocnder P. van Gemen B, Koolcn MJ, van der
Groen G. Hoogenboom HR, Arends JW (1998) Seleetion of human anti-human
immunodeficiency virus type I envelope single-chain antibodies from a peripheral blood
cell-based phage repertoire. J, GV«. 17m/ 79: 2883-2894
17. Yip YL, Hawkins NJ, Clark MA, Ward RL (1997) Evaluation of different lymphoid
tissue sources for the construction of human imnuinoglobulm gene libraries.
/mmu/io/ffAffo/ogr 3: 195-203
18. Zhang H. Lake DF, Barbuto JA. Bemstem RM. Grimes WJ. Hersh EM (1995) A human
monoclonal antimelannnw single-chain Fv antibody derived from tumor-infiltrating
lymphocytes. Ca/i«v/to. 55: 3584-3591
19. Sambrook T, Fritsch EF, Maniatis T (1989) eds. Molecular Cloning: A Laboratory
Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbour, p
20. Dower WJ, Miller JF, Ragsdale CW (1988) High efficiency transformation of Li. coli by
high voltage electroporation. M«t7eic /4c/a*.s / to. 16: 6127-6145
21. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswcll DJ, Hudson P, Winter G (1991 )
Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying
antibody (Fab) heavy and light chains. M/c/t'/c/leu/.v /to. 19: 4133-4137
22. Roovers RC, Henderikx P, Helfrich W, van dcr Linden F.. Rcurs A, de Bruine AP,
Arends JW, de Leij L, Hoogenboom HR (1998) High-affinity recombinant phage
antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting,
fir J. Cancer 78: 1407-1416
23. Mutuberria R, Hoogenboom HR, van der Linden E, de Brume AP, Roovers RC (1999)
Model systems to study the parameters determining the success of phage antibod y
selections on complex antigens. 7. //n/nwno/. A/er/fac/.v 231: 65-81
24. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating
inhibitors. /Voc. M///. ^carf. &/. £7. S. /I. 74: 5463-5467
25. Di Giorgio A, Botti C, Tocchi A, Mingazzini P, Flammia M (1992) The influence o f
tumor lymphocytic infiltration on long term survival of surgically treated colorecta I
cancer patients. /«/. Surg. 77: 256-260
26. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjancn K
(1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Aur. 7.
Camtr28A: 859-864
27. Persson MA, Caothien RH, Burton DR (1991) Generation of diverse high-affinity human
monoclonal antibodies by repertoire cloning. Proc. A/a//. /4caa*. 5c7. I/. 5. /(. 88: 2432-
-209-
Chapter 9
2436
28. Leyendeckers H, Odendahl M, Lohndorf A, Irsch J, Spangfort M, Miltenyi S,
Hunzclmann N, Assenmacher M, Radbruch A, Schmitz J (1999) Correlation analysi s
between frequencies of circulating antigen-specific IgG-bearing memory B cells an d
serum titers of antigen-specific IgG. £wr. J. /mm««»/. 29: 1406-1417
29. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG (1987)
The role of clonal selection and somatic mutation in autoimmunity. Ato/wre 328: 805-811
30. Apel M, Bcrck C (1990) Somatic mutations in antibodies expressed by germinal centr e
B cells early after primary immunization. /«/. //wnnno/. 2: 813-819
31. Jonsson U, Fagerstam L, Ivarsson B, Johnsson B, Karlsson R, Lundh K, Lofas S, Persson
B, Roos H, Ronnbcrg I, ct al. (1991) Real-time biospecific interaction analysis usin g
surface plasmon resonance and a sensor chip technology. 5/'o7«7iw/</Me.v 11: 620-627
32. Mosolits S, Harmcnbcrg U, Ruden U. Ohman L, Nilsson B, Wahren B, Fagerberg J,
Mcllstcdt H (1999) Autoantibodies against the tumour-associated antigen GA733-2 i n
patients with colorectal carcinoma. Cawcer /m/ww/io/. /m/nMno/Aer 47: 315-320
33. Nossal GJ (1994) Negative selection of lymphocytes. CW/ 76: 229-239
34. Pulcndran B, van Dricl R, Nossal GJ (1997) Immunological tolerance in germinal
centres. /mmnm>/. 7VK/«V 18: 27-32
35. Takahashi M, Chen W. Byrd DR. Disis ML. Huseby ES, Qin H. McCahill L. Nelson H,
Shimada H, Okuno K. Yasutomi M, Peace DJ, Cheever MA (1995) Antibody to ras
proteins in patients with colon cancer. (Y/'n. Cantw/?e.v. 1: 1071-1077
36. Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized
with genetically modified autologous tumor cells: Selection of specific antibodies fro m
single-chain Fv fusion phagc libraries. /Vw. M///. /<<•«</. Sc/. (7. 5. .4. 92: 6537-6541
37. Sahin U, Tureci (), Schmitt H, Cochlovius B. Johannes T. Schmits R. Stenner F. Luo G,
Schobert 1, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune
responses in the autologous host. / W . Ato//. .4<W. &•/. (' 5. .4 92: 11810-11813
38. Scanlan MJ. Gordan JD. Williamson B, Stocked E. Bander NH. Jongcneel V. Gure AO,
Jager I). Jager II, Knuth A, Chen YT, Old LJ (1999) Antigens recognized by autologous
antibody in patients with renal-cell carcinoma. /«/../. C«mrw83: 456-464
39. CJurc AO. Stocked E. Scanlan MJ. Kcresztes RS. Jager D. Altorki NK. Old U , Chen YT
(2000) Scrological identification of embryonic neural proteins as highly immunogenic
tumor antigens in small cell lung cancer. Prw. MJ//. .4ru</. SW. (7. 5. .4. 97: 4198-4203
40. Disis MI.. Pupa SM, Gralow JR. Dittadi R. Menard S. Cheever MA (1997) High-titer
HER-2/neu protein-specific antibody can be detected in patients with early-stage breast
cancer../ CYIM. ()«<•»/. 15: 3363-3367
41. Albanopoulos K. Annakolas A. Konstadoulakis MM. Leandros E, Tsiobanou E,
Katsaragakis S, Alcxiou D. Androulakis G (2000) Prognostic significance of circulatin g
antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.
,4m ./ (;u.v/m.7i/(7o/, 95: 1056-1061
42. Hammcl P. Ikiissier B, Chaumcttc MT. Piedbois P. Rotman N. Kouyoumdjian JC. Lubin
R. Dclchier JC. Soussi T (1997) Detection and monitoring of scrum p53 antibodies i n
patients with colorectal cancer. C7M/ 40: 356-361
43. Stocked E. Jager E. Chen YT. Scanlan MJ. Gout I. Karbach J. Arand M. Knuth A. O Id
LJ (1998) A survey of the humoral immune response of cancer patients to a panel o f
-210-
Evidence for a bias towards iniraceilular antigens in the local humoral anti-tumour immune response of a irolorectal
cancer palicnt rexcalcJ b> phjyc Ji>pla>
human tumor antigens. 7. £v/>. A/«/ 187: 1349-1354
44. Schlichtholz B. Tredanicl J. Lubin R. Zalcman G. Hirsch A. Soussi T (1994) Analyses
of p53 antibodies in sera of patients with lung carcinoma dctlnc immunodominan t
regions in the p53 protein, flr 7. (YiMcrr 69: 809-816
45. Schlichtholz B, Legros Y. Gillet D. Gaillard C. Marty M. Lane D. Calvo F, Soussi T
_„..=. (1992) The immune response to p53 in breast cancer patients is directed uguinst
immunodominant epiiopes unrelated to the mulational hot spot. Comer flew. 52: 63M0-
6384
-211-
Chapter 9
-212-
Chapter 10
Epilogue
Rob C. Roovcrs
-213-
Chapter 10
Epilogue
Since the proof of principle of the phage display technique, described in 1985 by George
Smith [I] for small peptides and in 1990 by John McCafferty and coworkers for antibody
molecules [2], the technique has evolved into an extensive area of research and it is used in a
variety of formats for a range of applications (reviewed in chapter 2 of this thesis). In this thesis,
the technique was used to obtain human antibodies to a known tumour antigen (chapters 3 to 6)
and to identify (possibly) new antigens expressed in colorectal carcinoma (chapters 7 to 9). To
this aim, large, non-immunised phagc antibody repertoires as well as repertoires made from
patient-derived lymphoid tissues were used to obtain recombinant antibody fragments that
recognise antigens expressed in CRC. In addition, subsequent V-gene engineering was used to
optimise their format for use in cancer targeting.
The first part of the work involved the isolation and development of fully human
antibodies to the Ep-CAM antigen. In chapter 2 and 3, antibody phagc display was used to isolate
the V-gcnes of a high affinity murine antibody to the Ep-CAM antigen; these genes were
subsequently engineered into multivalcnt molecules. Since increased affinity has been reported
to improve tumour targeting | 3 | . we first performed a systematic analysis of several well-
characterised antibodies to select the antibody with most favourable kinetics of antigen-binding.
The subsequent cloning of the V-gcncs encoding the selected antibody then provided the building
blocks for the engineering of this antibody into multivalent formats (chapter three). This
approach indeed resulted in multivalent species of the cloned antibody and the multivalent
formats were shown to have an increased apparent affinity in surface plasmon resonance (SPR)
analysis, caused by avidity. Whether these small bi- and trivalent species are sufficiently large
and will have enough flexibility to cross-link adjacent receptors on the same cell surface has still
to be determined. The relative structural rigidity of e.g. diabodies versus intact IgG [4, 5]may
hamper simultaneous binding of the two antigen binding sites to two antigen molecules. In an
in vivosctting, therefore, the avidity effect of multivalcnt scFv may not consist of simultaneous
binding of two (or more) antigen binding sites, but of quick rebinding of one arm when the other
has dissociated from antigen. Thus, this effect will be highly dependent on the concentration of
antigen at the cell surface. In addition, the structural architecture and particular the motility of
the antigen in the cell membrane will affect the avidity effect of scFv multimcrs The gain in
tumour targeting efficiency is therefore also dependent on the target antigen. However, since the
l-p-C'AM antigen has been shown to be expressed in high copy numbers at the cell surface of
t'Rf. the effect of nuilli valency on the tumour targeting properties of anti-Ep-CAM antibodies
is expected to be large and the in vivo performance of multivalcnt antibody formats to be
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outstanding. High concentrations of circulating antigen have been reported to negatively
influence the imaging of solid tumours (6). The L-p-C'AM antigen, however, is not shed into the
circulation, which further increases its potency as tumour target for radio-imnuino imaging.
Multivalent Fv's lack antibody Fc regions and arc therefore expected to have less background
binding to Fc-receptor expressing blood cells. In addition, their in vivo phnrmacokinctic
behaviour is suitable for rapid (1-2 days) imaging of patients [7. 8). When equipped with the
appropriate peptide tags for direct isotope labelling |^-l I ]. these engineered molecules may form
a new and promising generation of tumour imaging reagents. Indeed, rccomhmanl phagc
antibodies directed to CKA have been successfully used in radio-immuno guided surgery and
imaging [12. !3)ofCRC.
In chapter 4 we describe the successful humanisation of the MOC-31 anti-Fp-C'AM
antibody described in chapters two and three through a phage display procedure termed "guided
selection" [14]. This procedure has been used to develop the first phage antibody (an anti-TNF-
antibody [14]) to enter a phase III clinical trial. Recently, the technique has been successfully
used for the humanisation of a munne antibody targeting the CD30 receptor [15], which is
expressed on Hodgkin-Rced Stcrnbcrg cells in Hodgkin's lymphoma. Preservation of the exact
epitope specificity present in the original murine antibody was crucial in this case, since the
antibody inhibited shedding of the CD30 receptor. The original murine anti l-p-CAM antibody
and its derived human counterpart described in chapters 2 and 4 compete for binding to the Hp-
CAM antigen, which indicates that they recognise overlapping, if not identical epitoncs on the
antigen. In addition, their kinetics of antigen binding are very similar. Interestingly, however,
their mode of interaction with the antigen most probably is completely different, as determined
by molecular modelling of the antibody combining site. Whether these differences in interaction
between the original murine and its derived human antibody and the antigen have any influence
on their rumour targeting potential remains to be seen (see below).
Chapter 5 describes one of the few fully human antibodies to the Ep-C'AM antigen that
recognises an epitope outside of the "cluster 2" epitope [16], which is targeted by most of the
murine hybridomas described to date. This antibody was isolated from a large, non-immunised
scFv phage antibody repertoire. The targeting of a different epitope on this antigen offers exciting
possibilities for the engineering of antibody-based targeting molecules. "Chelating" antibodies
[ 17] may be synthesised that combine specificities for both epitopes on the same antigen in one
molecule and the effect of this bivalency on their in vivo targeting potential may be assessed. As
has already been shown in literature and is also described in chapter 5 of this thesis, large
improvements of the apparent affinities of antibodies may be achieved by increasing their
valency through antibody engineering, which may lead to improvements in the in vivo behaviour
of the antibody being studied [7,18]. We have set out to test the selected anti-Ep-C'AM antibody
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for its targeting capacity in an in vivo model for tumour targeting using athymic (nude) mouse
xcnografted with the human CRC cell line LS174T. However, radio-active labelling of the
rccombinant scFv with either '"I (targeting tyrosine residues) o r T c using HYNIC (via lysine
residues) resulted in a lack of immunoreactivity of the labelled protein. These results indicate that
direct isotope labelling strategies using genetic tags [9-11] may be necessary to preserve
antibody-binding capacity. These and similar studies are in progress and planned. Thus, antibody
phage display, together with protein (antibody-) engineering provides an excellent tool for a
systematic study of the effect of size, valency, charge and exact epitope specificity on the tumour
targeting properties of antibodies. In addition, it permits the generation and subsequent testing
of cocktails of antibodies directed to cither different cpitopes on the same tumour antigen, or
directed to different antigens (or even a combination of these), which may lead to important
improvements in antibody-based immunotherapy. We envisage that such studies will provide
further insight in the many parameters that determine the in vivo behaviour of antibody molecules
and will therefore aid in the development of antibody-based targeting molecules and
immunothcrapcutic strategies.
There is still a lack of understanding of the mode of action of the low affinity anti-Ep-
CAM (inlibody "Panorcx" that has been successfully used in the clinic [19, 20]. In this respect,
the recent report of the absence of a correlation between the presence of HAMA and an anti
idiotype response in patients treated with Panorex and their clinical response [21 ] is illustrative.
Clinical trials using high affinity antibodies to the lip-C'AM antigen have been aborted because
of the toxicity observed in the patients treated [22]. This indicates that high affinity antibodies
to the lip-C'AM antigen may not be suitable to directly deliver toxic signals to antigen positive
cells. However, their value for the visualisation of antigen-positive metastases [23] is
undisputed. An increase of the specificity of the Kp-CAM targeting approach may be achieved
by means of adenoviral vectors that deliver toxic genes to the tumour under the control of
tumour-specific promotors [24]. Such strategics are expected to markedly increase the
therapeutic window of antibodies targeting this antigen.
One aspect of targeting the Hp-C'AM antigen that has been given surprisingly little
attention until now. is the effect of antibody-targeting on the biological function of the protein.
The hp-CAM antigen has been shown to function as a homophilic cell adhesion molecule [25]
and to cross-talk with the cadhcrin-based intercellular junctions ( [26]; for review, see [27]).
However, the signal transduction cascade responsible for this effect has not yet been unravelled.
The Trop2 antigen is encoded by the GA733-1 gene, which has probably arisen by retroposition
of the GA733-2 gene encoding lip-CAM [28], Although this slightly homologous antigen (Trop2
and lip-C'AM share 49'\> of amino acid homology [29]) has been shown to influence intracellular
calcium levels [30], similar effects for lip-CAM have not yet been shown. Furthermore, the
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If antibody binding to the antigen would nssilt in an mtraeeiluliir signalling event that
the esdhenn-hased intefceilaiar junctions, this would increase the strength of
contacts and decrease meiastasis. Such receptot-modalatsng or antagonistic
antibodies may deliver a signal to the tumour that augments the antt-taiaoer effect of antibody
targeting atone, like $s the ease for the apostasis-inducing targeting of" she tl>20 antigen tn noa-
Hodgktn's iymphoaa.
The second part of the work involved the identification of possibly novet antigens
expressed in CRC using a phage antibody display appfoaeh. The idea hdiMui this approach isthe
following: by using sos-inMtninised pfeage antihtJtly rejseiiiiites or librwtes niatlc ftom pattent-
denved niaterial for the selectksi «t aatihtnlies reactive with eottwj Htfntnirs, antibtnlies timy be
identified that discriminate between tunwurand non-tuHRHtr, tw between meta j^iSK and nnfttary
tamoar. Thus, tamoar antigens may be identified by means of the antibodies that recogiiise them.
Ftstherawre, this strategy sin>ulianeously fsovides tally human antibodies to the respective
antigen together with their encoding V-genes, which may form useful buildsng bk»cks for the
engineering and development of antibody-based targeting molecules.
In this respect, several aspects of the technology should be considered. First, the choice
of the antigen source used for selection is not obvious and several (dis)advantages are inherent
to different formats of "antigen". Two important parameters dictate this choice of antigen source
and thereby also of the selection procedure used: On the one hand, the whole selection procedure
should be efficient in the selection of binding (specific) phage over non-binding phage; on the
other hand, the antigen source used should as closely as possible mimic the in vivo antigen
expression profile of the tumour. The model systems that we have set up to study the selection
of phage antibodies on such complex antigen mixtures (described in chapter 6) show that there
are large differences in the efficiency of phage antibody selection on different complex antigen
sources. However, the selection protocol giving the highest enrichment of specific over non-
specific phage, i.e. selection on whole, live cells using a CRC cell line, proved not to be optimal
with regard to its antigenic expression profile. As shown in chapter 8, selections on this cell line
using a non-immunised phage antibody repertoire also resulted in clones that recognised antigens
that were unique to the cell line and that were not expressed in patient-derived tumours. Similar
results have been obtained by others in our department with selections on lymphoid cell lines
(Petrarca et al., unpublished results). As described in chapter 7, the use of patient-derived tumour
material for selection was able to circumvent the selection of antibodies to epitopes unique for
a cell line. This method was successful in the selection of antibody clones that react with a broad
range of colon tumours and also with other epithelial-derived carcinomas. Two antibodies
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broadly reacted with epithelial-derived tumours and with a restricted set of normal tissues and
one antibody stained stroma and stromal cells in CRC only. Since the latter antibody only reacted
with a very restricted panel of normal tissues, it may be a potential tumour-stroma antigen useful
for targeting, analogous to the ED-B domain of fibronectin [31, 32].
In the latter strategy, the retrieval procedure used to isolate tumour cells from patient-
derived tissue caused modification of cell-surface antigens and this, in turn, caused the selection
of antibodies that recognised modified instead of native antigens. Whether the exact epitope
recognised by the selected antibodies is composed of a partially unfolded protein, or is formed
by a portion of a cell-surface receptor that normally interacts with (an) other protein(s) could not
be assessed yet. This lack of immunoreactivity towards the native antigen seriously hampered
the characterisation of the selected antibodies and thereby the identification of the target antigens.
Whether the target antigens have any value for immunopathological diagnosis of CRC remains
to be determined. However, this may be limited because of their expression pattern in normal
tissues. It will be interesting to study any possible correlation between different histological
parameters of colorectal tumours (grade, stage, differentiation) and the expression pattern of
these antigens.
As described in chapter 7 and 8 of this thesis, direct selection of phagc antibody libraries
on tumour material is not likely to lead to the identification of clones that truly discriminate
between CRC and normal colon. To direct the selection more towards tumour-specific epitopes,
subtraction and/or depletion strategies should be used to delete cross-reactive clones from the
pool of selected phagc. We have developed and performed depletion strategies using normal
colonic crypts isolated from normal colon epithelium before selecting on patient-derived tumour
cells. After three rounds of selection, this resulted in a very different set of selected antibodies
compared with selections without depiction, but none of these were reactive in
immunohistochemislry on CRC. Since theoretical calculations lead us to believe that subtraction
and depiction methods will work most efficiently for antigens that are expressed at high levels,
these results indicate that tumour specific epitopes are not likely to be abundant. Even more
careful design of such selections using patient material may thus result in the identification of
more tumour-specific antigens. In addition, selection and screening of phage antibodies not for
binding, but for a differential biological effect on tumour versus normal cells may be an exciting
and promising approach in the identification of antibody-based cancer immunotherapeutics.
These selection strategics may well require an engineered, multivalent antibody format, since it
has been shown that homodimcrs of whole lgG are far more potent in delivering an apoptosis-
inducing signal to cells than IgG [33].
Another aspect of the phage technology crucial for the outcome of selection is the size
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and quality' of the phage antilxxly repertoire and especially the source of V-genes from which the
repertoire was made. Chapter 8 shows that the antibody specificities selected from libraries made
from different. CRC patient-derived material were all reactive with allogeneic uimoui .uul were
all directed to intracellular antigens. Surprisingly, none of the selected clones recognised an
antigen unique to the cell line used for selection. This shows that the B-cclls from which the V-
genes used for the construction of the "immune" phage antibody repertoires were derived and
therefore the humoral immune response in the patient studied was heavily biased towards
intracellular antigens. Although these intracellular targets will not provide new handles for
immunotargeting purposes, identification of the antigens may offer insight into the
immunogenicity of CRC in the patient studied. Such studies may eventually lead to
improvements in the design and generation of tumour vaccines.
Using the phage display technology, the quest for novel tumour antigens remains a
laborious and technically challenging task. Recently, different genetic approaches have been
described that allow a simultaneous study of the expression of a range of genes [34-38] and
thereby also the identification of genes that arc associated with malignancy or metastatic spread
of cancer. Although the latter will not necessarily identify genes that may be used as target for
immunothcrapcutic intervention (e.g. cell-surface expressed molecules), the wealth of
information becoming available will certainly lead to a better understanding of the genetic
changes underlying the basis of malignancy. Since the phage display system is amenable to
automation, large numbers of simultaneous selections and high throughput screening of selected
populations has become possible. Therefore, we envisage that the phage antibody display
procedure will be an invaluable tool in target validation and in "proteomics", the study of protein
expression and biological function of the very many unknown genes that arc now being
identified.
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Straifiisry •
The « a t described in this thesis fimsseson two grais in the fieM of tumour immunology
/ trBmttnotherapy of hamass caneer Hie selection, engineering and development of antibodies to
dse known colon tumour antigen Ep-C AM are described in the fin* chapters and the selection
and eharactensatwrt of antibodies to possibly novel furnoar antigens in She last chapters of this
thesis*
Chapter one introduces the concept of tamour targeting and «nm«notherapy of human
cancer using antibodies, Since the ides of She *magk bullet', originally introduced by Paul
Ehriich, immuiKJtlierapy of cancer based on antibodies directed to tunwnir-as!«>ctatetl antigens
has processed tremendouslj•. This is evidenced hy the recent H >A-approval of several ;s»tibody-
based drags for the treatment of e.g. lytrtphoma and breast carcinoma 1 his chanter describes the
different antibody formats used for tumour targeting, the various ssr.stcpd tlut h.n >.• Kv» siM-d.
tfie varioas pfftfefems associated with these strategies and recent advances made by means of
molecular engineering techniques, notably the phagc display technology.
Chapser two gives 3 detailetl overview of the phage display technology and its
applkatkfrss. ll first describes the bask concept of linking genotype ami phem^ype ol'tinitJuHhes
to a feaetefiophage display system. The genes encoding ant ihtniics are cloned into the phage
genome as a fusion to one of the coat proteins, thereby providing a means of selecting those
genes that code for antibodies with the desired antigen-specificity. The various possible selection
strategies are described, as well as the many different screening methods used to identify clones
with the desired characteristics.
Chapter three describes a systematic comparison of the antigen-binding kinetics of five
different murine whole antibodies directed to the colon rumour associated antigen Hp-CAM and
the subsequent cloning of the genes of those antibodies with most favourable kinetics. The genes
encoding these antibodies were formatted as single-chain Fv (scFv), expressed in bacteria and
further characterised with respect to their specificity and affinity for the Ep-CAM antigen.
Chapter four reviews the design and synthesis of multimeric antibody fragments by
shortening the peptide linker between VH and VL in a scFv. By truncating the linker sequence
separating VH from VL, intra-chain pairing of the domains is prevented and inter-chain pairing
is favoured. This results in bi- tri- and tetravalent antibody fragments, depending on the linker
length and orientation of VH and VL in the scFv module. These multivalent fragments have
distinct advantages over monovalent scFv molecules in cancer targeting applications.
Chapter five describes the humanisation of the murine anti Ep-CAM antibody of which
the cloning is described in chapter one by a procedure termed 'guided selection'. Using a phage
display strategy, the genes encoding the VH and VL domains of the murine antibody were
subsequently replaced by libraries of respectively human VH and VL genes. After each round
of'chain shuffling', selection on antigen was used to obtain those human genes that encoded
antigen-binding antibodies. The murine antibody and its human equivalent were shown to have
-223-
the same epitope-specificity and comparable antigen-binding kinetics. However, structural
modeling revealed that the molecular interactions of both antibodies with the Ep-CAM antigen
differed significantly.
Chapter six reports the direct selection of completely human antibodies to the Ep-CAM
antigen from a large, non-immunised human phage antibody repertoire. Two antibodies were
identified that specifically reacted with recombinant antigen; however, one of the antibodies
showed cross-reactivity with antigens expressed in tumour stroma. Using antibody engineering,
the Ep-CAM specific antibody was then converted to the so-called 'minibody' format, which is
more suitable for in vivo targeting applications. This bivalent antibody construct was then shown
to have an increased affinity for the antigen, caused by the presence of the two antigen binding
sites in the same molecule.
In chapter seven, a model study examining the parameters important for successful phage
antibody selection on complex antigens is described. Two phage antibodies, directed to the Ep-
CAM antigen and to the endothelial marker E-selectin, were used in these models. Mixing
specific phage with non-specific, non-binding phage that conferred a different antibiotic
resistance gene to the bacterial host permitted the calculation of enrichment of specific over non-
specific phage after one round of selection. Selection on a variety of complex antigen sources
such as cell-surfaces, tissue cryoscctions or on in vivo grown solid tumours revealed that there
arc iiuiiciiuou.s iiilicrcnccs in selection ctticacy, depending on the selection method used. I his
study has implications for the design of phage selections on these complex antigen mixtures,
notably aimed at the identification of possibly novel antigens expressed on colorectal cancr.
Chapter eight reports the selection of antibodies directed to antigens expressed in
colorectal carcinoma using a large, non-immunised phage antibody repertoire and patient-derived
tumour material as "antigen'. Three different antibodies were selected that each recognised
antigens expressed in a number of colon tumours of different patients. These antigens were
expressed in only a limited number of normal, adult tissues and can thus be categorised as
tumour-associated antigens.
Chapter nine describes a case study of the humoral immune response in a colorectal
cancer patient using a phage display approach. 'Immune' phage antibody repertoires were
constructed from the lymph nodes draining a colorectal tumour and of the lymphocytes
infiltrating that (same) tumour. These repertoires were then compared with a large, non-
immunised repertoire for the selection of antibodies reactive with colorectal tumours. Using a
colon cell line as antigen', all antibodies selected from the immune repertoires reacted with
patient-derived allogencic tumour material. However, all antibodies reacted with intracellular
antigens, whereas selections using the non-immunised repertoire readily yielded antibodies
reactive with antigens expressed on the cell surface. Thus, the humoral immune response in the
patient studies was heavily biased towards intraccllular target antigens.
Chapter ten finally discusses the results obtained in the various studies.
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Met eoderzoei: da£ ttew&FCverc siaai in dit procfschrift richf ?ich op Jwee doeisteilingen
het vakgetwei lanwr-itiMnsiioJogie ' immutimhcrapie van kanker, Dc seieclie, he*
r « i de onfwikkefing vaa anlistofTen gericht tegen bet beiende ftunor-antigeen Fn-
CAM I'Epithelial ceil adhesion mokcuie*)slaM beschnrven »n dc cerate hoofdstukken van het
fsroefscrift. ferwij! de lasts?? fsoofdstakken gerkrfsf ?qn op de selcetie en karakterisatse van
srKisJofFen gericla tegen mogeiijk nicawc fmmw-aniigenen.
Hoofdsluk I wtroduceert h« cooecpt v»i *^ajnw tai^eling* en inronmniiwrapje van
Icanker met feehafp van snfistaflbj. Siisfc hel ids* van de 'magisehe koge!* wcid
door Paul Ehrikh heeft fmmuusthenipje v»j kanker een st<«tnachligc oniwikkciing Ax
Dit wssd lacaitdijk m ^ Msfcrsfttsf* dow de goedkeuring van cen aantai anfJichaam-p
drags voor de behaisdclmg van kanker door de FDA. Dit ntK*fdi.tuk htfschrijft dc
formatai vau autisJolTea die xijn gebraikt v«sr tumor-targeting, de verschiJIende strafcgicn en
de prcsWenjen inherent aan de?e roetlioden en de reeente vtmraitgang die me! behujp vats
moleeuiaire "engineering* technieken is geboekt, ai.fi. door hd gchntik van de faag-dispiay
techiKjIogie,
Hoofdstuk 2 geeft een gedetailieerd overzicht van de faag-display technologic en van dc
verschillende toepassingen van de technick. Het bcschrijft eersl het principe van dc koppcling
van genotype en fenotype van een antistof in een bacteriofaag systeem. Dc genen die codercn
voor antistoffen worden geklonccrd in hcl genoom van een baccrifaag als Ilisic aan ccn van dc
mantel-eiwitten van dc faag. Hicrdoor ontstaat dc mogclijkhcid om die genen tc sclcctcrcn die
coderen voor antistofTen met dc gewenste antigeen-specificiteit. IX' verschillende mogclijkc
selectie-strategien worden beschreven, naast het scala aan scrccnings-mcthodcn dat wordt
gebruikt om clones met de gewenste karakteristieken tc identificeren.
Hoofdstuk 3 beschrijft een systcmatische vcrgclijking van dc antiecn-bindings kinctick
van vijf verschillende muize-antistofTen gericht tegen het colon tumor-antigcen (lp-('AM en dc
klonering van de genen van de antistoffen met beste kinetischc cigenschappen. Dc coderende
genen van deze antistofen werden her-formatteerd als enkcle-kcten antistof-fragmenten (scFv),
in bacterien tot expressie gebracht en verder gekarakterisecrd wat bctreft hun specificitcit en
affinitiet voor het Ep-CAM antigeen.
Hoofdstuk 4 geeft een overzicht van het ontwerp en de synthese van multimcrc antistof-
fragmenten door inkorting van de peptidc linker tusscn VH en VL in een scFv. Door het
verkorten van de linker sequentie die VH en VL van elkaar scheidt wordt intra-molcculairc
paring van VH en VL voorkomen en inter-moleculaire paring bevorderd. Dit rcsultcert in bi-, tri-
en tetravalente antistof-fragmenten, afhankelijk van de lengte van de linker en dc orientatie van
VH en VL in de scFv-cassette. Deze multimere fragmenten hebben vcrschillendc voordclcn ten
opzichte van monomere fragmenten voor het gebruik in tumor-targeting.
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Hoodstuk 5 beschrijft de humanisering van de muize-antistof gericht tegen het Ep-CAM
tumor-antigen waarvan dc kloncring beschreven staat in hoofdstuk drie met behulp van de
'gcleide-selectie' techniek. Met behulp van een faag-display procedure werden de genen die de
VH en VL domeinen van de muize-antistof coderen na elkaar vervangen door een bank van
humane VH en VL domeinen respectievelijk. Na iedere ronde van 'keten-verwisseling' werden
door middcl van sclectic op hct antigcen die humane genen verkregen die codeerden voor
antistoffen die bonden aan hct antigcen. Van dc originele muize- en afgeleide humane antistof
werd aangctoond dat zc dczelfde cpitoop-specificteit hadden en een vergelijkbare antigeen-
bindings kinctiek. Echter, moleculairc model structuur-analyse liet zien dat de moleculaire
interactics van bcidc antistoffen met het Ep-CAM antigcen sterk van elkaar verschilden.
Hoofdstuk 6 beschrijft dc dircctc sclectie van complect humane antistoffen gericht tcgen
het p-CAM tumor antigcen uit een grotc, nict-gcimmuniseerde faag antistof bibliotheek.. Twee
antistoffen werden geidentificcerd die specifiek met het recombinante antigeen reageerden;
echter, een van dczc antilichamen kruis-reagcerde met antigenen die tot expressie kwamen in
tumor stroma. Met behulp van antilichaam 'engineering' technieken werd het Ep-CAM
specifickc untilichuum omgcbouwd tot hct zogchctcn 'minibody' formaat, dat zeer geschikt is
voor gcbruik in in vivotocpassingen in tumor-targeting. Van dit bivalent antilichaam construct
wen! vervolgens aangctoond dat hct een verhoogde affiniteit had voor hct antigcen, veroorzaakt
door de aanwezighcid van twee antigcen bindingsplaatsen in een en hetzelfde molecuul.
In hoofdstuk 7 wordt een model studic beschreven naar dc parameters die een succcsvolle
selcctic van faag-antistoffen op complcxc antigenen mogelijk maken. Twee faag-antilichamen.
gcriclit tegen hct lip-t'AM antigen en tcgen dc cndothecl-ccl mcrker E-selectine, werden gcbruikt
in dc/e modellen. Door het mengen van specifickc fagen met niet-spccifickc die ccn andere
antibioticum-resistentie aan dc bacterie geven was het mogelijk om de verrijking van specifieke-
over nict-spccificke fagen te berekenen na een (I) selectie rondc. Sclectie op een scala aan
comlcxc anligenen, /oals de oppervlakte van ccllcn, vriescoupes van weefsel of in vivogroeiende
solide tumorcn liet /ien dat er ga>tc vcrschillen bestaan in de selcctic efficientie, afhankelijk van
dc gcbruikte selectie methode. Dcze studc hceft consequcnties voor het ontwerp van faag
(antistof-) sclcctics op dezc complcxc antigeen-mengsels. met name gericht op de identificatie
van mogelijk nieuwe tumor antigenen op colorcctaal carcinoom.
Hoofdstuk acht beschrijft de selectie van antistoffen gericht tegen antigenen die tot
expressie komen op colorcctale tumorcn. gebruik makendc van een grote, niet-geimmuniseerde
faag antistof bibliotheek en patient-afgelcid tumor matcriaal als 'antigcen'. Dric vcrschillende
antistoffen werden geselecteerd die icder antigenen herkenden die op een scala aan colon
tumorcn tot cxprcssie kwamen. Van de antigenen werd aangctoond dat zc selectief in een aantal
normale weefsels voorkwamen; dczc antigenen kunncn daarom worden gecategorisccrd als
' tumor-geacssocieerd".
Hoofdstuk ncgen beschrijft een studic van dc humoraie immuun respons in een patient
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met colorectaal carvtnoom. gebruik makende van de faag-dispiay technologic "vieimmunisecrde*
faag anttstof banken werden geconstrueerd van de tumor-drainerende lymfeklieren en van de
tumor-tnfiltrerende lymfocyten van de patient. Deze faag bibliotheken werden vcrvolgens
vergeleken met een grote, met-geimmuniseerde faag anltstot bank met betrekking toi de selectic
van antistoften die reageerden met coton tumoren. (iebnnk makende van een colon cel-lijn als
'antigen* Week dat alle antistoften die werden geselecteerd uit de gctmmuniseerde bibliotheken
reageerden met patteni-afgeleid allogcen tumor maicnaal. I-.chter. ulie untisiofen rcugeerden met
tntracellulaire antigenen, terwijl uit de niet-gei'mmuniseerdc antislot bunk genuikkelijk
antistoffen geselecteerd konden worden die antigenen hcrkenden op dc oppcrvlakle van tumor
cellen. De humorale tmuun resptms in de bestudeerde patient was daarom sterk gcrichl bepcrkt
naar intracellulairc antigenen.
Hootdstuk tien, lenslottc, bediscussteert dc resultaten die werden verkregen in d«
vcrschillende studies. j ^ * * >f -, ' ^ ; e^i
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Dankwoord >' -.••-*. ?SSR
•  Het is een van de laatste stukken van je proefschrift die je schrijft, vaak een van de
eersten die mensen lezen en misschien wel een van de moeilijkste om te schrijven: het
dankwoord. Natuurlijk is het wcrk dat beschreven staat in dit proefschrift niet het werk van mij
allcen gewcest, maar van een hele groep mensen. Ook vanzclfsprekend is dat ik op deze plaats
nict icderecn die in mcer of minderc mate heeft bijgedragen aan dit proefschrift met naam en
toenaam kan nocmen. Toch wil ook ik de mensen die het nauwst betrokken zijn geweest bij mijn
promotie hicr bedanken. In de eerste plaats mijn paranimf, collega en mede-werker Edith. Edith:
zondcr jouw hulp was het nooit zo'n dik boekje geworden!! Bedankt voor je enorme inzet, maar
vooral voor jc fantastischc collcgialitcit en vriendschap, die het samenwerken met jou tot een
waar genot hebben gemaakt. Dan natuurlijk mijn bcgclcidcrs Jan-Willem, Adriaan en Hennie.
Jan-Willcm, bedankt voor het vcrtrouwen in die sollicitant uit Frankrijk. voor het mogelijk
maken van mijn promotie en voor alle hulp en adviezen bij het schrijven van mijn proefschrift.
(Irotc Adclaar: bedankt voor de altijd scherpe blik, de vele uren van discussie en het mee-sturen
van mijn ondcr/ock. Jouw bijdragc was ongemerkt altijd groot! Hennie: als directe begeleider
(en soms bcgelijder). medc-autcur en medestander heb ik heel veel van jc gelecrd. Ik denk met
genocgen terug aan on/.c samenwerking en ben blij dat ik als eerste AiO voor je mocht komen
werken. Bedankt voor al die bcgclciding, wijze lessen en discussies, maar ook voor de prettige
en gczelligc steer waarin we het ondcr/ock hebben verricht. Mijn (cx-)kamergenoten. vrienden
en vriendinncn Birgit (Mother). Esther (Hippie). Sigrid (Tetu). Vcerlekind (Belg). Solange (uit
vroeger tuilcn). Han (voisami) en Meindert (amice) wil ik bedanken voor allc grappen, grollen.
vcrhulen. sketches en one-man shows die ik heb gegeven (en waar jullic dus mec opgezadeld
werden!!) en die ik van jullic heb mogen ontvangen/mccmaken. Bedankt voor alle gezelligheid,
maar vooral ook voor dc stcun in mocilijkc tijden.... we houden contact! Ook alle andere (ex-)
collega's (Mat, Peter, Simon, Alex, Don, Rocl. Barry, Paula. Ivo, Patrick, Louise, Riki, Claudia,
Nicole. Hans. Anneke. Cor. C'orine. Caroline. Rene, Twan. Anita. Judy. Ricardo. Rob, Henk en
verder iedcrecn die ik nog vergeten ben), Bianca en Martijn die bij mij stage hebben gelopen en
de mensen van dc klinische kant van dc Pathologie wil ik bedanken voor de fantastischc tijd op
de afdcling. Otto Bocrman en Cathclijne Frielink uit Nimwcghcn wil ik bedanken voor hun inzet
en vtHir de prettigc samenwerking, al wilden dc in vivo(muizen-) experimentcn helaas niet erg
vlotten! Aneta and Pete: thanks for the nice and successful collaboration on the MOC31 work.
I'm looking forward to the publication of our paper! Mensen van het sccrctariaat (i.h.b. Sherlock)
en van dc afdcling fotografic (Gccrt-Jan): bedankt voor alle hulp. RPBS: ook al was Bottom er
niet vaak bij. hij hecft er altijd van genoten en dc avonden waren gedenkwaardig!! Ries: al bende
en blijfde unne levensgrote badaap en moettc af en toe unne schup ondcr oew kreegen. ik ben
vcreerd een (foute) vriend /oals jij te hebben!! As-ge moar nic als lievchirsbisjc komt teedens
dc promotie!! Blonde Hedonis: we zicn elkaar veel te weinig! Arno en Marion: hopelijk komt
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er toch ook snel een vervolg op het "Nier over de rooie (piste)" ik zal MrtfAMrMiNn!! Als
laatste, 'but by far not the least', wil ik hier mijn ouders bedanken voor alle steun. liefde en het
vertrouwen die ze me altijd gegevcn hcbbcn. Moekc: samen komcn we d'r wel!!! "S-pap mocht
dit helaas niet meer mccmaken, maar toch is hij er nog altijd en zal hij cr altijd ook bij
blijven en we hebben elkaar! Ma vicillc: het /it cr (cindclijk) op Na al die jarcn apart nu
gclukkig eindclijk tijd voor en met elkaar ik genict cr iedcrc dag wcer van!! Dc woorden van
Brcl zeggen genocg
-229-
Curriculum Vitae >*'- v- - J ^ - ' ' ^ '
Dc autcur van dit procfschrift wcrd geboren op 5 September 1971 te Tilburg. Na in 1989 het VWO
(gymnasium B) diploma bchaald tc hcbbcn aan hct Mill-Hillcollcge te Goirle, werd in datzclfdc jaar
bcgonncn aan dc studic scheikundc aan dc Katholiekc Univcrsiteit Nijmcgcn. In 1991 wcrd tcvens
gcstart met dc studic Frans aan dc/clfde universitcit, waarvan het propaedeutisch examen werd
bchaald in 1992. Na cen buitcnlandsc stage van zeven maanden in Parijs (november 1994 - juni
1995) wcrd in 1995 hct doctoraaldiploma scheikundc bchaald. Vanaf juli 1995 tot juli 2000 was dc
autcur wcrkzaam als assistcnt in oplciding (AiO) aan dc Univcrsiteit Maastricht, vakgrocp
Pathologic (hoof'd: Prof. dr. J.W. Arcnds; bcgcleidcrs: Dr. Ir. H.R. Hoogenboom en Dr. A.P.dc
Hruinc). Tijdcns dczc pcriodc wcrd hct ondcrzock vcrricht dat beschrcven staat in dit procfschrift.
Vanaf augustus 2000 is dc autcur wcrk/aam als post-doc aan hct Ncdcrlands Kankcr Instituut
(Antoni van Lccuwcnhockhuis tc Amsterdam), afdcling Cclbiologic (hoofd: Dr. J. Collard).
-230-
List of publications if*'
Roovers, RC; van der Linden. E; Zijlema. H; de Bruine, A; Arends. J-W ai\d Hoogcnhooni. HR
(1997) Human phage antibodies to colon tumor antigens from patient-based antibody repertoires.
Immunology Letters56. 191
Helfnch, W; Kroesen, BJ; Roovers. RC; Westers. L; Molcma. (i; Hoogcnboom. HR and de Leij.
L (1998): Construction and characterization of a bispecific diabody for retargeting T cells to
human carcinomas. Int. J. Cancer 76(2), 232-239
Hoogenboom, HR; dc Bruine, AP; Hufton, SE; Hoet, RM; Arendi, JWnd Roovers. RC (1998):
Antibody phage display technology and its applications. Immunotechnology4( I). 1-20
Roovers. RC; Hcndcrikx. P; Helfrich. W; van der Linden. L; Reurs, A; de liruinc. AP; Arends.
J-W; de Lcij, L and Hoogcnboom. HR (1998): High-affinity recombinant phuge antibodies to the
pan-carcinoma marker epithelial glycopmtein-2 for tumour targeting. Br J. Cancer 78( 11), 1407-
1416
Klimka, A; Barth. S; Matthey, B; Roovers, RC; Lcmke. H; Hanscn. H; Arends. J-W; Dichl. V;
Hoogenboom. HR and Engert. A (1999): An anti-CD30 single-chain Fv selecled by phugc
display ans fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin
against a Hodgekin-derived cell line. Br. J. Cancer 80(8), 1214-1222
de Haard, HJ; van Neer, N; Reurs, A; Hufton, SE; Roovers, RC; Hendcrikx, P; de Bruine, AP;
Arends, J-W and Hoogenboom, HR (1999): A large non-immunized human l-'ab fragment phage
library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. them.
274(26), 18218-18230
Mutubcrria, R; Hoogenboom, HR; van der Linden, F.; de Brume, AP and Roovers, RC (1999):
Model systems to study the parameters determining the success of phage antibody selections on
complex antigens. J. Immunol. Methods 231 (1-2), 65-81
Beiboer, SHW; Reurs, A; Roovers, RC; Arends, J-W; Whitclegg, NR; Rces, AR and
Hoogenboom, HR (2000): Guided Selection of a Pan-Carcinoma Specific Antibody Reveals
Similar Binding Characteristics yet Structural Divergence between the original Murine Antibody
and its Human Equivalent. J. Mol. Biol. 296 (3), 833-849
Klimka, A; Matthey, B; Roovers, RC; Barth, S; Arends, J-W; Engcrt, A and Hoogcnboom, HR
(2000): Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell
panning. Br. J. Cancer 83(2), 252-260
Todorovska. A; Roovers, RC; Dolezal, O; Kortt, AA; Hoogenboom, HR and Hudson, PJ (2000):
Design and application of Diabodies, Triabodies and Tetrabodies for Cancer Targeting. J.
Immunol. Methods, in press
-231-
Roovers, RC; van der Linden, E; de Brume, AP; Arends, J-W and Hoogenboom, HR (2000): In
vitro characterisation of a monovalent and bivalent form of a fully human anti Ep-CAM phage
., antibody. Cancer Immunol. Immunother, Accepted for publication
Roovers, RC; van der Linden, E; de Brume, AP; Arends, J-W and Hoogenboom, HR (2000):
Identification of colon tumour-associated antigens by phage antibody selections on primary
colorcctal carcinoma. Submitted for publication
Roovers, RC; van der Linden, E; Zijlema, H; de Brume, AP; Arends, J-W and Hoogenboom, HR
(2000): Evidence for a bias towards intracellular antigens in the local humoral anti-tumoi
>• ^ immune response of a colorcctal cancer patient revealed by phage display. Submitted foi
. publication
• • . - . . - : • ; • • * • - ' « ' . ! « • , - • • •
! ,, ! j ' l? ! '
•232-


